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Abstract 
 
DNA methylation is a reversible and inheritable chemical modification which involves 
the addition of a methyl group to DNA catalyzed by DNA methyltransferases (DNMTs), 
resulting in the conversion of the cytosine to 5’-methylcytosine, where the cytosine 
residue is followed by a guanine residue (CpG).  
In mammals, there are unusually dense clusters of CpG dinucleotides in the promoters of 
genes which are called “CpG islands”. For many housekeeping genes, these CpG islands 
are unmethylated in normal healthy tissue. However, CpG islands methylation is often 
associated with gene silencing and changed patterns of DNA methylation, associated with 
altered patterns of gene transcription, contribute to the aetiology of several diseases and to 
ageing.  
 
The overall aim of this project was to characterise the changes in DNA methylation which 
are observed during cell senescence (in the human cell line MRC-5) and during ageing 
and in response to dietary energy restriction (in various mice tissues). For this purpose: i) 
global DNA methylation was quantified using various techniques (ELISA, LINE-1, B1 
and LUMA assays and HPLC); ii) site-specific genome-wide screening for methylation 
changes was performed using the MeDIP technique followed by hybridization to DNA 
microarrays; iii) validation of the results for selected candidates was performed by 
pyrosequencing and iv) investigation of mitochondrial DNA methylation was conducted 
using bisulphite-modified-DNA PCR direct sequencing. Effects of senescence on gene 
expression were assessed by transcriptome microarrays and by RT-qPCR studies. During 
the study, previously established methods for the investigation of global DNA 
methylation (LUMA) and site-specific methylation (MeDIP) were improved. 
 
Whilst global DNA methylation changes were detectable in senescence and after short-
term dietary energy restriction, DNMTs/Dnmts expression changes were observed in 
senescence, ageing and following dietary energy restriction and were tissue- and 
treatment-specific. In parallel, site-specific aberrant DNA methylation was found in the 
promoters of the genes CTTN, GLIPR2, NPTX1 and SLC39A14 in replicative senescent 
MRC-5 human fibroblasts. These changes were validated by pyrosequencing and were 
accompanied by changes in expression of the corresponding genes. Also, in a pilot study, 
promoter methylation of several cell cycle genes was altered in replicative senescence 
with associated changes in gene expression. Concordant methylation changes were found 
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in the promoters of 47 gene in ageing mouse and heart tissues including the genes Wnt5a, 
Map4k5, Apcdd1, Chp2 and Rasgrp2. In addition, dietary energy restriction counteracted 
the age-related DNA methylation changes in the promoters of 40 genes, including Aifm1, 
Irf8, Rarg, Nmi, Maf1, Rab33a and Fxn in mouse liver. Finally, mitochondrial DNA 
methylation studies revealed that senescence affected the DNA methylation patterns of 
the MT-COI and MT-ND1 gene coding sequences in MRC-5 fibroblasts whilst ageing 
affected the DNA methylation pattern of the D-Loop region in mouse liver, but this was 
not reversed by dietary energy restriction.  
 
Pathway analysis revealed that senescence- and age-related aberrant DNA methylation 
affected genes involved in inter-cellular communication, stress response, malignant 
transformation, cellular development/proliferation control, cell growth/differentiation and 
survival, apoptosis and immune response. As these genes contribute to the maintenance of 
cellular and tissue homeostasis, these findings suggest a potential role for altered DNA 
methylation in the aetiology of senescence and ageing. On the other hand, short-term 
dietary energy restriction modulated some of the age-related aberrant DNA methylation 
patterns of the ageing mouse liver, in particular those in promoters of genes involved in 
apoptosis regulation, inflammatory and immune response to viral infections, transcription 
regulation, vesicle trafficking and mitochondrial iron transport and respiration. Finally, 
mitochondrial DNA aberrant methylation - found to occur at genes belonging to Complex 
IV and to Complex I - may contribute to the accumulation of hazardous superoxide 
species in senescent cells whilst DNA aberrant methylation at the D-Loop mitochondrial 
regulatory region may contribute to age-related mitochondrial dysfunction.  
 
In conclusion, these findings suggest that altered DNA methylation may have a role in the 
aetiology of senescence and ageing and that some of the effects of dietary energy 
restriction in slowing down the ageing process and also delaying the onset of age-related 
diseases may occur via epigenetic mechanisms, including amelioration of age-related 
aberrations in patterns of DNA methylation. 
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Chapter 1. Introduction 
 
1.1 Epidemiology of ageing 
The world population is increasingly growing older; in the developed countries this is the 
result of a decline in the leading causes of mortality in combination with a decline in the 
number of births (Ferrucci et al., 2008). According to the most recent data of the World 
Health Organization (WHO, 2013), in 2011 in the UK: 
 
 life expectancy at birth was 80 years (compared with 76 years in 1990) 
 the probability of dying between the age of 15 and 60 was 0.09% (against 0.13% 
in 1990)  
 the median age of the population was 40 years 
 the percentage of the population aged under 15 years old was 17% 
 the percentage of the population aged over 60 years old was 23% 
 the annual growth rate was 0.5% 
 
The increase in life expectancy is the result of better life conditions and of the progress of 
the medical sciences, but brings new social, economic and medical challenges, which 
modern society is not entirely equipped to cope with. In fact, older people often face 
chronic and/or progressive age-related diseases (see Table 1.1, (Ferrucci et al., 2008)) 
which may cause severe disability, have a major impact on the quality of life, may require 
long-term care need and are common causes of death (see Figure 1.1).  
 
Table 1.1. Most commonly reported chronic conditions per 100 persons aged > 65 in 
2005 (from (Ferrucci et al., 2008)). 
 
Condition Men Women 
Hypertension 44.6 51.1 
Arthritis diagnosis 40.4 51.4 
Chronic joint symptoms 39.7 47.7 
Coronary heart disease 24.3 16.5 
Cancer (any type) 23.2 17.5 
Vision impairment 14.9 18.7 
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Diabetes 16.9 14.7 
Sinusitis 11.5 16.0 
Ulcers 13.1 10.4 
Hearing impairment 14.8 8.4 
Stroke 8.9 8.2 
Emphysema 6.3 4.1 
Chronic bronchitis 4.5 6.3 
Kidney disorders 4.1 3.9 
Liver disease 1.4 1.4 
 
 
 
Figure 1.1. Death by underlying or multiple cause, expressed in rates per 100,000 people, 
for the 2001 US population aged 85 and older (from the National Center for Health 
Statistics, Data Warehouse on Trends in Health and Aging). 
 
Ageing is a main factor in the development of cancer, cardiovascular and 
neurodegenerative disorders (Niccoli and Partridge, 2012), although other factors can 
contribute to their onset; for example, genetic factors such as APOE4 genotype 
predispose to Alzheimer’s disease (Blennow et al., 2006) and mutations in the leucine-
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rich repeat kinase 2 (LRRK2) gene to Parkinson’s disease (Lesage and Brice, 2009). 
Lifestyle choices can also have a major impact in the onset of age-related diseases: 
cholesterol-rich, fat-rich and glucose-rich diets and being overweight or obese have long 
being associated with the risk of cardiovascular disease, type 2 diabetes, cancers and 
dementia (Everitt et al., 2006). There is therefore evidence that a healthy diet, together 
with weight control and exercise, can help in the prevention of age-related diseases 
(Aballay et al., 2013), resulting in increased life expectancy and in an improvement of the 
overall quality of life of older people. In particular, there is a strong evidence that 
adherence to a Mediterranian eating pattern is associated with reduced mortality and 
lower risk of age-related diseases (Sofi et al., 2010). Elucidating more risk factors that are 
implicated in the development of age-related diseases, and their reduction or elimination, 
can also help to achieve these goals.  
 
1.2 Definitions and theories of biological ageing 
In biology, ageing is described as a complex and progressive process which takes place in 
living organisms over time and is characterised by: 
 
 an exponential increase in mortality with age; 
 physiological changes leading to functional decline;  
 increased susceptibility to many common diseases (summarized in Table 1.1 and 
Figure 1.1)   
 
and can be defined as:  
 
 the accumulation of changes which lead an organism to death (Medawar, 1952); 
 a gradual deterioration of physiological functions (Partridge and Mangel, 1999);  
 the irreversible process of loss of viability and increase in vulnerability (Comfort, 
1964). 
 
Many hypotheses have been formulated to explain the ageing process, but none of them 
seems to be able to describe all aspects of the process (Lopez-Otin et al., 2013). This is 
due to the extensive heterogeneity of ageing between species and between individual 
organisms within a species - from the macroscopical to the microscopical level - and also 
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to the impact of different stochastic events. Rattan (Rattan, 2006) concluded that “ageing 
has no universal cause, phenotype and consequence, except death”. 
The following sections summarise some of the hypothesis that scientists have formulated 
to try to explain the ageing process. 
 
1.2.1 The evolutionary principle 
The evolutionary principle is based upon the Darwinian definition of essential lifespan of 
a species (ELS), which is defined as the time that an organism requires to reproduce itself 
and therefore guarantee the continuity of its species (Rattan and Clark, 2005). 
In general, species that quickly develop to adulthood and have a high potential of 
reproduction have a short ELS, while species that grow slowly and produce few offspring 
have a long ELS. In a protected environment, such as modern societies for humans or 
laboratories for mice, living organisms can live longer than their ELS and it is in this 
further period of life that ageing occurs (Rattan, 2006). 
 
1.2.2 The molecular principle 
The molecular theories state that ageing occurs because of progressive accumulation of 
damaged and damaging molecules and macromolecules within cells and tissues; some 
examples of those are: 
 
 reactive oxygen species (ROS) and free radicals (FR) generated by exposure to 
external oxidising agents (e.g. UV rays), or by increased internal production due 
to reduced mitochondria respiratory capacity (Passos and von Zglinicki, 2005). 
As an example, the resulting lipid peroxidation products exert cytotoxic and 
genotoxic effects (Niki et al., 2005);  
 long lived-proteins which do not undergo turnover e.g. crystallin, collagen and 
elastin. Since they may persist for a long time within tissues, these proteins are 
particularly prone to the accumulation of damage and this damage may affect 
tissue function and contribute to ageing (Toyama and Hetzer, 2013);  
 insoluble proteins that accumulate in the intra and extracellular spaces are also 
thought to contribute to the ageing process: Hallen (Hallen, 2002) hypothesized 
that biological ageing could depend on this deleterious accumulation of proteins 
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that have escaped from proteolytic degradation, which impairs intracellular 
transport mechanisms.  
Glycation – the covalent binding of glucose to proteins - contributes to this 
process and has been linked with increased risk of diseases such as diabetes, 
cataract, Alzheimer’s, dialysis related amyloidosis (DRA) and atherosclerosis 
(Suji and Sivakami, 2004); 
 errors in the transfer of genetic information from DNA through replication, 
transcription, translation and in post-transcriptional and post-translational 
modifications (Rattan, 2006);  
 protein errors, which have been widely studied in attempts to understand ageing. 
The induction of translational errors can accelerate the ageing process in human 
cells (Holliday, 1996; Rattan, 1996) and in bacteria (Nystrom, 2002). Conversely, 
increasing the accuracy of the translation machinery, has led to a longer lifespan 
(Silar and Picard, 1994; Silar et al., 2000; Holbrook and Menninger, 2002). 
  
1.2.3 The genetics principle 
Many attempts have been made to identify gerontogenes, that is genes directly involved 
in the process of ageing, but there seems to be no genes with the specific purpose of 
causing ageing (Rattan, 1996; Johnson, 2002); nonetheless, it has been demonstrated that 
mutations in genes encoding for kinases, kinases receptors, transcription factors, DNA 
helicases, membrane glucosidases, GTP-binding proteins coupled receptors, chaperons, 
and products involved in cell cycle checkpoints and energy metabolism pathways can 
affect life span and/or cause premature ageing in humans (Kenyon, 2005; Martin, 2005; 
Christensen et al., 2006). In addition, altered epigenetics patterns which may cause 
dysregulation of gene expression is common in age-related diseases and this issue will be 
discussed in detail later in this Chapter. 
 
1.2.4 The homeodynamics  principle 
A living organism can be considered as a dynamic system, which responds to external 
stimuli through internal reassessments. This reassessment is called homeodynamics, that 
is “stability through change” (Rattan, 2006). 
Examples of biological pathways involved in assuring homeodynamics include: 
 pathways of nuclear and mitochondrial DNA repair; 
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 processes for sensing and responding to intra- and extra-cellular stressors; 
 pathways for the removal and degradation of defective proteins; 
 antioxidative and enzymic defences against reactive oxygen species (ROS); 
 processes for the detoxification of harmful chemicals ingested in the diet or 
entering the body via the lungs or skin; 
 cellular and humoral immune responses against pathogens and parasites, including 
apoptosis; 
 processes of wound healing and tissue regeneration. 
 
Over time, organisms become progressively less efficient  in maintaining homeostasis; 
therefore, accumulation of damage and progressively less efficient mechanisms of self-
defence may contribute to the ageing process. 
 
1.2.5 The disposable soma theory 
Every organism has finite resources and therefore needs to “budget” its metabolic 
resources between the demands for somatic maintenance and those of growth and 
reproduction. According to the disposable soma theory, because of the dominant 
requirement for reproduction, natural selection favours a strategy that invests fewer 
resources in maintenance of somatic cells and tissues than are necessary for indefinite 
survival (Kirkwood, 1977). 
From Drenos (Drenos and Kirkwood, 2005): 
“The disposable soma theory thus closes the gap between mechanistic and evolutionary 
theories of ageing by suggesting that ageing results from progressive accumulation of 
molecular and cellular damage, as a direct consequence of evolved limitations in the 
genetic settings of maintenance and repair functions”. 
 
1.3 Cellular senescence 
Cellular senescence is defined as an irreversible cell cycle arrest state which was first 
described in normal human diploid cell cultures by Hayflick  and Moorhead (Hayflick 
and Moorhead, 1961; Hayflick, 1965), who observed that these cells, when cultured under 
optimal conditions, could only perform a limited number of divisions, or population 
doublings, the so-called “Hayflick limit”. Hayflick  and Moorhead identified three 
different phases undergone by primary cells in culture: a first stage of slow proliferation, 
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during which the culture is established (phase I), a second stage of rapid growth (phase II) 
and a third stage, characterized by progressive reduction in rate of cell proliferation, 
culminating in an inevitable and irreversible arrest of cells growth during which cells 
remained metabolically active (Hayflick and Moorhead, 1961). 
Cellular senescence is characterized by morphological changes, chromatin structure 
reorganization and specific gene expression profiles. In particular, cells become larger 
and show increased granularity (Nishio et al., 2001) and the formation of senescence 
associated heterochromatin foci (SAHF) is observed (Zhang et al., 2007). Gene 
expression changes in senescence are strongly cell line specific, one example being the 
chronic inflammatory phenotype seen in senescent fibroblasts (Shelton et al., 1999). 
Table 1 summarizes the main categories of senescence, with  two major types termed 
replicative senescence and premature senescence respectively, and further subtypes of the 
latter class, termed stress-induced premature senescence, oncogene-induced senescence 
and PTEN loss induced cellular senescence (Vargas et al., 2012). However, it must be 
noted that this classification does not refer to independent molecular mechanisms of 
senescence, but only to the different terminologies adopted by various authors.  
Replicative senescence is typical of cells which stop proliferating as a consequence of 
telomere shortening and have reached their Hayflick limit (Wright and Shay, 2001). 
Telomeres are single-stranded DNA stretches located at the end of chromosomes and are 
formed by TTAGGG repeats folded back on themselves, so that no single-stranded 
regions of DNA, which could be sensed as DNA damage, are detectable (Moyzis et al., 
1988; Meyne et al., 1989). The main function of telomeres is the maintenance of genome 
integrity, through the protection of chromosome ends from degradation and the 
prevention of chromosome ends fusion upon replication (Chakhparonian and Wellinger, 
2003; Bailey and Murnane, 2006). The inability of DNA polymerase to replicate 
telomeric sequences (Wright and Shay, 2000), combined with the repression of TERT 
enzyme (Telomerase Reverse Transcriptase, a ribonucleoprotein polymerase that 
maintains telomere ends by addition of the telomere repeat) in postnatal somatic cells and 
to oxidative stress (von Zglinicki, 2002; Kawanishi and Oikawa, 2004), leads to 
progressive erosion of telomeres with each cell division. This shortening has been 
strongly associated with cellular senescence (Sherr, 2000) and a functional link is 
suggested by the fact that most cell lines which overexpress TERT escape senescence 
(Bodnar et al., 1998; Vaziri and Benchimol, 1998; Yang et al., 1999) and are therefore 
termed “immortalized”. 
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The other senescence categories refer to senescence states which are telomere shortening 
independent. This is the case for oncogene-induced senescence, which is promoted by the 
overexpression of oncogenes (Gorgoulis and Halazonetis, 2010) and for stress-induced 
premature senescence, which can be triggered by several kinds of stress, such as DNA 
damage, suboptimal culture conditions and oxidative stress (Chen and Ames, 1994; Di 
Leonardo et al., 1994; Chen et al., 1995; Robles and Adami, 1998; Rodier et al., 2009). 
However, in some instances, replicative and stress-induced senescence might overlap: this 
is the case of oxidative stress, that contributes to telomeres shortening in fibroblasts (von 
Zglinicki et al., 1995; von Zglinicki, 2002; Von Zglinicki, 2003). 
PTEN-loss induced senescence is considered a separate process by some authors because, 
although sharing several features with oncogene-induced senescence, it does not require 
activation of the DNA damage response or hyper-proliferative activity to be induced 
(Shelton et al., 1999). 
All these types of senescence have  in common transcriptional activation of the RB-E2F 
complex response, which ultimately leads to the irreversible arrest of the cell cycle. 
 
Table 1.2. Summary of senescence categories; the classification refers to the triggering 
mechanism (adapted from (Vargas et al., 2012)). 
 
Type of senescence Mechanism 
Replicative senescence 
Senescence dependent on telomere length and blocked by hTert 
expression. 
Premature senescence Any senescence that is not replicative. 
Stress-induced premature 
senescence 
Senescence induced by several kinds of stresses, such as DNA 
damage, oxidative stress and culture conditions. 
Oncogene-induced senescence 
(OIS) 
Senescence induced by oncogenes such as RasG12V, cMYC or 
BRafV600E; involves signalling pathways such as p38MAPK and 
the DNA damage response. 
PTEN loss-induced cellular 
senescence 
Shares several features with OIS but can also be induced through 
mechanisms that do not involve DNA Damage Response or p53 
signalling. 
 
Several transducers commonly mediate the activation of the senescence programmes 
(Lowe et al., 2004), e.g. the DNA damage response proteins 53BP1, NBS1, MDC1, ATM 
and ATR (d'Adda di Fagagna et al., 2003), p53 (Fujita et al., 2009), p16
INK4A
 and RB 
(Ben-Porath and Weinberg, 2005; Campisi, 2005). These are summarized in Figure 1.2. 
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Figure 1.2. Molecular pathways triggering cell senescence (adapted from (Vargas et al., 
2012)). Several signal transducers are involved in the activation of the senescence 
programme, including inhibitors of the expression and/or the activity of cyclins (p15, p16, 
p18, p19, p21, p27 and p53), cell division cycles (CDCs) and cyclin-dependent kinases 
(CDKs) and DNA Damage Response proteins. 
 
1.3.1 Biomarkers of cellular senescence 
Numerous biomarkers have been used to identify senescent cells in vitro, but, to date, 
none of them alone is sufficient to identify a senescent state (Kuilman et al., 2010). 
Together with the above mentioned activated (phosphorylated) transducers, 
morphological changes and the appearance of senescence-associated heterochromatic foci 
(SAHF), the following other biomarkers are also used to identify senescent cells: 
 
 induction of Senescence Associated-β-Galactosidase (SA-β-GAL) activity (Dimri 
et al., 1995) at pH = 6, a suboptimal condition for non-senescent cells, for which 
pH = 4 is optimal for enzyme activity; 
 increased mitochondrial Reactive Oxygen Species (ROS) content (Lu and Finkel, 
2008; Moiseeva et al., 2009; Lawless et al., 2010; Lawless et al., 2012); 
 telomere shortening (Cristofalo et al., 2004); 
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 telomere-associated DNA damage response (Herbig et al., 2006; Hewitt et al., 
2012). 
 
1.3.2 The senescence secretome and cellular senescence in vivo 
Senescent cells secrete several cytokines and chemokines (Campisi, 2005) and therefore 
communicate with neighbouring cells through what it is termed the senescent-associated-
secretory phenotype (SASP) (Coppe et al., 2008; Rodier et al., 2009). As previously 
mentioned, fibroblasts undergoing senescence show a strong inflammatory response 
(Shelton et al., 1999) which, depending on the genetic context of the cells “receiving the 
message”, can result in a pro-oncogenic response (Krtolica et al., 2001). Communication 
with neighbouring cells can also be mediated by ROS and induce senescence in normal 
cells (the so-called senescent cell bystander effect) (Nelson et al., 2012). Once 
established, the senescence phenotype is stabilized and maintained by a long-term 
activation of p21, with the induction of mitochondrial dysfunction and ROS production, 
which, in turns, contribute to persistent DNA damage and to a continuous DNA damage 
response (Passos et al., 2010). In addition, chemokines (Acosta et al., 2008) and 
interleukins (Kuilman et al., 2008) contribute to the reinforcement of senescence through 
a self-amplifying secretory mechanism. 
The accumulation of senescent cells can be detected in vivo in ageing organisms. For 
example, SA-β-GAL activity at pH = 6 has been described in the skin of the older people 
(Dimri et al., 1995) and in endothelial cells from atherosclerosis patients (Foreman and 
Tang, 2003), whilst decreased telomere length has been correlated with chondrocyte 
senescence in osteoarthritis (Price et al., 2002). Partial confirmation of the utility of these 
putative markers of senescence in vivo is provided by findings from a study of dermal 
fibroblasts from ageing compared with young baboons, which showed increased markers 
of DNA damage and of heterochromatinization localized at telomeres and accompanied 
by increased p16
INK4A
  expression (Herbig et al., 2006). DNA damage foci - in particular 
accumulation of γ-H2A.X foci (see section 1.4.1) – have been observed in ageing mice 
lung, spleen, dermis, liver and gut epithelium. This accumulation, a major trigger of 
senescence, seemed to be associated with tissue sections subjected to higher oxidative 
stress (e.g. centrilobular area of the liver), but not necessarily to telemore shortening (e.g. 
intestine crypts), suggesting that stress-dependent senescence might contribute to ageing 
of some tissues in a telemore-independent manner (Wang et al., 2009). Post-mitotic cells, 
such as neurons, progressively show several senescence markers in ageing mice 
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(Senescence Associated-β-Galactosidase activity, ROS and inflammatory chemokines 
production) as a consequence of a DNA damage response (Jurk et al., 2012). 
Cellular senescence is regarded as an important regulator of tissues homeostasis and 
constitutes a barrier against tumour formation by preventing uncontrolled cell 
proliferation (Wright and Shay, 2001). However despite the evidence that senescent cells 
accumulate in ageing tissues, their role in contributing to the ageing phenotype has 
remained under debate for a long time. Recent findings have demonstrated that clearance 
of p16
Ink4a
-expressing cells (used as a marker for senescence) delays the onset of age-
related phenotypes in certain mouse tissues (Baker et al., 2011), thus suggesting that the 
accumulation of senescent cells within a tissue has a causal role in the ageing process. 
 
1.4 Epigenetics 
Epigenetics is defined as “the inheritance of changes in gene function without any 
changes in the DNA nucleotide sequence” (Fraga and Esteller, 2007). 
Epigenetics plays important roles in biological processes, one example of which is 
cellular differentiation, as reviewed in (Mohn and Schubeler, 2009). All the nucleated 
cells in an organism contain the same genomic DNA, but only some genes are expressed 
in a given tissue, while other genes are silenced. These differential patterns of gene 
expression underpin the phenotypic heterogeneity of cell types within a higher organism.  
The three best known epigenetic mechanisms are histone modifications, DNA 
methylation and non-coding RNAs. 
 
1.4.1 Histone modifications 
Within the nucleus, DNA is wrapped around an octet of globular proteins called histones. 
This structure is called the nucleosome and it is constituted by two copies of each of the 
core histone proteins (H2A, H2B, H3 and H4) and 146 bp of double-stranded superhelical 
DNA. Nucleosomes are the basic unit of DNA packaging in eukaryotic cells, 
indespensable for the storage of genetic information in cell nuclei and are connected to 
each other by a short stretch of DNA (up to 80 bp) and one copy of the linker histone H1 
(Luger et al., 1997). 
The ends of histones which protrude from the globular core are known as histone tails and 
several amino acid residues in these tails are post-translationally modified. The most 
characterised histone modifications are acetylation, methylation, phosphorylation and 
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ubiquitination. Whilst more than 60 such modifications have been detected so far using 
different methodologies (Kouzarides, 2007), the function of most of them is still 
unknown. They can be classified into two main groups:  
 
 activating modifications, which are related to chromatin accessibility and 
transcriptional activity, even if not directly; 
 repressive modifications, which are related to heterochromatin and  genes 
repression. 
 
This is only a general classification. Indeed, in many cases a single histone modification 
has different functions depending on modifications of other amino acid residues nearby.  
The first described histone modification was acetylation (Phillips, 1963), which is often 
associated with active gene transcription (Zentner and Henikoff, 2013). Typically, core 
histones are acetylated at several lysine residues by specific enzymes termed Histone 
Acetyltransferases (HATs) and the mechanism proposed for gene transcription activation 
is based on the fact that acetylation counteracts the positive charge of lysines, inhibiting 
interactions between histones and DNA in the nucleosomes and rendering the DNA more 
accessible to transcriptional complexes (Zentner and Henikoff, 2013).  
Another well characterized histone modification is methylation, which occurs not only at 
lysine residues within core histones, but also at arginines (Bedford and Clarke, 2009). 
Methylation can be a single modification (monomethylation) or a multiple modification 
(di- or trimethylation). These modifications have been associated with both 
transcriptional activation and repression, depending on the residue on which they occur. 
However, their direct effect on regulation of transcription may be relatively small 
(Lenstra et al., 2011; Jiang et al., 2011) and regulation of gene expression may be 
indirect, through modulation of histone affinity for protein complexes involved in the 
transcription process (Taverna et al., 2007; Schmitges et al., 2011). 
Phosphorylation is another well characterized histone modification and it is thought to 
affect transcription through a similar mechanism of action as for acetylation, i.e. through 
directly modifying the charge on the histone tail and rendering DNA more accessible for 
transcription (Banerjee and Chakravarti, 2011). Histones are phosphorylated in many 
contexts. For example, phosphorylation of the histone variant H2A.X at Ser139 following 
double-strand breaks (indicated as γ-H2A.X) recruits the repair complexes at the sites of 
damage and it is used widely as a marker for DNA damage (Paull et al., 2000; Sharma et 
al., 2012). 
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With the use of Chromatin Immunoprecipitation techniques, many other histone 
modifications have been identified; a comprehensive guide to the known histone 
modifications can be found at the “Human Histone Modification Database” 
(http://bioinfo.hrbmu.edu.cn/hhmd) (Zhang et al., 2010). However, for most of them, 
functions and/or mechanisms of action are still to be fully elucidated. 
 
1.4.2 DNA Methylation and DNA Methyltransferases 
DNA methylation is a reversible and heritable chemical modification which involves the 
addition of a methyl group to DNA, described for the first time in calf thymus (Hotchkiss, 
1948). In mammals this addition of methyl groups occurs exclusively on Cytosines within 
CpG dinucleotides (i.e. where a Cytosine residue is followed by guanine residue) and it 
results in the conversion of the Cytosine to 5’-methylCytosine. 
 
 
 
 
Figure 1.3. Cytosine methylation to 5’-MethylCytosine. The reaction is catalysed by a 
DNA MethylTransferase (DNMT) in the presence of S-Adenosyl-methyonine. 
 
Figure 1.3 shows the Cytosine methylation reaction, which is catalysed by a group of 
enzymes called DNA Methyltransferases (Dnmts), responsible to transfer a methyl group 
from the donor S-adenosyl-methionine (SAM) to the 5’ carbon of an unmethylated 
Cytosine. 
The class of DNA Methyltransferases includes enzymes that share similarities within the 
C-terminal catalytic domains, but little homology at the N-terminal domains (see Figure 
1.4). 
 
CH3 
Dnmt 
SAM 
Cytosine 5’-MethylCytosine 
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Figure 1.4. Organization of the three main mammalian DNA Methyltransferases. The 
Roman numerals in the C-terminal part indicate the amino acids motifs that show strong 
homology to prokaryotic DNA-(Cytosine-C5)-MTase (from  (Robertson and Wolffe, 
2000). PCNA = proliferating cell nuclear antigen interaction domain; NLS = nuclear 
localization signal; (KG)n = lysine-glycine repeat hinge region; HDAC = histone 
deacetylase interaction domain; PHD = plant homeodomain motif that shows homology 
to the ATR-X ( -thalassaemia, mental retardation, X-linked) gene. 
 
Dnmt1 was the first DNA methyltransferase to be discovered (Gruenbaum et al., 1982) 
and is commonly termed “the maintenance Dnmt” since it binds to the daughter strand of 
DNA during replication and methylates it according to the pattern of methylation marks 
on the parental strand. This assures the inheritance of the methylome (the totality, and 
patterns, of methylated DNA sites) during cell replication (reviewed by (Hermann et al., 
2004a)).  
Group 3 includes Dnmt3A and Dnmt3B, which are de novo methylases (reviewed by 
(Hermann et al., 2004a), and Dnmt3L, which is expressed only in germ cells. Although 
the latter has not been shown to have methyltransferase activity, it is essential to set the 
correct imprinting in oocytes and prospermatogonia (Bourc'his et al., 2001; Hata et al., 
2002) and it has also been identified as a stimulator of the activity of Dnmt3a (Chedin et 
al., 2002). 
15 
 
The formerly termed Dnmt2 is the most conserved Dnmt, but the least known enzyme of 
this family. Its structure allows us to classify it as a Dnmt but, to date, there is no 
evidence that it has any methyltransferase activity and, even though it is expressed 
ubiquitously, it seems not to be essential for survival (Goll and Bestor, 2005). Since the 
discovery that this enzyme is able to methylate Cytosine-38 residue of aspartic acid 
transfer RNA (Goll et al., 2006), it is has been renamed tRNA aspartic acid 
methyltransferase 1 (TRDMT1). 
 
In mammals, DNA methylation marks are found throughout their genomes e.g. in 
transposable elements, gene bodies and intergenic regions. 
Although overall the CpG dinucleotide is under-represented in the genome, there are 
unusually dense clusters of CpG dinucleotides in certain areas of the genome, which are 
called “CpG islands”. In mathematical terms, they are defined as sequences longer than 
200 bp with CG content of at least 55% and a ratio observed/expected of CpG frequency 
of at least 0.6 (Takai and Jones, 2002). However, in order to avoid false positives in the 
identification of CpG islands, it has become a standard to consider as CpG islands 
sequences to which the above criteria apply, but with a minimum length of 500 bp 
(Illingworth et al., 2008). Islands predicted using these methods have been seen to overlap 
promoter regions of 50%-60% of human genes (Wang and Leung, 2004), thus suggesting 
that DNA methylation plays a role in the regulation of gene expression; in fact, DNA 
methylation is associated with gene silencing: methylated Cytosines can either physically 
impede the binding of transcription factors or bind methyl-CpG-binding domain proteins 
which in turns recruit other proteins, such as histone deacetylases, and inactivate 
chromatin, as reviewed by (Zou et al., 2012). 
 
Many functions for DNA methylation have been hypothesized and some have been 
demonstrated. 
The first group includes: 
 
 evolution: spontaneous mutations are the biological driver for evolution so it is 
logical to assume that DNA methylation could be a mechanism for “increasing 
genetic and biological diversity” (Cooper and Gerber-Huber, 1985); 
 apoptosis: “the suicidal function” of Cytosines methylation could be due to the 
high mutational rates at these sites, thus leading to progressive genome instability 
and to programmed cell death (Mazin, 2009). 
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In the second group of functions there are: 
 
 dosage compensation in mammals. While males have only one X chromosome, 
females have two. DNA methylation randomly silences one of the female X 
chromosomes so that there is the same amount of X-related gene products in 
individuals of both sexes. This process is called X-chromosome inactivation 
(XCI) and starts in early mammalian development (Heard and Disteche, 2006); 
 genomic imprinting. This term refers to the fact that, in placental mammals, some 
autosomal genes are expressed from only one of the two parental alleles, i.e. 
parent-of-origin specific expression. Usually, imprinted genes are found in 
clusters where they are controlled by a unique imprinted control region (ICR) rich 
in CpG, which are methylated in one of the two strands (Spahn and Barlow, 
2003). The methylated allele is transcriptionally silent; 
 genome defence from molecular parasites. About 45% of the human genome and 
37% of the mouse genome is composed of transposable elements, which include 
Long Terminal Repeats (LTR)-Retrotransposons, Long and Short Interspersed 
Nuclear Elements (LINE and SINE, respectively) and DNA transposons. These 
sequences could interfere with the regulation of gene expression and genome 
structure by means of insertions, deletions, inversions and translocations of 
genomic sequences. However, this potential damage is prevented by methylation 
of most Cytosines within CpG dinucleotides in these repeat regions and most of 
them resides in heterochromatin regions (Kim et al., 2009b);  
 development and cell/tissue differentiation: reprogramming of methylation 
patterns occurs during different stages of mammalian development. In primordial 
germ cells there is a global demethylation, while in preimplantation embryos a 
remethylation occurs (Reik et al., 2001; Cantone and Fisher, 2013); 
 chromatin remodelling and regulation of gene expression: approximately half of 
mammalian genes have CpG islands in their promoter regions (Antequera and 
Bird, 1993); DNA methylation can suppress their transcription preventing the 
binding of transcription factors or promoting the binding methyl-CpG-binding 
proteins (i.g. MeCP2, MBD2), which draw in situ chromatin inactivators (i.g. 
histone deacetylases and methyltransferases) (Richardson, 2003). 
 
Altered patterns of DNA methylation are observed frequently in many common 
pathologies and include the following: 
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 hypomethylation and demethylation, which are associated with some chronic 
autoimmunodiseases, such as Systemic Lupus Erythematosus (Rahman and 
Isenberg, 2008) and tumours which develop in several tissues/organs, including 
stomach, kidney, colon, pancreas, liver, uterus, lung and cervix (Hirst and Marra, 
2009). Demethylation is associated with vascular disease (Castro et al., 2003), 
congenital anomalies of the central nervous system and schizophrenia and other 
personality disorders (Susser et al., 1996; Hoek et al., 1998; Nishioka et al., 2012; 
Byrne et al., 2013); 
 hypermethylation, which is also seen in cancer development and it is likely to be 
causal for tumourigenesis when it occurs in the promoter regions of tumour 
suppressor genes (because it silences the tumour suppressor gene) or of DNA 
repair genes such as MLH1 (when gene silencing leads to the accumulation of 
DNA damage and can be detected via instability of DNA repeat sequences) 
(Esteller et al., 1998). Similar effects are seen in Fragile X Syndrome (Crawford et 
al., 2001); 
 specific genetic defects, which are observed in genes encoding components of the 
DNA methylation machinery. For example, Prader-Willi Syndrome and 
Angleman Syndrome are due to loss of imprinting and are characterised by mental 
retardation and behavioural abnormalities (Lossie et al., 2001; Nicholls and 
Knepper, 2001; Goldstone, 2004).  
 
1.4.3 Noncoding RNAs  
The term noncoding RNAs (ncRNAs) refers to a wide set of functional RNA molecules 
that do not encode a protein product. The first RNAs belonging to this category to be 
identified were RNAs involved in the translation process, such as ribosomal RNAs 
(rRNAs) (Palade, 1955) and transfer RNAs (tRNAs) (Hoagland et al., 1958). More 
recently, several other species of noncoding RNAs were discovered which can be 
generally divided into two main categories - small noncoding RNAs and long noncoding 
RNAs - . These are of particular interest for epigenetics because they have been shown to 
be involved in post-transcriptional gene silencing (reviewed in (Castel and Martienssen, 
2013). In the first category we can find microRNAs (miRNAs), small interference RNAs 
(siRNAs) and Piwi-interacting RNAs (piRNAs). 
MiRNAs are short non-coding RNAs about 22 nucleotides long which can inhibit the 
translation of messenger RNAs by binding - through base-pairing complementarity - to 
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their 3’-untranslated region and targeting them for degradation or affecting their stability 
(Esquela-Kerscher and Slack, 2006). They are transcribed by RNA polymerase II (Lee et 
al., 2004) or may derive from splicing of introns (Berezikov et al., 2007). To date, >1000 
human miRNAs have been described and miRNAs target many mRNAs (Griffiths-Jones 
et al., 2008). As a consequence, miRNAs are implicated in the regulation of many cellular 
processes including development, cell cycle regulation, differentiation, energy 
metabolism, tumour suppression and apoptosis, as reviewed in (Grillari and Grillari-
Voglauer, 2010). There is increasing interest in miRNAs not least because of the recent 
discovery that miRNAs-encoding loci can be polymorphic and that SNPs and 
translocations at these loci are correlated with certain diseases and phenotypes (Duan et 
al., 2009). Thus, these small molecules have become potential new therapeutic targets 
(Mishra et al., 2009; Mishra and Bertino, 2009).  
SiRNAs are short double-stranded RNAs (20-25 bp) which are not encoded by specific 
genes (as miRNAs are), but are produced from the cleavage of long double-stranded and 
small hairpin RNAs; these reactions are catalysed by the endoribonuclease Dicer 
(Bernstein et al., 2001). SiRNAs most known function is transcriptional gene silencing 
through base-pairing complementarity, as reviewed in (Castel and Martienssen, 2013). 
Surprisingly, in humans, siRNAs can also activate gene expression by targeting specific 
promoters (Li et al., 2006).  
PiRNAs are the most abundant small noncoding RNAs, are 26 to 31 nucleotides long and 
are encoded in clusters throughout the genome (Seto et al., 2007). PiRNAs interact with 
Piwi proteins to form RNA-protein complexes, which have been related to epigenetic and 
post-transcriptional gene silencing in germ line cells (specifically in the testis for 
mammals) (Siomi et al., 2011). Because of their sequence complementarity to 
transposons, piRNAs are thought to specifically silence transposons, contributing to 
genome stability (Malone and Hannon, 2009).  
LncRNAs are very abundant in the genome (Carninci et al., 2005) and lack or have a 
small open reading frame (ORF) (Dinger et al., 2008). However, some mRNAs can also 
function as lncRNAs, thus showing bifunctionality (Dinger et al., 2011). LncRNAs are 
transcribed in the same way as mRNAs (Guttman et al., 2009) and can be found 
throughout the genome within intergenic regions and often clustered with mRNAs 
(Carninci et al., 2005). Despite the abundance of these molecules, only about 100 of them 
have been functionally annotated so far (Amaral et al., 2011). Known functions of 
lncRNAs include gene-specific transcription regulation (by targeting and modulation of 
transcriptional activators or repressors and different components of the transcription 
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machinery (Goodrich and Kugel, 2006)), post-transcriptional regulation (by base 
complementarity to a target mRNA. As a consequence, lncRNAs might influence all the 
steps in mRNA processing, such as splicing (Beltran et al., 2008) and translation 
(Centonze et al., 2007), epigenetic regulation (by modification of the accessibility to 
chromatin accessibility of modifying proteins (Rinn et al., 2007)), participation in the 
imprinting process (Pauler et al., 2007) and in X-chromosome inactivation occurring in 
females (Morey et al., 2004) and possibly by contributing to telemore stability and 
integrity (Azzalin et al., 2007)).  
 
1.5 DNA methylation in senescence and ageing 
The first studies focusing on epigenetics of ageing have demonstrated a significant 
reduction of in the global 5mC content occurring in mouse, hamster and human 
fibroblasts with time in culture (Wilson and Jones, 1983) and also in a variety of ageing 
mammalian tissues (Zin'kovskaia et al., 1978; Wilson et al., 1987; Golbus et al., 1990; 
Singhal et al., 1987), although this is tissue-specific (Thompson et al., 2010). This loss of 
methylation could be explained if considering the following observations: 
 
 there is a gradual loss of repetitive DNA regions (such as telomeres) over time; 
these regions contain a significant proportion of the 5mC in mammalian genomes 
(Fraga et al., 2005);  
 DNMT1 level decreases with age (Zhang et al., 2002b); 
 there is a loss of fidelity and efficacy of DNMT1 with age (Casillas et al., 2003); 
 DNMT1 targeting by cofactors is progressively impaired with age (Casillas et al., 
2003). 
 
Despite the global loss of methylation, ageing cells show aberrant patterns of 
hypermethylation in some gene promoters and, therefore, altered gene expression levels. 
Pioneering studies have detected promoter hypermethylation of  MLH1 and p14ARF 
(Shen et al., 2003), ER, MYOD1, IGF2 and N33 (Issa et al., 1994; Issa et al., 1996; Ahuja 
et al., 1998) genes in ageing tissues. Interestingly, those promoters are also aberrantly 
hypermethylated in cancer, corroborating the assumption that ageing is a primary risk 
factor for cancer (Fraga and Esteller, 2007; Tapp et al., 2013). 
Another characteristic of ageing tissues and cells is the progressive accumulation of 
mutations at CpG methylation sites, which are the most common hotspots for C>T and 
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G>A transitions in human genes; in addition, these sites are target for most spontaneous 
G>C/T and C>A/G transversions, deletions, insertions, tandem, multiple and complex 
mutations (Cooper and Krawczak, 1989; Walsh and Xu, 2006; Mazin, 2009). 
It is known that single base substitutions contribute to cancer development (Cooper and 
Youssoufian, 1988; Mazin, 1995; Walsh and Xu, 2006), so the age-related accumulation 
of such mutations helps explain why malignant neoplasia is a common cause of death 
among older people (see Figure 1.1). 
Figure 1.5 shows some epigenetics differences between a young (healthy) cell and an 
aged cell. Young cells are characterised by dense methylation of repetitive sequences, 
unmethylated CpG islands of housekeeping genes and high levels of monoacetylated 
Lys16 and trimethylated Lys20 of H4. In contrast, aged cells show lower Cytosine 
methylation in repetitive regions and hypermethylation in promoter regions, together with 
decreased SIRT1 histone deacetylase activity. The resulting changes in gene expression 
and in genome stability lead to a decreased proliferation/lifespan of the cells. 
 
 
 
Figure 1.5. Epigenomes of young and aged cells. White and black circles are 
unmethylated and methylated Cytosines, respectively (adapted from (Fraga and Esteller, 
2007). 
 
Lamin A/C and WRN in Figure 1.5 are proteins involved in the development of two 
“progeroid” syndromes, in which affected patients show clinical features resembling 
premature ageing, such as cataracts, type 2 diabetes, osteoporosis, arteriosclerosis, 
hypogonadism and susceptibility to cancer at young age. 
The lamin A/C gene encodes for lamins A and C - deriving from alternative RNA 
splicings - which are involved in the positioning of subchromosome domains in the 
organisation of chromatin. Hutchinson-Gilford progeria is caused by a point germline 
mutation in this gene (Taddei et al., 2004),  with the direct consequence of nuclear 
disorganization.  
Young Cell Aged Cell 
•Accumulation of cell division 
•Lack of energy restriction 
 
 
•DNA damaging agents 
•Environmental epigenetic modifiers 
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Werner syndrome is caused by an autosomal recessive mutation in WRN gene, which 
encodes a member of the RecQ family helicases, known to be involved in maintaining 
genome stability (Brosh and Bohr, 2002). Werner syndrome patients have defects in DNA 
replication and repair pathways. 
Recently, it has been shown that these syndromes can also be caused by epigenetic 
inactivation of the same genes (Fraga and Esteller, 2007). This is stimulating research 
interest in epigenomic alterations and their relationships with ageing and in the possibility 
of slowing ageing, or reduce its adverse effects, through targeting these age-related 
epigenomics events.  
 
1.6 Dietary Energy Restriction 
The first study aimed to investigate the effect of dietary energy restriction on mammalian 
lifespan was conducted on rats as early as 1935. McCay and colleagues found that 
feeding rats and mice with reduced dietary energy intake, but making sure that the diet 
provided adequate and balanced amounts of all nutrients, prolonged average and 
maximum lifespan of the animals of both sexes by 30%-40% and delayed the onset of 
age-related diseases (McCay et al., 1989). 
Since then, dietary energy restriction (ER) without malnutrition has become a powerful 
and well established tool to study the positive effects that reduced food intake has on 
lifespan, both in lower and in higher eukaryotes.  
ER has been used extensively in longevity studies on Saccharomyces cerevisiae, also 
known as budding yeast, a single-cell organism in which it is easily possible to monitor 
replicative lifespan - the number of daughter cells generated by a mother cell - and 
chronological lifespan - the lifespan of a non-dividing cell. In these studies, dietary 
energy restriction is achieved by diminishing the growing media glucose concentration, 
e.g. down from the usual 2% to 0.05%. Such experiments showed that both replicative 
and chronological lifespan were increased up to 3-fold compared with controls (Lin et al., 
2000; Kaeberlein et al., 2005; Smith et al., 2007; Wei et al., 2008). Starvation by 
substituting the growing media with water doubled the chronological lifespan, but 
affected replicative capacity of the cells (Longo et al., 1997; Wei et al., 2008). 
As reviewed in (Mair and Dillin, 2008), in the nematode worm Caenorhabditis elegans, 
dietary restriction is achieved by removing the bacterial feeding layer (axenic culture), or 
diluting it, and also by genetic manipulations that, for example, introduce defects in the 
pharyngeal pumping capacity and so limits the amount of food intake. Such dietary 
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restriction extends lifespan of C. elegans by 2 to 3-fold compared with controls (Fontana 
et al., 2010). 
In the fruit fly, dietary energy restriction is achieved by diluting the food (Chapman and 
Partridge, 1996; Bass et al., 2007) and it can yield a 2-fold increase in lifespan (Fontana 
et al., 2010). 
In mammals, the most of dietary energy restriction studies have been performed on 
rodents, where this manipulation has increased lifespan by up to 60% and has delayed the 
onset of age-realated diseases (Anderson et al., 2009). However, a reduced dietary energy 
intake has also been demonstrated to have deleterious effects, such as impairment of the 
ability to heal wounds in long term dietary energy restricted mice (Reed et al., 1996) and 
increased susceptibility to infections (Kristan, 2008). Animals genetic background seems 
to play a major role in the response to dietary energy restriction which, in some cases, 
resulted in a shorter lifespan (Swindell, 2012; Liao et al., 2013). 
In primates, a long term study (20+ years) is being conducted on rhesus monkeys and 
recently published results demonstrated that dietary energy restriction of 30% decreased 
age-related mortality (Colman et al., 2009). Dietary energy restricted animals showed a 
lower incidence of neoplasia formation and cardiovascular disease, compared with 
normal fed individuals, and none of them developed diabetes; in addition, reduced 
oxidative damage, inflammation and brain atrophy were observed. However, another 
study conducted on rhesus monkeys showed no significant improvement of survival 
outcomes in dietary energy restricted animals compared with control group animals 
(Mattison et al., 2012). Austad (Austad, 2012) commented on these contrasting results 
suggesting that those could be due to differences in the diet compositions or to the fact 
that in the second study the control group was not fed an ad libitum diet, but a diet which 
would prevent obesity, therefore being partially dietary energy restricted. The author 
suggests that, if this proved true, the effects of dietary energy restriction could be 
beneficial for overweight individuals, but only minimal for people who already maintain 
a healthy body weight. 
For both practical and technical reasons, long-term randomized studies of effects of ER in 
humans have not been carried out. However, there have been a number of short-term 
studies of dietary energy restriction in humans. For example, Fontana and colleagues 
reported that adults from both sexes exposed to dietary energy restriction lasting 1 or 6 
years showed lower serum levels of atherosclerosis risk factors, such as LDL cholesterol, 
ratio total cholesterol/HDL cholesterol, triglycerides and fasting glucose and insulin 
(Fontana et al., 2004; Fontana et al., 2007). In the latter study, the authors concluded that 
23 
 
20% dietary energy restriction has the same beneficial effects in lowering levels of 
atherosclerosis risk factors as a 20% increase in energy expenditure. Both interventions 
were found to decrease the amount of oxidative damage to DNA and RNA in white blood 
cells.  
The CALERIE project (Comprehensive Assessment of Long-Term Effects of Reducing 
Calorie Intake) has concluded Phase I with three pilot studies in which healthy and non-
obese subjects were subjected to 6 to 12 months of 20-25% dietary energy restriction; 
results were similar to those reported by Fontana and colleagues (Racette et al., 2006; 
Heilbronn et al., 2006; Rochon et al., 2011; Meydani et al., 2011). 
Members of the Caloric Restriction Society (CRS) showed, together with lower serum 
levels of atherosclerosis factors, also lower plasma level of TNFα, a proinflammatory 
cytokine (Fontana et al., 2004; Holloszy and Fontana, 2007). Interpretation of these 
results is not straight forward because members of the CRS are self-selected and the 
apparent effects of dietary energy restriction may be confounded by other lifestyle 
factors,  notably physical activity and smoking behavior, and/or by genetic factors, which 
may influence willingness to join the CRS. 
Recent studies have correlated the Body Mass Index (BMI, a measure of general 
adiposity based on an individual's weight and height) to mortality and found that the latter 
was lowest at BMI included between at about 22.5–25, while it increased in a direct 
proportional manner at BMIs higher than 25 and in an inverse proportional manner at 
BMIs lower than 22.5, mainly due to smoking-related diseases (Prospective Studies et al., 
2009). Maintaing a healthy body weight throughtout life might therefore help reducing 
the risk of age-related diseases; this can be achieved by eating a balanced diet and 
practising regular exercise (Handschin and Spiegelman, 2008). 
 
1.6.1 Molecular mechanisms of dietary energy restriction-mediated increased lifespan 
Age-related changes seem to be tissue specific (Anderson and Weindruch, 2010); 
nonetheless there are some that seem to play a pivotal role in the synchronization of the 
ageing process at a whole organism level (Zahn et al., 2007). Dietary energy restriction 
counteracts the most common ones, such as increased expression of genes involved in the 
immune and inflammatory responses and mitochondrial dysfunction (Park and Prolla, 
2005; de Magalhaes et al., 2009).  
Many pathways and molecular mechanisms have been suggested to be mediators of this 
action and of the resulting extended and healthier lifespan; so far, the most characterized 
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ones are the TOR signalling pathway, the IGF/insulin pathway, adiponectin expression 
and epigenetics mechanisms - DNA methylation and histone acetylation/deacetylation 
and miRNA expression, as reviewed by (Ribaric, 2012) -. DNA methylation will be 
discussed in Chapter 1.6. 
Figure 1.6 summarizes the engagement of the TOR and IGF1 signalling pathways in 
various organisms subjected to dietary energy restriction. 
 
 
Figure 1.6. Nutrient signalling pathways involved in the dietary energy restriction-
mediated lifespan extension in lower and higher eukaryotes. From (Fontana et al., 2010). 
 
TOR signalling pathway and its ageing promoting action is conserved in yeast, worms, 
flies and mice (Fontana et al., 2010); this pathway is a master regulator of protein 
synthesis, contributing to cell growth and proliferation (Hay and Sonenberg, 2004).  
Reduced levels of cellular aminoacids, as it occurs under dietary energy restriction 
conditions, inhibit TOR activity and promote a longer lifespan, partially by increasing 
autophagy (Yen and Klionsky, 2008).  
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In yeasts, the inhibition of the TOR signalling pathway and the resulting inactivation of 
its downstream target SCH9  have been linked to extented lifespan, which correlates with 
altered protein synthesis (Kaeberlein et al., 2005; Powers et al., 2006). 
In mammals, mTOR (mechanistic TOR, formerly mammalian TOR) forms two big 
protein complexes, named mTORC1 and mTORC2. mTORC1 is the most known one and 
acts as a stress sensor: when conditions of nutrient depletion (Blommaart et al., 1995), 
energy decrease or hypoxia (Inoki et al., 2003) or growth factors unbalance occur within 
the cells, mTORC1 becomes inactivated and unable to phosphorylate its numerous 
effectors, as reviewed in (Laplante and Sabatini, 2012). The same effects are seen when 
the complex is genetically targeted, as in the case of deletion of TOR1 in yeasts 
(Kaeberlein et al., 2005; Powers et al., 2006; Wei et al., 2008) or pharmacologically 
targeted with rapamycin (Powers et al., 2006) again in yeasts, but also in mice (Harrison 
et al., 2009). In this latter study, rapamycin fed mice showed a slower ageing rate 
compared with control, which was associated with decreased tissue degeneration. 
Although the downstream effector responsible in modulating ageing is still unknown, it 
has been observed that reduction in the activity of S6K1 is correlated with an increase in 
lifespan of various species (Kapahi et al., 2010) and that overexpression of 4E-BP1 
extends lifespan in flies under normal diet conditions, while its loss does not extend it 
under a dietary energy restriction regimen (Zid et al., 2009). As reviewed in (Kapahi et 
al., 2010) the effect of these mediators is believed to be due to the impairment of the 
translational process.  
Rapamycin has also been shown to decelerate cellular senescence and to be able to 
reverse the senescence phenotype in human and rodents cell lines (Demidenko et al., 
2009), thus reinforcing the existence of a link between cellular senescence and ageing; 
further confirmations arise from studies showing that dietary energy restriction - which 
usually extends lifespan and delays age-related diseases onset - inhibits cellular 
senescence in vivo (Wang et al., 2009).  
 
The insulin/IGF1 signalling pathway seems to be another evolutionarily conserved 
mediator of the beneficial effects of dietary energy restriction on longevity. Studies in 
worms have shown that a reduced activity of this pathway, which could be achieved by 
diminishing food intake, increases lifespan, as it does in flies and rodents  (Johnson, 
2008; Piper et al., 2008; Bartke, 2005). However, in humans dietary energy restriction has 
not been demonstrated to decrease IGF1 serum levels without being combined to a 
restriction of the protein intake (Fontana et al., 2008).  
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IGF1 and insulin inhibit a class of transcription factors termed FOXOs (forkhead box O) 
by translocating them from the nucleus through various insulin receptor substrates (IRS) 
and kinases (PDPK1, PTDINS-3K); FOXOs control several cellular functions such as cell 
cycle, apoptosis, differentiation and the expression of DNA repair related genes and genes 
involved in the stress response, therefore their up-regulation is considered one of the 
mechanism through which dietary energy restriction mediates lifespan increase (Qin et 
al., 2008).  
Nonetheless, although low levels of IGF1 and mutations of the IGF1 receptor gene are 
associated with longevity in humans (Bonafe et al., 2003; Suh et al., 2008), there is 
increasing evidence that the insulin/IGF1 signalling pathway inhibition could be only a 
secondary cell response towards increased lifespan dietary energy restriction mediated: in 
fact, GHRKO (Growth Hormone Knock Out) mice showed only a minimal extension of 
lifespan (and only females) when subjected to dietary energy restriction in comparison 
with ad libitum fed mice controls (Bonkowski et al., 2006), corroborating the hypothesis 
that GH signalling could be crucial to delayed ageing in mammals, with the inhibition of 
the Insulin/IGF1 pathway being only its secondary effect (Brown-Borg and Bartke, 
2012).  
 
Adiponectin is a hormone secreted by adipocytes of the white adipose tissue; it has been 
shown to promote fatty acid oxidation within this tissue and to reduce the accumulation of 
lipids in other tissues (Zhu et al., 2007). It is also implicated in the control of glucose 
metabolism and thus it suppresses metabolic perturbations which could lead to the 
development of some age-related diseases, such as obesity, type 2 diabetes, 
atherosclerosis and metabolic syndrome (Ukkola and Santaniemi, 2002; Diez and 
Iglesias, 2003; Renaldi et al., 2009). Adiponectin plasma levels are inversely correlated to 
the amount of body fat in adults (Ukkola and Santaniemi, 2002; Meier and Gressner, 
2004), so that under dietary energy restriction regimen, an increase of its plasma 
concentration is observed (Shinmura et al., 2007). High levels of circulating adiponectin 
stimulate AMPK, which, in turns, favours mitochondrial biogenesis and energy 
production (Civitarese et al., 2006). The beneficial effects of the adiponectin increased 
plasma levels are also mediated by the inhibition of proinflammatory cytokines, such as 
TNFα (Fernandez-Real et al., 2003; Aldhahi and Hamdy, 2003; Ouchi et al., 2003); in 
fact, at least two different dietary energy restriction studies conducted in humans have 
demonstrated decreased serum or plasma levels of C-reactive protein (an inflammation 
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positive acute-phase protein) of the subjects compared with controls (Fontana et al., 2004; 
Fontana et al., 2007). 
 
Histone modifications play a major role in the regulation of chromatin structure, 
rendering it more or less accessible to transcription factors and thus regulating gene 
expression (Clayton et al., 2006). Histone acetylation/deacetylation are among the most 
studied histone modifications and they’re carried out by histone acetyltransferases 
(HATs) and Histone deacetylases (HDACs), two classes of enzymes which transfer an 
acetyl group from the acetyl CoA coenzyme or remove it, respectively.  
Dietary energy restriction increases HDAC activity in human cell culture models and this 
is associated with expression changes of p16
INK4α 
and hTERT (Meyerson et al., 1997; 
Kanaya et al., 1998; Li et al., 2010). SIRT1, a class III NAD
+
 dependent histone 
deacetylase, is thought to have a main role in mediating the increase in lifespan under 
dietary energy restriction conditions: its expression has been shown to increase in rats 
subjected to dietary energy restriction (Guarente and Picard, 2005) and this is likely due 
to inhibition of p53 and FOXOs, which ameliorate cellular stress resistance (Luo et al., 
2001; Langley et al., 2002; Brunet et al., 2004; Motta et al., 2004) and also by regulation 
of PGC-1α, a known regulator of mitochondrial biogenesis (Vega et al., 2000; Schilling et 
al., 2006). Interestingly, SIRT1 is able to deacetylate also non-histone substrates 
(Guarente and Picard, 2005; Wakeling et al., 2009) as in the case of p53 (Luo et al., 2001; 
Langley et al., 2002; Vaziri et al., 2001) and FOXO proteins (Brunet et al., 2004; Motta et 
al., 2004), hence directly impairing apoptosis and senescence. 
 
Given their high number of targets, miRNAs are being studied to understand their 
implications in the modulation of the ageing process through gene expression regulation. 
Figure 1.7 presents a summary of the known miRNAs that regulate genes belonging to 
the high conserved ageing pathways discussed above. 
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Figure 1.7. miRNAs involved in the regulation of conserved ageing pathways genes. 
Adapted from (Grillari and Grillari-Voglauer, 2010). 
 
Dietary energy restriction has been shown to change expression levels of some miRNA in 
mice, which correlated with the reduction of risk factors for age-related diseases: a recent 
genome-wide study conducted on murine serum identified circulating miRNAs belonging 
to pathways relevant to ageing and whose serum levels were increased with age and 
decreased by ER (Dhahbi et al., 2013). Another study showed that miR-203 increased in 
dietary energy restricted mice breast tissue, thus decreasing expression of two proteins 
involved in tumourigenesis and invasiveness, i.e. CAV1 and p63 (Orom et al., 2012). A 
further example is the decrease in the BCL2-targeting miR30, miR34a and miR-181a 
observed in the brain of dietary energy restricted mice; the resulting increase in BCL2 
expression and decrease in the activity of BAX and Caspases 3 and 9, which are 
associated with a reduction in apoptosis (Khanna et al., 2011), could slow down the onset 
and progression of neurodegenerative diseases, indeed characterized by high expression 
of both BAX and Caspase 3 (Paradis et al., 1996; Louneva et al., 2008). 
 
Anderson and colleagues have proposed a model which integrates the contributions of all 
the above discussed molecular mechanisms (and DNA methylation, discussed in the next 
section) in mediating the increase of lifespan through dietary energy restriction (Figure 
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1.8). In essence, it is proposed that cells respond to the diminished food (and energy) 
intake by activating master regulators within nutrient-sensing pathways which drive a 
shift in energy metabolism, decreasing the rate of ageing hence securing longevity 
(Anderson et al., 2009). 
 
 
 
Figure 1.8. Model of interaction between nutrient-sensing pathways in response to 
dietary energy restriction. From (Anderson et al., 2009). 
 
1.6.2 Dietary modulation of the epigenome 
Diet can modulate the epigenome, as reviewed in (McKay and Mathers, 2011).  
Between the dietary components that are able to mimic the effects of dietary energy 
restriction, resveratrol (3,5,4'-trihydroxy-trans-stilbene) has been identified as the most 
potent enhancer of SIRT1 (a deacetylase) in vitro (Howitz et al., 2003). It has been shown 
to extend lifespan of various invertebrate and vertebrate species - S. cerevisiae, C. 
elegans, D. melanogaster and N. furzeri (Howitz et al., 2003; Wood et al., 2004; 
Viswanathan et al., 2005; Baur et al., 2006; Valenzano et al., 2006) - and to revert the 
effects of a high-fat diet in mice, inducing effects associated with a healthier lifespan, 
such as increased insulin sensitivity, reduced insulin-like growth factor-1 (IGF-I) levels, 
increased AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated 
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receptor-γ coactivator 1α (PGC-1α) activity, increased mitochondrial number, and 
improved motor function (Baur et al., 2006). However, no change in levels of free fatty 
acids and cholesterol or effects on lifespan were observed when comparing the control 
mice group with the high-fat diet group. Other studies on mice have confirmed the lack of 
resveratrol-dependent improval on lifespan (Pearson et al., 2008; Miller et al., 2011). 
Studies in humans have demonstrated the positive effects on insulin and metabolic 
functions (Crandall et al., 2012; Timmers et al., 2011).  
The effects of resveratrol on longevity in higher-order animals may not be apparent in 
complex organisms due to experimental factors or because the effects of dietary energy 
restriction involve several degrees of interactions other than the one activated by 
resveratrol alone (Hector et al., 2012).    
 
1.7 DNA methylation and dietary energy restriction 
As already outlined in section 1.5, generally there is a global demethylation and a local 
hypermethylation within ageing tissues. Diet can greatly influence those aberrant patterns 
and beneficial effects have already been demonstrated for folate and vitamin B12,  
choline, as reviewed by (McKay and Mathers, 2011) and by dietary energy restriction, as 
reviewed by (Li et al., 2011). In particular, dietary energy restriction exerts its ageing-
delaying action increasing genome stability (Vaquero and Reinberg, 2009; Munoz-Najar 
and Sedivy, 2011) by reverting age-related aberrant methylation patterns (or preventing 
them) at specific genomic loci, rather than globally (Munoz-Najar and Sedivy, 2011). 
Examples of genes promoters in which those changes are seen include age-related and 
cancer-related genes promoters, thus reinforcing the importance of a healthy diet in the 
prevention and in the onset delaying of age-related diseases and ageing itself. 
Dietary energy restriction was shown to increase promoter methylation of the proto-
oncogene H-ras in rats pancreas compared with ad libitum fed controls, thus decreasing 
gene expression (Hass et al., 1993); the same hypermethylation/down-regulation has been 
seen for the tumour suppressor and ageing/senescence associated gene p16
INK4A 
in an in 
vitro model (Li et al., 2010; Li and Tollefsbol, 2011). Two recent studies have identified 
three human genomic loci in which DNA methylation significantly changes after short 
dietary energy restriction regimens; these are the promoters of the genes ATP10, WT1 
(Milagro et al., 2011) and TNFα (Campion et al., 2009), which have been proposed as 
early indicators for dietary energy restriction response. 
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1.8 Mitochondrial DNA (mtDNA) and mtDNA methylation 
Mitochondria are small size organelles often referred to as the cell “power plants”: 
they’re in fact responsible for the production of ATP, the cells main energy, through a 
process called oxidative phosphorylation.  
Mitochondria have their own genome, called mitochondrial DNA (mtDNA), which is a 
small, circular, double-stranded DNA molecule, that replicates independently from the 
nuclear genome and shows some peculiarities, such as a complete maternal inheritance in 
vertebrates (with few exceptions) (Giles et al., 1980) and the use of alternative start 
codons to the conventional AUG: AUA and AUU are common in humans, while AUA, 
AUU and AUC are common in mice, as reviewed by (Osawa et al., 1992) and (Jukes and 
Osawa, 1993).  
MtDNA molecules are composed of a light strand (C rich) and a heavy strand (G rich), 
which are both transcribed to produce polycistronic RNAs and replicate starting from a 
triple-stranded structure called D-Loop, which constitutes the origin of replication 
(reviewed by (Shadel and Clayton, 1997)). They are organized in clusters, in the so called 
nucleoids, which are devoid of histones (Satoh and Kuroiwa, 1991). 
Despite the high numbers of proteins required for mitochondrial functions, only 13 of 
them are encoded by the mitochondrial DNA; those are polypeptidic components of the 
oxidative phosphorylation chain, the main metabolic pathway involved in ATP 
production. The other genes featured in this small molecule encode for 22 transfer RNAs 
and for the small and large subunit of the ribosomal RNA (Anderson et al., 1981). 
MtDNA is of particular interest in the context of ageing studies because spontaneous 
deletions in its sequence have been observed to arise with normal ageing, especially in 
postmitotic tissues, such as brain, skeletal muscle and heart (Cortopassi et al., 1992; 
Corral-Debrinski et al., 1992; Simonetti et al., 1992; Meissner et al., 2008). These 
deletions are also found in the substantia nigra of Parkison’s disease patients, leading to 
the hypothesis that the resulting mitochondrial defect and bioenergetics unbalance could 
be causal for the development of the disease (Bender et al., 2006; Kraytsberg et al., 2006).  
As it happens in the nuclear genome, CpG sites are underrepresented and not evenly 
distributed in both human (Figure 1.9) and murine mitochondrial genome (Chinnery et 
al., 2012). 
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Figure 1.9. Organization of the human mitochondrial genome (centre) and distribution of 
CpG sites in its context (black outer ring). The intermediate red ring shows positions and 
relative frequencies of mtDNA variants. OH = heavy strand origin of replication; OL = 
light strand origin of replication; PH = heavy strand promoter site; PL = light strand 
promoter site (from (Chinnery et al., 2012)). 
 
The first evidence of the existence of methylated Cytosines within mtDNA molecules 
came from an in vitro study conducted on a mouse cell culture model, in which the 
authors detected very low levels of global mtDNA methylation (between 3% and 5%) 
(Pollack et al., 1984). In a more recent publication, the four main regulatory regions 
within the human mtDNA have been analysed - the transcription termination region 
(TERM) within the tRNA
Leu(UUR)
, the heavy and light strand promoters (HSP and LSP) 
and the origin of replication of the light strand (OL) - and have been found to be protected 
from methylation during in vitro methylation assays performed with prokaryotic DNA 
methyltransferases (Rebelo et al., 2009). The authors noticed an inverse correlation 
between methylation rate and protein occupancy and concluded that DNA regions 
associated to proteins (including transcription factors) are less accessible to DNA 
methyltransferases and therefore protected from methylation, seemingly being 
transcriptionally active (Rebelo et al., 2009). Although mtDNA methylation has been 
investigated and demontstrated in other studies, both in humans and rodents (Nass, 1973; 
Shmookler Reis and Goldstein, 1983; Pollack et al., 1984; Hecht et al., 1984; Maekawa et 
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al., 2004), it was not until recently that there’s been proof of the existence of a 
mitochondrial isoform of DNMT1, which is able to bind mtDNA and methylate it (Shock 
et al., 2011). In this study, the authors concluded that, as DNMT1 is the only DNMT 
present in human and mice mitochondria, this must also have de novo methylase activity, 
contrary to what previously believed by the scientific community. 
Albeit some studies have demonstrated the inefficacy of aberrant mtDNA methylation 
patterns as markers for cancer diagnosis and prognosis (Maekawa et al., 2004), new 
technologies pave the way to more precise quantification of DNA methylation, so it is 
possible that this opinion could be reversed in the future. 
  
1.9 Methodology 
A wide number of laboratory techniques have been developed to study DNA methylation 
and nowadays it is possible to focus on specific DNA regions and to carry out genome-
wide analysis. 
The principles upon which these techniques are based include the following: 
 
 separation of Cytosines and 5mC according to their different size; 
 use of restriction enzymes: a methyl-sensitive restriction enzyme is used to digest 
unmethylated CpGs, enriching for methylated DNA sequences;  
 bisulphite conversion: bisulphite treatment selectively deaminates unmethylated 
Cytosines to uracils; 
 affinity purification: an antibody or a methyl-binding protein that recognize 5-
methylcytidine is used to immunoprecipitate the methylated fraction of the 
sample. 
 
1.9.1 Quantification of Global DNA Methylation in Mammals 
One of the first methods for detecting global methylation in mammalian genomes is 
HPLC (High Performance Liquid Chromatography) after DNA digestion into single 
nucleotides. The chromatography column contains a stationary phase which separates 
each nucleotide according to its size; Cytosines, which are lighter than 5mCytosines will 
be therefore eluted earlier. The instrument produces a real time graph with peaks 
corresponding to the different nucleotides; in addition, the area of each peak is 
proportional to its content in the original sample (Kuo et al., 1980). 
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This method is highly quantitative and reproducible, but it requires large amounts of 
starting material (DNA) and it does not give any indication about the location of the 
methylations in the genome analysed. 
 
Three more common methods for global methylation quantification take advantage of the 
fact that the majority of methylated CpG sites in mammalian genomes resides in 
repetitive regions; therefore, quantifying them can give an estimate of the overall 
methylation content of the sample analysed. 
The first step of the Alu and LINE-1 assays for human DNA (Yang et al., 2004) and of 
the B1 assay for mouse DNA (Jeong and Lee, 2005) is the bisulphite conversion of the 
DNA (Clark et al., 1994) (Figure 1.10), followed by PCR of the bisulphite modified 
DNA: 
 
 
 
Figure 1.10. Deamination of Cytosine to Uracil, which is commonly termed Bisulphite 
Conversion, as it is carried out in the presence of Sodium Bisulphite. 
 
In the Alu and LINE-1 methods, the changes in the BM-DNA PCR products are 
investigated by Pyrosequencing (Ronaghi et al., 1996) or by means of MboI and HinfI 
restriction enzymes, which cut only methylated Cytosines. The digestion products are 
loaded on polyacrylamide gel and analyzed by densitometry: the ratio between the 
intensity of the bands is the ratio methylated: unmethylated CpG sites. This last part of 
the method has previously been used for studying methylation at specific loci and it is 
known as COBRA (Combined Bisulphite Restriction Analysis) assay (Xiong and Laird, 
1997). 
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In the original B1 assay (Jeong and Lee, 2005), after bisulphite modification, a 
methylation specific PCR (MSP) is performed: two couple of primers are designed to 
amplify either the unconverted (methylated) or the converted (unmethylated) DNA, so 
that it is possible to estimate the ratio between methylated and unmethylated Cytosines by 
densitometry on the resulting PCR products (Herman et al., 1996). PCR products can also 
be analysed by Pyrosequencing to obtain a more quantitative measurement. 
 
Compared with HPLC, PCR based methods are less expensive and require a minimal 
amount of starting material, but they do provide only approximate methylation levels.  
 
The LUMA assay (Karimi et al., 2006a; Karimi et al., 2006b) is based upon the use of the 
isoschizomeres MspI and HpaII, which recognise the same sequence (CCGG), but cut in 
different ways according to its methylation state: MspI cuts the sequence regardless of 
methylation status whereas HpaII cuts only at sites where the internal C is not 
methylated. The digestions are run in parallel on the same sample and then loaded in a 
Pyrosequencer. In the instrument, a known sequence of nucleotide is dispensed and 
luciferin is converted to light in a proportional amount to the number of cuts that each 
enzyme has done. 
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Figure 1.11. Steps involved in the LUMA assay (adapted from (Karimi et al., 2006b). 
 
1.9.2 Detection and Quantification of Site Specific Methylation  
Several methods have been developed to assess the methylation state of specific DNA 
loci and nowadays it is possible to test several of them in once and even performing 
genome-wide methylation analysis. 
The COBRA (COmbined Bisulfite Restriction Analysis) assay, already described briefly 
above, can be used to test a specific sequence. In brief the assay involves the preparation 
of bisulphite modified DNA, amplification and then cutting with a methyl sensitive 
enzyme. After electrophoresis on Ethidium Bromide acrilamyde gel, the percentage of 
fully methylated restriction sites can be calculated from the brightness ratio between the 
cleaved PCR product and the total amount of PCR product.  
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Figure 1.12. Outline of the COBRA assay (from (Xiong and Laird, 1997). 
 
Pyrosequencing is a technology based upon sequencing by synthesis (Ronaghi et al., 
1996). 
In the context of DNA methylation studies, it can be used to detect and quantitate 
bisulphite converted and unconverted Cytosines using a biotin labelled sequencing 
primer. The primer is hybridized to the single-stranded bisulphite treated template, and 
incubated with the enzymes (DNA polymerase, ATP sulfurylase, luciferase, apyrase) and 
the substrates (adenosine 5' phosphosulfate or APS and luciferin). 
When the first complementary dNTP is added to the reaction mixture, DNA polymerase 
catalyzes its incorporation into the DNA strand. Each incorporation event is accompanied 
by release of pyrophosphate (PPi) in a quantity equimolar to the amount of incorporated 
nucleotide. 
ATP sulfurylase converts PPi to ATP in the presence of APS; this reaction drives the 
luciferase-mediated conversion of luciferin to oxyluciferin, which generates visible light 
in amounts that are proportional to the amount of ATP. The light produced is then 
detected by a camera and seen as a peak in a graph called Pyrogram. The height of each 
peak (light signal) is proportional to the number of nucleotides incorporated. 
Apyrase continuously degrades unincorporated nucleotides and ATP. When degradation 
is complete, another nucleotide is added. 
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Figure 1.13. Steps of the Pyrosequencing technology. 
 
 
 
Figure 1.14. Example of a DNA Pyrogram. 
 
In the MeDIP (Methylated DNA ImmunoPrecipitation) technique (Weber et al., 2005; 
Weber et al., 2007), total genomic DNA is sonicated into fragments, which are then 
immunoprecipitated with an antibody that recognises 5’-MethylCytidine. The starting 
sample, called Input, contains both methylated and unmethylated fragments, while the 
MeDIP sample mainly contains methylated fragments. 
After the IP reaction, the two samples can be labelled with different dyes and co-
hybridized as a two colour experiment array containing a very large number of probes. In 
this way it is possible to have a genome-wide assessment of methylation status. Samples 
can also be analysed with specific primers in PCR or by Real Time PCR to calculate the 
relative enrichment of a specific sequence between the MeDIP and its relative Input. 
This technique will be described in further details in Chapter 4 – Standardization and 
quality control for the Methylated DNA Immunoprecipitation technique -. 
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Figure 1.15. Different molecular biology techniques used in the analysis of methylated 
versus unmethylated DNA sequences after affinity enrichment. 
 
Several other methods for DNA methylation quantification have been developed from 
previously established ones; between those  
 
 the MethylLight technique (Eads et al., 2000): a variation of the MSP in which 
Real Time PCR is used for methylation quantification of the samples under 
investigation; 
 the Methyscreen technique (Holemon et al., 2007): an assay that utilizes a 
combined restriction from both methylation-sensitive restriction enzymes 
(MSREs) and methylation-dependent restriction enzymes (MDREs), followed by 
qPCR; 
 cloning and sequencing of BM-DNA PCR products (Frommer et al., 1992): BM-
PCR product are cloned into a vector, transfected, grown with a selection 
antibiotic and single clones are sequenced. This method allowes for allele-specific 
methylation quantification if a sufficient numbers of clones are sequenced; 
 MALDI-TOF Mass Spectrometry of BM-DNA PCR products (Ehrich et al., 
2005): in this method a region of interest is amplified with primers containg a T7 
RNA polymerase tag, in vitro translated with T7 polymerase and subsequently cut 
with a ribonuclease; the digestion products  are then quantified in a mass 
spectrometer; 
DNA MicroArray 
MeDIP Input 
PCR 
qPCR 
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 Restriction Landmark Genome Scanning (RLGS) (Costello et al., 2002): this 
technique uses a mixture of methyl-sensitive restriction enzymes and then 
radioactive labelling of the genomic DNA under investigations, followed by a 
two-dimensional electrophoresis of the labelled restriction fragments, and allows 
for the methylation quantification of several (thousands) CpG sites at a time; 
 Methylation-Specific Digital Karyotyping (MSDK) (Hu et al., 2005): methylation-
sensitive enzymes are used to cut genomic DNA and the resulting fragments are 
then sequenced and mapped to the genome; this technique requires large amounts 
of DNA; 
 libraries construction (Rollins et al., 2006): in this method, genomic DNA is cut 
either with a methyl-sensitive enzyme or a methyl-independent enzyme to produce 
fragments which are ligated into a plasmid, tranformed into E. coli to obtain 
colonies which will be sequenced; 
 direct sequencing: various algorithms have been developed for the analyses of 
BM-PCR products sequenced directly with the Sanger method (Sanger and 
Coulson, 1975), allowing for rapid screening of multiple CpG sites in sequences 
of DNA which can go up to 500-600 bp; a few examples are: (Jiang et al.; Lewin 
et al., 2004; Leakey et al., 2008); 
 Methylation-sensitive High Resolution Melting (MS-HRM) (Wojdacz and 
Dobrovic, 2007): this method apply the use of High Resolution Melting 
technology post-qPCR to detect methylation levels as low as 0.1%. 
 
Figure 1.16 summarizes the most common methods for the study of DNA methylation. 
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Figure 1.16. Summary of the most common methods for the study of DNA methylation. 
HPLC = High Performance Liquid Chromatography; RLGS = Restriction Landmark 
Genomic Scanning; MSP = Methyl Specific PCR (modified from (Shen and Waterland, 
2007). 
 
1.10 Aims and objectives of the study 
The aim of this project was to characterise the changes in DNA methylation which occur 
in cellular senescence, during ageing and in response to dietary energy restriction; the 
human cell line MRC-5 and various tissues from ageing and dietary energy restricted 
mice were used to this purpose. Specific objectives for the study were: 
 
Objective 1: measurement of global 5’-mC methylation level and assessment of 
DNMTs/Dnmts gene expression in senescence, ageing and dietary energy restriction 
conditions. Methylation studies were conducted using an ELISA-based assay, BM 
followed by PCR of repetitive regions (human LINE-1, murine B1 element), the LUMA 
assay and HPLC, while gene expression studies were conducted using RT-qPCR (Chapter 
3). 
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Objective 2: Establishment and validation of the MeDIP technique for whole genome 
DNA methylation studies (Chapter 4). 
Objective 3: Characterisation and quantification of  genome-wide promoter methylation 
and of gene expression in replicative senescent and premature senescent compared with 
young replicative MRC-5 human lung fibroblasts using the MeDIP technique and BM-
PCR followed by pyrosequencing for methylation studies and RT-qPCR for gene 
expression studies (Chapter 5).  
Objective 4: Comparison of genome-wide promoter methylation in heart and liver from 
young and ageing mice and assessement of the impact of dietary energy restriction (ER) 
in mice on genome-wide promoter methylation in liver using the MeDIP technique 
(Chapter 6). 
Objective 5: Quantitative analysis of  DNA methylation in selected mitochondrial 
genomic regions in i) DNA from replicative senescent and premature senescent compared 
with young replicative MRC-5 human lung fibroblasts, ii) liver from ageing mice vs their 
young counterparts and iii) liver from dietary energy restricted mice vs liver from ad 
libitum fed mice using BM-PCR followed by direct sequencing (Chapter 7). 
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Chapter 2. Materials and Methods 
 
2.1 Cell culture 
MRC-5 human lung fibroblasts (Jacobs et al., 1970) (ATCC, CCL-171) and LN-229 
human glioblastoma epithelial cells (ATCC, CRL-2611) were cultured at 37°C in 5% 
CO2 atmosphere in DMEM High Glucose Medium (Gibco) supplemented with 10% Fetal 
Bovine Serum (FBS; Lonza), 100 U/mL Penicillin and 100 µg/mL Streptomycin 
(Mediatech). Culture media was replenished every 3 to 4 days. When confluent, cells 
were washed with Phosphate Buffer Saline (PBS; Mediatech; 17 mM KH2PO4, 5 mM 
Na2HPO4, 150 mM NaCl, pH 7.4) and trypsinized for 5 minutes at 37°C. Trypsin was 
neutralized with 2 volumes of complete media, cells collected into a polypropylene 
conical tube, centrifuged at 500 x g for 5 minutes at room temperature and subcultured at 
a ratio of 1:4 with fresh medium. Cell stocks were prepared resuspending 3 x 10
6
 cells in 
1 mL of freezing solution (DMEM medium containing 60% of FBS and 10% DMSO), 
storing for at least one day at -80° C and then transferring in liquid nitrogen for future 
use. When needed, cells were thawed in 37° C warm water, resuspended in 5 mL of 
complete medium, centrifuged and cultured with fresh medium.  
Cell cultures were tested periodically for mycoplasma contamination by PCR using the 
Bioo Scientific Mycoplasma Primer Sets. Primer set A amplified a 569 bp conserved 
region of M. orale, M. salivarium, M. hominis, M. hyorhinis, M. fermentans, M. 
gallisepticum and A. laidlawii; primer set B amplified a 698 bp conserved region of M. 
genitalium, M. hyponeumoniae and M. flocculare. To prepare the PCR templates, 500 µL 
of conditioned media were centrifuged at 800 g for 5 minutes and transferred 400 µL of 
the supernatant to another tube; after a second centrifugation step at 12000 rpm, 10 
minutes, 4° C, 350 µL of the supernatant were discarded. The remaining 50 µL were 
diluted 1:2 with water and 5 µL were used for PCR in a final volume of 25 µL with 300 
nM final concentration of  either primer set A or B and Maxima Hot Start PCR Master 
Mix (Fermentas). Reaction conditions were as follows: 
 
95° C, 4 minutes 
95° C, 30 seconds 
55° C, 30 seconds 
72° C, 1 minute 
72° C, 10 minutes. 
35 cycles 
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PCR products were loaded in 1% agarose/TBE gel with 0.4 µg/mL of Ethidium Bromide 
and PCR products analyzed. Cell lines that showed positive in at least one of the reactions 
were discarded and a new aliquot of cells was thawed and kept in culture. 
To compare replicating cells with premature senescent cells and replicative senescent 
cells, without cell cycle bias, 100% confluent cells were harvested after 30 population 
doublings (Young Confluent samples, YC). Premature senescent cells were prepared by 
irradiating subconfluent cells with 20 Gy of γ-radiation and harvesting after 48 hours 
(early stress-induced premature senescent samples, ESIPS samples); replicative senescent 
cells were prepared by culturing cells until they reached the Hayflick limit (Hayflick, 
1979) (Replicative Senescent samples, RS). Growth curves were produced counting the 
average number of cells in three 1 mm
2
 cells of an improved Neubauer haemocytometer 
and applying the formula in (Lawless et al., 2010) to calculate the cells population 
doublings. 
For all downstream applications, cell pellets were washed 3 times with cold PBS, 
centrifuged at 800 x g for 5 minutes and stored at -80°C until use. 
 
2.1.1 Beta Gal senescence associated assay 
Cells were plated in 12 wells plates containing round sterile cover glasses and allowed to 
settle for 2 days. The Senescence β-Galactosidase Staining Kit (Cell Signaling) was used 
as follows: growth medium was removed, cells were rinsed twice with PBS and fixed 
with 500 µL of Fixative Solution 1x (2% formaldehyde, 0.2% glutaraldehyde in PBS) for 
15 minutes at room temperature. After 2 rinses with PBS, 500 µL of β-Galactosidase 
Staining Solution (465 µL 1x Staining Solution, 5 µL Staining Supplement A and B, 25 
µL of X-gal 20 mg/mL in DMF, pH 6) were added and plates were incubated at 37° C in 
a dry incubator for 4 to 6 hours and monitored frequently for the development of blue 
colour. Cover glasses were mounted and the slides were counterstained with DAPI on 
frosted slides with Vectashield Mounting Medium with DAPI (1.5 µg/mL, Vector 
Laboratories) and photographed using a UV-visible light microscope.  
 
2.2 Sampling of mouse tissues 
Heart and colon tissues were obtained from male C57Bl/6 mice aged 3 and 32 months 
old; livers were collected from male ICRFa mice at 7, 17 and 30 months of age fed ad 
libitum fed (AL) and from male mice at 17 months of age that were dietary energy 
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restricted (ER) by feeding 60% of food relative to the AL animals for the last three 
months of their life (Cameron et al., 2011). ICFRa mice are a long-established sub-strain 
of C57Bl/6, which had been selected for use in studies of intrinsic ageing because it is 
free from specific age-associated pathologies and thus provides a good general model of 
ageing (Rowlatt, 1979). Some of the ICRFa animals acquired MHV seropositivity which, 
in the opinion of the unit’s veterinarian, was due to transient cross-infection from another 
imported stock. No significant symptoms of active infection were noted in the aged 
animals and there was no indication of lesions in the liver or gut upon dissection. 
Furthermore, in spite of the seropositivity, longevity did not appear to have been 
compromised (data not shown). I used only the distal part/rectum of the colon because it 
appears to less affected by the virus in asymptomatic infections (Baker, 1998). Three 
animals per group were killed by neck dislocation, colons were flushed with PBS and cut 
in half, livers were divided into lobes and heart dissected as a whole. 
Tissues were snap-frozen in liquid nitrogen and then kept at -80’C. To ensure 
representative tissue sampling and to help with tissue lysis, the frozen tissues were 
pulverized using a mortar and a pestle cooled in liquid nitrogen.  
 
2.3 Genomic DNA (gDNA) extraction 
Cell pellets (1 to 5 x 10
6
) and ground samples (10 to 50 mg) were digested overnight at 
56° C in 500 µL of the following solution: 
 
50 mM Tris HCl (pH = 8) 
12.5 mM EDTA 
0.5% SDS 
0.03 U/µL Proteinase K (Fermentas).  
 
Lysates were then mixed with one volume of a solution 24:1 chloroform: isoamyl alcohol 
(Sigma Aldrich) and centrifuged in 2 mL PhaseLock Heavy tubes (5 Prime) at 13000 rpm 
for 5 minutes to allow separation of the phases. The acqueous phase, which contained the 
nucleic acids, was recovered and RNA digested for 30 minutes at 37’C with RNase A/T1 
mix (Fermentas) at a final concentration of  80µg/mL RNAse A and 0.2 U/mL RNase T1. 
DNA was then precipitated at room temperature by adding 1/10 of volume of NaAc 3M, 
1 volume of isopropanol and 40 µg glycogen (Fermentas). After centrifugation at 13000 
rpm for 5 minutes, pellets were washed twice with 500 µL EtOH 70%, air dried for 10 
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minutes and resuspended in 50 µL of TE buffer (10 mM Tris HCl pH = 8, 1 mM EDTA). 
200 ng of each extraction were checked on 1% agarose/TBE gel for integrity and absence 
of RNA contamination. 
Heart samples were not washed at the dissection stage so it was necessary to perform a 
double step of red blood cell lysis with 500 µL RBC Lysis Solution purchased from 
QIAgen. In initial trials (where this RBC lysis step was not done), the spectrophotometric 
reading of the extracted DNA showed a low 260/230 ratio, probably due to the catalysis 
of haemoglobin into bilirubin and its yellow colour was clearly visible in the DNA 
suspension.  
 
2.4 RNA extraction 
For RNA extractions, I developed a protocol combining a lysis step in TriReagent 
(Ambion) and a purification step using the E.Z.N.A. Total RNA Kit I (Omega Bio-Tek). 
Cell pellets (1 to 5 x 10
6
) and ground samples (10 to 50 mg) were homogenised with a 
hand-held homogenizer in 500 µL of TRiReagent solution to assure a complete lysis of 
the samples in a RNA denaturing environment; 100 µL 1, 3-BromoChloroPropane 
(Sigma Aldrich) were added to the lysates and, after centrifugation (12000 g, 10 minutes, 
4° C), the aqueous phase (containing RNA) was recovered. The RNA-containing solution 
was mixed with 200 µL TRK lysis buffer from the kit and 300 µL 100% EtOH and 
loaded into the columns. From this point on, the manufacturers’ protocol was followed, 
except in the elution step where I used 1mM sodium citrate instead of water, because it 
keeps the RNA more stable. This method has allowed me to obtain maximum RNA yields 
and purity. Concentrations of RNA in samples were quantified spectrophotometrically 
(Nanodrop 2000) and 500 ng of each extraction were checked on 1% agarose/TBE gel 
and 1 uL was loaded on the Agilent Bionalyzer. Both methods indicate the integrity level 
of the nucleic acid. 
 
2.5 DNA and RNA quantification by means of nucleic acids stains 
For most of the applications, DNA and RNA were quantified spectrophotometrically 
using a Nanodrop 2000 (Thermo Scientific).  However, in some cases, e.g. where the 
nucleic acids quantifications were used directly to normalize assays values or the amounts 
to be quantified were lower than the detection linearity range of the Nanodrop (4 ng/µL), 
a more precise quantification method based upon the use of SYBR nucleic acids stains 
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was developed. For DNA, 1 µL of each sample was dispensed into a 96-well Black Clear-
Bottom Plate (Corning Costar), 200 µL of a 1:1000 dilution of SYBR Green I (10000x in 
DMSO, Invitrogen) in TE buffer was added; a standard curve with 1:2 serial dilution of 
Lambda DNA (Fermentas) ranging from 1 ng/µL to 512 ng/ µL was prepared and read 
together with the samples. 
For RNA, 1 µL of each sample was dispensed in a 96-well Black Clear-Bottom Plate 
(Corning Costar), 200 µL of a 1:10000 dilution of SYBR Green II (10000x in DMSO, 
Invitrogen) in TE buffer was added; the standard curve was prepared with 1:2 serial 
dilution of ssRNA Ladder (New England Biolabs) ranging from 3.9 ng/µL to 500 ng/ µL 
was prepared and read together with the samples.  
Fluorescence was read in a microplate reader with the following settings: 
 
Excitation: 485 nm 
Emission: 535 nm 
Integration time: 1 s; 
 
sample concentration was calculated from the standard curve equation. 
 
2.6 Methylated DNA Immunoprecipitation (MeDIP) 
 
2.6.1 Samples sonication 
10 μg gDNA was diluted to 450 μL with TE buffer and sonicated in cold water for 2 min 
at 20% pulse and 5 Volts of power output with an Ultrasonic Homogenizer 4710 Series 
(Cole-Parmer Instrument Co.). Extent of sonication was assessed by loading 15 μL of 
sample on 1% agarose/TBE gel with 0.4 μg/mL of Ethidium Bromide. Successfully 
fragmented DNA samples (fragment size ranging from 200 bp to 1000 bp) were 
concentrated with the DNA Clean & Concentrator – 25 kit (Zymo Research) as follows: 2 
volumes of DNA Binding Buffer were added to each sonicated DNA sample and the 
mixture was transferred into a Zymo-Spin Column; after centrifugation at 13000 rpm for 
1 minute, the flow-through was discarded and 2 washes with 300 µL of reconstituted 
Wash Buffer (6 mL concentrated Wash Buffer plus 24 mL 100% ethanol) performed, 
followed by centrifugation at 13000 rpm for 1 minute. DNAs were eluted with 50 μL in 
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TE buffer after an incubation at room temperature for 1 minute. All centrifugation steps 
were carried out at room temperature. 
 
2.6.2 Spike Positive and Negative Control Preparation  
Both Positive and Negative Controls were prepared from Lambda Phage gDNA dam
-
 
dcm
-
 (Fermentas) by PCR and were about 600 bp in length (average size of fragments for 
immunoprecipitation). Fragment A starts at base 2576 and ends at base 3200 of the 
Lambda phage genome and contains 41 CpG sites, while Fragment B starts at base 919 
and ends at base 1524 and contains 35 CpG sites.  
Reactions were set up in a total volume of 20 μL with 10 ng template DNA, 500 nM final 
primers concentration (see Table 1 for sequences) and FastTaq Mix (Fermentas). PCR 
conditions were as follows:  
 
95°C, 1 minute 
95°C, 1 second 
60°C, 15 seconds 
72°C for 10 seconds. 
 
Table 2.1. Primer sequences for λ DNA Fragment A and B preparation. 
 
Primer Sequences Amplicon Length 
Fragm. A FOR1 - AGC AAC CAA CAA GAA AAC ACT  
Fragm. A REV1 - TCA TCC TCG GCA AAC TCT TT  
625 
Fragm. B FOR1 - GTG AGG TGA ATG TGG TGA AGT 
Fragm. B REV1 - TCG CAG AGA TAA AAC ACG CT 
606 
 
PCR products were loaded on agarose/TBE gel 1% plus 0.4% of Ethidium Bromide, 
excised and purified with the GeneJet PCR Purification kit (Fermentas) as follows: 1 
volume of Binding Buffer was added to the PCR reaction and, after thorough vortexing, 
the mixture was loaded into a GeneJET PCR purification column and centrifuged at 
13000 rpm. The flow-through was discarded and the column washed with 700 µL of 
Wash Buffer reconstituted as indicated by the manufacturer (9 mL of concentrated buffer 
plus 45 mL of 100% ethanol). The column was then centrifuged for an additional minute 
30 cycles 
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to remove any residual ethanol and purified DNA eluted in 30 µL of Elution Buffer, 
centrifuging at 13000 rpm for 1 minute, after 1 minute of incubation at room temperature.  
To prepare the fully methylated positive control, Lambda DNA Fragment A was in vitro 
methylated with M.SssI (New England BioLabs) as follows: 
 
1 µg DNA 
5 µL NEBuffer 2 
1 µL S-adenosylmethionine (32 mM) 
Water to 50 µL, 37° C, 4 hours. 
 
The reaction was re-purified with the GeneJet PCR Purification kit (Fermentas) and DNA 
eluted in 30 µL of TE buffer. In vitro methylated fragment A (Positive Control) and 
unmethylated fragment B (Negative Control) were then diluted to 10 ng/µL in TE buffer 
and stored as single-use aliquots at -20°C. To determine if those were suitable controls, I 
digested 200 ng of each with the isoschizomers MspI and HpaII and also with the 
methylation sensitive enzyme AciI (all enzymes were purchased as Fast Enzymes form 
Fermentas). Reactions were set up as follows: 
 
200 ng DNA 
2 µL Green FD buffer  
1 µL of MspI or HpaII or AciI 
Water to 20 µL, 37° C, 1 hour. 
 
Digestions were loaded on 2% MetaPhor High Resolution Agarose/TBE (Lonza) gel with 
0.4 μg/mL of Ethidium Bromide.  
 
2.6.3 Immunoprecipitation 
4 μg of the sonicated DNA were diluted in a final volume of 450 μL with TE buffer and 
40 ng of Positive Control and 40 ng of Negative Control (Lisanti et al., 2012) were added 
up to a total volume of 495 μL. Samples were denatured at 99º C for 10 minutes in a 
thermocycler and then immediately cooled in ice for 10 minutes; 45 μL of them were kept 
at 4º C as Inputs. 
After the addition of 51 μL of 10x IP buffer (100 mM Na-Phosphate pH 7.0; 1.4  M 
NaCl; 0.5 % Triton X-100) and 12 μL of mouse monoclonal 5-methylcytidine antibody 
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100 mg/mL (Eurogentec), the reaction mixture was incubated for 2 h on a rotating wheel 
at 4º C. 
For each sample, 48 μL of Invitrogen Dynabeads M-280 sheep anti-mouse IgG were 
washed twice with 800 μL of 1x IP buffer, 5 minutes, at room temperature with shaking, 
re-suspended in 48 μL of 1x IP buffer and added to the primary Ab-DNA complexes. 
A further incubation of 2 hours on a rotating wheel at 4º C was performed. The beads 
were recovered and washed 3 times at room temperature with 700 μL of 1x IP buffer (10 
mM Na-Phosphate pH 7.0; 140 mM NaCl; 0.05 % Triton X-100) for 10 minutes with 
shaking and the bound DNA was eluted with 70 μg of Proteinase K (Roche) in 250 μL of 
Proteinase K buffer (50 mM Tris-HCl pH 8; 10 mM EDTA; 0.5% SDS). 
The immunoprecipitated fractions were purified with the DNA Clean & Concentrator –5 
kit (Zymo Research) as follows: 5 volumes of DNA Binding Buffer were added to each 
sonicated DNA sample and the mixture was transferred into a Zymo-Spin Column; after 
centrifugation at 13000 rpm for 1 minute, the flow-through was discarded and 2 washes 
with 300 µL of reconstituted Wash Buffer (6 mL concentrated Wash Buffer plus 24 mL 
100% ethanol) performed, followed by centrifugation at 13000 rm for 1 minute. DNAs 
were eluted with 15 μL in TE buffer after an incubation at room temperature for 1 minute. 
All centrifugation steps were carried out at room temperature. 
Purified DNA samples were spectrophotometrically quantified using a Nanodrop 2000 
Thermo Scientific). 
Each MeDIP experiment yielded approximately 5% of the starting amount of DNA.  
 
2.6.4 Test for the specificity of the immunoprecipitation 
A preliminary PCR was performed on the Input and MeDIped samples to assess if the 
immunoprecipitation worked successfully. The primers pairs used were also designed to 
work for Real Time qPCR (see Table 2) and were used at a final concentration of 250 nM 
each, with 2 ng of Input or MeDIP sample and Fast Hot Start Taq PCR Master Mix from 
Fermentas. The reactions were carried out up to 15 cycles, to make sure that the 
amplification was still in the exponential phase. Cycling conditions were as follows: 
 
95º C   1 minute 
95º C   1 second 
60º C   3 seconds 
72º C   10 minutes 
15 cycles 
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PCR products were loaded and analyzed on 2% agarose/TBE gel plus 0.4% of Ethidium 
Bromide. Primer sequences are listed in Table 2. 
 
2.7 Whole Genome Amplification (WGA) 
Whole Genome Amplification (WGA) was necessary to obtain enough material to be 
analysed by Real Time qPCR and DNA MicroArray. The GenomePlex WGA2 kit (Sigma 
Aldrich) was used according to the manufacturer’s protocol, but omitting the initial DNA 
fragmentation, as our samples were already fragmented because of the sonication step. 
The kit is based upon the linker adaptor approach: each end of the small fragments of 
genomic DNA is ligated to an adaptor (library preparation) and these known adaptor 
sequences are used as priming sites for the following PCR reaction (library 
amplification). 
For the library preparation reaction mixtures were prepared and incubated as follows: 
 
4 μL Library Preparation Buffer 
2 μL Library Stabilization Solution 
22 μL Input or MeDIP sample (2 ng/μL), 95º C for 2 minutes, followed by cooling in ice. 
 
After the addition of 2 μL of Library Preparation Enzyme, samples were incubated in a 
thermocycler as follows: 
 
16º C   20 minutes 
24º C   20 minutes  
37º C   20 minutes 
75º C   5 minutes. 
 
Libraries were cooled in ice and a mix containing the following reagents was added: 
15 μL 10x Amplification Master Mix           
       
95 μL Nuclease-free Water 
10 μL WGA DNA Polymerase 
The amplification mixes were incubated as follows: 
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95º C   3 minutes 
94º C   15 seconds 
65º C   5 minutes. 
 
Reactions were cleaned up with the GenElute PCR Clean-Up kit (Sigma Aldrich) and 
eluted in 50 µL of water and quantified at the Nanodrop 2000 (Thermo Scientific). 500 μg 
of reaction product were loaded on 1% agarose/TBE gel to check fragments size, which 
should reflect the one of the Input material before the Whole Genome Amplification 
process. 
In general, WGA generated between 300-700 fold amplification of the starting amount.  
 
2.8 Quantitative PCR (qPCR) 
The relative enrichment methylated fraction/unmethylated fraction between MeDIP and 
Input samples can be calculated from qPCR data using the Pfaffl method (Pfaffl, 2001) or 
the simplified ΔΔCt method (Livak and Schmittgen, 2001). In this study, I used the first 
method, which accounts for differences in amplification efficiency of the primer pairs 
used. 
To design and perform all qPCR assays the Minimum Information for Publication of 
Quantitative Real-Time PCR Experiments Guidelines (Bustin et al., 2009) were followed. 
Primer pairs were designed to have an annealing temperature of 60°C and to produce 
amplicons of 90 to 150 bp (with the Thermo Scientific webtool Reviewer: 
http://www.thermoscientificbio.com/webtools/reviewer/) and in-silico tested to confirm a 
unique amplification product at http://genome.ucsc.edu/. Efficiency and linearity of 
amplification were calculated from 10-fold or 5-fold dilution curves of the template 
DNA; each primer pair was also tested in 3 different final concentrations (100 nM, 200 
nM, 300 nM). PCR reactions were carried out in triplicate in a LightCycler 480 (Roche) 
with 1 µL of template and Maxima SYBR Green qPCR Master Mix (Fermentas) in the 
following conditions: 
 
95°C for 10 minutes 
95°C for 15 seconds 
60°C for 1 minute 
 
Melting curves were obtained as follows:  
14 cycles 
 
45 cycles 
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95°C for 5 seconds 
65°C for 1 minute 
from 65°C to 97°C, with a ramp rate of 0.11° C/second. 
 
The acquisition of the fluorescence signal was set as a single reading during the annealing 
step and as a continuous reading during the melting curve. Primer concentrations were 
300 nM for the endogenous gene assays and 100 nM for the spiked positive and negative 
control assays. For the dilution curves, template DNA was Lambda Phage gDNA dam
-
 
dcm
-
 (Fermentas) for spike controls assays (dilutions ranging from 500 ng/µL to 50 
fg/µL), gDNA from young confluent MRC-5 (dilutions ranging from 200 ng/µL to 200 
pg/µL) for human gene specific assays, gDNA from 3 months old mouse liver (dilutions 
ranging from 200 ng/µL to 200 pg/µL) and sscDNA obtained by reverse transcription of 
500 ng of total RNA from 3 months old mouse liver (dilutions ranging from 1:2 to 
1:2000). 
PCR products were also loaded in 2% agarose/TBE gel plus 0.4% of Ethidium Bromide 
to confirm the presence of a unique DNA band. 
Table 2 and 3 list the sequences for the primers used in the qPCR assays. Dilution curves 
and melt curves for each primers pair are shown in Appendix A. 
 
Table 2.2. Primers sequences for λ DNA Spike Positive and Negative Controls specificity 
test and qPCRs. 
 
Primer Sequences Amplicon Length 
Fragm. A FOR2 – TAC AGA AAG ACG GAC GAA GG 
Fragm. A REV2 - TGG TGG GCG TTT TCA TAC AT 
143 
Fragm. B FOR2 - TTC GTG ATA TTC CGT CGC TG 
Fragm. B REV2 - AGT TTT TTG CCG CTT TAC CG 
132 
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Table 2.3. Primers sequences for qPCR on MeDIP samples. The symbol “*” indicate 
primers previously used in (Weber et al., 2005). 
 
Specificity Primers Sequences Amplicon Length 
Human 
H19 ICR * 
FOR - GAGCCGCACCAGATCTTCAG 
REV - TTGGTGGAACACACTGTGATCA 
134 bp 
Human 
HIST1H2BA 
FOR - TGTTTGTTTACTTGGCGAGAC 
REV - GGTTACACAGCACTTTCCAG 
91 bp 
Human 
GAPDH 
FOR - CTCTCTCCCATCCCTTCTCC 
REV - CAAGTTGCCTGTCCTTCCTA 
91 bp 
Human 
CD7 
FOR - CACGCATGGAGTCAAGTG 
REV - CACGCATGTGCAGAGATG 
132 bp 
Human 
DCHS1 
FOR - GAGAGATCAAGCAGAAGGGG 
REV - TCTTTTTCCCAACCGTCATCT 
131 bp 
Human 
MLNR 
FOR - TTGTGGTGCTCTTGGTGGAT 
REV - TCTTCACTTTCTTCCTTTACCCA 
127 bp 
Human 
OR5AP2 
FOR - TCTGATGTTTTCTGGTTCTCTTG 
REV - AGATTGTAAGAATGAGTAGGCATC 
112 bp 
Human 
PRDM8 
FOR - ACTTTCATCTCTTCTATCTCAACAC 
REV - ATGGCATTCATTAGCACGGG 
177 bp 
Human 
RAB5C 
FOR - CTCCAGATCAGCGAGTTCAC 
REV - TGGAAGAAGGCAGAGGATTG 
104 bp 
Mouse 
H19 ICR * 
FOR - ACATTCACACGAGCATCCAGG 
REV - GCTCTTTAGGTTTGGCGCAAT 
146 bp 
Mouse 
Hist1h2ba  
FOR - TAAGGTGCTGAAACAAGTGCA 
REV - ATGTCTGTCACAAAGGAGTTCA 
81 bp 
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Mouse 
Actb 
FOR - TTTCTGTCACTCTTCTCTTAGGT 
REV - AGGTCTTTACGGATGTCAACG 
97 bp 
Mouse 
Gapdh 
FOR - CTCTGCTCCTCCCTGTTCC 
REV - TCCCTAGACCCGTACAGTGC 
133 bp 
 
2.9 PCR cloning 
To confirm the identity of the qPCR products for human H19, HIST1H2BA, GAPDH and 
murine H19, Hist1h2ba, Actb and Gapdh, amplicons were cloned into a blunt linearized 
plasmid for sequencing using the CloneJET PCR Cloning kit (Fermentas). Ligation 
mixtures were prepared as follows: 
 
1 µL non-purified PCR product 
10 µL Reaction Buffer 2x 
1 µL pJET1.2/blunt Cloning Vector (50 ng/µL) 
T4 DNA Ligase 
water to 20 µL, incubation at room temperature for 5 minutes. 
 
A parallel control reaction was set up including all the components except the PCR 
product. For each ligation, one 50 µL aliquot of E.coli Subcloning Efficiency DH5α 
Chemically Competent Cells (Invitrogen) was thawed in ice and gently resuspended; after 
the addition of 5 µL of the ligations, the suspensions were incubated in ice for 30 
minutes, at 42° C in a water bath for 20 seconds and again in ice for at least 2 minutes. 
950 µL of SOC medium (Mediatech Inc.; 2% peptone, 0.5% Yeast extract, 10mM NaCl, 
2.5mM KCl, 10mM MgCl2 , 10mM MgSO4, 20 mM glucose) were added, followed by a 1 
hour incubation at 37° C with orbital shaking at 220 rpm. 1/10 of the transformation was 
spread onto LB Miller agar plates (1% Tryptone, 0.5% Yeast extract, 0.05% Sodium 
chloride, 1.5% Agar) containing 50 µg/mL of Ampicillin (Sigma Aldirch) as a selection 
antibiotic and incubated at 37° C overnight. 
 
2.9.1 Screening and confirmation of the cloning products 
A preliminary colony PCR screening was performed to detect E.coli colonies containing 
successfully cloned PCR products setting up the reactions as follows: 
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5 µL of bacteria colony resuspended in 50 µL of water 
300 nM of each primer 
12.5 µL HotStart Maxima PCR Master Mix 2x (Fermentas) 
water to 25 µL. 
 
Primer sequences are listed below: 
 
pJET1.2 FOR: CGACTCACTATAGGGAGAGCGGC 
pJET1.2 REV: AAGAACATCGATTTTCCATGGCAG; 
 
Reactions were incubated as follows: 
 
95° C for 4 minutes 
95° C for 30 seconds 
60° C for 30 seconds 
72° C for 9 seconds 
72° C for 10 minutes. 
 
5 µl of each PCR product were loaded into 2% agarose/TBE gel with 0.4 μg/mL of 
Ethidium Bromide and electrophoresed.  
Among the clones that showed successful amplification, two were chosen at random for 
plasmid DNA extraction, restriction digestion analysis and sequencing confirmation. 5 
mL of a selected clone culture in LB Miller medium (1% Tryptone, 0.5% Yeast extract, 
0.05% Sodium chloride) plus 100 µg/mL Ampicillin (Sigma Aldrich) were incubated 
overnight at 37° C with orbital shaking at 220 rpm. The morning after, bacteria cells were 
centrifuged at 3500 rpm for 15 minutes at 4° C, medium discarded and plasmid DNA was 
extracted using the GeneJET Plasmid Miniprep Kit (Fermentas) as follows: pelleted cells 
were resuspended in 250 µL of Resuspension Solution (containing 0.1 µg/µL of RNase 
A) and transferred to a microcentrifuge tube, 250 µL of Lysis Solution was added, the 
mixture inverted several times and incubated at room temperature for 5 minutes. After the 
addition of 350 µL of Neutralization Solution and several inversions, samples were 
centrifuged at 13000 rpm for 5 minutes and supernatant loaded into a GeneJET spin 
column to be further centrifuged at 13000 rpm for 1 minute. Plasmid DNA, now bound to 
the silica column, was washed twice with 500 µL of Wash Solution (reconstituted adding 
70 mL of ethanol 100% to 100 mL of the supplied concentrated Wash Buffer) and 
30 cycles 
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centrifuged at 13000 rpm for 1 minute. An additional centrifugation step was performed 
to remove residual ethanol from the column. Plasmid DNA was eluted with 50 µL of 
Elution Buffer after 2 minutes of incubation at room temperature, followed by 
centrifugation at 13000 rpm for 1 minute. All centrifugation steps were carried out at 
room temperature. 
Restriction digestion analysis was set up using the same enzymes used for cloning, as 
follows: 
 
1 µg plasmid DNA 
2 µL FastDigest Green Buffer 2x  
1 µL FastDigest BglII (Fermentas) 
water to 20 µL, incubation at 37° C for 1 hour. 
 
Digests were loaded into 1% agarose/TBE gel plus 0.4 µg/mL of Ethidium Bromide to 
assess the release of the cloned promoters from the vector backbone. 
To confirm the sequence of the cloned products, 1 µg of each plasmid DNA was 
sequenced with both Forward and Reverse pJET1.2 primers in an ABI 3130xl sequencer; 
sequences were then aligned with the expected promoter sequences with the aid of the 
webtool Chromas, Version 2.33 (Technelysium, South Brisbane, Australia). 
 
2.10 Whole Genome Amplification (WGA) Bias Assessment 
To determine whether the WGA process introduced any methylation-related bias, 
Fragment A and B were prepared to be used as Negative Control and Positive Control, 
respectively. Briefly, Fragment B was in vitro methylated as described in section 2.6.2, 
while Fragment A was left unmethylated. A MeDIP reaction was set up with the usual 
Positive and Negative Controls and a parallel one was set up with the controls prepared as 
stated above. WGA was performed as described in section 2.7, relative enrichments of 
Controls was determined by qPCR (see section 2.8) also in Pre-WGA mixtures and 
compared. To determine whether WGA introduced any sequence-related bias, four 
additional Lambda DNA fragments of various sizes (in the range of the sonicated gDNAs 
size – 200 to 1000 bp) were prepared by PCR and spiked in one of the samples at the 
usual 1:100 ratio. Again, qPCR was performed on both Pre-WGA and Post-WGA 
mixtures and the relative enrichments compared. Primers sequences for fragments 
preparation and qPCR are listed in Table 2.4. 
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Table 2.4. Primers sequences for λ DNA Fragment Spikes preparation (pairs 1) and 
qPCRs (pairs 2) for the assessment of Whole Genome Amplification length related bias. 
 
Primer Sequences Amplicon Length 
Spike 208 FOR1 -  CGTTTCCTTTCTCTGTTTTTGTC 
Spike 208 REV1 - CAATTTCAGCATCCCTTTCGG 
Spike 208 FOR2 -  CAATGGAAGTCAACAAAAAGCA 
Spike 208 REV2 - CATAAAGCACCTCATTACCCTT 
208  
  
126 
Spike 400 FOR1 - CCATCAATAAAACCTATACCCGC 
Spike 400 REV1 - AGTATTTTTTTCCTGCCATCCAC 
Spike 400 FOR2 - CGAAACAAAAACGGGGTTTAC 
Spike 400 REV2 - TTATTCGGGAAGTGAACGGC 
400  
  
128 
Spike 800 FOR1 -  GGCGAATGACCAAAGAGACT 
Spike 800 REV1 - ATAAAAAAATCCCGTAAAAAAAGCC 
Spike 800 FOR2 -  GACGAGACGAAAAAACGGAC 
Spike 800 REV2 - CGTAAAAAAAGCCGCACAGG 
800 
  
99 
Spike 1000 FOR1 - CATAAAAGGTCTTGAGCAGGC 
Spike 1000 REV1 - CGGCATTGTAGGATTTGGTAC 
Spike 1000 FOR2 – TGTTTTTGATGAGGCGGATTTT 
Spike 1000 REV2 - TGAGCAGGCAGGAAAACTTC 
1000  
  
126 
 
2.11 MeDIP arrays and data analyses  
To obtain DNA methylation data, 3 µg of WGA Input and MeDIP samples were sent to 
Nimblegen Roche, where they were labelled with Cy3 and Cy5, respectively, and 
hybridized onto HG18_RefSeq_promoter Arrays (human samples) or 
MM9_CpG_Refseq_promoter Arrays (murine samples). For the HG18_RefSeq_promoter 
Arrays, tiling of promoter regions was based on human RefSeq genes (HG18; NCBI 
Build 36) and included 2200 bp upstream and 500 bp downstream of the transcriptional 
start, with an interval spacing of 100 bp between probes. For the 
MM9_CpG_Refseq_promoter Arrays, tiling of promoter regions was based on refFlat file 
downloaded from UCSC on May 19th 2009 and included 2960 bp upstream and 740 bp 
downstream of the transcriptional start, with an interval spacing of 100 bp between 
probes. 
Data analyses were carried out by M. Adriaens (Maastricht University, The Netherlands). 
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2.11.1 Data preprocessing 
For the analysis of the MeDIP microarray data, the enrichR package was used, running in 
R (version 2.15.1) with Bioconductor (version 2.10). A full description of all functions 
and required packages is available from 
http://www.bigcat.unimaas.nl/wiki/index.php/EnrichR. 
After importing the files containing the raw probe intensities (Nimblegen PAIR-files) into 
R, quality control was performed using the arrayQualityMetrics package (Kauffmann et 
al., 2009), revealing no data quality issues. Raw data were normalized using T-quantile 
normalization, performed separately on the channels, and separately on each experimental 
group (Adriaens et al., 2012). Nimblegen employs two-channel microarray technology, 
where one channel contains the MeDIP enriched sample and the other channel contains a 
total DNA reference sample. Hence after normalization, for each microarray the log2 
ratios between the MeDIP enriched channel and the total DNA channel were calculated 
and used thereafter as relative probe intensities. 
 
2.11.2 Enrichment analysis 
To quantify the relative degree of DNA methylation, enrichment analysis was applied 
using a sliding window approach. A window is defined as the genomic region centred on 
a probe and containing all neighbouring probes within a span of 750 bp. The null 
hypothesis is that the normalized intensities of a set of probes in a window are sampled 
from the null distribution, defined as the distribution of all probe intensities in the dataset. 
The alternative hypothesis is that probe intensities in the window are drawn from a 
distribution that has a higher mean than the null distribution. The procedure is similar to 
the ACME approach (Scacheri et al., 2006), the difference being that here a one-sided 
two-sample Kolmogorov-Smirnov test is performed using the normalized probe 
intensities directly, instead of a χ2-test on dichotomized probe values, acquired by setting 
a specific intensity cut-off. The test applied here is more appropriate for the continuous 
nature of DNA methylation data, whereas the standard procedure in ACME was designed 
to take account of the binary nature of DNA binding events in most ChIP-on-chip 
experiments (Adriaens et al., 2012). It is important to note that for this analysis, replicate 
measurements were pooled for each experimental group. After the enrichment analysis, 
the resulting p-values were negative log10-transformed to yield enrichment scores. In 
accordance with the manufacturer’s protocol, if a window has an enrichment score of 2 or 
higher, it is considered enriched, indicating some degree of DNA methylation in the 
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window region. The higher the enrichment score, the more likely the relative degree of 
DNA methylation is high.  
 
2.11.3 Identification of differentially methylated regions 
For each promoter region on the microarray, the most enriched region for each 
experimental group plus the corresponding regions in the other two experimental groups 
were returned. To assess differences in DNA methylation between experimental groups, 
differential enrichment analysis was performed by applying an ANOVA between each 
two groups, using all normalized probe intensities in the returned regions. As with the 
enrichment analysis, replicate measurements were pooled for each experimental group. 
A region of interest is defined as having a significant difference in probe intensities 
between any two experimental groups, with as large a difference as possible in 
enrichment score, preferably having an enrichment score lower than 2 in one condition 
and much higher than 2 in the other. Such regions were prime candidates for having 
functionally large differences in DNA methylation. 
 
2.12 Transcriptome arrays and data analyses  
To obtain gene expression data, RNA were extracted as previously described (see section 
2.4) in triplicate and sent to Affymetrix for hybridization onto 
Affymetrix.GeneChip.NuGO_Hs1a520180 arrays.  
Data analyses were carried out by M. Adriaens (Maastricht University, The Netherlands). 
 
2.12.1 Data analyses  
Files containing the raw probe intensities (Affymetrix CEL-files) were imported in the 
statistical programming language R (version 2.15.1) using standard Bioconductor 
(version 2.10) procedures (R-Core-Team, 2012; Gentleman et al., 2004). Quality control 
was performed using the standardized microarray quality control service offered on 
www.arrayanalysis.org (Eijssen et al., 2013), revealing no data quality issues. The data 
were normalized using the GCRMA (GeneChip Robust Multi-Array Analysis) 
normalization (Wu and Irizarry, 2004; Zhang et al., 2004) and annotated using the most 
up-to-date Entrez Gene based annotation available from the BrainArray project (Dai et 
al., 2005) of the University of Michigan (http://brainarray.mbni.med.umich.edu/). 
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Differences in gene expression between experimental groups were assessed using linear 
modelling and the empirical Bayes methods of the limma package (Smyth, 2004).  
 
2.13 Reverse Transcription (RT) and RT-qPCR 
To eliminate contaminating gDNA prior to reverse transcription, total RNAs were 
digested in duplicate reactions with DNaseI (Fermentas) as follows:  
 
500 ng total RNA 
1 µL DNAse I 10x buffer with 25 mM MgCl2 
0.5 U DNaseI, RNase-free 
Water to 10 µL, 37° C for 30 minutes. 
 
After the addition of 1 µL of EDTA 50 mM, samples were incubated at 65° C for 10 
minutes and cooled in ice. A reverse transcription mix with the following composition 
was prepared with the reagents included in the Maxima Universal First Strand cDNA 
Synthesis kit (Fermentas) and added to each sample: 
 
0.25 µL 100 µM oligo (dT)18 primers 
0.25 µL 100 µM random hexamers primers 
1 µL 10 mM dNTP mix 
4 µL 5x RT buffer 
1 µL RiboLock RNase Inhibitor (20 u/µL) 
Water to 8 µL. 
 
1 µL of Maxima Reverse Transcriptase (200 u/µL) was added to one of the duplicate 
reaction and 1 µL of water was added to the second reaction, which was later used as no 
template control. Mixes were incubated as follows: 
 
25° C for 10 minutes 
50° C for 15 minutes 
85° C for 5 minutes. 
 
Single strand cDNAs (sscDNAs) and control reactions were diluted 1:20 with water and 
stored at -80° C until used as templates in qPCR assays; reactions were set up as 
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described in section 2.8 with primers listed in Table 2.5. Dilution curves and melt curves 
for each primer pair are shown in Appendix A. 
 
Table 2.5. Primers sequences for RT-qPCR assays. 
 
Specificity Primers Sequences Amplicon Length 
Human 
DNMT1 
FOR - AAACAAAGGGAAGGGCAAGG 
REV - AGAAAACACATCCAGGGTCC 
118 bp 
Human 
DNMT3A 
FOR - GCCTCAATGTTACCCTGGAA 
REV - CAGCAGATGGTGCAGTAGGA 
127 bp 
Human 
DNMT3B 
FOR - CCCATTCGAGTCCTGTCATT 
REV - GGTTCCAACAGCAATGGACT 
126 bp 
Mouse 
Dnmt1 
FOR - TGAGGAAGGCTACCTGGCTA 
REV - GTCTGCCATTTCTGCTCTCC 
142 bp 
Mouse 
Dnmt3a 
FOR - ACCAGGCCACCTACAACAAG 
REV - GCTTGTTCTGCACTTCCACA 
150 bp 
Mouse 
Dnmt3b 
FOR - GCATGAAGGCCAGATCAAAT 
REV - GCTTCCACCAATCACCAAGT 
97 bp 
Human 
CCNB2 
FOR - GGAAGAGATATAAATGGACGCAT 
REV - TGGCTGAACCTGTAAAAATCG 
135 bp 
Human 
DLGAP5 
FOR - ACTTTTTGTTTGGTTGAGGTTTC 
REV - AGACAGTGATTTCCTATGAGCA 
133 bp 
Human 
FANCG 
FOR - TGGAGGGAAAAGAATGACCG 
REV - CCAAGGGAAGAACAGGAACA 
163 bp 
Human 
MMP3 
FOR - GGACAAAGGATACAACAGGGA 
REV - GTGAGTGAGTGATAGAGTGGG 
124 bp 
Human 
PNMA2 
FOR - AACCCGTCCATCAGTGTAGA 
122 bp 
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REV - ACCTTCTCTCCTTCCTCCTG 
Human 
TMSB15A 
FOR - CGAACAGCCTTTCACGAGTC 
REV - GTCAAACTTCTCCACTTCCGA 
92 bp 
Human 
CTTN 
FOR - GGATCGGATGGATAAGAATGC 
REV - TGATGTTACTTGTTTTGCTGGT 
110 bp 
Human 
GLIPR2 
FOR - CACAATGAGTACCGGCAGAA 
REV - CCATCTATCAGCCACCTCCT 
201 bp 
Human 
NPTX1 
FOR - CAAACTTTGCAATCGCTCAA 
REV - GATCCTTGAGGCTGTTGGTC 
91 bp 
Human 
SLC39A14 
FOR - TGTCTCCAAGTCTGCAGTGG 
REV - AATGGCTGTGTCCATGATGA 
113 bp 
Human 
mtDNMT1 
FOR - AGCAAACCGTGGAGCTTG 
REV - CAAACGGAGAGAGGCGATAC 
134 bp 
Mouse 
mtDnmt1 
FOR - ATGGTCTTCCCCCACTCTCT 
REV - TGCAGACGACAGAACAGCTC 
126 bp 
Human 
B2M 
FOR - CGCTACTCTCTCTTTCTGGC 
REV - AATTTGACTTTCCATTCTCTGCT 
93 bp 
Human 
GAPDH 
FOR - TCAAGAAGGTGGTGAAGCAG 
REV - GTGTCGCTGTTGAAGTCAGA 
97 bp 
Human 
HPRT1 
FOR - AAGTTTGTTGTAGGATATGCCC 
REV - GCTTTGTATTTTGCTTTTCCAGT  
98 bp 
Human 
UBE2B 
FOR - TCTTAACATCAATTCAGTCTCTGC 
REV - ACTCTTTTCTCATATTCTCGTTTGT 
109 bp 
Mouse 
Actb 
FOR - CCCAGAGCAAGAGAGGTATC 
REV - ATTGTAGAAGGTGTGGTGCC 
104 bp 
Mouse 
B2m 
FOR - ATGCTGAAGAACGGGAAAAAAA 
REV - CAGTGTGAGCCAGGATATAGAA 
91 bp 
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Mouse 
Gapdh 
FOR - AGGACACTGAGCAAGAGAGG 
REV - TGTTATTATGGGGGTCTGGGA 
91 bp 
Mouse 
Hprt 
FOR - AGGAGAGAAAGATGTGATTGATATT 
REV  -TCCACTGAGCAAAACCTCTT 
96 bp 
 
2.14 LUminometric Methylation Assay (LUMA) 
One of the methods applied to determine global DNA methylation content in the samples 
under study was the LUMA assay (Karimi et al., 2006a; Karimi et al., 2006b), with a 
small modification consisting in the substitution of the normalizer restriction enzyme 
EcoRI with MunI, as described in section 3.5. This modification was important in 
producing better standard curves (see section 3.3) and lower reading variability between 
replicates (data not shown) (Lisanti S., Omar W.A.W. et al., accepted). 
gDNAs were double digested as follows: 
 
600 ng gDNA  
3.5 µL 10x Tango buffer (Fermentas) 
0.6 µL MspI (or HpaII) 20 U/µL (Fermentas)  
0.6 µL MunI 20 U/µL (Fermentas) 
water to 35 µL, 37°C for 4 hours. 
 
After the addition of 35µL of annealing buffer (Biotage), the digestions were distributed 
in triplicates (3x 20µL) in a 96-well PCR plate for analysis by pyrosequencing as 
described in section 2.20, in a PyroMark MD instrument, Biotage. The deoxynucleotide 
dispensation order was: GTGTCACATGTGTG and the percentage of global genome 
CpG methylation was calculated from the HpaII/MspI digestions ratio as follows: 
 
[1 - [(HpaII ΣC / ΣA) / (MunI ΣC / ΣA)] / [(MspI ΣC / ΣA)/ (MunI ΣC / ΣA)] x 100 
(adapted from (Karimi et al., 2006b)), 
 
where C and A are the overhangs left by the restriction enzymes cuts. 
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2.15 Measurement of total 5’-methylCytosine content by means of High 
Performance Liquid Chromatography (HPLC) 
For some of the samples, the genomic content of the nucleoside 5-methyl-2’-
deoxycytidine by quantified by HPLC with UV detection as described (Rozhon et al., 
2008) with minor modifications. These measurements were carried by S. De Prins, G. 
Jacobs and G. Koppen at the Environmental Risk and Health Unit of the Flemish Institute 
of Technological Research, Belgium. 
Frozen tissues and cell pellets gDNAs were extracted as described in section 2.3 and 
digested overnight at 37° C with a mixture of DNaseI and Nuclease P1. Next, nucleotide 
monophosphates were dephosphorylated overnight at 37 °C with calf intestine alkaline 
phosphatase. The content of 5’methylCytosine was estimated using a Waters Acquity 
Ultra Performance Liquid Chromatography (UPLC) system. The HPLC protocol was 
based on isocratic separation using a Nucleosil SA cation exchange silica 150 x 4.6 mm x 
5 µm column (Macherey-Nagel); the column temperature was maintained at 30 °C. The 
acidic mobile phase consisted of 50 mM ammonium acetate in 15% acetonitrile with a pH 
of 4.8 and the flow rate was 0.5 ml/min. Samples were cooled at 4 °C and 30 µl were 
injected in the column. UV detection was performed at 278 nm for mdC with a bandwith 
of 9.6 nm. Levels 5’mC were estimated based on the corresponding standard curve (2 – 
0.008 µg/mL). A standard sample (0.5 µg/mL) was measured at the beginning, at the end 
and 3 additional times throughout the run to check for intra-assay variation. 
 
2.16 Global DNA Methylation Colourimetric Assay 
A second approach used to determine the total content of 5-methylCytosines in the 
samples under investigation was a colourimetric assay based upon the use of a capture 
and a detection antibody applied to the sample gDNA, followed by methylation 
quantification based on a standard curve prepared with increasing concentration of a 
control DNA samples of known methylation content. For this purpose, the MethylFlash 
Methylated DNA Quantification kit (Epigentek) was used. 
gDNAs were quantified as described in section 2.5, diluted to a final volume of 8 µL with 
TE buffer, mixed to 80 µL of ME2 Binding Solution and dispensed in a clear 96-well 
plate. In parallel, 1 µL of ME3 (Negative Control, 20 ng/µL), 1 µL of the following 
dilutions of ME4 (Positive Control at 50% of methylation content, 20 ng/µL): 0.5 ng/µL, 
1 ng/µL, 2 ng/µL, 5 ng/µL, 10 ng/µL, all in TE buffer, were also added to prepare a 
methylated DNA standard curve. Plates were sealed with Parafilm M and incubated at 
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37° C for 90 minutes. After removal of the ME2 Binding Solution, wells were washed 
with 150 µL of ME1 Wash Buffer 1x three times and 50 µL of ME5 Capture Antibody 
(1:1000 dilution in ME1 Wash Buffer 1x, to obtain a final concentration of 1 ng/µL) were 
added; plates were incubated at room temperature for 1 hour, followed by removal of 
diluted ME5 and 3 washes with 150 µL of ME1 Wash Buffer 1x. 50 µL of ME6 
Detection Antibody (1:2000 dilution in ME1 Wash Buffer 1x, to obtain a final 
concentration of 0.2 ng/µL) were added and plates incubated at room temperature for 30 
minutes. After four washes with 150 µL of ME1 Wash Buffer1 x, 50 µL of ME7 
Enhancer Solution (1:5000 dilution in ME1 Wash Buffer 1x), plates were incubated at 
room temperature for 30 minutes and washed five times with 150 µL of ME1 Wash 
Buffer1 x; 100 µL of ME8 Developer Solution was added to each well, followed by 10 
minutes of incubation at room temperature in the dark. The colourimetric reaction was 
stopped with the addition of 50 µL of ME9 Stop Solution and absorbance at 495 nm was 
recorded after 5, 10 and 15 minutes in a microplate reader. Coefficient of determination 
(R
2
) of the standard curve was calculated for each time point and data readings 
corresponding to the R
2
 closest to 1 were used for the calculation of the total methylation 
content in the samples, applying the following formulas: 
 
5-mC (ng) = (sample OD – ME3 (Negative Control) OD) / Slope x 2, 
 
where 2 is a normalization factor, as the ME4 Positive Control contains only 50% of 5-
mC; 
 
5-mC% = (5-mC amount (ng)) / (amount of input gDNA (ng)) x 100. 
 
2.17 Bisulphite Modification (BM) 
All bisulphite modification (BM) reactions were conducted using 350 ng of starting 
genomic DNA and the EZ DNA Methylation-Gold kit (Zymo Research). The CT 
Conversion Reagent was supplied in lyophilized aliquots and prepared adding 900 µL of 
water, 300 µL of M-Dilution Buffer and 50 µL of M-Dissolving Buffer for each aliquot, 
followed by vortexing for 10 minutes. Unused CT Conversion Reagent was stored at -20° 
C and warmed at 37° C for 10 minutes prior to use and used within a month from 
dissolution. M-Wash Buffer was prepared adding 96 mL of 100% ethanol to the supplied 
24 mL of concentrated buffer.  
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gDNAs were diluted to 20 µL of final volume with TE buffer in PCR tubes and 130 µL of 
reconstituted CT Conversion Reagent were added; mixtures were incubated in a thermal 
cycler as follows: 
 
98° C for 10 minutes 
64° C for 2.5 hours 
storage at 4° C for up to 20 hours. 
 
600 µL of M-Binding Solution were added to Zymo-Spin IC Columns together with the 
samples and, after several inversions, columns were centrifuged at 13000 rpm for 1 
minute at room temperature. The column was washed once with 100 µL of M-Wash 
Buffer and the bound DNA was desulphonated by the addition of 200 µL of M-
Desulphonation Buffer, followed by 20 minutes of incubation at room temperature. The 
columns were washed twice with 200 µL of M-Wash Buffer and the BM-DNA eluted in 
25 µL of M-Elution Buffer. BM-gDNAs were stored at -80° C until use and for up to 3 
months. 
 
2.18 Bisulphite modified DNA PCRs (BM-PCR) 
Bisulphite modified DNA PCRs (BM-PCR) were set up as follows: 
 
2 µL of BM-DNA 
300 nM of each primer 
12.5 µL of Maxima HotStart Taq Master Mix 2x (Fermentas) 
water to 25 µL. 
 
Primer pairs were designed to amplify sequences between 200 and 500 bases of length 
using the webtool MethPrimer (Li and Dahiya, 2002) and annealing temperatures were 
optimized by gradient PCR testing a range included between ±5° C of the single primers 
melting temperatures. Cycling conditions for each pair are listed in Table 2.6; an initial 
denaturation step (95° C for 4 minutes) and a final elongation step (72° C for 10 minutes) 
were performed for all the reactions and cycling programs were repeated 45 times. 
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Table 2.6. Primers sequences for BM-PCR. The symbol “*” indicates an assay for which 
template DNA was diluted 1:200 before use. The symbol “**” indicates primers 
previously used in (Jeong and Lee, 2005). The symbol “***” indicates an assay requiring 
a final concentration of 3.5 mM MgCl2, instead of the usual 2 mM obtained by using the  
Maxima HotStart Taq Master Mix. 
 
Specificity Primers Sequences 
Cycling 
conditions 
Amplicon 
Length 
λ-DNA 
Fragment A * 
FOR - GGTATTGTATGATTTGATGATAGGTA 
REV - AATTAAACAACAAAACTACATCCAC 
95º C, 30 sec 
58.8º C, 30 sec 
72ºC, 20 sec 
325 bp 
Human 
LINE-1 
FOR -TTATTAGGGAGTGTTAGATAGTGGG 
REV -CCTCTAAACCAAATATAAAATATAATCTC 
95º C, 30 sec 
56.7º C, 30 sec 
72ºC, 15 sec 
245 bp 
 
Mouse 
B1 element ** 
FOR - GGTGGTGGTGGTGGTTGAGATAG 
REV - AATAACACACACCTTTAATCCCAACACT 
95º C, 30 sec 
64.9º C, 30 sec 
72ºC, 10 sec 
155 bp 
Human 
H19 ICR 
FOR - TGGGTATTTTTGGAGGTTTTTTT 
REV -TCCCATAAATATCCTATTCCCAAA 
95º C, 30 sec 
56º C, 30 sec 
72ºC, 15 sec 
220 bp 
Human 
HIST1H2BA 
FOR - ATTTGTTATTTGATTGGTTGATGGT 
REV - ACACTTTCCAATACTCAACAACTCTT 
95º C, 30 sec 
58º C, 30 sec 
72ºC, 15 sec 
247 bp 
Human 
GAPDH 
FOR - TTAAAGGTTAGGTTGTAAATGTTAT 
REV - ATATTTAACCTCAAACCAAAATAC 
95º C, 30 sec 
55º C, 30 sec 
72ºC, 15 sec 
128 bp 
Mouse 
H19 ICR 
FOR – AAGGAGATTATGTTTTATTTTTGGA 
REV - CCACAACATTACCATTTATAAATTCC 
95º C, 30 sec 
56º C, 30 sec 
72ºC, 15 sec 
152 bp 
Mouse 
Hist1h2ba  
FOR - GAATTTTTTTGTGATAGATATTTT 
REV - CCTTTAAATTTATTATAAACCCTAC 
95º C, 30 sec 
52º C, 30 sec 
72ºC, 15 sec 
222 bp 
Mouse 
Actb 
FOR – GGAGAAGAGTTATGAGTTGTTTGA 
REV -  TAAACTACAACTTACCCAAAAAAAA 
95º C, 30 sec 
56º C, 30 sec 
72ºC, 15 sec 
110 bp 
Mouse 
Gapdh 
FOR - GGGGAAATGAGAGAGGTTTAGTTAT 
REV -  AAAAAACAAAAAACACCAAAAAAA 
95º C, 30 sec 
56º C, 30 sec 
72ºC, 15 sec 
183 bp 
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Human 
MT-COI 
FOR - ATTTTTTATAAATTATAAAGATATTGGAAT 
REV - AAACTATTCAACCTATTCCTACTCC 
95º C, 30 sec 
55.4º C, 30 sec 
72ºC, 23 sec 
365 bp 
Human 
MT-non coding region 
FOR - TTGGGATTAGATATTTTATTATGTTTAGTT 
REV - ATAACCCATTTCTTACCACCTCATA 
95º C, 30 sec 
59.3º C, 30 sec 
72ºC, 23 sec 
297 bp 
Human 
MT-ND1 
FOR - ATGGTTAATTTTTTATTTTTTATTGTATTT 
REV - TAATTTAAATTTAATACTCACCCTAATCAA 
95º C, 30 sec 
57.5º C, 30 sec 
72ºC, 23 sec 
374 bp 
Human 
MT-ND4 *** 
FOR - TTTTTGAGTTAATAATTTAATATGATTAGT 
REV - ACTTCAAAAAATTTAAATAAAAATAACTAT 
95º C, 30 sec 
55.4º C, 30 sec 
72ºC, 15 sec 
361 bp 
Human 
MT-ND5 
FOR - GTTTTTTAAATATTTATTTATTTTTTTAAT 
REV - CCTAATTAAACTAATTTACCTACTACTACT 
95º C, 30 sec 
53º C, 30 sec 
72ºC, 23 sec 
336 bp 
Mouse 
MT-D-Loop 
ATTTGGTTTATTAATTTATTATTTTT 
CTATATACTATCCTTTCATACCTTAAC 
95º C, 30 sec 
46.1º C, 30 sec 
72ºC, 19 sec 
304 bp 
Mouse 
MT-non coding region 
GGAATGTTTAAAGGAAAGATTTAAAAAG 
TCAACCTCTTCACTAAAAAATCAATTT 
95º C, 30 sec 
50.6º C, 30 sec 
72ºC, 19 sec 
268 bp 
 
2.19 BM-PCR sequencing and BM-cloning sequencing  
BM-PCR products were treated to eliminate primers and nucleotides prior to sequencing 
(Werle et al., 1994), as follows: 
 
5 µL PCR product containing 15 ng of DNA for each 100 bp of amplicon length 
1 µL FastAP Thermosensitive Alkaline Phosphatase 1 u/µL (Fermentas) 
0.5 µL Exonuclease I (Fermentas), incubate at 37°C for 15 minutes and at 85° C for 15 
minutes.  
 
Sequencing was performed with the Reverse primer (unless otherwise indicated) in an 
ABI 3130xl sequencer. Chromatograms were subject to visual quality control and areas 
with wide/overlapping peaks were excluded from subsequent analyses. A further quality 
control was performed with BiQ Analyzer software (Bock et al., 2005) to ensure a 
minimum of 70% identity match with the expected PCR product sequence and a 
minimum of 80% conversion rate of unmethylated Cytosines to thymines. For data 
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presented in Chapter 3 and Chapter 4, Cytosine methylation content was determined by 
applying the following formula: 
 
% C Methylation = C peak height / (C peak height + T peak height) * 100 (Jiang et al.). 
 
When direct sequencing did not pass BiQ quality controls or sequencing chromatograms 
were not optimal, the BM-PCR products were cloned as described above in section 2.9, 
plasmid DNA was purified from 10 clones and sequenced with the pJET1.2 FOR primer. 
Sequences were aligned as described above and aggregated methylation data graphs 
produced. 
For data presented in Chapter 5 and Chapter 7, Cytosine methylation content was 
determined using Epigenetic Sequencing Methylation analysis software (ESME) (Lewin 
et al., 2004). This program calculates methylation levels by comparing the C to T peaks at 
CpG sites after alignment of the ABI sequencers trace files to a reference sequence (the 
unconverted PCR product) after having performed a quality control, normalised the 
signals and corrected for incomplete bisulphite conversion. Quality control output for all 
analyzed sequences is given in Appendix B. 
 
2.20 Pyrosequencing 
Predesigned assays for Pyrosequencing (PyroMark CpG Assays, including PCR and 
sequencing primers for Pyrosequencing analysis of gene-specific CpG methylation after 
DNA bisulfite conversion) were obtained from QIAgen Sciences, Germantown, MD. 
Primer sequences were protected from copyright, therefore are not known; Table 2.7 lists 
the available informations for those assays. Methylation standards measurements and 
pyrograms are presented in Appendix C. 
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Table 2.7. Specifications for PyroMark CpG Assays used in the present study. CpG sites 
under investigation are underlined. The symbol “*” indicates assays that required a final 
concentration of 3 nM of MgCl2, instead of the usual 1.5 mM obtained by using the  
PyroMark PCR Master Mix. 
 
Specificity 
Assay name 
Catalog Number 
Amplicon 
Length 
Sequence to analyse 
Human 
Hs_CTTN_01 
PM00151844 
114 bp 
GGGGGCACGGAGGGCTTGGGGCTGGGGTCC
GCGGA 
Human 
Hs_GLIPR2_01* 
PM00141176 
152 bp 
GGCTGTCCTCGGGACAGCCGAGCGGGGCAA
ACTGCTTCGC 
Human 
Hs_NPTX1_03* 
PM00182035 
78 bp CAGCCCGGCTCCAAACGACCCCGGC 
Human 
Hs_NPTX1_07* 
PM00182063 
181 bp 
CGGGGGTCACCGGGCCGCCCCGCGTTTCTTA
GATGTCCGT 
Human 
Hs_SLC39A14_01* 
PM00136598 
125 bp GGCTAGGCGGTGAGAGCTTCCCGCGT 
Human 
Hs_SLC39A14_02* 
PM00136605 
261 bp 
GAGCGGGCGCCGACCACAGCCAGGGCCGCG
AGGCGC 
 
To prepare samples for Pyrosequencing, gDNAs were bisulphite modified as described in 
section 2.17 and BM-PCR products were prepared in triplicate reactions using the 
PyroMark PCR Kit following the manufacturer’s instructions, as follows: 
 
2 µL BM DNA 
25 µL PyroMark PCR Master Mix, 2x 
2.5 µL CoralLoad Concentrate, 10x 
2.5 µL Primers Mix 3 µM (including a Biotinylated Reverse Primer)  
water to 25 µL. 
 
Cycling conditions were: 
 
95° C for 15 minutes 
94° C for 30 seconds 
56° C for 30 seconds 
72° C for 30 seconds 
72° C for 10 minute. 
45 cycles 
72 
 
10 µL of each PCR product were electrophoresed in a 2% agarose/TBE gel plus 0.4% of 
Ethidium Bromide to check for the presence of a unique band and samples leftovers were 
sent to EpigenDx, Hopkinton, MA, for Pyrosequencing in a PyroMark Q96 MD 
instrument. Briefly, the following mix was prepared for each biotinylated PCR product in 
a 96-well PCR plate: 
 
10 µL biotinylated BM-DNA PCR product 
2 μl GE Healthcare Streptavidin Sepharose High Performance beads 
40 μl QIAgen PyroMark Binding Buffer  
water to 80 μl. 
 
PCR plates were sealed and mixed at 1400 rpm for 10 minutes at room temperature, 
allowing the immobilization of the PCR products to the streptavidin-coated beads. 
Strand separation was performed with the aid of probes applying vacuum in a PyroMark 
Q96 Vacuum Workstation by soaking the captured beads in 70% ethanol, then in 
PyroMark Denaturation Solution (QIAgen) and then in PyroMark Wash Solution 
(QIAgen); finally, beads were released into a PyroMark Plate containing 12 µL of 300 
nM sequencing primer resuspended in PyroMark Annealing Buffer (QIAgen) in each 
well, heated at 80° C for 10 minutes, allowed to cool to room temperature and run into the 
instrument. 
CpG sites that did not pass the instrument quality control were excluded from further 
analyses. 
 
2.21 Promoter-reporter assays 
2.21.1 Promoter identification and cloning 
To determine whether the genomic regions that showed differential methylation could act 
as promoters for the related downstream genes, bioinformatics analyses were performed 
using the webtool http://genome.ucsc.edu/cgi-bin/hgBlat to determine the presence of 
regulatory elements (Transcription Factors Binding Sites, Transcription Start Sites in the 
proximity, Regulatory Regions and Polymorphisms). In addition, a high density of CpG 
dinucleotides was confirmed using the webtool 
http://www.ebi.ac.uk/Tools/emboss/cpgplot, applying the default criteria. As previously 
described, these genomic regions spanned a 750 bp size (the window size used for the 
bioinformatics analyses). A murine Secreted Embryonic Alkaline Phosphatase (mSEAP) 
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reporter plasmid without a promoter, an enhancer and completely devoid of CpG 
dinucleotides was obtained (Invivogen); the plasmid map is shown in Figure 2.1. 
 
 
 
Figure 2.1. Map of the pCpGfree-basic plasmid (adapted from 
http://www.invivogen.com/pcpcgfree-basic). 
 
The plasmid is 3837 bp in size and has the following features: 
 
Ori: E. coli origin of replication R6K gamma ori (modified to eliminate all CpG sites), 
activated by the pir gene-activated protein ∏ (Wu et al., 1995); 
EM2K: bacterial promoter EM7 (modified to eliminate all CpG sites); 
Zeo: CpG-free synthetic allele of the Zeocin resistance gene; 
mSEAPΔCpG: a modified version of the murine Secreted Embryonic Alkalyne 
Phosphatase without CpG sites; 
pAn: CpG-free polyadenylation signal of the SV40 polyadenylation signal; 
MAR: Matrix Attached Regions (Bode et al., 1996); this plasmid includes two naturally 
CpG-free MARs: one upstream of the IFNB1 gene and one upstream of the HBB gene; 
MCS: Multiple Cloning Site, featuring the following restriction sites form 5’ to 3’: SdaI, 
Bsp120I, AvrII, NsiI, Prpu10I, ScaI, BamHI, SpeI, HindIII. 
 
The promoters of interest were PCR amplified from gDNA of replicative MRC-5 
fibroblasts according to the following reaction set up: 
200 ng of gDNA 
300 nM of each primer 
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0.75 µL DMSO (final concentration 3%) 
12.5 µL Phusion High-Fidelity PCR Master Mix 2x with HF Buffer (Finnzymes) 
water to 25 µL. 
 
Reactions were prepared in triplicates and incubated as follows: 
 
98° C for 30 seconds 
98° C for 10 seconds 
71.5° C for 30 seconds 
72° C for 24 seconds 
72° C for 10 minutes. 
 
Primer sequences are listed in Table 2.8. 
 
Table 2.8. Primers sequences for CTTN and GLIPR2 promoters cloning; BamHI and 
HindIII restriction sites are underlines in the FOR and REV sequences, respectively. 
 
Primer Sequences Amplicon Length 
CTTN Prom. FOR: CAGGGATCCCCGGGCGAGCTCTGCAGA 
CTTN Prom. REV: CAGAAGCTTCTTTCCTTGAGACCCCCCACACC 
780 
GLIPR2 Prom. FOR: CAGGGATCCCCCAGAGTCACCGGAGATGGG 
GLIPR2 Prom. REV: AGAAGCTTTGGCCTCCTGAAACAAAGCAGAAC 
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PCR products were electrophoresed in a 1% agarose/TBE gel plus 0.4% of Ethidium 
Bromide and DNA bands excised with the aid of a transilluminator. DNAs were purified 
using the GeneJET Gel Extraction Kit (Fermentas), according to the following protocol: 1 
volume of Binding Buffer was added to the gel slice (volume: weight) and the mixture 
incubated at 60° C for 10 minutes to completely solubilize the gel. This solution was then 
transferred to a GeneJET purification column and centrifuged at 13000 rpm for 1 minute, 
the flow-through discarded  and  the column washed with 700 µL of Wash Buffer 
reconstituted as indicated by the manufacturer (9 mL of concentrated buffer  plus 45 mL 
of 100% ethanol). The column was centrifuged for an additional minute to remove any 
residual ethanol and DNAs eluted in 30 µL of Elution Buffer, centrifuging at 13000 rpm 
for 1 minute, after 1 minute of incubation at room temperature.  
30 cycles 
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Purified promoters were double digested as follows: 
 
30 µL of purified DNA 
3 µL Fast Digest Green Buffer 10x  
1 µL Fast Digest BamHI (Fermentas) 
1 µL Fast Digest HindIII (Fermentas) 
water to 40 µL, incubate at 37° C for 1 hour. 
 
A parallel digestion with the same enzymes and 1 µg of pCpG-free plasmid DNA was set 
up, electrophoresed and purified from gel with the GeneJET Gel Extraction Kit 
(Fermentas) as described above. The digested promoters were cleaned up using the DNA 
Clean & Concentrator-5 kit (Zymo Research), as described in section 2.6.3. 
1 µL of each purified DNA was quantified on agarose/TBE gel by comparison with 1 µL 
of 1 Kb Plus DNA Ladder, ready-to-use (Fermentas). 
The following equation was applied to calculate the optimal amount of fragment (digested 
promoter) to be incubated with the vector (digested plasmid) in a ligation reaction: 
 
3 : 1 = amount of fragment (ng) / fragment size (bp) : vector amount (ng) / vector size 
(bp).  
 
Ligation reactions were set up as follows:  
 
50 ng of vector  
30 ng of  fragment (CTTN promoter or GLIPR2 promoter) 
2 µL T4 DNA Ligase Reaction Buffer 
1 µL T4 DNA Ligase 0.4 U/mL (New England Biolabs) 
water to 20 µL. 
 
A parallel control ligation was set up with all reagents except the fragment (digested 
promoter). The reaction mixtures were incubated at room temperature for 2 hours and 
cleaned up using the DNA Clean & Concentrator-5 kit (Zymo Research) as described in 
section 2.6.3, but eluting in 10 µL of water.  
Ligations were transformed as described in section 2.9, but using the E.coli, strain GT115 
(Invivogen; genotype: F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacX74 recA1 
rspL (StrA) endA1 ∆dcm uidA(∆MluI)::pir-116 ∆sbcC-sbcD), suitable for the replication 
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of plasmids featuring the R6K gamma ori. LB Lennox agar plates (Teknova; 1% 
Tryptone, 0.5% Yeast Extract, 0.5% Sodium Chloride, 2.0% Agar) containing 25 µg/mL 
Zeocin (Teknova) as a selection antibiotic were used for the colonies overnight growth. 
 
2.21.2 Screening and confirmation of the cloning products 
A preliminary colony PCR screening was performed to detect E.coli colonies containing 
successfully cloned promoters setting up the reactions as follows: 
 
5 µL of bacteria colony resuspended in 50 µL of water 
300 nM of each primer 
1.25 µL DMSO (5% final concentration) 
12.5 µL HotStart Maxima PCR Master Mix 2x (Fermentas) 
water to 25 µL. 
 
The Forward primer (FOR) was designed upstream of the plasmid multiple cloning site 
(MCS) and Reverse primer (REV) was designed downstream of the MCS; sequences are 
listed below: 
 
pCpGfree-basic FOR: ACTGATTTTTGTTTATGTGAGC 
pCpGfree-basic REV: GCAATAGCAGACAGGCAC; 
 
Expected amplicon length was 953 bp for the CTTN promoter cloning and 965 for the 
GLIPR2 promoter cloning. 
Reactions were incubated as follows: 
 
95° C for 4 minutes 
95° C for 30 seconds 
55° C for 30 seconds 
72° C for 48 seconds 
72° C for 10 minutes. 
 
5 µl of each PCR product were loaded into 1% agarose/TBE gel with 0.4 μg/mL of 
Ethidium Bromide and electrophoresed.  
30 cycles 
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Among the clones that showed successful amplification, two were chosen at random for 
plasmid DNA extraction, restriction digestion analysis and sequencing confirmation. 5 
mL of a selected clone culture in LB Lennox medium (Teknova; 1% Tryptone, 0.5% 
Yeast Extract, 1.0% Sodium Chloride, pH 7.5) plus 25 µg/mL Zeocin (Invitrogen) were 
incubated overnight at 37° C with orbital shaking at 220 rpm. The morning after, plasmid 
DNA was extracted using the GeneJET Plasmid Miniprep Kit (Fermentas) as described in 
section 2.9.1.  
Restriction digestion analysis was set up using the same enzymes used for cloning, as 
follows: 
 
1 µg plasmid DNA 
2 µL FastDigest Green Buffer 2x  
1 µL FastDigest BamHI (Fermentas) 
1 µL FastDigest HindIII (Fermentas) 
water to 20 µL, incubation at 37° C for 1 hour. 
 
Digests were loaded into 1% agarose/TBE gel plus 0.4 µg/mL of Ethidium Bromide to 
assess the release of the cloned promoters from the vector backbone. 
To confirm the sequence of the cloned products, 1 µg of each plasmid DNA was 
sequenced with both pCpGfree-basic primers in an ABI 3130xl sequencer and sequences 
aligned with the expected using the webtool Chromas, Version 2.33.  
 
2.21.3 Preparation of promoter-reporter construct at increasing concentration of DNA 
methylation content 
To study the effect of DNA methylation on gene expression for the promoters under 
investigation, fully methylated promoter-reporter construct were prepared as described in 
section 2.6.2 and purified with the GeneJet PCR Purification kit, as also described in 
section 2.6.2. To test the efficiency of in vitro methylation (IVM), 200 ng of the IVM 
constructs were digested with MspI and HpaII isoschizomers in parallel reactions, as 
described in section 2.6.2. Fully methylated and unmethylated constructs for the same 
cloned promoter were mixed to obtain 0%, 25%, 50%, 75% and 100% of CpG promoter 
final methylation content. 
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2.21.4 Transfection of cells 
2.5 x 10
5
 LN-229 cells were plated in 24 well plates the day before transfection in 500 µL 
of complete DMEM medium (Sigma Aldrich) supplemented with 10% FBS, 100 U/mL 
Penicillin and 100 µg/mL Streptomycin. 170 ng of each plasmid DNA (prepared as 
described in section 2.21.3) were added to 17 µL of Opti-MEM Reduced Serum Media 
(Invitrogen). In parallel, 1 µL of Lipofectamine Transfection Reagent (Invitrogen) was 
added to the same volume of Opti-MEM. Both mixes were incubated for 5 minutes at 
room temperature, combined and further incubated for 20 minutes at room temperature. 
After two washes with 1 mL of Opti-MEM, the growth medium was replaced with 200 
µL of Opti-MEM, transfection mixes were added to the wells and plates were incubated 
for 5 hours at 37° C in a 5% CO2 incubator. At the end of this incubation time, cells were 
washed twice with 1 mL of complete DMEM and placed in the incubator with 500 µL of 
complete DMEM until assayed (3 days after transfection). 
 
2.21.5 Secreted Embryonic Alkaline Phosphatase (SEAP) Assay  
SEAP levels can be measured in the conditioned media of cells transfected with a 
pCpGfree-basic plasmid in which a functional promoter was cloned at 5’ end of the 
mSEAPΔCpG gene. For this purpose, the Secreted Alkaline Phosphatase Reporter Gene 
Assay Lit – Luminescence (Cayman Chemical Company) was used. 10 µL of each 
conditioned media were transferred to a 0.2 mL PCR tube and heated at 65° C for 30 
minutes in a thermal cycler; this step inactivated endogenous alkaline phosphatase, but 
not the SEAP, which is stable at this temperature. Samples were equilibrated at room 
temperature, transferred to a white 96 well plate and 50 µL of Substrate were added to 
each well. After incubation at room temperature for 30 minutes, luminescence was read in 
a plate reader at intervals of 30 minutes for up to 3 hours. In parallel, a standard curve 
with serial dilutions of the Cell-Based Alkaline Phosphatase Standard 5U/mL was 
prepared (dilution curve range: 156.25 µU/mL to 1 µU/mL), using the culture medium 
used with the cells and performing the inactivation. The time point showing the standard 
curve best coefficient of determination (2 hours) was chosen for the data analysis. Data 
are shown setting as reference/normalization value the luminescence of the unmethylated 
sample. 
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2.22 Methylscreen 
To perform a promoter methylation screening on cell cycle genes, I used the 
Methylscreen technology (Holemon et al., 2007). The following reagents were obtained 
from QIAgen: 
 
EpiTect Methyl II DNA Restriction Kit (containing 5X Restriction Digestion Buffer, 
Enzyme A (Methylation-Sensitive) and Enzyme B (Methylation-Dependent) 
RT² SYBR® Green qPCR Mastermix, catalog number 330520 
qPCR plates containing pre-dispensed primers: Human Cell Cycle DNA Methylation 
PCR Array, Signature Panel: EAHS-201Z 
 
Briefly, 1 µg of genomic DNA from each sample (replicative senescent and young 
confluent MRC-5) was split in 4 tubes and incubated overnight in a final volume of 30 µL 
at 37°C in the presence of 1X digestion buffer and: 
 
1. No restriction enzymes (Mock digestion) 
2. 1 µL Methylation Sensitive Enzyme (digestion A) 
3. 1 µL Methylation Dependent Enzyme (digestion B) 
4. 1 µL of  both Methylation Sensitive and Dependent enzymes (digestion A+B) 
 
After enzymes inactivation (65°C, 20 minutes), samples were prepared for qPCR as 
follows: 
 
30 µL of either Mock digestion, digestion A, B or A+B 
330 µL RT² SYBR® Green qPCR Mastermix 
water to 660 µL. 
 
According to the manufacturer’s suggested layout, 25 µL of each mix were dispensed in 
the qPCR plates wells, which contained primers for amplification, and incubated as 
follows: 
 
95° C for 10 minutes 
99° C for 30 seconds 
72° C for 1 minute 
 
3 cycles 
80 
 
97° C for 15 seconds 
72° C for 1 minute 
 
Melting curves were obtained as described in section 2.8; the acquisition of the 
fluorescence signal was set as a single reading during the annealing step and as a 
continuous reading during the melting curve. 
Methylation rates were calculated from the Cq values obtained after the Real Time qPCR 
run using an Excel template provided by the manufacturer. 
 
2.23 Statistical analyses and data analysis of gene overlaps 
Statistical analyses were performed using standard statistical software (Microsoft Office 
Excel® 2010; Systat Software SigmaPlot® for Windows Version 11.0 Build 11.0.1.80; 
Minitab® 16.1.0). 
 
For gene overlaps in Chapter 5 and Chapter 6, representation factors and hypergeometric 
probabilities were calculated.The representation factor (r) indicated whether the number 
of common genes was higher (r > 1), equal (r = 1) or lower than what would be expected 
by chance (r < 1), if the genes were drawn from two independent lists of genes. The 
representation factor  was calculated by applying the following formula: 
 
r = X / [ ( n x D ) / N], 
 
where X was the number of common genes, n was the number of gene in one list, D was 
the number of genes in the other list and N was the total number of genes. 
 
The hypergeometric probability (h) indicated the probability that the number of common 
genes resulted in greater than or equal to X overlaps and it was calculated by applying the 
following formula: 
 
h ( ≥ X; N, n, D ) = [ DCX ] [ N-DCn-X ] / [ NCn ],  
 
where X was the number of genes common between groups, n was the number of genes 
in one list, D the number of genes in the other list, N the total number of genes and DCX 
is the number of combinations of D things, taken X at a time. 
40 cycles 
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Chapter 3. Effects of senescence, ageing and dietary energy restriction 
on expression of DNA Methyltransferases and global DNA methylation 
 
3.1 Outline 
Altered global DNA methylation content (hypomethylation and hypermethylation) is a 
feature of several conditions. Global hypomethylation of DNA is associated with some 
chronic autoimmunodiseases (Rahman and Isenberg, 2008) and tumours (Hirst and 
Marra, 2009). In contrast, hypermethylation of the promoter regions of tumour suppressor 
genes and of DNA repair genes, such as MLH1, causes gene silencing and contributes 
causally to tumourigenesis (Jones and Baylin, 2002). Similar effects are seen in Fragile X 
Syndrome (Crawford et al., 2001; Penagarikano et al., 2007). Altered patterns of DNA 
methylation are also observed during ageing (Thompson et al., 2010), some of which 
correlate with age-related frailty (Bellizzi et al., 2012) and other age-related phenotypes 
(Bell et al., 2012).  
Although CpG islands are present in mammalian genomes and overlap promoter regions 
of 50%-60% of human genes (Wang and Leung, 2004) - thus suggesting that DNA 
methylation plays a role in the regulation of gene expression - most of the DNA 
methylation in mammalian genomes is found in repetitive elements, such as transposons 
and endogenous retroviruses (Schulz et al., 2006). Transposable elements, which include 
Long Terminal Repeats (LTR)-Retrotransposons, Long and Short Interspersed Nuclear 
Elements (LINE and SINE, respectively) and DNA transposons constitute about 45% of 
the human and 37% of the mouse genome, as reviewed in (Burns and Boeke, 2012). 
These sequences could interfere with the regulation of gene expression and genome 
structure by means of insertions, deletions, inversions and translocations of genomic 
sequences. However, this potential damage is prevented by high levels of CpG 
methylation (Schulz et al., 2006; Kim et al., 2009b) and this methylation is thought to 
contribute to genome stability. 
HPLC-based assays (outlined in section 1.8.1) were one of the first methods developed to 
quantify global Cytosine methylation. Although HPLC has the advantage of being both 
robust and sensitive, this technique is relatively laborious and requires relatively large 
amounts of starting DNA, so alternative methods aimed at the estimation of global 
methylation content of DNA have been established. These alternative assays are based on 
estimating the methylation content of genomic repeats by e.g. pyrosequencing or by direct 
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sequencing after bisulfite modification of DNA or on the use of methylation-sensitive 
enzymes. Although these alternative assays actually measure site-specific methylation, 
they may provide researchers with useful estimates of global DNA methylation (because 
these repeats domains constitute a large part of the genome) and their advantages include 
the small amount of starting material (DNA) needed and the widespread availability of 
the appropriate technologies. 
 
In this chapter, I first measured the relative expression of the genes that encode for the 
enzymes that catalyze the addition of a methyl group to the 5’ position on Cytosines 
residues in DNA in the context of CpG dinucleotides (DNA Methyltransferases; DNMTs, 
Dnmts) in young replicative (YC) and senescent (ESIPS, RS) cells in culture, in young 
and ageing heart, colon and liver samples from mice and in liver samples from ad libitum 
fed and dietary energy restricted mice. Secondly, I measured the global DNA methylation 
content of each of the samples using different experimental approaches. Finally, I 
investigated potential releationships between DNMTs/Dnmts expression and estimates of 
global DNA methylation content of the cells and tissues. 
 
3.2 Assessment of the senescence state of MRC-5 cells 
Before starting with the methylation experiments, it was important to determine whether 
the cell cultures showed the expected expression pattern of a widely utilized senescence-
associated marker i.e. β-Gal senescence-associated expression at pH = 6. For this 
purpose, I stained young confluent (YC), early stress-induced premature senescent 
(ESIPS; 20 Gy, harvesting after 48 hours) and replicative senescent (RS) MRC-5 cells, as 
described in section 2.1.1. For the latter samples, replicative senescence was determined 
by the aid of growth curves, generated as described in section 2.1. As shown in Figure 
3.1, no β-Gal expression was detected under the experimental conditions in both YC and 
ESIPS cells, while an intense cytoplasmic and perinuclear β-Gal expression was detected 
in RS cells. This provided further confirmation of the suitability of my RS and YC cell 
cultures for further studies. In a previously published report, MRC-5 fibroblasts irradiated 
with 10 or 40 Gy and harvested after 72 hours stained positively, but weakly, for β-Gal 
(Bluwstein et al., 2013), thus it is possible that my irradiated cells (ESIPS) stained 
negative for  β-Gal simply because I harvested at an earlier timepoint. As shown later in 
this thesis (see Chapter 5 and CD insert), I obtained proof of the senescent state of my 
irradiated (ESIPS) MRC-5 fibroblasts by transcriptome analyses. These observations 
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suggest that, although a widely used marker for senescence, the β-Gal increased activity 
at pH 6 is not an essential marker for senescence. 
 
A 
 
 
B 
 
 
C 
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Figure 3.1. β-Gal senescence-associated assay performed on young confluent (panel A), 
early stress-induced premature senescent (20 Gy, harvesting after 48 h; panel B) and 
replicative senescent MRC-5 cells (panel C). Left pictures show β-Gal cytoplasmic and 
perinuclear stainings and right pictures show DAPI staining of the cell nuclei in the same 
fields. 
 
3.3 DNA Methyltransferases expression in senescent cells and in ageing and dietary 
energy restricted mouse livers 
As a first approach to study global DNA methylation changes occuring in senescence, and 
in response to ageing and to dietary energy restriction (ER), I quantified the expression of 
the three main DNA Methyltransferases (DNMT1/Dnmt1, DNMT3A/Dnmt3a and 
DNMT3B/Dnmt3b) at the mRNA level. I designed and performed assays for Reverse 
Transcription quantitative PCR assays (RT-qPCR; see sections 2.4 and 2.13, Table 2.5 
and Appendix A for details) and normalized the data using the Pfaffl method (Pfaffl, 
2001), choosing as normalizer the gene that showed the lowest Cq (cycle for 
quantification) standard deviation between the samples under investigation. The 
normalizers tested were ACTB, B2M, GAPDH and UBE2B for the MRC-5 cells assays 
and B2m, Hmbs, Hprt and Gapdh for murine samples. The chosen normalizers for the 
qPCR calculations were GAPDH for the cells-based assays, Gapdh for the heart and 
colon assays and B2m for the liver assays. 
Expression of DNMTs was significantly down-regulated in RS (DNMT1 fold change = 
0.61, DNMT3A fold change = 0.38 and DNMT3B = 0.51) and also in ESIPS cells 
(DNMT1 fold change = 0.54 and DNMT3A fold change = 0.52) each compared with YC 
cells, with the only exception of DNMT3B, which showed a similar, but not significant 
trend (data shown in Figure 3.2). Significant changes in expression were observed for the 
de novo methylase Dnmt3b and for Dnmt1, which were down-regulated by ageing in the 
liver (fold change = 0.56) and colon (fold change = 0.64) when compared with young 
counterparts, whereas Dnmt3b was significantly up-regulated in liver with short-term 
dietary energy restriction (fold change = 8.05) (data shown in Figure 3.3 and 3.4, 
respectively) compared with ad libitum diet. Colon or heart samples from dietary energy 
restricted mice were not available; this precluded the investigation of effects in those 
tissues. 
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Figure 3.2. DNMTs expression at mRNA levels in early stress-induced premature 
senescence (ESIPS) and replicative senescence (RS) compared with young confluent 
MRC-5 fibroblasts. Data are shown as average expression ratios using GAPDH as 
normalizer; error bars indicate ± SD of n =3 biological replicates. * = p < 0.05; ** = p 
< 0.01; *** = p < 0.001 for student’s unpaired t-test. 
 
A 
 
 
 
 
 
 
 
86 
 
B 
 
 
C 
 
 
Figure 3.3. Dnmts expression at mRNA levels in ageing (32 m.o.) mouse liver (panel A), 
heart (panel B) and colon (panel C) compared with their young (3 m.o.) counterparts. 
Data are shown as average expression ratios using B2m as normalizer for livers and 
Gapdh for heart and colon samples; error bars indicate ± SD of n =3 biological 
replicates. * = p < 0.05; ** = p < 0.01 for student’s unpaired t-test. 
 
87 
 
 
 
Figure 3.4. Dnmts expression at mRNA levels in dietary energy restricted mouse liver 
compared with ad libitum fed mice livers. Data are shown as average expression ratios 
using B2m as normalizer; error bars indicate ± SD of n =3 biological replicates. ** = p 
< 0.01 for student’s unpaired t-test. 
 
3.4 Global DNA methylation content in senescent cells vs young replicative cells and 
effects of ageing and dietary energy restriction on global DNA methylation in mouse 
livers 
To measure the global DNA methylation content in my samples, I used four different 
approaches: a colourimetric ELISA-based method (MethylFlash Methylated DNA 
Quantification Kit, Epigentek) and a PCR based method (LINE-1 assay for human cells 
samples and B1 element assay for mice samples). I then quantified global methylation in 
subsets of my samples using a methyl-sensitive restriction enzyme based assay followed 
by Pyrosequencing (LUMA) and by the gold standard for global methylation content 
measurement (HPLC) to further validate my results. Experimental procedures and 
reagents are described in sections 2.14, 2.15, 2.16, 2.17, 2.19 and Table 2.6. 
 
3.4.1 Global DNA methylation measurement by means of an ELISA-based 
colourimetric assay 
For these measurements, I first established a standard curve with dilutions of DNA of 
known methylation content (provided with the kit) and determined the reading time point 
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which resulted in a coefficient of determination (R
2
) as close as possible to 1. For this 
purpose, I chose 3 time points included within the time frame for reading suggested by 
the manufacturer (between 2 to 15 minutes); these were 5 minutes, 10 minutes and 15 
minutes. The best linearity curve was obtained after 5 minutes from colour development 
(see Figure 3.5), hence sample readings obtained at this time point were used for the 
global methylation content amount calculations, applying the following formula:  
 
5-mC (ng) = (sample OD –Negative Control OD) / Slope x 2, 
 
where 2 is a normalization factor, as the Positive Control used for the standard curve 
preparation contains only 50% of 5-methylCytosines. 
 
The percentage of 5-methylCytosine content was then calculated as follows: 
5-mC% = (5-mC amount (ng)) / (amount of input gDNA (ng)) x 100. 
 
 
 
Figure 3.5. Example of linearity curve for global methylation colourimetric assay using 
the Epigentek MethylFlash Methylated DNA Quantification Kit; data were collected after 
5 minutes of colour development. The line equation was used for samples global 
methylation content calculations. 
 
Figure 3.6 summarises the results of global DNA methylation obtained using this 
technique in human cells. There was a trend for global methylation to decrease in the 
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order YC > ESIPS > RS, but these differences were not statistically significant because of 
the relatively high inter-sample differences for these assays. Global DNA methylation 
was relatively similar in all 3 mouse tissues (heart, liver and colon) examined (Figure 3.7) 
Perhaps surprisingly, global DNA methylation tended to be higher in tissues from the 
older compared with the younger mice but this difference was not statistically significant, 
when considering each single tissue separately in the statistical analysis, or when both age 
and tissue were included as factors in a two-way ANOVA (Figure 3.7). 
 
 
 
Figure 3.6. ELISA-based colourimetric global methylation assay results for young 
confluent (YC), early stress-induced premature senescent (ESIPS) and replicative 
senescent (RS) MRC-5 cells. Results are shown as average percentage of 5-
methylCytosine content. Error bars show ± SD, n = 4 biological replicates. 
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Figure 3.7. ELISA-based colourimetric global methylation assay on mouse tissues. Panel 
A: global methylation content for young vs old murine livers, hearts and colons; panel B:  
global methylation content for livers from ad libitum (AL) vs dietary energy restricted 
mice (ER). Results are shown as average percentage of 5-methylCytosine content. Error 
bars show ± SD, n = 3 biological replicates.  
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3.4.2 Repetitive elements methylation measurements as surrogates for global DNA 
methylation content measurements: LINE-1 and B1 element assays 
Given the high variability between replicates seen with the ELISA-based method for 
estimating global DNA methylation, I moved on to a different methodology and designed 
a direct sequencing assay to monitor 12 CpG sites within the human LINE-1 Long 
Interspersed Element, which, with about 500000 copies per genome, is the most highly 
represented domain in the human genome (Yang et al., 2004). For murine samples, I used 
an already published assay to monitor 3 CpG sites within the mouse B1 short interspersed 
element, of which there are about 30000 copies in the murine genome (Jeong and Lee, 
2005). Genomic regions of interest are illustrated in Figure 3.9 and 3.11, respectively, 
while experimental procedures, reaction conditions and primer sequences are listed in 
sections 2.17, 2.18 and 2.19 and Table 2.6.  
I used a Bisulphite Modified (BM) DNA PCR direct sequencing technique to quantify 
methylation at each of the CpG sites within the region of interest. To assess the suitability 
of this method, I monitored 1 CpG site of know methylation level in the Lambda DNA 
Fragment A sequence (see section 4.2). To prepare a methylated fragment, I in vitro 
methylated Fragment A, as described in section 2.6.2 and mixed the unmethylated and the 
fully methylated preparations in different proportions to obtain mixtures with the 
following methylation levels: 0%, 5%, 25%, 50%, 75%, 95% and 100%. Then I PCR-
amplified the mixtures using the primer pairs and reaction conditions listed in Table 2.6. 
The linearity curve for observed vs expected methylation is shown in Figure 3.8. 
Although the measured methylation content was lower than expected for the CpG of 
interest (reaching only 85% instead of 100%) - probably due to incomplete in vitro 
methylation of the starting DNA – the assay showed a good linearity (R2 = 0.98) and the 
technique was therefore deemed suitable for the assay. 
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Figure 3.8. Optimization of Bisulphite Modified (BM) DNA PCR direct sequencing. 
Observed vs expected methylation of 1 CpG site within a Lambda DNA sequence 
(Fragment A, see section 4.2). 
 
Human LINE-1 transposon (L1Hs) DNA 
GenBank: X58075.1 
 
1 gggggaggag ccaagatggc cgaataggaa cagctccggt ctacagctcc cagcgtgagc 
61 gacgcagaag acgggtgatt tctgcatttc catctgaggt accgggttca tctcactagg 
121 gagtgccaga cagtgggcgc aggccactgt gtgcgcgcac cgtgcgcgag ccgaagcagg 
181 gcgaggcatt gcctcacctg ggaagcgcaa ggggtcaggg agttcccttt ccgagtcaaa 
241 gaaaggggtg acggacgcac ctggaaaatc gggtcactcc cacccgaata ttgcgctttt 
301 cagaccggct taagaaacgg cgcaccacga gactatatcc cacacctggc tcagagggtc 
361 ctacgcccac ggaatctcgc tgattgctag cacagcagtc tgagatcaaa ctgcaaggcg 
421 gcaacgaggc tgggggaggg gcgcccgcca ttgcccaggc ttgcttaggt aaacaaagca 
481 gccgggaagc tcgaactggg tggagcccac cacagctcaa ggaggcctac ctgcctctgt 
541 aggctccacc tctgggggca gggcacagac aaacaaaaag acagcagtaa cctctgcaga 
601 cttaagtgtc cctgtctgac agctttgaag agagcagtgg ttctcccagc acgcagctgg 
661 agatctgaga acgggcagac tgcctcctca agtgggtccc tgacccctga cccccgagca 
721 gcctaactgg gaggcacccc ccagcagggc acactgacac ctcacacggc agggtattcc 
781 aacagacctg cagctgaggg tcctgtctgt tagaaggaaa actaacaacc agaaaggaca 
841 tctacacgaa aacccatctg tacatcacca tcatcaaaga ccaaaagtag ataaaaccac 
901 aaagatgggg aaaaaacaga acagaaaaac tggaaactct aaaacgcaga ggccctctcc 
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961 tcctccaaag gaacgcagtt cctcaccagc aacagaacaa agctggatgg agaatgattt 
1021 tgacgagctg agagaagaag gcttcagacg atcaaattac tctgagctac aggaggacat 
1081 tcaaaccaaa ggcaaagaag ttgaaaactt tgaaaaaaat ttagaagaat gtataactag 
1141 aataacc 
 
Figure 3.9 LINE-1 transposon sequence as published in (Crowther et al., 1991). Genomic 
regions used as priming sites for methylation studies are underlined; CpG sites 
investigated in this study are indicated in bold orange font. 
 
 
 
Figure 3.10. Human LINE-1 CpG methylation quantification by means of bisulphite 
modified DNA PCR direct sequencing in young confluent (YC), early stress-induced 
premature senescent (ESIPS) and replicative senescent (RS) MRC-5 fibroblasts. Bars 
represent average Cytosine methylation for n = 3 biological replicates, error bars show 
±SD. * = p < 0.05; ** = p < 0.01; *** = p < 0.001 for student’s unpaired t-test.  
 
Using the LINE-1 assay, I observed that methylation differed between individual CpG 
sites across the region of interest being at or close to 100% for CpG sites 9 to11 and 
approximately 70% at CpG site 1. There was significant demethylation at 8 out of 12 of 
the tested CpGs for RS compared with YC MRC-5 and in 2 CpGs in ESIPS compared 
with YC MRC-5 cells. The extent of decrease in methylation at single CpG sites ranged 
from 2% to 13% for RS compared with YC cells and from 2% to 3% for ESIPS compared 
with YC cells. 
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Methylation of the 3 CpG sites within the murine B1 element ranged from 51% to 80% 
(see Figure 3.11 for sequence). None of the 3 CpG sites analyzed showed different levels 
of methylation between age groups for liver, heart and colon samples (Figure 3.12, panels 
A, B and C, respectively) or between dietary groups (Figure 3.12). However, absolute 
methylation values across this B1 repeat region differed significantly between tissue 
types, with heart showing the lowest methylation (51% to 76%), liver showing 
intermediate methylation (64% to 79%) and colon being the most highly methylated 
tissue (68% to 80%), as calculated by ANOVA followed by Holm-Sidak or Kruskal-
Wallis ANOVA, followed by Dunn’s multiple comparisons test (data not shown). 
 
 
Figure 3.11. Murine B1 Short Interspersed Nuclear Element (SINE) sequence. Genomic 
regions used as priming sites for methylation studies are highlighted in dark grey; CpG 
sites are highlighted in light grey and CpG sites investigated in this study are marked 
with a black dot and a progressive number. Adapted from (Jeong and Lee, 2005). 
 
 
 
A 
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Figure 3.12. Quantification of murine B1 element CpG methylation by bisulphite 
modified DNA PCR direct sequencing in young (3 m.o.) and old (32 m.o.) mouse livers 
(panel A), hearts (panel B) and colons (panel C). Bars represent average Cytosine 
methylation for n = 3 biological replicates, error bars show ±SD. 
 
B 
C 
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Figure 3.13. Quantification of murine B1 element CpG methylation by bisulphite 
modified DNA PCR direct sequencing in ad libitum fed (AL) and dietary energy restricted 
(ER) mouse livers. Bars represent average Cytosine methylation for n = 3 biological 
replicates, error bars show ±SD.  
 
3.5 Use of methylation-dependent isoschizomers to estimate global methylation 
content and confirmation of the results by HPLC 
Two further approaches were used to quantify global DNA methylation on a subset of 
samples. Based on the amount of material available, the chosen samples were DNAs 
isolated from young and old mouse liver and colon and liver from ad libitum and dietary 
energy restricted mice. The additional analytical approaches used included the 
LUminometeric Methylation Assay - LUMA- (Karimi et al., 2006a; Karimi et al., 2006b), 
which has been described in sections 1.8.1; experimental procedures are given in section 
2.14. Briefly, this assay is based upon the use of the isoschizomeres MspI and HpaII, 
which recognise and cut the same sequence (CC↓GG), but with differential cutting 
according to its methylation state: MspI cuts the sequence regardless of methylation 
status, whereas HpaII cuts only at sites where the internal C is not methylated. The 
digestions are run in parallel on the same sample and then the extent of cutting is 
quantified in a pyrosequencer. Each reaction is performed in combination with another 
enzyme cutting at a separate site which theoretically is not affected by methylation (that 
is, not containing CpG dinucleotides) and that acts as a loading normalizer. EcoRI is used 
as the normalizator in the published method (Karimi et al., 2006b). 
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In setting up this assay in our laboratory, I repeated the validations performed previously 
by Karimi at al. including quantification of Lambda DNA at different levels of 
methylation to produce a standard curve. However, I noticed high variability in the 
reading produced by the pyrosequencer instrument and the calculated coefficients of 
determination were never higher than 0.8 (data not shown). 
To address this issue, I first checked on agarose/TBE gel the Lambda DNA digestions 
products and, surprisingly, I found that the EcoRI enzyme pattern of digestion was 
different from what expected. Computational analyses predicted that there should be no 
bands visible below 3 Kb, but this was not what was observed (Figure 3.13). 
 
 
                                               
              
 
Fig. 3.14: Lambda Phage DNA digestion patterns with EcoRI restriction enzyme (panel 
A, lane 2; lane 1 is 1 Kb DNA ladder) and virtual agarose/TBE gel showing EcoRI 
digestion of unmethylated Lambda DNA (panel B, adapted from NEBcutter, 
http://tools.neb.com/NEBcutter2/). 
 
The EcoRI altered digestion pattern was probably due to high star activity of the enzyme. 
It is well established that many restriction endonucleases show “relaxed” activity when 
the template DNA is “overdigested” (i.e. incubation for more than one hour with more 
than 5 U/μg DNA) and/or when the digestion in set up in a non-optimal buffer (see 
http://www.thermoscientificbio.com/restriction-enzymes/ecori/). These conditions were 
all satisfied by Karimi’s method, in which the reactions are run for 4h, the enzyme 
concentration is 25U/μg DNA and 1x Tango Buffer is not recommended for EcoRI 
digestion by the manufacturers (Fermentas). 
1 2 
3 Kb 
B A 
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As previously published, EcoRI restriction site is G↓AATTC, while in conditions of 
relaxed specificity it can be N↓AATTN, where N can be any base (Bishop, 1979). 
Theoretically, this should not influence the results of the LUMA, because the overhangs 
left after the cuts are all AATT, but I think it is possible that the higher number of cuts 
could affect the reading of the Pyrosequencer instrument. In addition, cutting by EcoRI is 
impaired by CpG methylation when the initial G in the recognition site is preceded by a 
methylated C (Figure 3.15) (see http://www.thermoscientificbio.com/restriction-
enzymes/ecori/). I therefore substituted EcoRI with another enzyme leaving the same 
overhangs, but which was not showing any star activity under the experimental conditions 
applied. MunI, which cuts C↓AATTG was a commercially available candidate, so I 
validated the method including it as normalizer in my assays (Lisanti S., Omar W.A.W. et 
al., accepted). Figure 3.16 compares LUMA validation curves generated by using either 
EcoRI (panel A) or MunI as normalizers (panel B) (W. A. W. Omar, Newcastle 
University, personal communication): MunI normalization resulted in an improved 
linearity of the relationship of observed vs expected methylation EcoRI (R
2
 > 0.99 and R
2
 
> 0.93, respectively). In addition, I noticed that EcoRI normalization was C-biased 
(tended to overestimate methylation) for low methylation content standards and T-biased 
(tended to underestimate methylation) for high methylation content standards. As shown 
in Figure 3.16, panel B, when using MunI normalization, measured methylation 
percentages were very close to the expected methylation levels. 
 
 
 
 
Figure 3.15. Fragment sizes after cutting unmethylated and methylated Lambda Phage 
DNA with EcoRI and MunI restriction enzymes. Lane 1 = 1 Kb DNA Ladder; Lane 2 and 
3 = EcoRI digestion patterns on unmethylated and methylated Lambda DNA using the 
published LUMA protocol, respectively; Lane 4 and 5 = MunI digestion patterns for 
1 4 5 3 2 
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unmethylated and methylated Lambda DNA using the published LUMA protocol (Karimi 
et al., 2006b), respectively. 
 
A                                                                       B 
 
 
Figure 3.16. Plots of observed vs expected methylation for samples of Lambda DNA of 
known methylation content quantified using the LUMA Pyrosequencing assay. Data were 
normalized with EcoRI (Panel A) or MunI (Panel B); reactions were carried out for 4 h in 
the presence of 1x Tango Buffer (Fermentas) (W.A.W. Omar, Newcastle University, 
personal communication). 
 
Having chosen MunI as normalizer, I used the modified LUMA assay to estimate global 
DNA methylation in liver and colon tissue from young and old mice. Global methylation 
was more variable for livers (means ranged between 64% and 70%) than for colon (means 
ranged between 72% and 73%) (Figure 3.17 and Figure 3.18). There was no detectable 
difference in methylation for either liver or colon for old compared with young mice 
(Figure 3.17, panels A and B, respectively). However, dietary energy restriction 
significantly decreased global DNA methylation by 6% (p = 0.026) in murine liver 
(Figure 3.18). 
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Figure 3.17. Global DNA methylation estimated using a modified Luminometric 
Methylation assay for young (3 m.o.) and old (32 m.o.) mouse liver (panel A) and colon 
DNA (panel B). Bars represent average Cytosine methylation for n = 3 biological 
replicates, error bars show ± SD. 
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Figure 3.18. Global DNA methylation estimated using a modified Luminometric 
Methylation assay for ad libitum fed (AL) and dietary energy restricted (ER) mouse liver 
DNA. Bars represent average Cytosine methylation for n = 3 biological replicates, error 
bars show ± SD. * = p < 0.05 for student’s unpaired t-test. 
 
Finally, I estimated global DNA methylation using the gold standard HPLC approach, 
which quantifies 5’-methylCytosine directly in hydrolised DNA (see section 1.8.1 for the 
technique outline and section 2.15 for the experimental procedures). This work was 
undertaken in collaboration with the Environmental Risk and Health Unit of the Flemish 
Institute of Technological Research (Belgium), using the ageing liver samples, which 
were the ones from which I had the highest amount of available DNA. This assay showed 
that mean 5’-methylCytosine content of mouse liver DNA was approximately 3% of all 
Cytosines,  with no detectable difference in methylation between age groups (Figure 
3.19). 
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Figure 3.19. HPLC measurement of global methylated Cytosine content in young (3 m.o.) 
and old (32 m.o.) mouse liver DNA.  Bars represent average percentage of methylated 
Cytosines on total Cytosine content for n = 3 biological replicates, error bars show ± SD. 
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3.6 Discussion  
There is evidence that global methylation shows gender specific differences (El-Maarri et 
al., 2007) and that it alters during ageing (Bollati et al., 2009; Cedar and Bergman, 2012) 
and may be influenced by nutritional interventions such as dietary energy restriction 
(Mathers, 2006; Ribaric, 2012). Since DNA methylation is catalyzed by DNMT enzymes, 
we hypothesized that alterations of global DNA methylation in response to ageing and/or 
dietary restriction could be related to changes in expression of DNMTs. To test this 
hypothesis, expression of the best known DNMT enzymes at the mRNA level were 
quantified by RT-qPCR and global DNA methylation was assessed by a number of 
different assays which aimed to estimate DNA methylation content directly (ELISA-
based colourimetric assay and HPLC) or indirectly (human LINE-1 and murine B1 
element PCR-based assays and the LUMA assay).  
DNMT1/Dnmt1 is the key maintenance methyltransferase, featuring a high preference 
(average 24 fold) for hemimethylated Cytosines within CpG sites compared with 
unmethylated ones (Hermann et al., 2004b). Most previous studies of expression of 
DNMTs/Dnmts and global methylation have focused on DNTM1/Dnmt1 gene expression 
only, although there is now compelling evidence that the maintenance of the correct 
methylation DNA pattern relies upon cooperation between the three main DNA-
Methyltransferases and in particular upon the recognition of hemimethylated DNA by 
DNMT1/Dnmt1 and the specific localization of DNMT3A/Dnmt3a and 
DNMT3B/Dnmt3b to methylated DNA-containing chromatin regions (Kim et al., 2002). 
This cooperation between three DNMTs is believed to ensure high-fidelity for the 
process. For this reason, here I have quantified not only DNMT1/Dnmt1, but also 
DNMT3A/Dnmt3a and DNMT3B/Dnmt3b expression and investigated relationships with 
global Cytosine methylation content of cells and tissues. 
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3.6.1 Summary of the main findings of expression of DNMTs/Dnmts and of global 
methylation in senescence, ageing and following dietary energy restriction 
Table 3.1. Summary of main findings of expression of DNMTs in early stress-induced 
premature senescent (ESIPS) and replicative senescent (RS) compared with young 
confluent (YC) MRC-5 human fibroblasts. Data are expressed as average ratios using 
GAPDH as normalizer. * = p < 0.05; ** = p < 0.01; *** = p < 0.001 for student’s 
unpaired t-test vs YC sample. 
 
 ESIPS MRC-5 vs YC MRC-5 RS MRC-5 vs YC MRC-5 
DNMT1 expression 0.54* 0.61* 
DNMT3A expression 0.52* 0.38*** 
DNMT3B expression 0.47 0.51* 
 
Table 3.2. Summary of main findings of estimates of global DNA methylation in young 
confluent (YC), early stress-induced premature senescent (ESIPS) and replicative 
senescent (RS) MRC-5 human fibroblasts. Data are expressed as percentage of 
methylated Cytosine within CpG dinucleotides. * = p < 0.05; ** = p < 0.01 for student’s 
unpaired t-test vs YC sample; # = data refer to CpG no. 3; NP = not performed. 
 
 YC MRC-5 ESIPS MRC-5 RS MRC-5 
Global CpG methylation (ELISA) 3% 2% 2% 
Global CpG methylation (LINE-1) # 80% 78%** 76%* 
 
Table 3.3. Summary of main findings of expression of Dnmts in heart, colon and liver 
from older animals compared with tissue from young animals and in liver from dietary 
energy restricted animals compared with tissue from ad libitum fed animals. Data are 
expressed as average ratios using Gapdh as normalizer for heart and colon samples and 
B2m as normalizers for liver samples. * = p < 0.05; ** = p < 0.01 for student’s unpaired t-
test vs Young or AL sample sample. 
 
 Heart  
Old vs Young 
Colon  
Old vs Young 
Liver  
Old vs Young 
Liver  
ER vs AL 
Dnmt1 expression 1.01 0.64** 1.27 1.22 
Dnmt3a expression 0.90 0.84 1.07 1.07 
Dnmt3b expression 0.82 1.04 0.56* 8.05** 
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Table 3.4. Summary of main findings of estimates of global DNA methylation in heart, 
colon and liver from older animals compared with tissue from young animals and in liver 
from dietary energy restricted animals compared with tissue from ad libitum fed animals. 
Data are expressed as percentage of methylated Cytosine within CpG dinucleotides. * = p 
< 0.05 for student’s unpaired t-test vs Young or AL sample sample; # = data refer to CpG 
no. 3; NP = not performed. 
 
 Young 
heart 
Old 
heart 
Young 
colon 
Old 
colon 
Young 
liver 
Old 
liver 
AL 
liver 
ER 
 liver 
Global CpG 
methylation 
(ELISA) 
3% 
 
3% 
 
2% 
 
3% 
 
3% 
 
3% 
 
4% 
 
4% 
 
Global CpG 
methylation 
(B1 element)  
71% 
 
72% 
 
78% 
 
78% 
 
75% 
 
78% 
 
76% 
 
76% 
 
Global CpG 
methylation 
(LUMA) 
NP NP 73% 
 
72% 
 
65% 
 
70% 
 
70% 
 
64%* 
 
Global CpG 
methylation 
(HPLC) 
NP NP NP NP 3% 
 
3% 
 
NP NP 
 
3.6.2 Changes in DNMTs gene expression and in global DNA methylation with 
replicative and premature senescence 
In a common in vitro model of senescence, human MRC-5 fibroblasts, I found significant 
down-regulation of DNMT1, DNMT3A and DNMT3B when cells were cultured to reach 
replicative senescence (RS), and significant down-regulation in DNMT1 and DNMT3A 
expression, together with a trend towards down-regulation for DNMT3B (albeit not 
significant), when cells were γ-irradiated to prompt stress-induced premature senescence 
(ESIPS). The expression ratios calculated from RT-qPCR data and presented in this 
Chapter mirror data obtained from whole genome transcriptomic analysis of the same 
samples (see CD insert). These data were partially consistent with a previous study in 
which when compared with replicative (young) cells, DNMT1 was significantly down-
regulated in both ESIPS and RS cells but DNMT3A was up-regulated in premature 
senescent cells only and DNMT3B was up-regulated in replicative senescent cells only, in 
human embryonic lung fibroblasts (HEF cells) (Zhang et al., 2008). Various causes could 
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contribute to the discrepancies in gene expression changes between the two studies, e.g. i) 
the dose-response specificity to different senescence-inducing insults – for example, 
(Zhang et al., 2008) have indeed used hydrogen peroxide and not γ-rays to this purpose - 
and ii) the different time-points of cell harvesting after senescence induction.  
 
Using an ELISA-based method, I did not detect any significant DNA methylation 
changes occurring within senescence and premature senescence (although a progressive 
trend was seen towards demethylation), while a PCR-based method (LINE-1 assay) for 
quantifying global DNA methylation detected significant changes in 8 (RS) and in 2 
(ESIPS) out of the 12 CpGs under investigation. Both assays showed a tendency for 
global DNA methylation to decrease from YC > ESIPS > RS. However, as presented in 
Figures 3.6 and 3.7, the ELISA-based assay showed high variability between 
measurements - probably because of low experimental consistency - whilst the LINE-1 
showed very little variability (Figure 3.10). This assay variability probably explains why I 
was not able to detect significant changes in global DNA methylation using the ELISA-
based method, while small, but significant changes in estimates for global DNA 
methylation were detected by the latter (LINE-1) assay. Interestingly, the specific CpG 
sites which showed decreased methylation in the LINE-1 experiments for ESIPS cells 
were the same CpG sites which were demethylated in replicative senescent cells. On the 
assumption that the “premature senescence” model used here is an intermediate step 
towards “late” senescence, these findings suggest that demethylation occuring during 
senescence is progressive. This is coherent with a previous study in which DNA global 
methylation (investigated using a cell immunofluorescence approach) diminished 
progressively with premature senescence and replicative senescence (Zhang et al., 2008).  
 
3.6.3 Changes in Dnmts gene expression and in global DNA methylation with ageing 
and dietary energy restriction 
Previous studies have demonstrated organ specificity in gene expression profiles during 
ageing (Weindruch et al., 2002), and, consistent with these observations, I found that 
Dnmts expression changes with age were tissue-specific in ageing mice. The RT-qPCR 
data presented in this Chapter indicated that, compared with tissues from young mice, i) 
no changes in Dnmts gene expression occurred in heart tissue, ii) there was a decrease in 
Dnmt3b gene expression in liver and iii) there was a decrease in Dnmt1 gene expression 
in the colon tissue. In addition, a striking increase in Dnmt3b gene expression was 
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detected in liver tissue from dietary energy restricted animals compared with tissue from 
ad libitum fed animals. This was clearly opposed to the Dnmt3b gene expression down-
regulation which occurred with ageing. 
Dnmts down-regulation associated with ageing has been documented in previous studies 
including human T cells - that showed down-regulation of DNMT1 - (Zhang et al., 
2002b), hematopoietic stem cells - that showed down-regulation of DNMT3B - 
(Chambers et al., 2007) and murine hippocampi - that showed down-regulation of 
Dnmt3a, isoform a2 - (Oliveira et al., 2012). As reviewed in (Li et al., 2011), such down-
regulation of gene expression is opposed by dietary energy restriction. In summary, I 
believe that the greater expression of Dnmt3b seen in liver from dietary energy restricted 
animals, which is opposed to the down-regulation seen in ageing liver, may be one of the 
beneficial consequences of this dietary intervention which could contribute to the 
maintenance of a proper pattern of global DNA methylation. 
 
Despite the observed changes in Dnmt expression, there were no detectable changes in 
global DNA methylation, as measured by an ELISA-based method. This lack of effect on 
global DNA methylation was confirmed by the results from other approaches to global 
DNA methylation estimation including measurement of methylation of the B1 element 
using PCR-based method, by the LUMA assay and by HPLC measurements of total 5’-
MethylCytosine content of DNA for subsets of the samples. These findings are in contrast 
with previously published studies that have shown a general tendency of global DNA 
methylation to decrease with ageing in various murine tissues, including brain (Mays-
Hoopes et al., 1986), liver (Barbot et al., 2002) and oocytes (Yue et al., 2012). However, 
a direct comparison of my data for liver with the data from (Barbot et al., 2002) is 
difficult because the latter were obtained using a different assay (a methyl-sensitive 
enzymes based assay followed by Southern Blot analysis) that measured the methylation 
content of a different repeat region (the intracisternal A-particle) in a different mouse 
strain (BALB/c). In this contest, strain-specific differences in liver DNA methylation 
response to ageing have already been documented (Counts et al., 1997). 
To my knowledge, no studies that have investigated global DNA methylation changes 
with ageing in murine heart and colon have been previously published. 
 
Using the LUMA assay, there was small, but significant decrease in global DNA 
methylation in livers from dietary energy restricted animals. However, this decrease was 
not confirmed by any of the other methods used to quantify global DNA methylation. 
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Global hypomethylation could be potentially harmful because it contributes to genome 
instability (Rodriguez et al., 2006). However, it is difficult to interpret my data from a 
functional perspective because the LUMA assay does not provide information on where 
in the genome the changes in methylation have occurred. LUMA does not measure 
methylation at repeat regions only but can detect changes in methylation in the context of 
any CCGG site within the genome, including gene promoters. If the reduced methylation 
occurred in gene promoters, my data could suggest that livers from dietary energy 
restricted animals have a higher transcriptional activity compared with livers from ad 
libitum fed animals (Razin and Cedar, 1991). 
 
3.6.4 Comparisons between different methods for measurements/estimation of global 
DNA methylation content 
Correlation analyses performed on the data set from the ELISA-based method and the one 
from the LINE-1 assay at the representative CpG no. 3 yielded a not significant Spearman 
and Pearson correlation coefficients (probably due to the small number of pairs of data); 
however regression analysis yielded a coefficient of determination of 0.93 (data not 
shown). In parallel, no significant Spearman or Pearson correlation coefficient yielded 
from comparisons of data sets produced with the various applied methods for global DNA 
methylation measurements on murine samples (probably due to the small number of pairs 
of data), whilst regression analyses analyses yielded the following coefficient of 
determination: i) ELISA-based method vs B1 element assay at the representative CpG no. 
1 = 9.13 x 10
-4
; ii) B1 element assay at the representative CpG no. 1 vs LUMA assay = 
0.71 and ELISA-based method vs LUMA assay = 6.29 x 10
-2
 (data not shown). These 
data indicated that the data sets for measured global DNA methylation by LINE-1 assay 
and ELISA-based assay had a relationship very close to linearity for cell samples and that 
only data sets obtained by the B1 element and the LUMA assay had a relationship close 
to linearity for murine samples, respectively. A previous study has investigated 
correlations among assays for estimation of global DNA methylation in human white 
blood cells and found that those were highest for three repetitive elements methylation 
levels (ρ included between 0.39 and 0.64), whilst LUMA assay results were only 
modestly correlated with LINE1 (ρ included between 0.18 and 0.20) (Wu et al., 2011). 
Taken together, these results suggest that comparison between results arising from 
different global methylation measurement/estimation methods must be interpreted 
cautiously. The only comparison which I deem appropriate is the one between the 
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ELISA-based methods and the HPLC methods, which actually measure 5’-
MethylCytosine content in a given sample, irrespective of its genomic location. For all 
other cases, one has to keep into consideration that each assay investigates different 
genomic regions (repeats or CCGG sites), so it is possible that results obtained by 
different methods for the same sample differ not only in the absolute measurements, but 
also in the detected differences (compare Figure 3.7, panel B and Figure 3.13 with Figure 
3.18; compare Figure 3.7, panel A with Figure 3.10) (Lisanti S. Omar W.A.W., accepted).  
 
None of the assays considered in this study is universally better than another: researchers 
need to determine which is the most suitable for their purposes e.g. which assay is 
capable of detecting differences between samples under certain conditions. In my 
opinion, as a rule of thumb, small differences are better detected by PCR-based assays 
and bigger differences by HPLC, ELISA-based assays or methyl-sensitive enzymes-based 
assays. This is because, although PCR-based methods rely upon the measurement of 
abundantly repeated regions, they nevertheless detect changes in specific regions, which 
could be counterbalanced by changes in the opposite direction in other genomic regions 
or simply be so small not to be detected at a global level. 
 
HPLC data for the ageing livers showed little biological variability between samples 
(Figure 3.19); this which confirmed the previous assumption that ELISA-based 
measurements variations derive from technical variability. However, calculated 
methylation percentages were in the same range for both methods (around 3%), 
suggesting that the assays have similar sensitivity and confirming my assumption that 
results obtained with these techniques can be compared. If pipetting errors are an 
important source of inconsistency, then including an internal normalizator for DNA 
quantification (such as a total anti-Cytosine antibody or an in-well DAPI staining) might 
help to improve the reliability of ELISA-based methods. If this hypothesis proves right, 
such a modified assay could be developed as a useful and inexpensive alternative to the 
relatively laborious and high demanding HPLC-based techniques for quantifying global 
DNA methylation. 
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3.6.5 Correlation between DNMTs/Dnmts gene expression and global DNA 
methylation content 
As discussed in section 3.6.2 and section 3.6.3, there was a positive correlation between 
DNMTs gene expression and global DNA methylation content in replicative senescence 
(for all the DNMTs) and in premature senescent cells (for DNMT1/DNMT3A). These data 
are partially confirmed by a previous study in which authors found a positive correlation 
between DNMT1 expression and global DNA methylation, but a negative correlation 
between DNMT3B and global DNA methylation (Zhang et al., 2008). Contrasting 
findings may be explained taking into account the different cell types and experimental 
settings, as previously discussed. 
In contrast with the results from the cell-based work, there was no evidence of correlation 
between Dnmts gene expression and global DNA methylation content with ageing in 
murine tissues. Previously published research has shown that heterozygous mice Dnmt 
+/- 
maintain levels of global DNA methylation in T cells which are comparable with those in 
wild type mice Dnmt1
+/+
 (Ray et al., 2006). In parallel, mRNA levels for Dnmt3a and 
Dnmt3b increased with age, suggesting a compensatory mechanism that is capable of 
maintaining a global DNA methylation content which is characteristic of young cells 
(Ray et al., 2006). In my mouse study, tissue-specific changes in Dnmts expression were 
not associated with global DNA methylation changes and it logical to postulate that this 
was probably because not all Dnmts genes were affected in the same way and that 
compensatory mechanisms (one Dnmt increasing whilst another decreases) maintain 
global DNA methylation levels. In support to this hypothesis, it is of note that there was a 
direct correlation between DNMTs expression and global DNA methylation in replicative 
senescent cells. The measurement of protein levels, post-translational modifications and 
enzymatic activity changes could help in confirming this hypothesis; unfortunately, this 
was not possible for me because of lack of samples. 
 
3.7 Conclusions 
In the work described in this Chapter I found that: 
 
 DNMTs/Dnmts expression changes with senescence and ageing are tissue- and are 
treatment-specific; 
 global DNA methylation content is decreased during in vitro replicative 
senescence, but does not seem to be affected by ageing in various mice tissues; 
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  global DNA methylation is decreased in mouse livers in response to dietary 
energy restriction; 
 dietary energy restriction significantly counteracts the age-related Dnmt3b gene 
down-regulation in mouse liver 
 comparisons of results from different methods for estimating global DNA 
methylation are not always possible because these measure different aspects of 
DNA methylation (e.g. methylation of repeat regions or methylation of cytosine 
residues in specific genomic sequences).  
 
 
 
 
 
 
 
Related publication: 
 
Comparison of methods for quantification of global DNA methylation in human cells and 
tissues. PLoS ONE 8(11): e79044. doi:10.1371/journal.pone.0079044. 
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Chapter 4. Standardization and quality controls for the methylated 
DNA immunoprecipitation technique (MeDIP) 
 
4.1 Outline 
To study site specific methylation and how this varies in cellular senescence, ageing and 
dietary energy restricted animals, I chose to use the Methylated DNA 
Immunoprecipitation Technique (MeDIP) (Weber et al., 2005). 
MeDIP is an affinity based technique in which single-stranded methylated DNA 
fragments are bound by an antibody directed against 5-methylCytidine and separated 
from unmethylated fragments. MeDIP processed samples are suitable for investigation of 
the methylation status of specific genomic loci and for performing genome-wide 
screening, when hybridized to DNA methylation microarrays or analyzed by deep 
sequencing. In such experiments, it is usual to assess the efficacy and repeatability of the 
MeDIP step by enrichment estimation of genomic regions expected to be heavily 
methylated in the samples under investigation. This is done from qPCR data, comparing 
the pairs MeDIP/Input and normalizing with genomic regions expected to be 
unmethylated. However, the methylation status of specific loci is not always known for 
particular samples under the conditions of the specific study, which may render the choice 
of genomic regions for quality control problematical. In addition, although MeDIP is a 
widely used tool in epigenetics studies, to my knowledge, no comprehensive studies on 
possible biases occurring during any of the procedure steps have been conducted so far, 
nor universally accepted quality controls have been developed.  
I therefore proposed the introduction of external positive and negative controls (“spikes”) 
(Lisanti et al., 2012) to test the methylated fraction enrichment of any MeDIPed/Input 
sample pairs; these can also be used to verify that each batch of samples is successfully 
enriched for methylated regions and to ensure experimental reproducibility between 
samples and experiments within laboratories and between laboratories. Figure 4.1 outlines 
the MeDIP protocol and the introduction of the spikes suggested in my study. 
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Figure 4.1. Methylated DNA Immunoprecipitation (MeDIP) protocol. The black arrow 
indicates the introduction of exogenous controls described in my study. 
 
4.2 Development of internal controls for the MeDIP assays standardization and 
quality assessment 
Two fragments (Fragment A and Fragment B, see Figure 4.2) of similar length (625 and 
611 bp, respectively) and CpG content (41 and 35 CpG, respectively) were PCR 
amplified using primers and PCR conditions indicated in Table 2.1 and section 2.6.2. The 
fragments size was chosen to be the average size of the sonicated genomic DNA suitable 
for MeDIP (Weber et al., 2005; Weber et al., 2007). 
 
Fragment A 
AGCAACCAACAAGAAAACACTGGCAGATTACGCCCGTGCCTTATCCGGAGAG
GATGAATGACGCGACAGGAAGAACTTGCCGCTGCCCGTGCGGCACTGCATGA
CCTGATGACAGGTAAACGGGTGGCAACAGTACAGAAAGACGGACGAAGGGT
GGAGTTTACGGCCACTTCCGTGTCTGACCTGAAAAAATATATTGCAGAGCTG
GAAGTGCAGACCGGCATGACACAGCGACGCAGGGGACCTGCAGGATTTTATG
TATGAAAACGCCCACCATTCCCACCCTTCTGGGGCCGGACGGCATGACATCG
CTGCGCGAATATGCCGGTTATCACGGCGGTGGCAGCGGATTTGGAGGGCAGT
114 
 
TGCGGTCGTGGAACCCACCGAGTGAAAGTGTGGATGCAGCCCTGTTGCCCAA
CTTTACCCGTGGCAATGCCCGCGCAGACGATCTGGTACGCAATAACGGCTAT
GCCGCCAACGCCATCCAGCTGCATCAGGATCATATCGTCGGGTCTTTTTTCCG
GCTCAGTCATCGCCCAAGCTGGCGCTATCTGGGCATCGGGGAGGAAGAAGCC
CGTGCCTTTTCCCGCGAGGTTGAAGCGGCATGGAAAGAGTTTGCCGAGGATG
A 
 
Fragment B 
GTGAATGTGGTGAAGTCTGCCCGTGTCGGTTATTCCAAAATGCTGCTGGGTGT
TTATGCCTACTTTATAGAGCATAAGCAGCGCAACACCCTTATCTGGTTGCCGA
CGGATGGTGATGCCGAGAACTTTATGAAAACCCACGTTGAGCCGACTATTCG
TGATATTCCGTCGCTGCTGGCGCTGGCCCCGTGGTATGGCAAAAAGCACCGG
GATAACACGCTCACCATGAAGCGTTTCACTAATGGGCGTGGCTTCTGGTGCCT
GGGCGGTAAAGCGGCAAAAAACTACCGTGAAAAGTCGGTGGATGTGGCGGG
TTATGATGAACTTGCTGCTTTTGATGATGATATTGAACAGGAAGGCTCTCCGA 
CGTTCCTGGGTGACAAGCGTATTGAAGGCTCGGTCTGGCCAAAGTCCATCCGT
GGCTCCACGCCAAAAGTGAGAGGCACCTGTCAGATTGAGCGTGCAGCCAGTG
AATCCCCGCATTTTATGCGTTTTCATGTTGCCTGCCCGCATTGCGGGGAGGAG
CAGTATCTTAAATTTGGCGACAAAGAGACGCC GTTTGGCCTCAAATGGACGC 
CGGATGACCCCTCCAGCGTGTTTTATCTCTGCGA 
 
Figure 4.2. Sequences of the Lambda DNA Fragments used as spikes in my study. CpG 
sites are indicated by thick underlines, genomic regions used as priming sites for 
Fragments PCR amplification by dashed underlines and genomic regions used as priming 
sites for qPCR by wave underlines (see Table 2.1, Table 2.2, section 2.6.2 and section 2.8 
for primer sequences and reaction conditions). 
 
After PCR products purification, Fragment A was In vitro Methylated (IVM) using E. 
coli M.SssI methyltransferase, in the presence of S-Adenosyl Methionine (SAM), and 
used as Positive Control, while Fragment B (totally unmethylated) was used as Negative 
Control in subsequent MeDIP experiments. The efficiency of Fragment A IVM (Positive 
Control) was checked for 14 CpG sites by two methylation-sensitive restriction enzymes: 
AciI, which cuts blunt at CC↓CG sites (9 in the sequence) and HpaII, which cuts blunt at 
CC↓GG sites (5 in the sequence). Both enzymes cut DNA at the respective sequences 
only if the internal C is unmethylated. As a double check, I also used a third enzyme, the 
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HpaII-isoschizomer MspI, whose cutting is not affected by the internal C methylation. I 
ran the same set of digestions with Fragment B, which contains 6 AciI sites and 2 
MspI/HpaII sites. As expected, Fragment A IVM was cut by MspI (Fig 4.3, lane 2), but 
uncut by Acil (lane 1) or by HpaII (lane 3): the agarose/TBE gel shows a single band of 
625 bp long in these last two cases, as for the undigested fragment (lane 4). Full length 
Fragment B (lane 8), instead, was fully digested by AciI, MspI and HpaII (lanes 5, 6 and 
7, respectively). 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Digestion patterns of Positive and Negative Controls with the restriction 
enzymes AciI, MspI and HpaII on 2% Metaphor agarose/TBE gel. Panel A: lanes 1 and 5 
= AciI digestions of Positive and Negative Control, respectively; lane 2 and 6 = MspI 
digestions of Positive and Negative Control; lanes 3 and 7 = HpaII digestions of Positive 
and Negative Control; lanes 4 and 8 = undigested Positive and Negative Control; lane 9 
= 100 bp DNA Ladder. Panel B: virtual gel with the corresponding digestions patterns, 
as computed by the webtool http://tools.neb.com/NEBcutter2/. 
 
I then designed qPCR assays to amplify short stretches of the Positive and Negative 
Controls (see Table 2.2 for sequences); these assays were subsequently used to quantify 
the enrichment of methylated regions in my MeDIPed samples compared with their 
related Input samples, according to the following formula (Pfaffl, 2001): 
 
Enrichment = (E Pos.Ctrl.) 
∆Cq Pos. Ctrl. (Input - MeDIP)
/ (E Neg. Ctrl.) 
∆Cq Neg. Ctrl. (Input - MeDIP)
. 
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I tested assays linearity on 10 fold dilutions of each control and calculated their efficiency 
of amplification from the line equation (E = 10 
1/slope 
-1) (Bustin et al., 2009) (see 
Appendix A for standard and melt curves). The amplification linearity ranged over at 
least eight orders of magnitude for both controls (500 pg/μL to 50 ag/μL) and the Cq 
values obtained were in an acceptable scale (5 < Cq < 40, data not shown). In addition, 
the amplification efficiencies were good for both Positive Control (0.82) and Negative 
Control (0.85). I concluded that the chosen primer pairs were suitable for quantification 
of both methylated and unmethylated DNA controls and for estimation of enrichment 
using the Pfaffl method. Also, as the two efficiencies were similar, the user could 
simplify the enrichment calculation using the ΔΔCq approximation method (Livak and 
Schmittgen, 2001). 
The next step was to determine the optimal sample concentration to be used in the qPCR 
assays for quantification of the controls and to ensure that amplification efficiencies for 
the controls was similar when tested in the context of genomic DNA to be 
immunoprecipitated as when tested alone. I checked the amplification efficiencies of the 
controls in three 10-fold dilutions (100 pg/μL, 10 pg/μL and 1 pg/μL) of both Input and 
MeDIP samples from a randomly chosen immunoprecipitation experiment, which was 
conducted on gDNA from mouse liver. As shown in Figure 4.4, I observed very similar 
efficiencies (E) in the presence of both Input DNA and of methylation enriched (MeDIP) 
DNA for both Positive (panel A, E = 0.87 vs E = 0.81) and Negative Controls (panel B, E 
= 0.84 vs E = 0.87). I therefore concluded that: 
 
 the presence of Input and MeDIP DNA fractions did not influence the 
amplification efficiencies of the chosen primer sets for the controls; 
 20 pg of template DNA was an acceptable amount for control PCR reactions to 
ensure that the answers are in the linear range of the assay. 
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Figure 4.4. Positive (A) and Negative Control (B) qPCR assays linearity on 10-Fold 
Dilutions of the controls for MeDIP in the background of genomic DNA from mouse liver. 
Dashed lines show linear regression trendlines for Controls in the MeDIP samples and 
solid lines show trendlines for Controls in the Input samples. Efficiencies of amplification 
(E) are shown in the boxes.  
  
In addition, I found that the chosen primer pairs did not result in amplification of any 
unspecific DNA sequences or in false priming of human and mouse gDNA with the 
template amount chosen for control PCR reactions (Figure 4.5).  
 
 
 
 
 
 
A 
B 
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Figure 4.5. Absence of unspecific amplification of λ-DNA spike controls primer pairs 2 
(see Table 2.2 for sequences) in human and murine genomic DNA. Lane 1 and 8 = 1 Kb 
DNA ladder; lane 2 and 3 = Positive Control end-point PCR (30 cycles) on human and 
murine gDNA respectively; lane 4 and 5 = Negative Control end-point PCR (30 cycles) 
on human and murine gDNA respectively; lane 6 and 7 = non-template reaction controls 
for Positive Control and Negative Control primers, respectively. 
 
4.3 Sonication of Genomic DNA 
The first step of the MeDIP procedure is fragmentation of the DNA to be 
immunoprecipitated; this is usually done by sonication, although DNase digestion or 
restriction endonucleases can be used. However, this last method does not produce 
random fragments, as it is dependent on the restriction enzyme pattern of digestion, and 
can therefore introduce biases. 
For my experiments, I sonicated genomic DNAs as described in section 2.6.1 and ran a 
small amount on agarose/TBE gel to confirm: 
 the integrity of each DNA sample; 
 the absence of RNA.  
The latter is critical to avoid antibody capture by 5-mC that is known to be present in this 
nucleic acid (Klagsbrun, 1973; Motorin et al., 2009; Cantara et al., 2010; Karijolich et al., 
2010). Sonication patterns were assessed on agarose/TBE gels and optimally fragmented 
DNA samples, i.e., with fragment sizes 200 to 1000 bp (Weber et al., 2005; Weber et al., 
2007) (Figure 4.6), were purified using silica columns. I chose this method of purification 
because it is faster than the ethanol-based precipitation method proposed in the original 
method (Weber et al., 2005; Weber et al., 2007).  
 
1 2 3 5 4 6 7 8 
200 bp 
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Figure 4.6. Example of correctly sonicated genomic DNA samples for MeDIP. First and 
last lanes are 1 Kb DNA Ladder. 
 
4.4 Methylated DNA Immunoprecipitation and Spike Controls Enrichments 
As described in detail in section 2.6.3, I spiked genomic DNA with both Positive and 
Negative Control fragments in the ratio 1:100 control: genomic DNA. This resulted in Cq 
values ranging from about 14 to 23 for all my subsequent qPCR assays (data not shown). 
From these data, I inferred that users of my approach could reduce the proportions of 
control “spikes” to as low as 1:10000 in proportion to the total amount of sample DNA 
being investigated; in fact, this would result in Cq values up to about 30, which fall within 
the linear range of the qPCR assays (Appendix A, Figure A.1 and Figure A.2). However, 
the spiked amount that I suggested was high enough to allow detection using a minimal 
amount of IP reactions and was low enough to result in average total controls occupancy 
of 5.07% for pre-Whole Genome Amplification (WGA) samples and 3.32% for post-
WGA samples in the IPed samples (calculated from qPCR data, not shown). Since 
lambda DNA sequences do not share homology with human or mouse sequences (Butcher 
and Beck, 2010), they will not hybridize to human or mouse array chips and so will not 
interfere with downstream analysis. However, if deep sequencing is intended to be used 
for further interrogation of MeDIP samples, I suggest further optimization of the fragment 
lengths and amounts of spikes used to limit any potential redundancy in material to be 
sequenced (Butcher and Beck, 2010; Down et al., 2008; Feber et al., 2011).  
 
4.5 Whole Genome Amplification 
Whole Genome Amplification (WGA) is a necessary step in the preparation of MeDIP 
samples for arrays hybridization, deep sequencing or simple endogenous regions 
enrichment measurements in a MeDIPed specimen by means of qPCR. However, if my 
spiked controls are used, it is possible to assess the Positive Control/Negative Control 
enrichment both in the pairs MeDIP/Input both pre-WGA and post-WGA. Comparing 
pre- and post-WGA enrichments for all performed experiments, I noticed that the latter 
1000 bp 
200 bp 
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were significantly lower (p < 0.001 for student’s paired t-test) of about 32% than the 
related pre-WGA enrichments (Figure 4.7). This “loss” was manifest as an increase in the 
Cq values for the Positive Control of about 5 cycles, when the same sample (Input or 
MeDIP) was tested Pre-WGA and Post-WGA, while Cq values for the Negative Control 
remained similar pre- and post-WGA (data not shown). With the following experiments, I 
demonstrated that biases introduced by the WGA step were sequence specific and not 
dependent on the methylation state (Figure 4.8) or to the length of the target template 
(Figure 4.9). 
 
 
Figure 4.7. Descriptive statistics for fold enrichments Positive Control/Negative Control 
Pre-WGA and Post-WGA. Box plots show the percentiles and the median of column data. 
Box outlines define the 25th and 75th percentiles, with a line at the median and whiskers 
indicate the 10th and 90th percentiles. *** = p < 0.001 for student’s paired t-test, n = 33. 
 
In a first experiment, I in vitro methylated Fragment B and left Fragment A unmethylated 
(see Figure 4.8, panel A) and therefore used Fragment A as spiked negative control and 
Fragment B as positive control in one murine gDNA; the ratio between the sonicated 
DNA and the spikes was left constant at 100:1:1. I then proceeded to the WGA step and 
performed qPCR on pre- and post-WGA mixes. I noticed that the ratio of Fragment A: 
Fragment B after WGA was always about one sixth of the ratio before WGA, irrespective 
of the methylation status of the fragments (Figure 4.8, panel B), hence I concluded that 
WGA-related amplification biases were not due to the methylation status of a DNA 
sequence. 
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Figure 4.8. Left: digestion patterns of methylated and unmethylated Fragments A and B 
with the restriction enzymes AciI on 2% agarose/TBE gel. Lanes 2 and 3 = AciI 
digestions of Fragment A unmethylated and IVM, respectively; lane 4 and 5 = AciI 
digestions of Fragment B unmethylated and IVM, respectively; lanes 1 and 6 = 100 bp 
DNA Ladder. Right: amplification rate of Fragment A post-WGA/pre-WGA in a MeDIP 
experiment where either Fragment A (left bar) or Fragment B (right bar) act as 
methylated control in a MeDIP experiment. Error bars show ± SEM on 3 technical 
replicates. 
 
In another experiment, I spiked three randomly chosen sonicated gDNAs with six 
Lambda DNA fragments of defined lengths (in the range suggested by the WGA kit 
manufacturer, which was 100 bp to 1000 bp) and measured the amplification rate of those 
post-WGA/pre-WGA. As shown in Figure 4.9, panel B, different fragments showed 
different amplification rates, but no correlation between fragment length and 
amplification rate could be found; rather surprisingly, the shortest fragment presented the 
lowest amplification rate after WGA. I concluded that WGA-related amplification biases 
were not due the fragment length; this was already obvious for Fragment A and B, which 
are of very similar length, but together with the observation resulting from the previous 
experiment, led me to the conclusion that biases occurring during the WGA process were 
sequence related. I hypothesize that the annealing/extension temperature of the standard 
amplification step in the WGA procedure might not provide enough energy to unfold 
stable hairpins and helixes in the context of certain DNA sequences (and, in fact, 
Fragment A has a lower folding ΔG compared with Fragment B, as computed using the 
webtool http://mfold.rna.albany.edu/?q=mfold/DNA-Folding-Form). I think that the 
1 2 3 4 5 6 
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sequence-related amplification bias issue cannot be solved because of the complexity of 
the starting material: indeed it is possible to adjust the temperature for a specific target, 
but in doing so biases towards other targets might arise. 
 
 
 
 
 
 
Figure 4.9. Panel A: preparation of Lambda DNA spikes of different length. Lanes 2, 3 
and 4: Lambda DNA fragment of 208 bp, 400 bp and 1000 bp, respectively. Panel B: 
assessment of WGA amplification fragment length-related biases. Black bars represent 
the amplification rate Post-WGA/Pre-WGA of different length Lambda DNA fragments 
spiked in mouse genomic DNA. Error bars show ± SEM, n = 3. The table illustrates the 
primer sequences for λ DNA Fragment Spikes preparation (pairs 1) and qPCRs (pairs 2) 
for the assessment of Whole Genome Amplification length related bias. 
1 2 3 4 5 6 
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Although having demonstrated that WGA introduced biases in the processed samples, I 
noticed good correlation between pre- and post-WGA enrichments (Spearman correlation 
coefficient of 0.59, p < 0.001, Figure 4.10, panel A) and high DNA yields (between 11 µg 
and 17.3 µg, Figure 4.10, panel B); I therefore concluded that this is a cheap and simple 
method to prepare sufficient amount of DNA from MeDIP samples; however, if WGA 
samples are to be used to quantitate enrichments of endogenous regions, I suggest the 
users to perform a preliminary experiment in order to assess the loss of amplification of 
the region of interest after WGA. 
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Figure 4.10. Linear regression for pairs of Pre-WGA and Post-WGA spike controls 
enrichments, n= 33 (panel A) and DNA yield obtained from WGA reactions for n = 66 
samples; box plot shows the percentiles and the median of column data, box outlines 
define the 25th and 75th percentiles, with a line at the median and whiskers indicate the 
10th and 90th percentiles. 
 
4.6 Methylated endogenous regions enrichments assessments 
After having demonstrated that the spiked controls were a useful tool in assessing 
efficiency and specificity of the MeDIP procedure in a variety of samples, I also wanted 
to demonstrate that my assays were reproducible, that endogenous methylated regions 
were enriched by MeDIP and that my Negative Control is an optimal normalizer in the 
enrichment calculations. In fact, usually housekeeping genes promoters are used as 
normalizers, assuming that these are either unmethylated or methylated to the same extent 
in all tissues; this is not always the case, as I demonstrated here, and can mislead the 
interpretation of results. On the contrary, my Negative Control, which is not methylated 
and so is in all the experiments, is an alternative and more suitable choice as a normalizer, 
whenever enrichments comparison needs to be done between samples.  
I tested the reproducibility of all the performed assays and investigated the extent of the 
technical error on a subset of technical replicates, by comparing GAPDH-normalized 
enrichments of H19 and HIST1H2BA genes with Positive Control/Negative Control 
enrichments in post-WGA samples. As inferred from the data in Figure 4.11, percentage 
coefficient of variations for these assays ranged from 6% to 15%, indicating that the 
technical error of assays of the spike controls was similar to that for endogenous regions. 
It is to be noted that H19 enrichment was about half of HIST1H2BA enrichment; this is 
concordant with the fact that H19 ia an imprinted gene, and so heavily methylated only on 
one of the parental alleles (Gao et al., 2002) and that MeDIP enrichments are proportional 
to the methylation content of the immunoprecipitated fragments (Weber et al., 2005). 
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Figure 4.11. Gene specific enrichments after MeDIP followed by WGA for MRC-5 
fibroblasts DNA. Left: enrichment of the MRC-5 internal genes H19 (black bar) and 
HIST1H2BA (grey bar), both normalized to GAPDH. Right: Positive/Negative Control 
Enrichment Post-WGA. Error bars show ± SEM, n = 3 technical replicates. 
 
To demonstrate that endogenous normalizers could be a wrong choice in the enrichments 
calculations, I calculated enrichments in various murine MeDIPed samples for H19 and 
Hist1h2ba genes and normalized those with either Actb or Gapdh promoter regions 
(Figure 4.12 A and B). Extent of the two different normalized enrichments was 
substantially different in some of the samples, while similar in others, indicating that the 
normalizer is a source of variation between biological replicates. In these experiments as 
well, H19 enrichments were about half of Hist1h2ba enrichments, confirming what stated 
above for the cell line experiments. 
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Figure 4.12. Gene specific enrichments for H19 (panel A) and Hist1h2ba (panel B) in 
mice tissues normalized to either Actb (black bars) or Gapdh (white bars). Data are mean 
± SD, n = 3 biological replicates. AL = ad libitum fed, ER = dietary energy restricted. 
 
I then illustrated cases where: 
 
 normalization of endogenous gene enrichment by the Negative Control reduced 
experimental variability (Figure 4.13); 
 normalization of endogenous gene enrichment by the Negative Control reduced 
the impact of tissue-specific methylation of the normalizer gene (Figure 4.14). 
 
In Figure 4.13, left panel, enrichment following MeDIP was calculated from qPCR data 
after WGA from old mice heart gDNA for the endogenous gene Hist1h2ba with Actb as 
the normalizer and compared with estimate of enrichment obtained after normalization 
with the Negative Control. As shown in the right panel, normalization with the Negative 
A 
B 
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Control reduced considerably the coefficient of variation for the biological replicates 
(from 46% to 18%); this latter CV better represents the biological variability due to the 
methylated endogenous region.  
 
 
 
Figure 4.13. Normalization of endogenous gene enrichment by the Negative Control 
reduced experimental variability. Left panel: average fold enrichments for Hist1h2ba 
normalized with the endogenous region Actb (left column) or with the spiked Negative 
Control (right column) in old mice heart DNA. Data are mean ± SD, n = 3 biological 
replicates. Means are not significantly different (p = 0.41, student’s unpaired t-test). 
Right panel:  Black bars show Coefficients of Variation (CV) related to estimates in left 
panel. 
 
Figure 4.14 presents instead data on enrichments of the endogenous gene Hist1h2ba from 
heart and colon genomic DNA from young mice using either Actb or the spiked Negative 
Control as the normalizer: the apparently tissue-specific difference in Hist1h2ba 
methylation between colon and heart was no longer significant when the Negative spike 
Control was used as the normalizer (left panel). Constancy between spiked controls 
enrichments is confirmed in the right panel, showing very similar degrees of enrichment 
post-WGA for DNA from the same samples. 
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Figure 4.14. Normalization of endogenous gene enrichment by the Negative Control 
reduced the impact of tissue-specific methylation of the normalizer gene. Left panel shows 
the comparison between gene specific enrichments for Hist1h2ba calculated with the 
endogenous normalizer Actb (light blue bars) and with the Negative Control (aqua bars) 
for Young Colon samples (empty bars) and Young Heart samples (dashed bars). Right 
panel shows Positive Control/Negative Control Enrichment Post-WGA. Data are mean ± 
SD, n = 3 biological replicates. * p = 0.04, student’s unpaired t-test.  
 
4.7 Validation of the results by means of BM direct sequencing 
With the goal to confirm the results showed in in Figure 4.14 by means of an alternative 
method, I chose the BM direct sequencing, already optimized in section 3.4.2 (see section 
2.19 for experimental procedures). Briefly, primers for those assays were designed within 
600 bp sequences (the average length of the fragments for immunoprecipitation) centered 
on the qPCR products of Figure 4.12, 4.13 and 4.14. 
Results for the Hist1h2ba region are illustrated in Figure 4.15 and results for the 
endogenous normalizer Actb region are illustrated in Figure 4.16; this latter required 
cloning and subsequent sequencing of the BM-PCR products because of poor quality of 
some of the sequences reads. 
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Figure 4.15. Direct BM sequencing of murine Hist1h2ba from colon and heart genomic 
DNA; data are mean ± SD, n = 3 biological replicates. 
 
 
 
 
  
 
Figure 4.16. Panel A: colony PCR of Actb blunt cloning for one heart sample; lanes 2, 4, 
5 and 6 = successfully cloned Actb sequence, lane 3 = amplification occurring with a 
colony transformed with an empty vector; lane 1 = 100 bp DNA ladder. Panel B: 
aggregate representation of methylation data obtained by BM cloning and sequencing for 
Colon Actb sequencing Heart Actb sequencing 
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one colon and one heart sample, respectively. The bars indicate the percentage of clones 
which showed unmethylated (blue) or methylated (yellow) Cytosines at the CpG sites 
analysed (adapted from BiQ Analyzer v2.00). 
 
Heart samples showed lower methylation - especially at CpG no. 11 and 12 - in the 
Hist1h2ba region under investigation (Figure 4.15), and also lower methylation in the 
Actb region analyzed (Figure 4.16, panel B, right). The actual Hist1h2ba methylation is 
the one obtained when normalizing with the negative control, while the opposite result 
was obtained when normalizing with Actb (Figure 4.14, left panel), corroborating the 
need of proper choice of a normalizer for estimating and comparing methylation 
enrichments. 
Using the same methodology, I also confirmed the methylation status of all the genomic 
regions previously tested by qPCR in a subset of samples; these results were in agreement 
with what seen by qPCR and are presented in Figure 4.17 and 4.18. Primers sequences 
and reaction conditions are given in Table 2.6. 
Figure 4.17 shows the percentage of Cytosine methylation for MRC-5 fibroblasts in 3 
technical replicates (left panels A, C and E). CVs ranged from 1% to 9% across 15 CpGs 
for H19 and from 1% to 6% across 6 CpG for HIST1H2BA. This statistic could not be 
calculated for GAPDH, as bisulphite modification of this region resulted in complete C to 
T conversion, meaning that there was no detectable cytosine methylation across the 3 
CpGs analyzed. The mean percentage methylation for all the CpG sites examined was 
72% for H19 (panel A, right), 94% for HIST1H2BA (Panel B, right) and 0 for GAPDH 
(data not shown). These data provided evidence that, as expected, H19 was approximately 
hemi-methylated, HIST1H2BA was highly methylated and GAPDH was unmethylated. In 
addition, the ratio of mean methylation of HIST1H2BA/H19 was similar to the GAPDH 
normalized mean enrichment ratio of HIST1H2BA/H19 observed in my previous MeDIP-
qPCR experiments (1.31 fold vs. 1.60 fold, respectively, see Figure 4.11 for comparison). 
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Figure 4.17. Cytosine methylation quantification by BM direct sequencing of human 
MRC-5 H19 (panel A), HIST1H2BA (panel B) and GAPDH regions (panel C). Panels on 
the left Y axes present data measured for 3 independent technical replicates. Panels on 
the right present average methylation ± SD across the CpG sites analysed. 
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Figure 4.18 (panels A to D) shows the percentage of Cytosine methylation in mouse 
colon. As for the human orthologous regions, mean percentage methylation in both young 
and old mice was about 70% in H19 across 5 CpGs (panel A) and close to 100% in 
Hist1h2ba across 15 CpGs (panel B). Mean methylation of the housekeeping genes was 
approximately 70% across 3 CpGs for Actb (panel C) and 13% across 6 CpGs for Gapdh 
(panel D), consistent with the MeDIP-qPCR enrichments results, which were higher when 
normalized using Gapdh (Figure 4.12, panels A and B). Panel E shows the minimum and 
the maximum percentage CV calculated on the CpG analyzed, which spanned from 0 
(Hist1h2ba) to 89% (Gapdh), also consistent with data presented in Figure 4.12, where 
Gapdh was the normalizer which showed the biggest SDs. 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
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Figure 4.18. Cytosine methylation quantification by BM direct sequencing of H19 (panel 
A), Hist1h2ba (panel B), Actb (panel C) and Gapdh (panel D) regions of murine young 
(black bars) and old (grey bars) colon samples. Error bars present ± SD calculated on 
each single CpGs measurements of 3 biological replicates. Panel E shows minimum 
(white bars) and maximum (dashed bars) percentage CV determined on all the 
investigated CpGs measurements. 
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4.8 Discussion 
 
In the present study, I developed standardization protocols and quality controls to assess 
the specificity, reproducibility and efficiency of the Methylated DNA Immunoprecipition 
(MeDIP) procedure. By the use of “spiked” positive and negative controls, I provided an 
economical and fast method for quantifying success in enrichment of samples processed 
using the MeDIP technique. 
 
A common way to deal with enrichment data (ChIP or MeDIP), in particular in genome-
wide (array) contexts, is to normalize to input DNA, as a "genome-wide methylation 
state"; however, I believe that the use of internal controls (spikes) is an additional 
advantage since this allows users to take account of other sources of variation, such as 
efficiency of immunoprecipitation. Those spikes were designed with careful attention to 
the defined length and methylCytosine content; technical details of their preparation and 
assessment of suitability are abundantly discussed within this Chapter. 
When I checked for the presence of CpG islands in those spike controls using the 
software http://www.ebi.ac.uk/Tools/emboss/cpgplot/, I found one island of 520 bp in the 
Positive Control and one of 508 bp in the Negative Control; for prediction of CpG 
islands, I used the default settings of the program. I believe that my controls could well 
represent one methylated and one unmethylated CpG island from the human or murine 
genomes. In addition, since these Controls were not subjected to shearing (as prepared 
genomic DNA for MeDIP assays is), they had a constant length and number of 
methylated or unmethylated CpGs. Therefore their immunoprecipitation efficiency was 
constant and could be used with confidence to determine the consistency of the assays. 
 
In principle it is possible, of course, to choose a genomic region with no CpG sites and to 
use it as a normalizer. However, we have to keep in mind that fragments for MeDIP are 
of different length (200 bp to 1000 bp) and that, consequently, target regions for qPCR 
are contained in a pool of these variable length fragments. Thus, to be absolutely certain 
that there are no CpGs in a template, we would have to choose quite a long genomic 
region without any CpG site, which will be much more difficult to find. Assuming that 
we wish to design a qPCR assay that amplifies an amplicon of 100 bp, we would have to 
go upstream and downstream in the genome for 900 bp in each direction without 
encountering a single CG site, with the fragment size range used; this seems unlikely to 
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happen. These considerations reinforce the utility of my method in circumventing 
normalization issues.  
 
Common MeDIP follow-up techniques require more material than what is obtained from 
a typical immunoprecipitation (average yield is about 2% to 5% of the starting material); 
for example, semi-quantitative PCR and qPCR of a non-repetitive region usually 
necessitates of at least 10 ng-20 ng of gDNA for each replicate, while arrays 
hybridization and deep sequencing experiment require at least 3 µg-5µg DNA. Hence, 
WGA is often a mandatory step when preparing MeDIP samples starting from small 
amount of sonicated DNA (a typical quantity for an IP experiment is 1 to 10 µg, but 
smaller amounts have been successfully used). When I compared Positive Control 
enrichments pre- and post-WGA, I noticed that post-WGA enrichments were consistently 
lower by about 32% in all my assays; I found that this was due to unequal amplification 
efficiency of the WGA procedure of the fragments within a mix and I demonstrated that 
this bias was sequence-related and not due to the fragments length or methylation. It is 
possible to correct for it when estimating enrichment by qPCR, by simply calculating the 
amplification rate pre-WGA/post-WGA of a region of interest in a related sample, e.g. 
genomic DNA of the same species. Absolute methylation levels estimation is also 
possible when MeDIP followed by qPCR, by enrichment comparison of the region of 
interest with a known methylation content region with similar CpG density (efficiency of 
immunoprecipitation is in fact directly proportional to the amount of methylated 
Cytosines (Weber et al., 2005)). However, WGA biases cannot be corrected when 
performing MeDIP-arrays coupled experiments and regions which have enrichments 
affected by amplification bias could pass undetected. 
 
The quantity of spikes used in my study resulted in a total of about 3% of occupancy in 
MeDIP prepared after the WGA step; this amount did not seem big enough to affect 
quality of the arrays hybridization (to which, anyway, λ DNA sequences would not bind). 
I did not have experience on deep sequencing techniques, but 3% seemed reasonably low 
for those as well, if we take into account that almost half of the human and more than one 
third of the murine genome are made up by repeats (Burns and Boeke, 2012), which are 
considered “background noise” in this kind of experiments. Here, genomic DNA could be 
spiked with the controls before the sonication step, as average DNA fragments length 
should be smaller than the 600 bp used for arrays hybridization (usually around 200 bp 
(Butcher and Beck, 2010)); in alternative, shorter spikes could be prepared. This second 
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solution seems preferable, as keeping costant the spike controls length ensures that CpG 
content,  and consequently efficiency of immunoprecipitation, is always identical for each 
control molecule spiked in a MeDIP reaction, making enrichments comparison between 
samples more reliable. 
 
Overall, my endogenous regions methylation enrichments data indicate that there may be 
considerable inter-animal variation in methylation of conventional housekeeping genes 
and that researchers need to be alert to the possibility that their treatments may influence 
the methylation status of such genes. These observations reinforce the need for an 
external normalizer to provide a more precise and unbiased normalization of enrichment 
data, if a qPCR approach is used after MeDIP assays; in this context, my spikes method 
can be used as a semi-quantitative predictor for the calculation of methylation fold 
changes in samples to be compared, it eliminates the issue of finding a good endogenous 
normalizer and can be applied to a variety of samples from different species. 
 
Whenever ACTB/Actb or GAPDH/Gapdh are anyway chosen to be used as normalizers in 
qPCR assays using gDNA as template, I suggest researchers to assess whether the 
amplicons obtained correspond to a single genomic region; in fact, those genes have 
many pseudogenes and amplification of one or more of those could lead to confounding 
results, if the samples under investigation present a different content in methylation at 
those genomic locations. To exclude that this was happening in my assays, I double-
checked my primers design making sure of their specificity by in silico PCR (using the 
webtool http://genome.ucsc.edu/cgi-bin/hgPcr?command=start), melt curve analyses 
(Appendix A) , agarose/TBE gel runs and full length sequencing of the cloned PCR 
products (see Appendix D). 
 
4.9 Conclusions 
In conclusion, the method developed in this study can be used: 
 
 to test the reproducibility, specificity and efficiency of MeDIP assays; 
 as a quality control in the screening of MeDIP processed samples prepared for 
hybridization to methylation microarrays;  
 to minimize the risk of bias when making comparisons in the extent of 
methylation between treatments/conditions when there may be biological variation 
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not only in the DNA regions of interest, but also in the endogenous regions used 
as normalizers; 
 to normalize calculations of enrichment when the methylation status of DNA 
domains of interest is not known. I anticipate that the test protocols and quality 
controls described in this report will have utility when comparing results of 
MeDIP procedures between samples and experiments within laboratories and 
between laboratories. 
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Chapter 5. Identification of novel aberrantly methylated genomic 
regions in senescence and in early stress-induced premature senescence 
and effects of senescence on gene expression 
 
5.1 Outline 
Promoter-specific aberrant methylation was first described in cancer, with the first data 
published in the early ‘80s (Feinberg and Vogelstein, 1983). In the field of senescence 
and ageing, aberrant DNA methylation has become a top focus recently and nowadays 
databases for such data are readily available, one example being the “Epigenomics” 
section within PubMed database (http://www.ncbi.nlm.nih.gov/epigenomics/). 
Since 1995, there has been evidence of site-specific aberrant CpG methylation associated 
with cellular senescence for genes whose expression is known to be dysregulated during 
senescence. For example, studies conducted on human fibroblasts primary cultures have 
detected intragenic hypermethylation of the proto-oncogene MYC (Halle et al., 1995), of 
rRNA genes (Machwe et al., 2000), of the hTERT promoter (Shin et al., 2003), of the 
CDKN1A (p21) promoter (Zheng et al., 2006) and of the intragenic sequence of the 
CSNK2A1 gene (Kim et al., 2009a) in replicative senescent cells. With the establishment 
of microarray technology, it has been possible to undertake genome-wide profiling of 
CpG methylation, which has revealed aberrant methylation within promoter regions of 
homeobox genes and genes involved in cell differentiation (Bork et al., 2010), DNA 
replication and cell cycle (Koch et al., 2011; Choi et al., 2012). More recently, DNA 
methylation at specific CpG sites has been suggested as a molecular biomarker for 
senescence (Koch et al., 2012; Koch and Wagner, 2013). 
On the other hand, studies which have investigated site specific DNA methylation 
changes occuring within premature senescence induced by ionizing radiations have found 
contrasting results. Some studies have reported aberrant promoter methylation of genes 
involved in the cell cycle, DNA repair, and apoptosis pathways (Antwih et al., 2013), 
whereas others have failed to detect evidence of senescence-associated DNA methylation 
changes (Koch et al., 2013).  
   
This study was set up to screen for novel differentially methylated regions in replicative 
senescence (RS) and early stress premature induced senescence (ESIPS) compared with 
young confluent (YC) cells using the human lung fibroblasts cell line MRC-5 and to 
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assess whether those were associated with differential expression. To this purpose, I 
prepared 3 biological replicates for each sample type, isolated DNA and performed 
MeDIP, followed by hybridization onto Nimblegen DNA Methylation Arrays. In parallel, 
transcriptome data were obtained using AffimetrixData arrays. Arrays data analyses were 
conducted by M. Adriaeans, Maastricht University. Sample preparation, arrays and data 
analysis methods are described in sections 2.1, 2.3, 2.4, 2.6, 2.7, 2.8, 2.10, 2.11 and 2.12. 
In this Chapter, I describe, analyse and interpret the obtained genome-wide methylation 
and expression data. This includes consideration of genomic regions/genes which were 
altered in both RS and ESIPS cells when compared with YC cells and also consideration 
of the separate lists for each of the comparisons. Then from the RS vs YC cells list of 
comparison for both methylation and expression data, I chose 4 candidates for validation 
of methylation and gene expression. Briefly, methylation arrays and expression arrays 
data were sorted according to the observed fold changes and then bioinformatics analyses 
were performed to check for the presence of regulatory elements within the genomic 
regions identified by the methylation arrays (more details are given in section 5.6). 
Usually, there is an inverse correlation between promoter methylation and expression of 
the corresponding gene because when CpGs within a gene promoter are highly 
methylated this can impede the binding of transcription factors and therefore transcription 
of the related gene (Siegfried and Simon, 2010). However, cases have been reported 
where there is a positive correlation between promoter methylation and expression of the 
corresponding gene and authors have speculated that this may occur when highly 
methylated CpGs impair the binding of transcription repressors. One example is the 
BIRC5 gene, where hypermethylation of the promoter inhibits the binding of its 
transcriptional repressor p53, leading to increased gene expression (Nabilsi et al., 2009). 
With this background, the candidates chosen for validation included examples where 
there were either negative correlation or positive correlation between DNA methylation 
and gene expression changes. 
I concluded my study with a preliminary screening of methylation of the promoters of cell 
cycle genes, whose expression is known to be dysregulated in senescence (Rittling et al., 
1986; Goldstein, 1990). 
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5.2 Genome-wide methylation of replicative senescent and early stress-induced 
premature senescent MRC-5 cells compared with young confluent cells   
Figure 5.1 shows volcano plots for the genome-wide methylation data of RS compared 
with young confluent (YC) cells (left) and ESIPS compared with YC cells (right); 
significant hits lie above the blue line, which corresponds to the significance cut off (p = 
0.05). Only 2.06% and 2.68% of probes showed significantly different methylation 
between the comparison groups (RS vs YC and ESIPS vs YC, respectively); these 
corresponded to 365 and 476 genomic regions. Of those, about 58% were hypomethylated 
and 42% were hypermethylated in RS vs YC cells, while 89% were hypomethylated and 
11% were hypermethylated in ESIPS vs YC cells (data not shown). For a complete list of 
all the significant hits, see CD insert. 
 
 
 
 
A 
B 
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Figure 5.1. Descriptive statistics of MRC-5 cells DNA methylation data shown as volcano 
plots. Panel A: volcano plot showing the distribution significance/fold change of the 
methylation data for replicative senescent MRC-5 cells in comparison with young 
confluent cells; panel B: volcano plot showing the distribution significance/fold change of 
the methylation data for early stress-induced premature senescent MRC-5 cells in 
comparison with young confluent cells. Blue lines indicate the cut off above which the 
statistical significance criteria is met (p < 0.05 for student’s unpaired t-test). 
 
To determine whether there was a relationship between the methylation changes in the 
two pairs of comparison groups, I calculated the Spearman rank order correlation 
coefficient for all the significant differentially methylated Entrez Gene IDs in RS vs YC 
against all Entrez Gene IDs for ESIPS vs YC cells. As shown in Figure 5.2, panel A, this 
correlation was significant and positive, indicating that methylation changes occured in 
the same direction in the two groups. Figure 5.2, panel B, shows the analysis done with 
all significant differentially methylated Entrez Gene IDs in ESIPS vs YC against all 
Entrez Gene IDs for RS vs YC cells. Although still statistically significant, the Spearman 
rank order correlation coefficient for this dataset was much lower than in the previous 
case, but still indicated that methylation changes occured in the same direction. 
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Figure 5.2. Descriptive statistics of MRC-5 cells DNA methylation data: correlation 
between replicative senescence and early stress-induced premature senescence 
methylation changes. Panel A: correlation between replicative senescent and early stress-
induced premature senescent MRC-5 methylation data; panel B: correlation between 
early stress-induced premature senescent and replicative senescent MRC-5 methylation 
data. X-axes show only significant changes while y-axes show all methylation data. The 
Spearman’s rank correlation coefficient (ρ) and the p value for significance are indicated 
at the top right of each panel. 
 
I then identified 38 genomic regions with common behaviour, i.e. where the changes in 
methylation seen were similar for both RS vs YC and ESIPS vs YC comparisons. Of 
these 4 were hypermethylated and 34 were hypomethylated in both RS and ESIPS vs YC 
cells (Figure  5.3, Table 5.1 and 5.2). These numbers were higher than what would be 
expected by chance; in fact, the representation factors and hypergeometric probabilities 
were 9.07 and 9.11 x 10
-4
 for hypermethylation and 6.73 and 8.32 x 10
-19 
for 
hypomethylation repsectively. 
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Figure 5.3. Descriptive statistics of MRC-5 cells DNA methylation data: common 
behaviour for methylation between replicative senescent and early stress-induced 
premature senescent cells compared with young confluent cells. Panel A: Venn diagram 
showing the number and percentage of significantly hypermethylated Entrez Gene IDs in 
common between replicative senescent and early stress-induced premature senescent 
cells in each case compared with young confluent cells; panel B: Venn diagram showing 
the number and percentage of significantly hypomethylated Entrez Gene IDs in common 
between replicative senescent and early stress-induced premature senescent cells in each 
case compared with young confluent cells. 
 
Table 5.1. List of genes shown as their Entrez Gene IDs and official symbols which were 
significantly hypermethylated in both replicative senescent and early stress-induced 
premature senescent cells in each case when compared with young confluent cells. 
 
Entrez Gene ID Gene Official Symbol 
 924 CD7 
4 
(1.99%) 
34 
(5.65%) 
A 
B 
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3149 HMGB3 
7580 ZNF32 
27071 DAPP1 
  
Table 5.2. List of genes shown as their Entrez Gene IDs and official symbols which were 
significantly hypomethylated in both replicative senescent and early stress-induced 
premature senescent cells in each case when compared with young confluent cells. 
 
Entrez Gene ID Gene Official Symbol 
118 ADD1 
818 CAMK2G 
1634 DCN 
2268 FGR 
2972 BRF1 
3895 KTN1 
4121 MAN1A1 
4359 MPZ 
4833 NME4 
4884 NPTX1 
5534 PPP3R1 
5830 PEX5 
7483 WNT9A 
10455 ECI2 
10509 SEMA4B 
22884 WDR37 
23598 PATZ1 
23641 LDOC1 
26292 MYCBP 
27164 SALL3 
51646 YPEL5 
55608 ANKRD10 
56172 ANKH 
57156 TMEM63C 
57473 ZNF512B 
80305 TRABD 
80323 CCDC68 
80331 DNAJ5C 
84504 NKX6-2 
128372 OR6N1 
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130271 PLEKHH2 
220988 HNRNPA3 
246330 PELI3 
389136 VGLL3 
 
Although pathway enrichment analyses using the full list of 38 genes did not produce any 
significant result, Gene Ontology (GO) terms enrichment analyses identified 7 molecular 
functions terms and 19 biological processes terms which were significantly enriched 
when using the list of common hypomethylated genes and 2 molecular functions terms 
and 1 biological processes term which were significantly enriched when using the list of 
common hypermethylated genes. Top hits were, respectively, calcium-dependent protein 
serine/threonine phosphatase activity and transmission of nerve impulse for 
hypomethylation and phosphatidylinositol-3,4-bisphosphate binding and homeostasis of 
number of cells within a tissue for hypermethylation. 
To further unravel the biological meaning of the methylation data, I then considered the 
data sets for RS and ESIPS cells separately and ran pathway analyses on all significant 
differentially methylated Entrez Gene IDs (Appendix E, Table E.1 and Table E.2). Using 
data for replicative senescent cells yielded only one enriched canonical pathway, the 
Caspase 3 activation signalling, or TNFR1 signalling pathway (Table 5.3). However, 
analysis of data from the early induced stress premature senescent cells yielded 5 
enriched canonical pathways which were the signalling events mediated by Class III 
Histondeacetylases, the JNK and NF-kB cascade, N-cadherin and SMAD2/3 signalling 
and the IFN-γ and VEGFR1 pathways (Table 5.4).  
 
Table 5.3. Enriched pathways for significant differentially methylated Entrez Gene IDs 
between RS and YC MRC-5 cells. 
 
Enriched Pathway 
Genes 
observed/total 
p value 
Hypomethylated 
genes/Hypermethylated genes 
TNF signalling 4/32 7.36 x 10-3 2/2 
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Table 5.4. Enriched pathways for significant differentially methylated Entrez Gene IDs 
between ESIPS and YC MRC-5 cells. 
 
 
5.3 Genome-wide gene expression of replicative senescent and early stress-induced 
premature senescent MRC-5 cells compared with young confluent cells   
Figure 5.4 shows volcano plots for the genome-wide expression data of RS compared 
with young confluent (YC) cells (left) and ESIPS compared with YC cells (right), 
significant hits lie above the blue line, which corresponds to the significance cut off (p = 
0.05). 32.84% and 16.82% of Entrez Gene IDs showed significant different expression 
between the comparison groups (RS vs YC and ESIPS vs YC, respectively); these 
corresponded to 5596 and 2866 genes. Of those, about 48% were up-regulated and 52% 
were down-regulated in RS vs YC cells, while about 52% were up-regulated and 48% 
were dowregulated in ESIPS vs YC cells (data not shown). For a complete list of all the 
significant hits see CD insert. 
 
Enriched pathway 
Genes 
observed/total 
p value 
Hypomethylated 
genes/Hypermethylated 
genes 
Signalling events mediated by 
HDAC Class III 
16/40 5.60 x 10-15 14/1 
CD28 signalling ( CD4 T cell 
receptor signalling (JNK cascade) ) 
8/53 1.59 x 10-4 8/0 
N-cadherin signalling events 6/35 5.43 x 10-4 6/0 
Regulation of cytoplasmic and 
nuclear SMAD2/3 signalling 
4/21 3.25 x 10-3 4/0 
IKK-NF-kappaB cascade ( CD4 T 
cell receptor signalling ) 
8/94 7.14 x 10-3 8/0 
IFN-gamma pathway 5/43 9.09 x 10-3 5/0 
VEGFR1 specific signals 4/28 9.44 x 10-3 4/0 
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Figure 5.4. Descriptive statistics of MRC-5 cells gene expression data shown as volcano 
plots. Panel A: volcano plot showing the distribution significance/fold change of the 
expression data for replicative senescent MRC-5 cells in comparison with young 
confluent cells; the Panel B: volcano plot showing the distribution significance/fold 
change of the expression data for early stress-induced premature senescent MRC-5 cells 
in comparison with young confluent cells. Blue lines indicate the cut off above which the 
statistical significance criteria is met (p < 0.05 for unpaired student’s t-test). 
 
As for the equivalent genome-wide methylation data sets, to assess if there was a 
relationship between the expression changes of the two pairs of comparison groups, I 
calculated the Spearman rank order correlation coefficient for all the significant 
A 
B 
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differentially expressed Entrez Gene IDs in RS vs YC against all Entrez Gene IDs for 
ESIPS vs YC cells. As shown in Figure 5.5, left panel, this correlation was significant and 
positive. Figure 5.5, right panel, shows the same analysis done with all significant 
differentially expressed Entrez Gene IDs in ESIPS vs YC against all Entrez Gene IDs for 
RS vs YC cells: here, the Spearman rank order correlation coefficient was also significant 
and even higher than in the previous case. In both comparisons, the analyses indicated 
that expression changes occurred in the same direction in RS and ESIPS when compared 
with YC cells. 
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Figure 5.5. Descriptive statistics of MRC-5 cells gene expression data: correlation 
between replicative senescence and early stress-induced premature senescence 
expression changes. Panel A: correlation between replicative senescent and early stress-
induced premature senescent MRC-5 expression data; Panel B: correlation between early 
stress-induced premature senescent and replicative senescent MRC-5 expression data. X-
axes show only significant changes while y-axes show all expression data. The 
Spearman’s rank correlation coefficient (ρ) and the p value for significance are indicated 
at the top right of each panel. 
 
Comparison of the lists of significantly expressed Entrez Gene IDs revealed that 838 hits 
(25.37%) were commonly up-regulated, while 1072 hits (32.99%) were commonly down-
regulated in both RS and ESIPS vs YC cells (Figure 5.6, panels A and B, respectively). 
Those numbers were higher than would be expected by chance; in fact, representation 
factors were 3.63 and 4.49 for up-regulation and down-regulation, respectively, and 
hypergeometric probability was 0 in both cases. 
 
  
 
 
Upregulated Entrez Gene 
IDs RS vs YC
Upregulated Entrez Gene 
IDs ESIPS vs YC
1825 640
838
(25.37%)
Downregulated Entrez 
Gene IDs RS vs YC
Downregulated Entrez 
Gene IDs ESIPS vs YC
1861 316
1072
(32.99%)
A 
B 
150 
 
Figure 5.6. Descriptive statistics of MRC-5 cells gene expression data: common 
behaviour for expression between replicative senescent and early stress-induced 
premature senescent cells. Panel A: Venn diagram showing the number and percentage 
of significantly up-regulated Entrez Gene IDs in common between replicative senescent 
and early stress-induced premature senescent cells in each case compared with young 
confluent cells; Panel B: Venn diagram showing the number and percentage of 
significantly down-regulated Entrez Gene IDs in common between replicative senescent 
and early stress-induced premature senescent cells in each case compared with young 
confluent cells. 
 
Pathway analyses performed using the gene expression data sets for RS and ESIPS cells 
separately revealed several commonly enriched terms, many of them being cell cycle 
regulation and cell growth related (Table 5.5 and Table 5.6). 
 
Table 5.5. Enriched pathways for significant differentially expressed Entrez Gene IDs 
between RS and YC MRC-5 cells. 
 
Enriched Pathway 
Genes 
observed/total 
p value 
Up-regulated genes/Down-
regulated genes 
PLK1 signalling events 28/46 5.70 x 10-5 4/24 
cdk regulation of dna replication 14/18 9.46 x 10-5 2/12 
E2F transcription factor network 41/78 1.42 x 10-4 7/34 
ATR signalling pathway 24/40 2.66 x 10-4 0/24 
cell cycle: g1/s check point 18/28 4.86 x 10-4 5/13 
Effects of Botulinum toxin 8/9 7.12 x 10-4 7/1 
Aurora B signalling 23/40 8.33 x 10-4 1/22 
cyclins and cell cycle regulation 15/23 1.17 x 10-3 8/7 
Regulation of retinoblastoma protein 33/66 1.93 x 10-3 12/21 
spliceosomal assembly 7/8 1.97 x 10-3 0/6 
Hedgehog signalling events mediated 
by Gli proteins 
25/48 3.32 x 10-3 6/19 
Regulation of Telomerase 35/73 3.53 x 10-3 10/25 
p73 transcription factor network 35/75 6.10 x 10-3 14/21 
mechanisms of transcriptional 
repression by dna methylation 
10/15 6.51 x 10-3 2/8 
btg family proteins and cell cycle 
regulation 
7/9 6.72 x 10-3 2/5 
Signalling events mediated by HDAC 33/71 8.24 x 10-3 12/21 
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Class I 
BARD1 signalling events 18/34 9.78 x 10-3 0/18 
 
Table 5.6. Enriched pathways for significant differentially expressed Entrez Gene IDs 
between ESIPS and YC MRC-5 cells. 
 
Enriched Pathway 
Genes 
observed/total 
p value 
Up-regulated genes/Down-
regulated genes 
ATR signalling pathway 25/40 4.73 x 10-10 4/21 
PLK1 signalling events 23/46 7.26 x 10-7 4/19 
Aurora B signalling 20/40 3.92 x 10-6 2/18 
E2F transcription factor network 31/78 4.84 x 10-6 3/28 
cdk regulation of dna replication 12/18 7.21 x 10-6 1/11 
role of brca1 brca2 and atr in 
cancer susceptibility 
12/22 1.23 x 10-4 2/10 
ATM pathway 15/36 8.03 x 10-4 2/13 
BARD1 signalling events 14/34 1.38 x 10-3 1/14 
Regulation of Telomerase 24/73 1.57 x 10-3 7/17 
Aurora A signalling 13/31 1.67 x 10-3 4/9 
estrogen responsive protein efp 
controls cell cycle and breast 
tumours growth 
8/15 2.15 x 10-3 2/6 
cell cycle: g2/m checkpoint 10/22 2.81 x 10-3 5/5 
Caspase cascade in apoptosis 18/52 3.15 x 10-3 8/10 
p53 signalling pathway 7/13 3.85 x 10-3 4/3 
cyclins and cell cycle regulation 10/23 4.17 x 10-3 4/6 
FOXM1 transcription factor 
network 
15/42 4.88 x 10-3 2/13 
brca1 dependent ub ligase activity 5/8 6.59 x 10-3 0/5 
Validated targets of C-MYC 
transcriptional activation 
25/87 9.31 x 10-3 3/22 
 
5.4 Validation of data from methylation arrays by means of MeDIP-qPCR 
To validate the array methylation data, I sorted both RS vs YC and ESIPS vs YC data sets 
applying a significance cut off (p < 0.05) and then selected the most significant hits that 
appeared in a CpG island of at least 50 bp. The presence of CpG islands was assessed 
using the webtool “CpG finder”: http://www.ebi.ac.uk/Tools/emboss/cpgplot/. In this 
program, the default minimal length for CpG islands is set to 200 bp, but this parameter 
152 
 
was changed to 50 bp to make qPCR primer design easier under the chosen conditions 
(see section 2.8). Those regions were mapped to the PRDM8 gene promoter for RS cells 
and the DCHS1 gene promoter for ESIPS cells, respectively. To select additional 
candidates for both groups, I selected significant regions presenting CpG island computed 
as described above that also appeared among genes with the highest or lowest fold change 
and for which it was possible to design good qPCR assays. Those regions were mapped to 
the promoters of CD7 and RAB5C genes for RS cells and MLNR and OR5AP2 genes for 
ESIPS cells. The details of the qPCR reactions set up and conditions, primers sequences, 
dilution and melt curves for all assays are given in section 2.5, Table 2.3 and Appendix A. 
Results of these validations are shown in Figure 5.7 and, with two minor exceptions, were 
mostly in agreement with the methylation fold changes inferred from the methylation 
arrays, with a validation rate of 83.33% (see Table 5.7). The minor exceptions were the 
PRDM8 and RAB5C gene promoters, where MeDIP-qPCR results revealed a significant 
hypermethylation when comparing either RS or ESIPS cells with YC cells, while the 
arrays did not show any significant methylation changes under the same conditions. 
However, it should be noted that the fold changes detected with both techniques were 
relatively small. In addition, whilst the arrays were performed for three separate 
immunoprecipitations (i.e. estimated fold changes are the average of 3 independent 
replicates), the MeDIP-qPCR was performed only on one sample and so the reliability of 
the latter measurement is likely to be lower. 
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Figure 5.7.  DNA Methylation arrays validation by means of MeDIP-qPCR. Panels A, B, 
C, D, E and F show, respectively, methylation enrichment for CD7, DCHS1, MLNR, 
OR5AP2, PRDM8 and RAB5C genomic regions in MeDIPed samples compared with 
their related Inputs as calculated from qPCR data normalized on the Spike Negative 
Control content, as described in Chapter 4. Bar charts show average enrichment for one 
experiment; error bars show ± SEM of 3 technical replicates. * = p < 0.05; ** = p < 
0.01; *** = p < 0.001 for student’s unpaired t-test. 
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Table 5.7. Methylation fold changes as calculated from Roche Nimblegen DNA 
Methylation Arrays and from MeDIP-qPCR assays for the MeDIP-qPCR validation 
candidates (see Figure 5.7). Unless otherwise indicated with (n.s.), values are statistically 
significant (p < 0.05 for student’s unpaired t-test). 
 
Genomic region 
ESIPS vs YC 
methylation 
fold change 
(array) 
ESIPS vs YC 
methylation 
fold change 
(MeDIP-qPCR) 
RS vs YC 
methylation 
fold change 
(array) 
RS vs YC 
methylation 
fold change 
(MeDIP-qPCR) 
CD7 1.23 1.23 1.37 1.14 
DCHS1 0.75 0.46 0.89 (n.s.) 1.01 (n.s.) 
MLNR 0.77 0.75 1.07 (n.s.) 1.00 (n.s.) 
OR5AP2 0.74 0.84 0.99 (n.s.) 0.99 (n.s.) 
PRDM8 0.99 (n.s.) 1.24 1.37 1.30 
RAB5C 1.11 (n.s.) 1.33 1.31 1.51 
 
5.5 Validation of gene expression arrays by means of RT-qPCR 
To validate the gene expression data, I selected candidates from both groups of 
comparison; these were the most significant differentially expressed Entrez Gene IDs, the 
significant IDs with the lowest fold change and the highest fold change. For the RS vs YC 
comparison, those were, respectively, CCNB2, TMSB15A and PNMA2, while for ESIPS 
vs YC comparison, these were CCNB2, DLGAP5 and MMP3. As CCNB2 was common to 
both groups, a further candidate was selected in MMP3 by going down in the significance 
list for the ESIPS vs YC group. I then designed and optimized RT-qPCR assays; reactions 
set up and conditions, primers sequences, dilution and melt curves for all assays are given 
in section 2.13, Table 2.5 and Appendix A. 
Figure 5.8 shows expression ratios normalized to GAPDH for the selected genes; 
although fold changes were substantially different from the ones calculated from the  
Affimetrix Gene Expression Arrays data sets, the trend of the changes was confirmed for 
all the validation candidates (see Table 5.8). 
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Figure 5.8. Validation of gene expression arrays by means of RT-qPCR. Panels A to F: 
CCNB2, DLGAP5, FANCG, MMP3, PNMA2, TMSB15A relative cDNA content in ESIPS 
and RS MRC-5 fibroblasts compared with YC fibroblasts; expression data are normalized 
D 
E 
F 
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on GAPDH cDNA content and plotted as average fold change of 3 technical replicates ± 
SEM. * = p < 0.05; ** = p < 0.01; *** = p < 0.001 for student’s unpaired t-test. 
 
Table 5.8. Gene expression fold changes as calculated from Affimetrix Gene Expression 
Arrays and from RT-qPCR assays for the RT-qPCR validation candidates (see Figure 
5.8). All the values shown in the Table are statistically significant (p < 0.05 for student’s 
unpaired t-test). 
 
Gene 
ESIPS vs YC 
expression fold 
change (array) 
ESIPS vs YC 
expression fold 
change (RT-
qPCR) 
RS vs YC 
expression fold 
change (array) 
RS vs YC 
expression fold 
change (RT-
qPCR) 
CCNB2 0.02 0.09 0.03 0.13 
DLGAP5 0.007 0.05 0.007 0.04 
FANCG 0.2 0.23 0.2 0.39 
MMP3 19.4 9.25 11.6 83.11 
PNMA2 0.79 0.5 177 34.7 
TMSB15A 0.02 0.19 0.007 0.15 
 
5.6 Integration of methylation and expression arrays data sets and choice of regions 
of interest for combined methylation-expression functional studies 
Having assessed the reliability of both arrays datasets, I wanted to determine whether 
changes in promoter methylation could be causal for changes in expression of the 
corresponding gene. For this purpose, I selected four genomic regions/genes of interest 
from the replicative senescent cells data which showed either the expected inverse 
correlation between methylation and gene expression or opposite than expected 
correlation i.e. direct correlation between methylation and gene expression. The selection 
process consisted of four steps: 
 
1. the methylation data set for RS vs YC cells was sorted as described in section 
2.11.3 to produce two lists of Entrez Gene IDs/regions of interest, one containing 
all hits showing either +2 or -2 of difference in enrichment score (list 1A) and one 
containing all hits showing enrichment score lower than 2 in one sample and 
higher than 2 in the other (list 1B);  
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2. all Entrez Gene IDs in list 1A and 1B which, in parallel, did not show any 
significant change in gene expression were excluded from next steps; 
3. the resulting candidate genomic regions from point 2 were analyzed with the 
program PromoterInspector (available on the Genomatix platform: 
http://www.genomatix.de/) for the presence of experimentally verified or 
computed regulatory elements and only the positive ones were used in step 4; 
4. the final selection was done choosing the genomic regions from step 3 for which 
pyrosequencing assays were commercially available.  
 
The selection process yielded 4 Entrez Gene IDs/genomic regions of interest, whose 
methylation and expression data are summarized in Table 5.9. The candidate gene with 
the expected negative relationship between promoter methylation and gene expression 
expression was CTTN and the candidates with the contrasting positive relationship 
between methylation and gene expression were GLIPR2, NPTX1 and SLC39A14. 
 
Table 5.9. Entrez Gene IDs candidates for methylation-expression integration studies and  
functional studies. Unless indicated by (n.s.), fold changes are statistically significant (p < 
0.05 for student’s unpaired t-test). 
 
Entrez 
Gene ID 
Gene 
symbol 
Methylation 
fold change 
RS vs YC 
Expression 
fold change 
RS vs YC 
Methylation 
fold change 
ESIPS vs YC 
Expression 
fold change 
ESIPS vs YC 
2017 CTTN 0.82 1.33 0.84 (n.s.) 1.25 
152007 GLIPR2 0.83 0.57 0.94 (n.s.) 0.82 (n.s.) 
4884 NPTX1 0.86 0.15 0.89 (n.s.) 0.78 (n.s.) 
23516 SLC39A14 0.89 0.60 0.90 (n.s.) 0.90 (n.s.) 
 
5.7 Pyrosequencing and gene expression analyses of genomic regions of interest 
To investigate CpG methylation in the chosen candidates, I obtained pyrosequencing 
primers from QIAgen. The relevant assays and experimental conditions are described in 
section 2.20 and the outputs from quality controls are presented in Appendix C. To 
quantify gene expression for the same candidates, I designed and optimized RT-qPCR 
assays and the relevant experimental conditions, primers sequences, dilution curves and 
melt curves are presented in section 2.13, Table 2.5 and Appendix A. 
160 
 
Figure 5.9, Figure 5.11, Figure 5.13 and Figure 5.15 illustrate the genomic regions 
identified by the methylation arrays and the CpG sites investigated by the pyrosequencing 
assays; Figures 5.10, Figure 5.12, Figure 5.14 and Figure 5.16 present methylation and 
expression data obtained by pyrosequencing and RT-qPCR, respectively. 
 
5.7.1. CTTN promoter CpG methylation and gene expression measurement 
Figure 5.10 shows the pyrosequencing and RT-qPCR validation results for the first 
candidate gene, CTTN. The results showed significant hypermethylation at the second 
CpG under investigation for the comparison RS vs YC MRC-5 cells (panel A). This was 
opposite of what seen in the data from the methylation arrays, where hypomethylation 
was detected (see Table 5.9). Significant gene up-regulation was found for the RS vs YC 
comparison only (panel B), partially confirming the transcriptome data, where significant 
up-regulation was detected also for the ESIPS vs YC cells comparison (see Table 5.9). 
 
>gi|51468880:467208-468208 Homo sapiens chromosome 11 genomic contig, reference 
assembly, genomic build 36.3 
1 gcagggggcg gggtcgcgcg gggacccgga tgcggccccg cccccgccct cggaaccgga 
61 agtagagcct ggtgcctggg agcggctggc gcggcggaat ccagggccga cccgggccgg 
121 accgacccca ggcggcggtg agcgagcgcg gcgtccgccc ggggtgcagg ccgggctctg 
181 cttcttccct cctgtggcgt cgcctggccg cgaaagggga aggaagcggc ggccgcagcg 
241 gtctcaccgc tcttccgctt gcggtttcgg gggccggggc agagtggcga ggctttcccg 
301 gcctggggcg gggcagggcg agggccgggg gtccgcgagg gccacgagga cgggtctggg 
361 cccaaggagg ccgggcaggg ggcaaggggg cacggagggc ttggggctgg ggtccgcgga 
421 ggaaggttag aaaggggcca aattggggta tcagctctga ggggagggtc cctgggcgcc 
481 ggggggctcc agggcaggag aggggccagg ctgggagggg tcttgggtcc gagggaatag 
541 gagaggggga tgggctccga gggggagggt attagggccc gagggagagg ggctgggcct 
601 gtggggttcg ggggtctgag cggagggggc cggggttcga ggggccaagg aaggtgggtg 
661 tggggggtct caaggaaagg gcgaggggtc tgagagggag gtgtctgggt gcagagggaa 
721 agggatgagg tccgagggga ggagattggg 
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Figure 5.9. CTTN promoter sequence (top) and graphic genomic location (bottom, 
adapted from http://genome.ucsc.edu/cgi-bin/hgBlat) for differentially methylated region 
between RS and YC MRC-5 cells as identified by methylation arrays. The sequence and 
the CpG sites under investigation are underlined and indicated in orange bold font, 
respectively; TSSs are indicated in blue bold font. 
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Figure 5.10. CTTN promoter methylation (panel A) and gene expression (panel B) in 
replicative senescence and early stress-induced premature senescence. Bar chart in panel 
A shows average methylation of 3 CpG sites measured by pyrosequencing; error bars 
represent + SD for at least 8 combined biological and technical replicates. Bar chart in 
panel B shows gene expression GAPDH-normalized; error bars represent ± SD for 4 
biological replicates. * = p < 0.05 for student’s unpaired t-test. 
 
5.7.2. GLIPR2 promoter CpG methylation and gene expression measurement 
Figure 5.12 shows the pyrosequencing and RT-qPCR validation results for the second 
candidate gene, GLIPR2. Although not significant, there was a trend towards 
hypermethylation trend in both ESIPS vs YC and RS vs YC cells comparisons (panel A). 
This was the opposite to what was expected from the methylation array, where 
hypomethylation was detected for theses comparisons (see Table 5.9). GLIPR2 
expression was down-regulated significantly for both pairs of comparison (panel B), 
confirming the transcriptome data for the RS vs YC comparison. Whilst the transcriptome 
array had identified a similar trend for ESIPS vs YC cells, this was not statistically 
significant (see Table 5.9). 
 
>gi|89029256:36126241-36127241 Homo sapiens chromosome 9 genomic contig, 
reference assembly 
1 gcgtgtccta ggagaggagc atccccctcc ccggaccagc cgccctccgg agcccagagt 
61 caccggagat gggggcacac cccggggctg cgtgtgtcgt gtcaggccgc ggcagggaga 
121 ggccgtcccc tggtggcgcc ggccggaacg cccctcgtgc cgcgaccgcg cgcccctctg 
181 tcctcgccgc gcgtcggcgc agagcagcca cccggggccc agcaggcgcg ggcttcccca 
241 cgcgccccgg gaagggacag ctcggtgtgg ggtccgggag gcttgagccc cgcggccgca 
301 tccggggagc cctcggcagt cgcggagctg cttcccaggg gtgagctctc cgggaggccc 
361 acggggtggc cccgggcgcc tccgccctca gctgtcgctc cttataaggc gggggccggg 
421 cggcgccgga ggaggggccg cggcatcagc ccggtcctgg gctctggggc ggcgctgggc 
481 cgggcgagcg cagtgcagcg cagccgcggg gagcgaggag cgcgcggagc cggccatggg 
541 caagtcaggt gagcccgcgg gctcgcccgc tgcggaatgg ttcggaaccc cgcgctcccg 
601 gacctcgccg tctccctcgt ccgccgcaag ccaggtcctg gggagtgcgg gagcccgggg 
661 tgcgggtgga gggcgcgcgg gcggagcgcc ccggcgcggt ttccggggaa cccgggggga 
721 aggcgagccc gagggaggcc cccgccggag agccggggat cgcgccaagt tgggcttccc 
781 gaccctgagg ggctgcgcgc cgcggcccgc caaggcgtgg cttctgcttt gtttcaggag 
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841 gccagactta gagttggaaa agtcaccaaa gtgtgacaac agctctcgct gcgaagcagt 
901 ttgccccgct cggctgtccc gaggacagcc ctgagcatcc ccctcatcca tttgttgttc 
961 cttctctcct gagcgcccgc gccgtgccgg gctccccctg t 
 
 
 
Figure 5.11. GLIPR2 promoter sequence (top) and graphic genomic location (bottom, 
adapted from http://genome.ucsc.edu/cgi-bin/hgBlat) for differentially methylated region 
between RS and YC MRC-5 cells as identified by methylation arrays. The sequence and 
the CpG sites under investigation are underlined and indicated in orange bold font, 
respectively; TSSs are indicated in blue bold font. 
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Figure 5.12. GLIPR2 promoter methylation (panel A) and gene expression (panel B) in 
replicative senescence and early stress-induced premature senescence. Bar chart in panel 
A shows average methylation of 1 CpG site measured by pyrosequencing; error bars 
represent + SD for 9 between biological and technical replicates. Bar chart in panel B 
shows gene expression GAPDH-normalized; error bars represent ± SD for 4 biological 
replicates. ** = p < 0.001 for student’s unpaired t-test. 
 
5.7.3. NPTX1 promoter CpG methylation and gene expression measurement 
Figure 5.14 shows the pyrosequencing and RT-qPCR validation results for the third 
candidate gene, NPTX1: here, a significant hypomethylation was detected in 3 CpG sites 
for the comparison RS vs YC cells (panel A and panel B); this was in agreement with the 
the methylation array results (see Table 5.9). No significant gene down-regulation was 
found for the comparison RS vs YC cells (panel C), although down-regulation trend was 
detected (see Table 5.9). 
 
>gi|37544588:c854818-854068 Homo sapiens chromosome 17 genomic contig, reference 
assembly, genomic build 36.3 
1 cctggcaagg ggaagctgct ggagacgcgg gcggctgctc ccgcggggcc cccttccgaa 
61 gcgccgctgc gaacgtccag ccccggcgac gccgcctgcc cgcgatcggg ccggcgccgc 
121 ggacaggaaa ggctcgatca gctaggtctg cctccgagaa gtccccagcg ccccgcccgc 
181 acggggtggg gactgacagt cccccgggga cggggccggg tccacagagc ccgggagctg 
241 ggggagggga ggcgccgggg gccccgaccc gtgggaagtc cctgtaccca ggctgcccgg 
B 
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301 cggcttctca atagcacacg gacatctaag aaacgcgggg cggcccggtg acccccgctc 
361 tggacttagt ggcgccgcga ggccccactc cgagccgttg accaccgggc actcgggtgt 
421 tgacgacctg ggtccttggg cacccagccc ggctccaaac gaccccggcc caagggtgtt 
481 cagtgcagcc aggagggccg aaccgaattc tatctcccgg acgcggtggt ttcccgcccg 
541 cctggagccc cgtcggaggt tcggggacac cacgcaggtg gtccatcctc gagtccgggg 
601 ccggagcccg acttccttcc ccctgagctc tcggagcctt cggggcagca gcgccggccc 
661 aggcgggggc gggggaggag ggggccgcgg cagctcccag aaggcggggg ggacgcgagc 
721 ggaggcagcc ccggtggcgc gctcgtgaga 
 
 
 
Figure 5.13. NPTX1 promoter sequence (top) and graphic genomic location (bottom, 
adapted from http://genome.ucsc.edu/cgi-bin/hgBlat) for differentiallly methylated region 
between RS and YC MRC-5 cells as identified by methylation arrays. The sequence and 
the CpG sites under investigation are underlined (smooth underline corresponds to assay 
NPTX1_03 and waved undeline corresponds to assay NPTX1_07) and indicated in 
orange bold font, respectively; TSS is indicated in blue bold font. 
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Figure 5.14. NPTX1 promoter methylation (panel A and panel B) and gene expression 
(panel C) in replicative senescence and early stress-induced premature senescence. Bar 
charts in panel A and panel B show average methylation of 3 and 6 CpG sites as 
measured by pyrosequencing; error bars represent + SD for 9 between biological and 
technical replicates; * = p < 0.05; ** = p < 0.01 for Mann-Whitney rank sum test for the 
comparison RS vs YC. Bar chart in panel C shows gene expression GAPDH-normalized; 
error bars represent ± SD for 4 biological replicates.  
 
5.7.4. SLC39A14 promoter CpG methylation and gene expression measurement 
Figure 5.16 shows the pyrosequencing and RT-qPCR validation results for the last 
candidate gene, SLC39A14: here, a significant hypomethylation was detected in one of 
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the CpG sites for the comparison RS vs YC cells (panel A); this was in agreement with 
the methylation array results (see Table 5.9). No significant gene down-regulation was 
found for the comparison RS vs YC cells (panel C), although a trend towards 
dowregulation was detected (see Table 5.9). 
 
>gi|51466739:598730-599480 Homo sapiens chromosome 8 genomic contig, reference 
assembly, genomic build 36.3 
1 gggagggaag agaaaagctt tttgggtgaa ccagaagtgg taaaatcaca ttcaaataga 
61 gtgggtagga ctctcctcca gggggtgtgg ggtggaggct aggcggtgag agcttcccgc 
121 gcccagggag caggtcttca cgggaggttt ccggaggcag gaggagcctg cgggtcctcg 
181 ggagtcacgg ccggatgaag gatgggagcg ggcgccgacc acagccaggg ccgcgaggcg 
241 caggagggcg caggctggcc aggtccccag cctgccggcc ccacgtggca gccccggggc 
301 gagcggggcg ggccgggggc gggtccggcc gctgacgcgc cgggtatata gccgggcatg 
361 cgcgcggtgc cggggcccgg acgcagtgag gggggtcggc gcgcgtgtct acgcggacgc 
421 accggctaag ctgcttctgc cgccgccggc cgcctgggac cttgcggtga ggctgcgcgg 
481 ggccgaggcc gcctccgagc gccaggtgag ggcggggacg ccaagggccg cgggatgggc 
541 agcggcggag gagccccgca ccccaggctg gggcagtggg tgggggcggg gacagccctg 
601 cgccgaggac cgggcgccgc tcccgggcac cggcacacgc ccggacggct gggtggaggc 
661 tgcacctggc cgtggtgccg cgctggcgag gggagaggtc aaggcgcggc ctgtccgcct 
721 ggagggtgcg ggatgctaga gccgcagaag 
 
 
 
Figure 5.15. SLC39A14 promoter sequence (top) and graphic genomic location (bottom, 
adapted from http://genome.ucsc.edu/cgi-bin/hgBlat) for differentiallly methylated region 
between RS and YC MRC-5 cells as identified by methylation arrays. The sequences and 
the CpG sites under investigation are underlined (smooth underline corresponds to assay 
SLC39A14_01 and waved undeline corresponds to assay SLC39A14_02) and indicated in 
orange bold font, respectively; TSSs are indicated in blue bold font. 
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Figure 5.16. SLC39A14 promoter methylation (panel A and panel B) and gene expression 
(panel C) in replicative senescence and early stress-induced premature senescence. Bar 
charts in panel A and panel B show average methylation of 3 and 6 CpG sites as 
measured by pyrosequencing; error bars represent + SD for 9 between biological and 
technical replicates; * = p < 0.05 for Mann-Whitney rank sum test for the comparison RS 
vs YC. Bar chart in panel C shows gene expression GAPDH-normalized; error bars 
represent ± SD for 4 biological replicates. 
 
5.8 Investigation, using a promoter-reporter assay, of the functional consequences of 
promoter methylation on gene expression 
For NPTX1 and SLC39A14 the overall trends of the methylation and expression changes 
detected by means of arrays and pyrosequencing/RT-qPCR were confirmed, while for 
CTTN and GLIPR2 this was validated only partially. To further investigate the effect of 
promoter methylation on gene expression, I optimized and applied the Secreted 
Embryonic Alkaline Phosphatase (SEAP) promoter-reporter assay, as described in section 
2.21. 
Briefly, the promoters of interest were cloned upstream of a murine Secreted Embryonic 
Alkaline Phosphatase gene in a plasmid without a promoter or an enhancer and which 
was completely devoid of CpG dinucleotides. This construct was in vitro methylated to 
produce a fully methylated product and then mixed with portions of the unmethylated 
construct in appropriate proportions to obtain mixtures with the following methylation 
levels: 0%, 25%, 50%, 75% and 100%. These mixtures were used to transfect LN-229 
cells and the SEAP content (a measure of expression of the corresponding gene 
downstream of the cloned promoter) was measured in the media 3 days after transfection 
by a luminometer. 
Figure 5.17 presents a dilution curve for assay of SEAP obtained with serial dilutions of a 
standard and shows that linearity of the assays was good (R
2
 > 0.99) and spanned over at 
least four 5-fold dilutions. SEAP assays for the chosen promoters revealed that, for both 
promoters, methylation impaired the expression of the downstream gene in a manner that 
was directly proportional to the methylation content (Pearson correlation coefficients 
were -0.998 for CTTN and -0.875 for GLIPR2, see Figure 5.18).  
 
170 
 
 
 
Figure 5.17. Standard curve for Secreted Embryonic Alkaline Phosphatase (SEAP) 
promoter-reporter assay. Luminescence of a standard serial dilutions was measured 
under the conditions used for all assays. RLU = relative luminescence units. 
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Figure 5.18. Relationship between CpG methylation content of the promoters of CTTN 
(panel A) and GLIPR2 (panel B) genes and expression. Estimates of expression of the 
reporter Secreted Embryonic Alkaline Phosphatase (SEAP) under the control of CTTN or 
GLIPR2 promoters with increasing methylation content are shown as luminescence 
readings normalized to the reading for the unmethylated promoter. The boxes inside the 
graphs show the Pearson correlation coefficients for the relationships between 
methylation and expression. 
 
5.9 Screening of cell cycle genes promoter methylation in replicative senescence 
To find further genomic regions of interest, I examined the expression data only and 
noted that one of the pathways which was most affected in both RS and ESIPS cells was 
the cell cycle pathway (see Table 5.5 and Table 5.6). I then screened genes in this 
pathway for altered methylation using the Methyl-Profiler DNA Methylation PCR array 
technology (QIAgen), as described in section 2.22. Briefly, this method is based on the 
digestion of the genomic DNA under investigation with methylation-sensitive and 
methylation-dependent restriction enzymes. Subsequent real-time qPCR allows the 
quantification of the uncut DNA. The relative DNA methylation content of a test sample 
compared with a control sample is then calculated with a comparative ΔCT calculation. 
Because of the high cost of the reagents, samples from RS and YC cells only were used in 
the screening. The method allowed me to screen the methylation status of 24 gene 
promoters involved in: 
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 G1 Phase and G1/S Transition: CCND1, CCNE1, CDK4, CDKN1B (p27KIP1); 
 S Phase and DNA Replication: MCM2, MCM4; 
 G2 Phase and G2/M Transition: CCNB1, CDK5RAP1, CKS1B; 
 M Phase: CCNF, MRE11A, RAD51; 
 Cell Cycle Checkpoint and Cell Cycle Arrest: ATM, BRCA1, BRCA2, CDK2, 
CDKN1A (p21CIP1/WAF1), CDKN1B (p27KIP1), CHEK1, GADD45A, RAD17, 
RAD9A, TP53; 
 Regulation of Cell Cycle: ATM, BRCA1, BRCA2, CCNB1, CCND1, CCNE1, 
CCNF, CDK2, CDK4, CDKN1A (p21CIP1/WAF1), CDKN1B (p27KIP1), CKS1B, 
GADD45A, RAD9A, RBL1, RBL2, TP53. 
 
Although efficiency of digestions were very good (the refractory fraction was always 
lower than 4% of the Input DNA, data not shown), I had to exclude 6 of the genes from 
the final analyses because their melt curves showed multiple peaks (data not shown), 
hence the specificity of amplification could not be proven. The excluded genes were: 
CCNF, MCM2, MCM4, RAD17, BRCA2 and CDKN1A. For the remaining 18 genes, 
calculated estimates of promoter methylation data are summarized in Figure 5.19. The 
assay detected low levels of promoter methylation for all genes under investigation: in 
fact, the percentage of CpG methylation was always lower than 7% and 3% in RS and YC 
cells, respectively. There was no evidence of consistent trend towards hypomethylation or 
hypermethylation and, when comparing RS with YC cells, 10 of the gene promoters 
showed increased methylation (CCNB1, CCNE1, CDK4, CDK5RAP1, CDKN1B, 
CHEK1, GADD45A, RAD51, RBL1 and RBL2) whilst other 7 showed lower methylation 
in the senescent cells (ATM, BRCA1, CDK2, CSK1B, MRE11A, RAD9A, TP53).  
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Figure 5.19. Young Replicative (YC) and Replicative Senescent (RS) MRC-5 fibroblasts 
CpG promoter methylation for cell cycle related genes measured by Methyl-Profiler DNA 
Methylation PCR array technology (QIAgen). Bars represent percentage methylation 
measured in one replicate and normalized as indicated by the manufacturer. 
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5.10 Discussion 
This study was designed to use genome-wide array-based approaches to identify novel 
aberrantly methylated genomic regions in DNA from cells undergoing replicative 
senescence and to assess whether those changes could be causal for changes in gene 
expression. My model of choice was the cell line MRC-5 i.e. fibroblasts isolated from 
fetal human lung. A parallel screening was conducted on early stress premature induced 
senescent cells (γ-irradiated). 
 
When compared with the control (DNA from YC cells), differentially methylated loci in 
DNA from early stress premature induced senescent cells were predominantly 
hypomethylated. In contrast, analysis of differentially methylated loci in DNA from RS 
cells revealed approximately equal numbers of hypomethylated and hypermethylated  
loci. This observation may indicate that demethylation of specific loci occurs more 
quickly than does hypermethylation of other loci and/or during the early stages of the 
senescent state induction. If such demethylation was linked with increased gene 
expression one might expect to see activation of the transcription of genes of the DNA 
repair and cell cycle control pathways. 
 
I observed that a few genes (n = 38) showed similar methylation changes in the two data 
sets i.e. those for the RS vs YC and for the ESIPS vs YC comparisons; this finding is in 
contrast with a recently published study, in which authors found no senescence-associated 
DNA methylation changes upon irradiation of in vitro cultured fibroblasts (Koch et al., 
2013). However, I found that hypergeometric probabilities were highly significant and 
representation factors were higher than 6 for both hypomethylation and hypermethylation, 
indicating that the gene methylation changes detected in common between early and late 
senescence were not due to chance. These short lists of Entrez Gene IDs did not reveal 
the identity of any significantly enriched pathway, suggesting that senescence-associated 
aberrant methylation involved single genes belonging to a number of pathways, but not to 
a single senescence-specific pathway. Further analysis of the enriched lists of 
differentially methylated Entrez Gene IDs for RS or ESIPS (see Appendix E, Table E.1 
and Table E2, respectively) showed that although each comparisons featured different 
genes, both sets of differentially methylated genes were involved in similar biological 
processes. These processes included inflammation, cell proliferation, differentiation and 
apoptosis. This observation suggests that similar cellular response are induced by both 
replicative senescence (characterized by telomere shortening) and by the use of DNA 
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damaging agents (γ-rays) to induce early stress premature senescence, as reviewed by 
(Kuilman et al., 2010). 
I also examined genome-wide changes in gene expression in exactly the same cells 
undergoing the same senescence-inducing procedures. These studies showed that, of the 
statistically significant changes, approximately half of the genes were  down-regulated 
and half were up-regulated in both samples sets. Pathway analysis showed similar 
enrichments in the two sample sets, indicating that the genes expression changes 
associated with the senescent state are relatively constant from “early” senescence to 
“late” senescence. Previous studies have also shown similar transcriptome pathways 
enrichment in stress-induced senescent and replicative senescent cells; for example 
(Pascal et al., 2005) have shown enrichment of genes involved in growth arrest and 
senescence morphogenesis in both experimental conditions. 
The observation that few common methylation changes and many common gene 
expression changes were detected in early and late senescence, may suggest that: i) a 
negligible part of the expression changes is ascribable to changes in methylation only and 
that other transcriptional mechanisms might be differentially involved during early and 
late senescence and that: ii) I was able to detect only a small part of the common 
occurring changes in methylation because the chosen array design did not include probes 
for CpG sites further away from the promoter regions e.g. in CpG island shores, shelves 
and open sea, which more recent work has suggested may be important in regulating gene 
expression (Irizarry et al., 2009). 
 
In the following sections, I will give a brief description of the functions and summarize 
the current status of knowledge for the chosen candidates of methylation-expression and 
functional studies which were identified from my genome-wide analysis (see section 5.7). 
I will then continue with the discussion of the experimental results. 
 
5.10.1 CTTN 
As reviewed by (Weaver, 2008), the CTTN gene encodes for a cytoskeleton protein 
(cortactin, also known as EMS1), which is a regulator of the actin filaments assembly and 
is highly expressed in many cellular compartments, at sites of vesicles trafficking and at 
intercellular junctions. In particular, cortactin is abundantly found in podosomes, 
lamellipodia and invadopodia; those are subcellular structures responsible for the 
remodelling/degradation of the extra-cellular matrix (ECM) and ultimately cell motility. 
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Podosomes are found in normal cells that have to pass through tissue barriers, such as 
osteoclasts and macrophages, while lamellipodia and invadopodia are abundantly found 
within tumoural cells, where they contribute to aggressiveness and invasiveness. 
Cortactin overexpression is therefore a feature of many types of human cancers and is 
associated with poor prognosis; however this does not seem to be related to tumour 
initiation, but rather to tumour progression and metastatic potential, as demonstrated by in 
vivo experiments in transgenic mice (van Rossum et al., 2006). 
Frequently, aberrant cortactin expression results from the amplification of the 
chromosomal region 11q13.3 (Myllykangas et al., 2007), but other mechanisms could 
contribute to it; however, to my knowledge no previous report about promoter DNA 
methylation regulation of the CTTN gene expression have been published, nor studies that 
correlate CTTN expression with senescence or age. Hence, this is the first study showing 
that altered promoter DNA methylation may have a causal role in CTTN overexpression 
occurring within senescence. 
CTTN gene overexpression seen in the transcriptome data set (see Table 5.9 and CD 
insert) was confirmed by RT-qPCR; on the other hand, pyrosequencing did not confirm 
CTTN promoter hypomethylation detected by the methylation arrays in the replicative 
senescent compared with young confluent MRC-5 (see Table 5.9 and CD insert). It is to 
be noted that I investigated a small number of the CpG sites included within the genomic 
area of interest identified by the methylation arrays (3 CpG sites out of 59, corresponding 
to about 5%), thus it is possible that the loss of methylation deteted by the arrays occurs 
in sites not included in the study;  in addition, the only CpG site in which I found a 
significant methylation change between RS and YC cells showed opposite than expected 
behaviour, i.e. hypermethylation. This CpG site is contained within a DNA motif which 
shares high similarity with the transcriptional factor ETS1 binding sequence (97% of 
similarity, as calculated using the webtool Genomatix MatInspector (Cartharius et al., 
2005)). As ETS1 can act as a transcriptional repressor (Hahne et al., 2009), I hypotesize 
that hypermethylation of this specific CpG site may impair ETS1 binding and thus 
contribute to the CTTN gene overexpression through diminished transcriptional 
repression. In parallel, ETS1 was also found to be down-regulated in replicative 
senescence from the transcriptome data (fold change 0.68, p = 0.019, data not shown), 
which could also be consistent with my hypothesis. In addition, promoter-reporter 
functional studies confirmed the hypothesis that CpG methylation could regulate 
expression for this gene (Figure 5.18, Panel A).  
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CTTN promoter aberrant methylation and the resulting overexpression occurring during 
senescence could: i) contribute to the invasive potential of cells capable of escaping the 
senescence barrier; ii) contribute to the enlarged and flattened morphology of senescent 
cells, which has been previously discussed in section 1.1 and was also found in my cell 
cultures (data not shown); iii) be one factors that contribute to increased risk of 
developing cancer with age. 
The fact that the pattern hypomethylation/overexpression was not detected in stress 
premature induced senescent cells could be simply due to the early time point of 
harvesting. I predict that γ-irradiated cells harvested at a later time point would present a 
methylation/expression pattern similar to the one of replicative senescent cells, but further 
experiments need to be conducted to verify this hypothesis. 
 
5.10.2 GLIPR2 
Little is known about the function of the product of the GLIPR2 gene (Golgi-associated 
plant pathogenesis-related protein 1 or glioma pathogenesis-related protein 2, also known 
as GAPR-1), which was discovered by two independent groups in 2002 (Eberle et al., 
2002; Eisenberg et al., 2002). Upon translation, the protein is targeted to the Golgi, but 
there is no evidence of its presence in the COPI-vesicles (coat-protein vesicles), thus it 
does not seem to be involved in the transport of proteins between different Golgi cisternae 
(Eberle et al., 2002). The same authors found that GLIPR2 protein is preferentially 
expressed in rat immunocompetent cells and organs (leukocytes, monocytes, lung and 
spleen), but not detectable in tissues like liver, heart and adrenal glands, suggesting a 
potential role in the innate immune response; this assumption is corroborated by the fact 
that high level of GLIPR2 protein are also found in embryonic tissues and in the 
prostasomes, small membranous vesicles secreted by prostate epithelial cells which  have 
been proposed to modulate immune cell response in the female reproductive tract and 
facilitate sperm motility (Aalberts et al., 2012).   
Observational studies conducted in human peripheral chondrosarcomas specimens have 
shown that GLIPR2 transcripts decrease in a proportional manner to increasing 
malignancy (Hameetman et al., 2006); in contrast, a study conducted in a mouse model 
for kidney fibrosis revealed that GLIPR2 protein is up-regulated in fibrotic kidneys 
compared with healthy controls. This overexpression is specific of epithelial cells, where 
it induces an epithelial-mesenchymal transition (EMT) (a process characterized by loss of 
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cell adhesion and increased cell motility), causing a cell morphology shift to fibroblastic 
phenotype (Baxter et al., 2007). 
More recently, GLIPR2 has been identified as a negative regulator of autophagy, a 
cellular mechanism necessary for cell survival, differentiation and organism’s 
development and defense from pathogens (Shoji-Kawata et al., 2013). As autophagy 
contributes to tissues homeostasis, its dysregulation could lead to the onset of infections, 
cancer, various diseases and also to ageing (Levine and Kroemer, 2008).  
Although methylation arrays detected significant hypomethylation in the promoter of the 
GLIPR2 gene in RS compared with YC MRC-5 fibroblasts (see Table 5.9 and CD insert), 
the subsequent attempt at validation using a pyrosequencing assay did not detect any 
significant change in methylation in the only CpG site investigated (Figure 5.12, Panel 
A). However, this was just CpG 1 site out of the 119 CpG sites found in the genomic area 
identified by methylation arrays and it is possible that methylation changes at this site 
were unrepresentative of the remainder of the genomic domain. RT-qPCR assays 
confirmed that expression was decreased during replicative senescence and also in early 
stress-induced premature senescent cells. For the latter, expression arrays had shown a 
trend towards transcriptional down-regulation although this was not statistically 
significant (Figure 5.12, Panel B; CD insert). 
The functional study conducted using the promoter-reporter assay showed clearly that 
there was an inverse relationship between GLIPR2 promoter methylation and gene 
expression (Figure 5.18, Panel B). This was in distinct contrast with the data from the 
genome-wide arrays, where hypomethylation was associated to decreased expression. 
Dependent on the specific CpG sites with altered methylation, it is possible that both 
hypermethylation and hypomethylation could be associated with gene down-regulation. A 
limitation of the data from methylation arrays is that it is not possible to identify which 
specific CpG sites show altered methylation. In contrast, pyrosequencing has considerable 
precision, but this approach has the limitation that each assay can interrogate only 
relatively few CpG sites. For this reason, it is difficult to provide a formal validation of 
the results of methylation arrays. 
To my knowledge, this is the first study of the effects of senescence on promoter 
methylation or gene expression for the GLIPR2 gene. This project has shown changes in 
DNA methylation (detected by the MeDIP technique)  and in gene expression (detected 
by transcriptome arrays and RT-qPCR) for GLIPR2 in response to induction of replicative 
senescence. 
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Changes in GLIPR2 promoter methylation and the resulting gene down-regulation may 
contribute to a number of different processes known to occur in senescence, including: i) 
ageing of the innate immune system (Gomez et al., 2008), because of the above 
mentioned possible involvement of GLIPR2 in the modulation of the immune system; ii) 
ECM degradation (Hornebeck, 2003), because GLIPR2 appears to act as an ECM 
deposition enhancer messenger, being a secreted protein whose up-regulation has been 
linked to fibrosis in the kidney (Baxter et al., 2007); this could also contribute to tumour 
metastatic potential by facilitating migration and invasion of transformed cells through a 
“relaxed” matrix and iii) enhancement of autophagy (Young et al., 2009), because 
GLIPR2 has been identified as a negative regulator of apoptosis (Shoji-Kawata et al., 
2013).  
  
5.10.3 NPTX1 
The product of the gene NPTX1, neuronal pentraxin 1, was first discovered in 2000 and 
identified as a ligand of taipoxin, one of the most potent snake venom neurotoxins known 
(Kirkpatrick et al., 2000). NPTX1 function remains still to be fully elucidated, although its 
high sequence homology to other well studied pentraxins genes lead to the hypothesis that 
it could be involved in the binding of diverse ligands during infection and inflammation 
processes, in the uptake of extracellular material and synaptic material during synapsis 
remodeling (Kirkpatrick et al., 2000). In addition, NPTX1 has been shown to be rapidly 
up-regulated upon hypoxia conditions and to function as a mediator of cell death in 
primary cortical neuron (Hossain et al., 2004), to be necessary for normal structural and 
physiological maturation of the visual system (Bjartmar et al., 2006) and to be 
accumulated in dystrophic neurites of Alzheimer's disease patients and around amyloid 
plaques in the cerebral cortex and hippocampus of a mouse model of Alzheimer’s disease, 
thus possibly contributing to the neurotoxicity of amyloid-beta accumulation (Abad et al., 
2006). In addition, upon neuronal damage, NPTX1 is overexpressed and targeted to the 
mitochondria, where it acts upstream of Bax and contributes to mitochondria 
fragmentation and apoptosis in cultured rat and mouse cerebellar granule neurons 
(Clayton et al., 2012). 
Originally believed to be exclusively expressed in the brain, NPTX1 has been also 
detected in several other tissues and cell types, including myogenic stem cell induced to 
differentiate (Wyzykowski et al., 2002) and in rat insulinoma β-cells (Brunner et al., 
2007) and pancreatic tissue (Schvartz et al., 2012), where overexpression occurs in 
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glucotoxic conditions, suggesting that the protein might have a role as an apoptotic 
mediator upon stress, as in the nervous system.  
With ageing, NPTX1 overexpression has been seen to be associated with progressive 
accumulation of amyloid-beta in human seminal vesicles and to correlate with 
hemospermia (Furuya et al., 2005), but its function in the male reproductive tract is 
currently not known. In the same study, the authors speculated that, in addition to the pro-
apoptotic function played also in other tissues, the protein could be involved in sperm-
oocyte interactions and therefore have a role in the regulation of reproductive functions. 
Interestingly, NPTX1 has been recently identified as an effector of mTOR, being up-
regulated by rapamycin - a known mTOR inhibitor - in a rare astrocytoma cell line, but 
not in normal human astrocytes (Tyburczy et al., 2010). In light of this consideration, 
NPTX1 down-regulation could play a role in the senescence and ageing phenotypes, as a 
result of the mTOR pathway substained activity.  
Various observational studies have found that NPTX1 down-regulation associates with 
increased incidence of adenomas in mice (Stearns et al., 2012) and its promoter 
hypermethylation associates with human pancreatic cancer (Hagihara et al., 2004), 
colorectal cancer (Mori et al., 2011) and cervical cancer (Ongenaert et al., 2008; Yang et 
al., 2009), while no data are available so far on NPTX1 promoter methylation occuring 
with senescence and ageing. 
In my study, I detected significant hypomethylation of the NPTX1 promoter and this was 
associated with a trend toward gene expression down-regulation (Figure 5.14; Table 5.9 
and CD insert); this was in contrast with the aforesaid findings, which correlated instead 
promoter hypermethylation to decreased gene expression; however, hypomethylation 
could favour the binding of transcriptional repressors. To test this hypothesis, I performed 
computational analyses of the sequences investigated by pyrosequencing using the 
webtool Genomatix MatInspector, as already done for the CTTN promoter region. I found 
that CpG 1 within assay NPTX1_03 was contained within the binding domain of the 
transcription factor PLAGL1, which can act as activator or repressor (Abdollahi, 2007), 
and of PBF and E2F factors, which act synergistically to repress transcription (Boeckle et 
al., 2002). In addition, CpG 3 within the same assay was contained in the binding domain 
of RREB1 and ZIC2, both capable of transcription repressional activity (Flajollet et al., 
2009; Pourebrahim et al., 2011). CpG 5 within assay number 7 was contained within the 
binding domain of the transcriptional repressor REST, which represses neuronal genes in 
non-neuronal tissues (Schoenherr et al., 1996); the same domain is shared by SP1 and 
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GLIS2, transcription factors which can both act as enhancers or repressors (Chu, 2012; 
Zhang et al., 2002a).  
In light of these considerations, I can speculate that NPTX1 promoter hypomethylation 
occuring with senescence can contribute to silencing of the NPTX1 gene and, although the 
function of this gene in tissues outside of the nervous system is still to be fully elucidated, 
its down-regulation could have a role in the dysregulation of the apoptotic program and in 
the increase of the inflammatory response seen in a senescent scenario. 
  
5.10.4 SLC39A14 
SLC39A14 has been originally identified as a transmembrane zinc transporter protein 
(Taylor et al., 2005), which was up-regulated during adipocyte differentiation (Tominaga 
et al., 2005). Studies in mice models have confirmed its role in the differentiation and 
systemic growth: in fact, Slc39a14 KO mice have reduced birth weight and size and show 
growth retardation, together with low plasma levels of GH, IGF and low Zn
++
 level in the 
pituitary gland (Hojyo et al., 2011).  
In addition, SLC39A14 plays a major role in the acute-phase response: upon activation by 
IL-6 and IL-1 (master regulators of the immune and inflammatory response), SLC39A14 
mRNA levels increase, as does intracellular Zn
++
 uptake (Liuzzi et al., 2005; Lichten et 
al., 2009). This involvement is also supported by the fact that SLC39A14 gene promoter 
contains response elements for several immune mediators (Liuzzi et al., 2005). 
Different splicing isoforms (4A and 4B) with tissue-specific pattern of expression have 
been identified (Girijashanker et al., 2008); in addition, altered ratio between these two 
isoforms have been associated with adenomas and various cancers, with a marked 
predominance of isoform 4B on isoform 4A (Thorsen et al., 2011). Contribution to 
tumourigenesis of SLC39A14 isoform 4B is believed to be its high affinity for Cd
++
, a 
potent carcinogen, and to the consequent increased intracellular Cadmium uptake. 
A study on pigs demonstrated that SLC39A14 expression level was down-regulated with 
age; this is in agreement with my findings in senescent cells (Figure 5.16, Panel C, Table 
5.9 and CD insert). However, no previous studies have been conducted on aberrant 
promoter methylation of this gene occuring during senescence and ageing. My 
pyrosequencing and RT-qPCR validation assays confirmed the significant trend 
hypomethylation/down-regulation detected by the genome-wide investigation for the 
comparison RS vs YC cells (Figure 5.16, Table 5.9 and CD insert). 
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Similarly to what previously done for the other candidate genes, I analyzed the genomic 
region investigated by the pyrosequencing assays with the webtool MatInspector and 
found that the hypomethylated CpG found within the SLC39A14_01 assay was contained 
in the binding motif of two transcription factors, MYT1L and GTF2B. MYT1L was 
found to be exclusively expressed in the nervous system (especially during development), 
the pituitary gland and testis (Jiang et al., 1996) and was not further kept in consideration. 
Very low MYT1L transcript levels in my samples were confirmed by transcriptome data, 
where the transcript featured at the 19
th
 percentile, when ordering probes by increasing 
measured intensity (data not shown). GTF2B is a general transcription factor ubiquitely 
expressed and correlated with increased gene expression upon binding to recognition sites 
within promoters of many genes. In theory, hypomethylation should increase its binding 
and favour gene expression, but this is in contrast with my findings, where 
hypomethylation was associated with gene down-regulation; however, a study 
demonstrated that, in the presence of a p53-mediated transcriptional response (and this is 
the case of the senescence scenario), GTF2B transcriptional activity is attenuated 
(Shandilya et al., 2012). This could explain the absence of increased SLC39A14 gene 
expression with promoter hypomethylation, but does not explain its down-regulation; I 
therefore concluded that a causal effect for promoter methylation on gene expression 
cannot be drawn referring only to this particular CpG site. 
Down-regulation of the SLC39A14 gene can contribute to decreased intracellular Zn 
uptake and participate in the pathogenesis of acute and chronic lung disease (Zalewski, 
2006) and therefore to the loss of physiological function observed in this tissue with 
ageing; Zn depletion plays, in fact, a part in the increase of the susceptibility of lung 
tissue to oxidative stress (Taylor and Bray, 1991), alcohol-induced (Joshi et al., 2009), 
and sepsis-induced (Knoell et al., 2009) injury and triggers pro-apoptotic stimuli. In 
addition, down-regulation of the SLC39A14 gene has been found in hepatoma cancer cell 
lines, where it occurs in the first stages of malignant transformation (Franklin et al., 
2012); this could corroborate the assumption that cancer is mostly a disease of the ageing 
cell. 
 
5.10.5. Methylation of the promoters of cell cycle genes in replicative senescence 
The investigation of promoter methylation of the cell cycle genes in replicative senescent 
cells described in this chapter should be considered as pilot data only because the study 
was performed just once. In consequence, I could not perform any statistical evaluation of 
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the collected data and so results must be interpreted cautiously. In addition, the identities 
of the CpG sites which showed differential methylation between the two conditions (YC 
and RS cells) were not known. This is because the primers used in the methylation assay 
were copyright protected, and the genomic regions which they amplified could not be 
identified. This meant that a direct comparison of these results with those obtained from 
the methylation arrays was not possible. Whilst the MethylProfiler array investigates a 
150-350 bp region known to be bound by transcription factors in the promoter of the 
chosen genes, this might not correspond completely with the region investigated in the 
methylation arrays. Also, although it was possible to compare changes in methylation 
with those in expression, conclusions about the causal relationship between changes in 
methylation and in gene expression could not be drawn. A possible experimental 
approach to address this issue could be based on the following  two steps: i) PCR-cloning 
and then sequencing of selected qPCR products obtained from the MethylProfiler array 
assays. This would unravel specific genomic loci under investigation and ii) 
pyrosequencing of multiple CpG sites within the identifed genomic loci. This would 
provide information on the methylation status of specific CpG sites. This may help to 
establish a functional link between aberrant methylation and changes in gene expression 
occuring during senescence.  
 
5.11 Conclusions 
In the work described in this Chapter I found that: 
 
 premature senescent and replicative senescent human lung fibroblasts share a 
small, but significant, number of changes in promoters DNA methylation when 
compared with young replicative cells. The genes affected in common include 
those which are involved in inflammation, cell proliferation, differentiation and 
apoptosis; 
 premature senescent and replicative senescent human lung fibroblasts share a 
relatively large number of changes in gene expression when compared with young 
replicative cells. However, the direction of change in promoter methylation and in 
gene expression differed between the two pairs of comparisons, suggesting that 
different mechanisms for regulation of transcription may be involved in “early” 
and “late” senescence; 
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 for CTTN, GLIPR2, NPTX1 and SLC39A14 genes, both promoter methylation and 
gene expression was altered in replicative senescence. The functional studies 
(gene-reporter assays) that I carried out and/or the literature support the 
hypothesis that aberrant promoter methylation occurring with senescence may be 
causal for the related gene expression dysregulation of CTTN and GLIPR2 which, 
in turn, could contribute to the senescent phenotype; 
 in a pilot study, I observed that promoter methylation of a number of cell cycle 
genes is altered in replicative senescence and that this was associated with altered 
gene expression. However a causal (functional) relationship between these two 
states  is still to be elucidated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Manuscript under preparation 
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Chapter 6. Investigation of effects of ageing and of dietary energy 
restriction on genome-wide patterns of DNA methylation in mouse 
tissues 
 
6.1 Outline 
Evidence of age-dependent aberrant DNA methylation at specific CpG sites in mouse has 
been shown for several genes including the proto-oncogenes Myc (Ono et al., 1986; Ono 
et al., 1989), Fos (Uehara et al., 1989) and Hras1 (Counts et al., 1997), for rRNA genes 
(Swisshelm et al., 1990), for genes involved in reproductive function (Liang et al., 2008), 
DNA repair (Conde-Perezprina et al., 2008) and cognitive function (Singh and Prasad, 
2008) and for genes regulating the circadian rhythm (Zhang et al., 2013). 
In parallel, aberrant patterns of gene expression which are characteristic of tissue ageing 
have been identified. These transcriptional changes contribute to progressive loss of 
cellular and tissue function with age (Lee et al., 2000; Zhang et al., 2003; Zahn et al., 
2007; Edwards et al., 2007; Fridman and Tainsky, 2008; de Magalhaes et al., 2009; 
Kuilman et al., 2010). Some of these changes  are counteracted by dietary energy 
restriction (Weindruch et al., 2001; Heilbronn and Ravussin, 2003). 
DNA methylation occurring at gene promoters is often accompanied by silencing of the 
corresponding gene so that aberrant DNA methylation occurring with ageing may 
contribute to the ageing phenotype. At this stage it is uncertain whether this is causal for, 
or a consequence of, ageing itself. Identification of novel aberrantly methylated gene 
promoters in ageing and assessment of their methylation state in response to dietary 
energy restriction could help in discerning the mechanisms by which this dietary 
intervention counteracts the effect of ageing in multiple species. In addition, the outcomes 
of such research may be help to establish dietary interventions aimed at slowing down 
ageing and reducing the risk of age-related diseases. 
  
This study aimed: i) to screen for age-associated DNA methylation changes in the 
promoters of all known mouse genes in DNA from heart and from liver and ii) to assess 
whether those changes were modified by short-term dietary energy restriction.  
For the first part of the study, I chose heart and liver as 2 tissues with different 
proliferative characteristics. By focussing on DNA methylation changes which were 
common to both tissues I hoped  to identify methylation changes that were not tissue-
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specific i.e. to identify gene whose methylation status might be universally susceptible to 
ageing. In the second part of the study, I compared changes in DNA methylation in 
response to ageing with those in response to short-term dietary energy restriction (3 
months). This work was restricted to liver only. 
 
6.2 Effects of ageing on methylation patterns in DNA from mouse heart and liver  
6.2.1 Overview of methylation changes observed in murine liver and heart tissues with 
ageing 
Genomic DNA from 3 animals for each age group/tissue was prepared. Hearts were 
obtained from male C57Bl/6 mice aged 3 and 32 months old; livers were collected from 
male ICRFa mice at 7 and 30 months of age. DNA samples were processed using the 
MeDIP technique, whole genome amplified, subjected to quality control to test for 
methylation enrichment and hybridized to Nimblegen promoter arrays, as described 
earlier (see sections 2.6, 2.7, 2.8 and 2.11 for experimental details). 
Figure 6.1, panel A and panel B, summarises the significant effects of age on genome-
wide methylation in both heart and liver. In each case, “hypomethylation” indicates that 
DNA from the older tissue was significantly less methylated than that from the young 
animals whereas the converse was true for “hypermethylation”. Only 5.05% and 6.68% of 
probes showed significantly different methylation between tissue from older animal vs 
tissue from young animal for heart and liver, respectively; these corresponded to 1007 
and 1331 genomic regions. In both tissues, a greater proportion of the differentially 
methylated genes in older tissue were hypomethylated (62.26% and 55.52% of all 
significant methylation changes in heart and liver, respectively). For a complete list of all 
the significant hits, see CD insert. 
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Figure 6.1. Significant effect of ageing on methylation in mouse heart (panel A) and liver 
(panel B). The pie charts illustrate the proportions of genes showing reduced (hypo) and 
greater (hyper) methylation in older when compared with young adults mice. The boxes 
in the bottom right of each panel indicate the total number of significant Entrez Gene IDs 
for which significant methylation changes were detected (p < 0.05 for student’s unpaired 
t-test). 
 
The list of common Entrez Gene IDs promoters affected by significant age-related DNA 
methylation changes in murine heart and liver contained 108 hits (Figure 6.2); this 
number exceeded what would be expected by chance; in fact, calculated representation 
factor and hypergeometric probability were 1.61 and 2.55 x 10 
-7
, respectively.  
A 
B 
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Figure 6.2. Common Entrez Gene IDs promoters affected by age-related DNA 
methylation changes in murine heart and liver shown as Venn diagram. Representation 
factor = 1.61; hypergeometric probability = 2.55 x 10 
-7
. 
 
These data indicated that there were more genes showing altered promoter methylation 
with ageing in both tissues than would have occurred by chance. The next steps were to 
determine whether i) the methylation changes  occurred in the same or in opposite 
direction (i.e. hypermethylation or hypomethylation) and ii) the number of same-direction 
or opposite-direction changes was significant. To address this issue, I used the lists of 
significantly hypermethylated and hypomethylated Entrez Gene IDs promoters separately 
and compared each pair of data as described below. The analyses yielded the following 
results: 
 
 Entrez Gene IDs that were significantly hypermethylated in both heart and liver 
tissue during ageing = 17 hits; representation factor of 1.51 and hypergeometric 
probability of 2.66 x 10 
-2
 (Figure 6.3, panel A); 
 Entrez Gene IDs that were significantly hypomethylated in both heart and liver 
tissue during ageing = 30 hits; representation factor of 1.29 and hypergeometric 
probability of 2.88 x 10 
-2
 (Figure 6.3, panel B); 
 Entrez Gene IDs that were significantly hypermethylated in heart tissue but 
significantly hypomethylated in liver tissue during ageing = 24 hits; 
representation factor of 1.70 and hypergeometric probability of 3.92 x 10 
-3
 
(Figure 6.3, panel C); 
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 Entrez Gene IDs that were significantly hypomethylated in heart tissue but 
significantly hypermethylated in liver tissue during ageing = 37 hits; 
representation factor of 1.99 and hypergeometric probability of 3.45 x 10 
-5
 
(Figure 6.3, panel D). 
 
These results indicated that for all the pairs of datasets considered the number of hits in 
common i.e. those indicated by the intersections of the two circles in the Venn diagrams 
in Figure 6.3 - was significantly higher than that which would be expected to occur by 
chance. 
  
 
 
 
 
 
 
 
A 
red = hypermethylation; 
blue = hypomethylation 
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B 
C 
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Figure 6.3. Common and opposite behaviour for age-related promoter methylation 
changes in murine heart and liver shown as Venn diagrams. Panel A shows number and 
percentage of significantly hypermethylated Entrez Gene IDs in both heart and liver 
tissue from older animals in each case compared with young animals; panel B shows 
number and percentage of significantly hypomethylated Entrez Gene IDs in both heart 
and liver tissue tissue from older animals in each case compared with young animals; 
panel C shows the intersection between significantly hypermethylated Entrez Gene IDs in 
heart tissue from older animals and significantly hypomethylated Entrez Gene IDs in liver 
tissue from older animals in each case compared with young animals; panel D shows the 
intersection between the significantly hypomethylated Entrez Gene IDs in heart tissue 
from older animals and significantly hypermethylated Entrez Gene IDs in liver tissue 
from older animals in each case compared with young animals. 
 
6.2.2 Pathway analysis for those genes which were differentially methylated in response 
to ageing and for which ageing effects were concordant in both liver and heart tissues 
The IDs and official gene symbols which appeared in the intersections shown in Figure 
6.3 are given in Table 6.1 and Table 6.2. Table 6.1 summarises those genes which showed 
the same methylation response to ageing in both tissues whereas Table 6.2 summarises 
those genes which showed contrasting methylation responses to ageing in the two tissue 
i.e. hypomethylation in liver but hypermethylation in heart and vice versa. 
 
Table 6.1. Genes which showed the same methylation response to ageing in both heart 
and liver. Hypermethylated genes are listed on the left and hypomethylated genes on the 
right. In each case the  Entrez Gene IDs and gene symbols are shown. The annotation 
(Gene ID withdrawn) indicates that the record has been discontinued and it is not in the 
current genome assembly. 
 
 
Entrez Gene ID Gene symbol Entrez Gene ID Gene symbol 
17880 Myh11 12315 Calm3 
22418 Wnt5a 14113 Fbl 
66061 Tctex1d2 14630 Gclm 
67711 Nsmce1 18769 Pkig 
70261 Chp2 19118 Prm1 
71947 2310067B10Rik 19331 Rab19 
Hypermethylation Hypomethylation 
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73991 Atl1 19395 Rasgrp2 
93873 Pcdhb2 54673 Sh3glb1 
112415 C030039L03Rik 59029 Psmd14 
226791 Lyplal1 67111 Naaa 
245884 Fam71f2 72144 Slc37a3 
269344 Ell3 74648 S100pbp 
399510 Map4k5 75083 Usp50 
494504 Apcdd1 76498 Paqr4 
624124 Gm6472 77521 Mtus2 
634044 (Gene ID withdrawn) 78625 1700061G19Rik 
670550 Gm11565 107271 Yars 
  140482 Zfp358 
  209478 Tbc1d12 
  218877 Sema3g 
  223435 Trio 
  228410 Cstf3 
  258462 Olfr1392 
  259300 Ehd2 
  328845 Acsbg2 
  380705 Tmem102 
  380755 Gm889 
  622568 Gm6334 
  100044829 LOC100044829 
  100044867 (Gene ID withdrawn) 
 
Table 6.2. Genes which showed contrasting methylation responses to ageing in heart and 
liver. Genes which are hypermethylated in ageing hearts but hypomethylated in ageing 
livers are listed on the left whilst genes which are hypomethylated in ageing hearts but 
hypermethylated in ageing livers are listed on the right. In each case, the Entrez Gene IDs 
and gene symbols are shown. The annotation (Gene ID withdrawn) indicates that the 
record has been discontinued and it is not in the current genome assembly. 
 
           
                                           
 
Entrez Gene ID Gene symbol Entrez Gene ID Gene symbol 
11474 Actn3 11702 Amd1 
13521  Slc26a2 14179 Fgf8 
14594 Ggta1 14562 Gdf3 
Hypermethylation in heart and 
Hypomethylation in liver 
Hypomethylation in heart and  
Hypermethylation in liver 
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22235 Ugdh 14744 Gpr65 
23879 Fxr2 17183 Matn4 
54369 Nme6 20618 Sncg 
67116 Cuedc2 20983 Syt4 
67381 Med4 22062 Trp73 
70605 Zdhhc24 22247 Umps 
75146 Tmem180 54003 Nell2 
104174 Gldc 56380 Arid3b 
104725 Sptssa 59002 Wrap73 
229906 Gtf2b 63959 Slc29a1 
231932 Gimap7 69241 Polr2d 
244179 Ubqlnl 71395 5430419D17Rik 
258268 Olfr1511 75986 Agmat 
258536 Olfr1360 80876 Ifitm2 
269587 Epb4.1 83995 Mmp1a 
317757 Gimap5 94180 Acsbg1 
320415 Gchfr 105450 Mmrn2 
381126 Garem 107652 Uap1 
435529 Gpr111 108013 Celf4 
640370 Gm7292 110175 Ggct 
100046163 (Gene ID withdrawn) 113865 Vmn1r25 
  170639 Olfr78 
  171195 Vmn1r30 
  193053 Olfr384 
  211550 Tifa 
  235854 Mrgpra4 
  238395 Serpina3j 
  238680 Cntnap3 
  241263 Gpr158 
  381809 Clec4b2 
  631287 LOC631287 
  637082 (Gene ID withdrawn) 
  100043304 Amd-ps3 
  100047905  (Gene ID withdrawn) 
 
To investigate the biological significance of my findings, I performed canonical pathways 
analysis and signal transduction pathways enrichment analysis using the Genomatix 
platform (http://www.genomatix.de/). This analysis revealed significant effects for three 
out of four of the intersections lists (Table 6.3). This was not surprising, as those lists 
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were made up by a small number of hits; in addition, some of the hits were predicted or 
inferred genes, whose biological function is still to be elucidated. 
 
Table 6.3. Canonical and signal transduction pathway analyses for common and opposite 
promoter methylation changes in ageing heart and liver. Panel A lists the significant 
signal transduction pathways for the common hypermethylated Entrez Gene IDs in ageing 
heart and liver; panel B lists the significant canonical pathways for the common 
hypomethylated Entrez Gene IDs in ageing heart and liver; panel C lists the significant 
signal transduction pathways for the intersection between hypermethylated Entrez Gene 
IDs in ageing heart and hypomethylated Entrez Gene IDs in ageing liver. 
 
A 
Signal Transduction Pathway p value Genes observed/total Genes official symbol 
Wingless type 2.90E-03 3/451 Map4k5, Apcdd1, Wnt5a 
Nuclear factor of activated T 
cells, cytoplasmic, calcineurin 
dependentT 
3.25E-03 2/121 Chp2, Wnt5a 
Glycogen synthase kinase 6.78E-03 2/176 Map4k5, Wnt5a 
Ryk receptor like tyrosine kinase 7.60E-03 1/10 Wnt5a 
 
B 
Canonical Pathway p value Genes observed/total Genes official symbol 
Regulation of Ras family 
activation 
9.37E-04 2/34 Calm3, Rasgrp2 
 
C 
Signal Transduction Pathway p value Genes observed/total Genes official symbol 
Cell division cycle 2, G1 to S 
and G2 to M 
5.49E-03 2/158 Cuedc2, Epb4.1 
 
For those genes which were hypermethylated in both heart and liver tissue from the older 
mice, analysis of the Entrez Gene IDs lists yielded 4 significantly enriched signal 
transduction pathways viz. the Wnt signalling pathway, the nuclear factor of activated T 
cells signalling pathway, the glycogen synthase kinase and the Ryk receptor like tyrosine 
kinase signalling pathways (Table 6.3, panel A). Similarly, for those genes which were 
hypomethylated in both heart and liver tissue from the older mice, analysis of the Entrez 
Gene IDs lists yielded a single enriched canonical pathway, i.e. the regulation of Ras 
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family activation pathway (Table 6.3, panel B). Next, I considered those genes showing 
discordant changes in methylation in liver and heart in response to ageing. For those 
genes (Entrez Gene IDs) which were hypermethylated in ageing hearts but were 
hypomethylated in ageing livers, this analysis revealed a single significantly enriched 
signal transduction pathway i.e. that for the cell division cycle 2, G1 to S and G2 to M 
signalling (Table 6.3, panel C). Finally, for those genes (Entrez Gene IDs) which were 
hypomethylated in ageing hearts but hypermethylated in ageing liver, no significantly 
enriched pathways were detected. 
 
6.3 Effects of short-term dietary energy restriction and of ageing on methylation 
patterns in DNA from mouse liver  
6.3.1 Overview of methylation changes occurring in murine liver in response to short-
term dietary energy restriction 
Genomic DNA from 3 animals for each diet group was prepared. Livers were obtained 
from male C57Bl/6 mice aged 17 months old; dietary energy restricted (ER) mice were 
fed 60% of the ad libitum (AL) diet for 3 months, starting at the age of 14 months. DNA 
samples were processed using the MeDIP technique, whole genome amplified, subjected 
to quality control to test for methylation enrichment and hybridized to Nimblegen 
promoter arrays (see sections 2.6, 2.7, 2.8 and 2.11 for experimental details). Figure 6.4 
summarises the significant effects of dietary energy restriction on liver genome-wide 
methylation, where “hypomethylation” indicated that DNA from the tissue from ER fed 
animals was significantly less methylated than that from the AL fed animals, whereas the 
converse was true for “hypermethylation”. A total of 1078 genomic regions (genes) 
corresponding to 5.41% of the array probes showed significantly different methylation in 
DNA from ER fed animals vs AL fed animals. A greater proportion of the differentially 
methylated genes in tissue from ER fed animals was hypomethylated compared with 
tissue from AL fed animals (60.02% of all significant methylation changes). For a 
complete list of all the significant hits, see CD insert. 
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Figure 6.4. Significant effect of short-term dietary energy restriction on DNA methylation 
in mouse liver. The box in the pie chart area indicates the total number of significant 
Entrez Gene IDs for which significant methylation changes were detected (p < 0.05 for 
student’s unpaired t-test). 
 
The list of common Entrez Gene IDs promoters affected by significant age-related and 
dietary energy restriction-related DNA methylation changes in murine livers contained 82 
hits (Figure 6.5); this number exceeded what would be expected by chance, although by a 
small amount; in fact, calculated representation factor and hypergeometric probability 
were 1.14 and 2.21 x 10 
-2
, respectively. 
 
 
 
Liver Old vs Young
(1249)
Liver ER vs AL
(918)
82
(3.65%)
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Figure 6.5. Common Entrez Gene IDs promoters affected by age-related and short-term 
dietary energy restriction-related DNA methylation changes in murine liver shown as 
Venn diagram. Representation factor = 1.14; hypergeometric probability = 2.21 x 10 
-2
. 
 
These data indicated there were more genes showing altered promoter methylation with 
ageing and in response to ER than would have occurred by chance. The next step was to 
determine whether these methylation changes  occurred in the same or opposite direction 
(i.e. hypermethylation or hypomethylation) and whether the numbers of same-direction or 
opposite-direction changes were significant. To address this issue, I used the lists of 
significantly hypermethylated and hypomethylated Entrez Gene IDs promoters separately 
and compared each pair of data as described below. The analyses yielded the following 
results: 
 
 Entrez Gene IDs which were significantly hypermethylated in both tissue from 
older animals compared with tissue from young animals AND in tissue from ER 
fed animals compared with tissue from AL fed animals = 15 hits; representation 
factor = 1.17, not statistically significant (Figure 6.6, panel A);  
 Entrez Gene IDs which were significantly hypomethylated in in both tissue from 
older animals compared with tissue from young animals AND in tissue from ER 
fed animals compared with tissue from AL fed animals = 27 hits; representation 
factor = 1.13, not statistically significant (Figure 6.6, panel B); 
 Entrez Gene IDs which were significantly hypermethylated in tissue from older 
animals compared with tissue from young animals AND significantly 
hypomethylated Entrez Gene IDs in tissue from ER fed animals compared with 
tissue from AL fed animals = 16 hits; representation factor = 0.83, not 
statistically significant (Figure 6.6, panel C); 
 Entrez Gene IDs which were significantly hypomethylated in tissue from older 
animals compared with tissue from young animals AND significantly 
hypermethylated Entrez Gene IDs in tissue from ER fed animals compared with 
tissue from AL fed animals = 24 hits; representation factor = 1.50 and 
hypergeometric probability = 1.13 x 10 
-2 
(Figure 6.6, panel D). 
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Liver Old vs Young
(712)
Liver ER vs AL
(620)
27
(1.99%)
red = hypermethylation; 
blue = hypomethylation 
A 
B 
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Figure 6.6. Effects of short-term dietary energy restriction on age-related DNA 
methylation changes in murine liver shown as Venn diagrams. Panel A shows common 
significantly hypermethylated Entrez Gene IDs in tissue from older animals compared 
with tissue from young animals and in tissue from ER fed animals compared with tissue 
from AL fed animal; panel B shows common significantly hypomethylated Entrez Gene 
IDs in tissue from older animals compared with tissue from young animals and in tissue 
from ER fed animals compared with tissue from AL fed animals; panel C shows 
intersection between hypermethylated Entrez Gene IDs in tissue from older animals 
compared with tissue from young animals and hypomethylated Entrez Gene IDs in tissue 
from ER fed animals compared with tissue from AL fed animals; panel D shows 
intersection between hypomethylated Entrez Gene IDs in tissue from older animals 
C 
D 
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compared with tissue from young animals and hypermethylated Entrez Gene IDs in tissue 
from ER fed animals compared with tissue from AL fed animals. 
 
These data indicated that the number of hits in the intersections was significantly higher 
than what would be expected to be found by chance only in the fourth intersection; for 
this reason, I provide below the hits list for this case, but not for all other cases (Table 
6.4). 
 
6.3.2 Pathway analysis for those genes which were differentially methylated in response 
to ageing and to short-term dietary energy restriction  
The IDs and official gene symbols which appeared in the intersections shown in Figure 
6.4, panel D are given in Table 6.4, which summarises those genes which were 
significantly hypomethylated in tissue from older animals compared with tissue from 
young animals and hypermethylated in tissue from ER fed animals compared with tissue 
from AL fed animals. 
 
Table 6.4. Genes which showed opposite methylation response to ageing and short-term 
dietary energy restriction in murine liver. Genes which are hypomethylated in liver tissue 
from older animals compared with liver tissue from young animals but hypermethylated 
in liver tissue from ER fed animals compared with AL fed animals are listed. The  Entrez 
Gene IDs and gene symbols are shown. The annotation (Gene ID withdrawn) indicates 
that the record has been discontinued and it is not in the current genome assembly. 
 
 
 
Entrez Gene ID Gene symbol 
13491 Drd4 
14113 Fbl 
14297 Fxn 
14594 Ggta1 
15900 Irf8 
19337 Rab33a 
19411 Rarg 
26926 Aifm1 
27274 Zfp354b 
Hypomethylation in ageing liver 
and Hypermethylation in ER liver 
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60613 Kcnq4 
64685 Nmi 
68877 Maf1 
74525 8430419L09Rik 
140482 Zfp358 
214305 Hhipl1 
215387 Ncaph 
230909 Gm572 
231932 Gimap7 
246177 Myo1g 
246728 Oas2 
317757 Gimap5 
100039672 Msmp 
100044605 (Gene ID withdrawn) 
100044829 LOC100044829 
 
Similarly to what previously done for the ageing vs young comparisons, I performed 
canonical pathways analysis and signal transduction pathways analysis using the list of 
genes in Table 6.4; this was because this intersection showed a representation factor 
higher than 1 and significant hypergeometric probability, indicating more overlap than 
expected of two independent groups. Results of such analyses are reported in Table 6.5 
and show one significantly enriched canonical pathway (opposing roles of aif in apoptosis 
and cell survival) and one significantly enriched signal transduction pathway (redox 
signalling). 
 
Table 6.5. Canonical (panel A) and signal transduction pathway analyses (panel B) for 
opposite promoter methylation changes in ageing and dietary energy restricted fed mice 
livers.  
 
A 
Canonical Pathway p value Genes observed/total Genes official symbol 
opposing roles of aif in apoptosis 
and cell survival 
6.11E-03 1/3 Aifm1 
 
B 
Signal Transduction Pathway p value Genes observed/total Genes official symbol 
REDOX 9.49E-03 2/126 Aifm1, Irf8 
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6.4 Discussion 
This study was designed to use genome-wide array-based approaches to identify: i) 
common aberrantly methylated genomic regions in DNA from two different tissues (heart 
and liver) obtained from older mice when compared with tissue obtained from young 
mice and ii) common aberrantly methylated genomic regions in DNA from liver from 
mice exposed to short-term dietary energy restriction when compared with tissue obtained 
from ad libitum fed mice and in DNA from liver obtained from older mice when 
compared with tissue obtained from young mice. 
  
6.4.1 Age-related DNA methylation changes in mouse heart and liver 
For the first part of the study, I chose 2 tissues with different proliferative capacities i.e. 
heart and liver. To a large extent, cardiomyocytes are post-mitotic cells, i.e. cells that 
unable to proliferate and that remain in an irreversible state of arrested cell cycle upon 
differentiation although it is recognised that the heart tissue can undergo limited repair 
and regeneration (Ellison et al., 2012). In contrast, hepatocytes are mitotic cells, that is 
cells capable of proliferation when stimulated to renew in response to damage (Campisi 
and d'Adda di Fagagna, 2007). It has been proposed that some of the processes 
contributing to the ageing phenotype may be different in mitotic and post-mitotic tissues 
(Campisi and Warner, 2001). In fact, post-mitotic cells are not replaced after death due to 
malfunction or progressive accumulation of damage whilst cells in mitotic tissues develop 
a senescent phenotype over time, thus compromising surrounding cells and the 
homeostasis of the whole tissue. More recently, it has been shown that cells in post-
mitotic tissues also develop a senescent phenotype and that this contributes to the 
accumulation of oxidative and inflammatory damage and which may exacerbate ageing of 
the whole tissue (Jurk et al., 2012).  
 
Given the evidence that some of the mechanisms contributing to the ageing process are 
shared among different tissues, I wanted to assess the extent to which different tissues 
showed the same changes in DNA methylation during ageing and thus identify genes 
whose methylation status may be particularly susceptible to age-dependent alteration and 
which may play a major role in the ageing process. This is the first study that has 
compared age-related site-specific aberrant DNA methylation in ageing heart and liver in 
mice. 
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Using the MeDIP technique followed by hybridisation to whole genome promoter 
methylation arrays, I found a that a similar proportion of gene promoters (around 5% or 
>1000 genes) were affected by ageing in both tissues and that more gene promoters 
showed hypomethylation than hypermethylation in both ageing heart and liver. Despite 
the relatively small number of gene promoters (n = 108) which were differentially 
methylated in ageing and the limited number of available animals (n = 3), over-
representation analyses yielded statistical significance for all of the intersections cases 
taken into consideration (see section 6.2.1). Thus, there is evidence that the observed 
same-direction and opposite-direction alteration of methylation patterns may not be 
totally stochastic. It should be noted that the statistical analyses provided reassurance that 
the number of genes featured in the various intersections was higher than what would be 
expected by chance but did not indicate, of course, which of these specific gene changes 
were truly in common since some of those gene showing methylation changes in common 
could have occurred by chance. In addition, a limitation of the present study design is that 
it does not allow me to distinguish between those methylation changes which might be 
causal for the ageing process and which are consequences of ageing. Hence, further 
experimental approaches are needed to be able to identify the genes which are relevant for 
the biology of ageing. However, whether causal or consequential, the genes which I’ve 
discovered show age-related aberrant DNA methylation could be potential markers of the 
ageing process. 
 
DNA methylation changes which occurred in the opposite direction in the 2 tissues (n = 
61) i.e. hypomethylated in one but hypermethylated in the other may be ascribed to the 
tissue-specificity of the DNA methylation patterns in ageing, which has already been 
documented (Thompson et al., 2010). In their study, (Thompson et al., 2010) compared 
age-related methylation changes in rat liver and adipose tissue and found that most of the 
high tissue-specificity resided at inter-genic sequences and conserved non-coding 
elements and not at gene promoters. Therefore, I hypothesize that concordant (or 
conserved) gene promoters aberrant DNA methylation (n = 41) may be of particular 
interest in the epigenetics of ageing in multiple species. 
Interpretation of the functional consequences of the observed methylation changes in the 
present study was limited by the lack of gene expression data from the same samples. As 
a result I was unable to determine whether the detected changes in DNA methylation 
were associated with altered gene expression and to establish if similar gene expression 
changes  occurred in both tissues (heart and liver). 
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Performing pathway analysis on the  concordant DNA methylation changes in DNA from 
the two tissues revealed that the genes whose  promoters where affected by ageing were 
involved in intercellular communication, cellular development/proliferation control, stress 
response (Wnt5a, Map4k5, Apcdd1) and malignant transformation (Chp2) for genes 
exhibiting hypermethylation and involved in cell growth/differentiation and survival 
(Rasgrp2) for genes exhibiting hypomethylation. Down-regulation of expression of the 
Wnt5a gene has been shown in mature osteoblasts from aged mice (Rauner et al., 2008) 
and this decreased Wnt5a expression could be consistent with the promoter 
hypermethylation detected in my study. Importantly, Wnt5a hypermethylation has been 
described in several cancers, including acute lymphoblastic leukaemia (Roman-Gomez et 
al., 2007), acute myeloid leukaemia (Martin et al., 2010), colorectal cancer (Rawson et 
al., 2011) and gastric carcinoma (Liu et al., 2013), which are amongst the most common 
cancers in older people (Hansen, 1998). To my knowledge, there have been no previous 
reports of changes in DNA methylation or in gene expression in ageing for the Map4k5, 
Apcdd1, Chp2 and Rasgrp2 genes so these are among the potential interesting targets for 
further investigation in the field of epigenetics of ageing. 
 
A number of different mechanisms may be responsible for the altered DNA methylation 
patterns observed in this study. For example, age-related hypomethylation could be the 
result of the incorrect functioning of the maintenance methyltransferase (Dnmt1) on 
hemimethylated DNA in liver cells during the DNA replication process. In addition, 
hydrolytic deamination of 5’-methylCytosine to Thymine, described by (Wang et al., 
1982) might be responsible for methylation changes in heart cells. On the other hand, age-
related hypermethylation in both tissues probably occurs due to incorrect targeting of the 
DNA Methyltransferases enzymes, as described in (Casillas et al., 2003). 
 
6.4.2 Effect of dietary energy restriction on age-related aberrant DNA methylation in 
mouse liver 
In the second part of this study, I found that the predominance of  hypomethylation in  
DNA from liver in old vs young animals was also apparent in the DNA from liver from 
dietary energy restricted vs ad libitum fed animals. The number of genes in intersection 
between age-affected and ER-affected genes showing altered promoter methylation was 
small but significant. About half of these genes (n = 42) showed concordant DNA 
methylation changes and for half (n = 40) the methylation changes occurred in the 
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opposite direction in response to ageing and to ER in DNA from liver. Given that mice 
used for the ageing study were killed at 30 months of age and mice used for the dietary 
intervention study were killed at 17 months of age, I hypothesize that same-direction 
DNA methylation changes may have been early-onset ageing related events which were 
unaffected by the short-term dietary energy restriction regimen. On the other hand, those 
genes showing changes in methylation in opposite directions in response to ageing and to 
ER may be responsible for  mediating the beneficial effects of the dietary energy 
restriction regimen in slowing the ageing process. 
 
Genes for which the promoters were hypomethylated in ageing samples and 
hypermethylated following dietary energy restriction were used in subsequent pathways 
analyses. The results of this bioinformatics analysis revealed that short-term dietary 
energy restriction affected promoter methylation of genes which play roles in apoptosis 
regulation (Aifm1) and in inflammatory responses to viral infection (Irf8). Previous 
studies have shown that even short-term dietary energy restriction affects the expression 
of genes involved in apoptosis in mouse hepatocytes (James et al., 1998) and liver (Cao et 
al., 2001), in human in vitro cell models and in C. elegans (Morselli et al., 2010) and 
genes involved in inflammation in mouse liver (Cao et al., 2001) and adipose tissue 
(Higami et al., 2006). Since both Aifm1 and Irf8 genes are included in the redox signaling 
transduction pathway, my observation that they show discordant changes in promoter 
methylation in response to ageing and to ER may be functionally important. This could 
suggest a possible epigenetic mechanism through which ER modulates the ageing process 
because ROS accumulation contributes to the biology of ageing through promotion of 
molecular damage, as outlined in Chapter 1 and reviewed in (Stadtman, 2004). However, 
to my knowledge, there have been no previous published studies of the effects of ageing 
and of ER on promoter methylation of the Aifm1 and Irf8 genes nor have data for 
corresponding gene expression profiles been published. Further work is warranted to 
discover whether these two genes are potential novel targets whose aberrant methylation 
in ageing is counteracted by dietary energy restriction which may help in elucidating the 
mechanisms through which dietary energy restriction exerts its anti-ageing effect.  
 
Other gene promoters for which age-related aberrant promoter methylation was 
counteracted by dietary energy restriction included genes involved in transcription 
regulation (Rarg), immune response to viral infection (Nmi, Maf1), vesicle trafficking 
(Rab33a) and mitochondrial iron transport and respiration (Fxn). I am not aware of any 
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previous studies which have reported changes in promoter methylation or gene expression 
patterns for these genes in ageing or following ER. Further studies including validation 
(by pyrosequencing) of the observed changes in DNA methylation integrated with gene 
expression studies may provide a molecular explanation for some of the beneficial effects 
of dietary energy restriction in delaying the ageing process and in reducing the risk of 
age-related diseases. 
 
6.5 Conclusions 
In the work described in this Chapter I found that: 
 
 in both mouse heart and liver, there were >1000 genes showing  age-related 
changes in promoter methylation changes and that most (about 95%) of these 
genes changes were tissue-specific; 
 a significant proportion of the genes showing age-dependent changes in promoter 
methylation were common to both liver and to heart suggesting that these genes 
may be universally susceptible to age-related aberrant methylation; 
 the ageing process in both mouse heart and liver is characterized by the 
dysregulation of normal DNA methylation profiles of promoters of genes involved 
in intercellular communication, stress response, malignant transformation, cellular 
development/proliferation control and cell growth/differentiation and survival; 
 the promoters of Wnt5a, Map4k5, Apcdd1, Chp2 and Rasgrp2 show aberrant 
methylation in DNA from both mouse heart and liver in ageing; 
 short-term dietary energy restriction of mice in mid-life (from 14 – 17 months of 
age) resulted in altered promoter methylation of 1078 genes in DNA  from liver 
compared with that from ad libitum-fed counterparts; 
 short-term dietary energy restriction appeared to counteract age-related 
methylation changes in the promoters of a significant proportion of the genes and 
the latter genes included those involved in apoptosis regulation, inflammatory and 
immune response to viral infections, transcription regulation, vesicle trafficking 
and mitochondrial iron transport and respiration; 
 age-dependent methylation of the promoters of Aifm1, Irf8, Rarg, Nmi, Maf1, 
Rab33a and Fxn genes was counteracted by dietary energy restriction. 
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Chapter 7. Mitochondrial DNA methylation in senescence and ageing 
and in response to dietary energy restriction 
 
7.1 Outline 
The recent discovery of the presence of the DNMT1/Dnmt1 proteins in human and murine 
mitochondria has raised interest in the study of methylation of mitochondrial DNA. 
(Shock et al., 2011) demonstrated that both human and murine genomes feature a 
mitochondrial importing sequence upstream of the DNMT1 and Dnmt1 genes; both 
importing sequences are transcribed and translated and are capable of translocating the 
related protein products into the mitochondria. In addition, the authors confirmed that 
both DNMT1 and Dnmt1 bind to mitochondrial DNA and that these are the only enzymes 
of the DNAMethylTransferases family that are found in the organelle. Their conclusion is 
that, given the presence of methylated Cytosines in the mitochondrial genome (Nass, 
1973; Shmookler Reis and Goldstein, 1983), DNMT1 and Dnmt1 must be responsible for 
the CpG methylation patterns found in the mitochondrial genome. 
Their hypothesis fits with the prior in vitro observation that human DNMT1 and murine 
Dnmt1 show, to a certain extent, de novo methyltransferase activity (Chen et al., 1998; 
Pradhan et al., 1997). In contrast, much previous work has been based on the assumption 
that DNMT1 and Dnmt1 behave as the maintenance DNA methyltransferases, which are 
responsible for copying DNA methylation patterns during DNA replication. 
 
In this study, I chose 5 CpG-rich regions within the human mitochondrial genome and 2 
within the murine mitochondrial genome and assessed their methylation status by BM-
DNA PCR and direct sequencing. The DNA for these studies was extracted from i) YC, 
ESIPS and RS MRC-5 human lung fibroblasts, ii) liver from young and old mice and iii) 
liver from both ad libitum fed and dietary energy restricted mice. In this way, I 
investigated whether senescence/ageing or dietary intervention altered in the patterns of 
mtDNA methylation. 
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7.2 Bioinformatics analyses of the human mitochondrial DNA molecule and choice 
of candidate regions for methylation studies 
The human mitochondrion genome is a 16569 bp circular double strand DNA molecule, 
present in several copies in each organelle. To select candidate regions for my 
methylation studies, I obtained its sequence from the PubMed database 
(http://www.ncbi.nlm.nih.gov/nuccore/NC_012920) and searched for putative CpG 
islands using the webtool CpG plot 
(http://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/), focussing on the sequences of the 
13 protein-encoding mitochondrial genes, the D-Loop regulatory region and a long non-
protein-coding region at the 5’ end of the ND1 gene. Applying the default settings of the 
program (island of at least 200 bp, % of C + G of at least 50% and C + G 
observed/expected ratio of at least 0.6), I identified a unique region that met the selection 
criteria, the COX2 gene encoding region. To identify a higher number of putative 
candidates for methylation analyses, I therefore decided to apply less stringent criteria, 
reducing the length of the islands to a minimum of 100 bp. By doing so, the following 
eight genomic regions were identified:  
 
 MT-non-coding region (5’ end of the MT-ND1 gene); 
 MT-ND1 coding region; 
 MT-COX1 coding region; 
 MT-COX2 coding region; 
 MT-ATP6 coding region; 
 MT-ND4 coding region; 
 MT-ND5 coding region; 
 MT-CYTB coding region. 
 
I designed, and attempted to optimize, primers for PCR amplification of bisulphite 
modified DNA, as described in section 2.18. However, the optimization failed to yield a 
unique product – or any product – in the PCR trials for the MT-COX2, the MT-ATP6 and 
the MT-CYTB gene sequences. These were removed from the gene panel and I therefore 
pursued methylation analyses of the other 5 genomic regions. Results of these analyses 
are reported in the section 7.3 below. 
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7.3 Quantification of CpG methylation at a single CpG level for five genomic regions 
within the human mtDNA in early stress-induced premature senescence and in 
replicative senescence 
After total genomic DNA extraction (see section 2.3), I performed bisulphite modification 
(see section 2.17), BM-PCR (see section 2.18) and sequencing (see section 2.19) on one 
sample from each YC, ESIPS and RS cells and performed statistical analyses on the 
measured methylation values across the analyzed genomic regions. For the latter a paired 
t-test was used which compared methylation values at each CpG site within the region of 
interest from each of the cell types. 
In the following sections, I provide the sequences of the DNA sequences under 
investigation and the related results for CpG methylation analyses. 
 
7.3.1 MT-COI mitochondrially encoded cytochrome c oxidase I [ Homo sapiens ], Gene 
ID: 4512 
1 atgttcgccg accgttgact attctctaca aaccacaaag acattggaac actataccta 
61 ttattcggcg catgagctgg agtcctaggc acagctctaa gcctccttat tcgagccgag 
121 ctgggccagc caggcaacct tctaggtaac gaccacatct acaacgttat cgtcacagcc 
181 catgcatttg taataatctt cttcatagta atacccatca taatcggagg ctttggcaac 
241 tgactagttc ccctaataat cggtgccccc gatatggcgt ttccccgcat aaacaacata 
301 agcttctgac tcttacctcc ctctctccta ctcctgctcg catctgctat agtggaggcc 
361 ggagcaggaa caggttgaac agtctaccct cccttagcag ggaactactc ccaccctgga 
421 gcctccgtag acctaaccat cttctcctta cacctagcag gtgtctcctc tatcttaggg 
481 gccatcaatt tcatcacaac aattatcaat ataaaacccc ctgccataac ccaataccaa 
541 acgcccctct tcgtctgatc cgtcctaatc acagcagtcc tacttctcct atctctccca 
601 gtcctagctg ctggcatcac tatactacta acagaccgca acctcaacac caccttcttc 
661 gaccccgccg gaggaggaga ccccattcta taccaacacc tattctgatt tttcggtcac 
721 cctgaagttt atattcttat cctaccaggc ttcggaataa tctcccatat tgtaacttac 
781 tactccggaa aaaaagaacc atttggatac ataggtatgg tctgagctat gatatcaatt 
841 ggcttcctag ggtttatcgt gtgagcacac catatattta cagtaggaat agacgtagac 
901 acacgagcat atttcacctc cgctaccata atcatcgcta tccccaccgg cgtcaaagta 
961 tttagctgac tcgccacact ccacggaagc aatatgaaat gatctgctgc agtgctctga 
1021 gccctaggat tcatctttct tttcaccgta ggtggcctga ctggcattgt attagcaaac 
1081 tcatcactag acatcgtact acacgacacg tactacgttg tagcccactt ccactatgtc 
210 
 
1141 ctatcaatag gagctgtatt tgccatcata ggaggcttca ttcactgatt tcccctattc 
1201 tcaggctaca ccctagacca aacctacgcc aaaatccatt tcactatcat attcatcggc 
1261 gtaaatctaa ctttcttccc acaacacttt ctcggcctat ccggaatgcc ccgacgttac 
1321 tcggactacc ccgatgcata caccacatga aacatcctat catctgtagg ctcattcatt 
1381 tctctaacag cagtaatatt aataattttc atgatttgag aagccttcgc ttcgaagcga 
1441 aaagtcctaa tagtagaaga accctccata aacctggagt gactatatgg atgcccccca 
1501 ccctaccaca cattcgaaga acccgtatac ataaaatcta ga 
 
Figure 7.1. MT-COI gene sequence. Genomic regions used as priming sites for 
methylation studies are underlined; CpG sites investigated in this study are indicated in 
bold orange font. 
 
Figure 7.2 shows the percentage of CpG methylation measured across 11 CpG sites 
within the MT-COI gene coding sequence in YC, ESIPS and RS MRC-5 cells: YC cells 
methylation ranged between 0% and 11% (median value = 4%), ESIPS cells methylation 
ranged between 0% and 38% (median value = 15%) and RS cells methylation ranged 
between 0% and 22% (median value = 5%). There was a statistically significant 
difference in methylation content between YC and ESIPS cells (p = 0.002) and between 
YC and RS cells (p = 0.025). 
 
 
Figure 7.2. MT-COI CpG methylation measured by BM PCR direct sequencing. Box plots 
show the percentiles and the median of the percentages of Cytosine methylation. Box 
outlines define the 25th and 75th percentiles, with a line at the median, and whiskers 
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indicate the 10th and 90th percentiles; dots indicate outliers. * = p < 0.05; ** = p < 0.01 
for student’s paired t-test in which methylation levels at individual CpG sites were 
compared across cell types. 
 
7.3.2 Homo sapiens mitochondrion genome, non-coding region, GenBank: J01415.2 
901 ggtcacacga ttaacccaag tcaatagaag ccggcgtaaa gagtgtttta gatcaccccc 
961 tccccaataa agctaaaact cacctgagtt gtaaaaaact ccagttgaca caaaatagac 
1021 tacgaaagtg gctttaacat atctgaacac acaatagcta agacccaaac tgggattaga 
1081 taccccacta tgcttagccc taaacctcaa cagttaaatc aacaaaactg ctcgccagaa 
1141 cactacgagc cacagcttaa aactcaaagg acctggcggt gcttcatatc cctctagagg 
1201 agcctgttct gtaatcgata aaccccgatc aacctcacca cctcttgctc agcctatata 
1261 ccgccatctt cagcaaaccc tgatgaaggc tacaaagtaa gcgcaagtac ccacgtaaag 
1321 acgttaggtc aaggtgtagc ccatgaggtg gcaagaaatg ggctacattt tctaccccag 
1381 aaaactacga tagcccttat gaaacttaag ggtcgaaggt ggatttagca gtaaactaag 
1441 agtagagtgc ttagttgaac agggccctga agcgcgtaca caccgcccgt caccctcctc 
 
Figure 7.3. Portion of the human mitochondrion genome non-protein-coding region. 
Genomic regions used as priming sites for methylation studies are underlined; CpG sites 
investigated in this study are indicated in bold orange font. 
 
Figure 7.4 shows the percentage of CpG methylation measured across 9 CpG sites within 
the human mitochondrion genome non-coding region sequence in YC, ESIPS and RS 
MRC-5 cells: YC cells methylation ranged between 0% and 13% (median value = 1%), 
ESIPS cells methylation ranged between 0% and 15% (median value = 4%) and RS cells 
methylation ranged between 0% and 9% (median value = 3%). There was no statistically 
significant difference in methylation content between YC and ESIPS cells, nor between 
YC and RS cells. 
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Figure 7.4. Human mitochondrion genome non-coding region CpG methylation measured 
by BM PCR direct sequencing. Box plots show the percentiles and the median of the 
percentages of Cytosine methylation. Box outlines define the 25th and 75th percentiles, 
with a line at the median, and whiskers indicate the 10th and 90th percentiles. 
 
7.3.3. MT-ND1 mitochondrially encoded NADH dehydrogenase 1 [ Homo sapiens ], 
Gene ID: 4535 
1 atacccatgg ccaacctcct actcctcatt gtacccattc taatcgcaat ggcattccta 
61 atgcttaccg aacgaaaaat tctaggctat atacaactac gcaaaggccc caacgttgta 
121 ggcccctacg ggctactaca acccttcgct gacgccataa aactcttcac caaagagccc 
181 ctaaaacccg ccacatctac catcaccctc tacatcaccg ccccgacctt agctctcacc 
241 atcgctcttc tactatgaac ccccctcccc atacccaacc ccctggtcaa cctcaaccta 
301 ggcctcctat ttattctagc cacctctagc ctagccgttt actcaatcct ctgatcaggg 
361 tgagcatcaa actcaaacta cgccctgatc ggcgcactgc gagcagtagc ccaaacaatc 
421 tcatatgaag tcaccctagc catcattcta ctatcaacat tactaataag tggctccttt 
481 aacctctcca cccttatcac aacacaagaa cacctctgat tactcctgcc atcatgaccc 
541 ttggccataa tatgatttat ctccacacta gcagagacca accgaacccc cttcgacctt 
601 gccgaagggg agtccgaact agtctcaggc ttcaacatcg aatacgccgc aggccccttc 
661 gccctattct tcatagccga atacacaaac attattataa taaacaccct caccactaca 
721 atcttcctag gaacaacata tgacgcactc tcccctgaac tctacacaac atattttgtc 
781 accaagaccc tacttctaac ctccctgttc ttatgaattc gaacagcata cccccgattc 
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841 cgctacgacc aactcataca cctcctatga aaaaacttcc taccactcac cctagcatta 
901 cttatatgat atgtctccat acccattaca atctccagca ttccccctca aaccta 
 
Figure 7.5. MT-ND1 gene sequence. Genomic regions used as priming sites for 
methylation studies are underlined; CpG sites investigated in this study are indicated in 
bold orange font. 
 
Figure 7.6 shows the percentage of CpG methylation measured across 12 CpG sites 
within the MT-ND1 gene coding sequence in YC, ESIPS and RS MRC-5 cells: YC cells 
methylation ranged between 0% and 29% (median value = 2%), ESIPS cells methylation 
ranged between 0% and 34% (median value = 7%) and RS cells methylation ranged 
between 0% and 38% (median value = 10%). There was a statistically significant 
difference in methylation content between YC and ESIPS cells (p = 0.011) and between 
YC and RS cells (p = 0.002). 
 
 
Figure 7.6. MT-ND1 CpG methylation measured by BM PCR direct sequencing. Box 
plots show the percentiles and the median of the percentages of Cytosine methylation. 
Box outlines define the 25th and 75th percentiles, with a line at the median, and whiskers 
indicate the 10th and 90th percentiles; dots indicate outliers. * = p < 0.05; ** = p< 0.01 
for student’s paired t-test in which methylation levels at individual CpG sites were 
compared across cell types. 
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7.3.4 MT-ND4 mitochondrially encoded NADH dehydrogenase 4 [ Homo sapiens ], 
Gene ID: 4538 
1 atgctaaaac taatcgtccc aacaattata ttactaccac tgacatgact ttccaaaaaa 
61 cacataattt gaatcaacac aaccacccac agcctaatta ttagcatcat ccctctacta 
121 ttttttaacc aaatcaacaa caacctattt agctgttccc caaccttttc ctccgacccc 
181 ctaacaaccc ccctcctaat actaactacc tgactcctac ccctcacaat catggcaagc 
241 caacgccact tatccagtga accactatca cgaaaaaaac tctacctctc tatactaatc 
301 tccctacaaa tctccttaat tataacattc acagccacag aactaatcat attttatatc 
361 ttcttcgaaa ccacacttat ccccaccttg gctatcatca cccgatgagg caaccagcca 
421 gaacgcctga acgcaggcac atacttccta ttctacaccc tagtaggctc ccttccccta 
481 ctcatcgcac taatttacac tcacaacacc ctaggctcac taaacattct actactcact 
541 ctcactgccc aagaactatc aaactcctga gccaacaact taatatgact agcttacaca 
601 atagctttta tagtaaagat acctctttac ggactccact tatgactccc taaagcccat 
661 gtcgaagccc ccatcgctgg gtcaatagta cttgccgcag tactcttaaa actaggcggc 
721 tatggtataa tacgcctcac actcattctc aaccccctga caaaacacat agcctacccc 
781 ttccttgtac tatccctatg aggcataatt ataacaagct ccatctgcct acgacaaaca 
841 gacctaaaat cgctcattgc atactcttca atcagccaca tagccctcgt agtaacagcc 
901 attctcatcc aaaccccctg aagcttcacc ggcgcagtca ttctcataat cgcccacggg 
961 cttacatcct cattactatt ctgcctagca aactcaaact acgaacgcac tcacagtcgc 
1021 atcataatcc tctctcaagg acttcaaact ctactcccac taatagcttt ttgatgactt 
1081 ctagcaagcc tcgctaacct cgccttaccc cccactatta acctactggg agaactctct 
1141 gtgctagtaa ccacgttctc ctgatcaaat atcactctcc tacttacagg actcaacata 
1201 ctagtcacag ccctatactc cctctacata tttaccacaa cacaatgggg ctcactcacc 
1261 caccacatta acaacataaa accctcattc acacgagaaa acaccctcat gttcatacac 
1321 ctatccccca ttctcctcct atccctcaac cccgacatca ttaccgggtt ttcctctt 
 
Figure 7.7. MT-ND4 gene sequence. Genomic regions used as priming sites for 
methylation studies are underlined; CpG sites investigated in this study are indicated in 
bold orange font. 
 
Figure 7.8 shows the percentage of CpG methylation measured across 8 CpG sites within 
the MT-ND4 gene coding sequence in YC, ESIPS and RS MRC-5 cells: YC cells 
methylation ranged between 0% and 9% (median value = 6%), ESIPS cells methylation 
ranged between 0% and 15% (median value = 4%) and RS cells methylation ranged 
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between 0% and 9% (median value = 3%). There was no statistically significant 
difference in methylation content between YC and ESIPS cells, nor between YC and RS 
cells. 
 
 
Figure 7.8. MT-ND4 CpG methylation measured by BM PCR direct sequencing. Box 
plots show the percentiles and the median of the percentages of Cytosine methylation. 
Box outlines define the 25th and 75th percentiles, with a line at the median. 
 
7.3.5. MT-ND5 mitochondrially encoded NADH dehydrogenase 5 [ Homo sapiens ], 
Gene ID: 4540 
1 ataaccatgc acactactat aaccacccta accctgactt ccctaattcc ccccatcctt 
61 accaccctcg ttaaccctaa caaaaaaaac tcataccccc attatgtaaa atccattgtc 
121 gcatccacct ttattatcag tctcttcccc acaacaatat tcatgtgcct agaccaagaa 
181 gttattatct cgaactgaca ctgagccaca acccaaacaa cccagctctc cctaagcttc 
241 aaactagact acttctccat aatattcatc cctgtagcat tgttcgttac atggtccatc 
301 atagaattct cactgtgata tataaactca gacccaaaca ttaatcagtt cttcaaatat 
361 ctactcatct tcctaattac catactaatc ttagttaccg ctaacaacct attccaactg 
421 ttcatcggct gagagggcgt aggaattata tccttcttgc tcatcagttg atgatacgcc 
481 cgagcagatg ccaacacagc agccattcaa gcaatcctat acaaccgtat cggcgatatc 
541 ggtttcatcc tcgccttagc atgatttatc ctacactcca actcatgaga cccacaacaa 
601 atagcccttc taaacgctaa tccaagcctc accccactac taggcctcct cctagcagca 
661 gcaggcaaat cagcccaatt aggtctccac ccctgactcc cctcagccat agaaggcccc 
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721 accccagtct cagccctact ccactcaagc actatagttg tagcaggaat cttcttactc 
781 atccgcttcc accccctagc agaaaatagc ccactaatcc aaactctaac actatgctta 
841 ggcgctatca ccactctgtt cgcagcagtc tgcgccctta cacaaaatga catcaaaaaa 
901 atcgtagcct tctccacttc aagtcaacta ggactcataa tagttacaat cggcatcaac 
961 caaccacacc tagcattcct gcacatctgt acccacgcct tcttcaaagc catactattt 
1021 atgtgctccg ggtccatcat ccacaacctt aacaatgaac aagatattcg aaaaatagga 
1081 ggactactca aaaccatacc tctcacttca acctccctca ccattggcag cctagcatta 
1141 gcaggaatac ctttcctcac aggtttctac tccaaagacc acatcatcga aaccgcaaac 
1201 atatcataca caaacgcctg agccctatct attactctca tcgctacctc cctgacaagc 
1261 gcctatagca ctcgaataat tcttctcacc ctaacaggtc aacctcgctt ccccaccctt 
1321 actaacatta acgaaaataa ccccacccta ctaaacccca ttaaacgcct ggcagccgga 
1381 agcctattcg caggatttct cattactaac aacatttccc ccgcatcccc cttccaaaca 
1441 acaatccccc tctacctaaa actcacagcc ctcgctgtca ctttcctagg acttctaaca 
1501 gccctagacc tcaactacct aaccaacaaa cttaaaataa aatccccact atgcacattt 
1561 tatttctcca acatactcgg attctaccct agcatcacac accgcacaat cccctatcta 
1621 ggccttctta cgagccaaaa cctgccccta ctcctcctag acctaacctg actagaaaag 
1681 ctattaccta aaacaatttc acagcaccaa atctccacct ccatcatcac ctcaacccaa 
1741 aaaggcataa ttaaacttta cttcctctct ttcttcttcc cactcatcct aaccctactc 
1801 ctaatcacat aa 
 
Figure 7.9. MT-ND5 gene sequence. Genomic regions used as priming sites for 
methylation studies are underlined; CpG sites investigated in this study are indicated in 
bold orange font. 
 
Figure 7.10 shows the percentage of CpG methylation measured across 10 CpG sites 
within the MT-ND5 gene coding sequence in YC, ESIPS and RS MRC-5 cells: YC cells 
methylation ranged between 0% and 17% (median value = 8%), ESIPS cells methylation 
ranged between 0% and 13% (median value = 2%) and RS cells methylation ranged 
between 0% and 17% (median value = 7%). There was no statistically significant 
difference in methylation content between YC and ESIPS cells, nor between YC and RS 
cells. 
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Figure 7.10. MT-ND5 CpG methylation measured by BM PCR direct sequencing. Box 
plots show the percentiles and the median of the percentages of Cytosine methylation. 
Box outlines define the 25th and 75th percentiles, with a line at the median, and whiskers 
indicate the 10th and 90th percentiles; dots indicate outliers. 
 
7.4 Bioinformatics analyses of the murine mitochondrial DNA molecule and choice 
of candidate regions for methylation studies 
The murine mitochondrion genome is a 16300 bp circular double strand DNA molecule, 
present in several copies in each organelle. To select candidate regions for my 
methylation studies, I obtained its sequence from the PubMed database 
(http://www.ncbi.nlm.nih.gov/nuccore/NC_010339) and looked for putative CpG islands 
using the webtool CpG plot (http://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/), 
focussing on the sequences of the 13 mitochondria-encoded genes, the D-Loop regulatory 
region and a long non-protein-coding region at the 5’ end of the Nd1 gene. Applying the 
default settings of the program (island of at least 200 bp, % of C + G of at least 50% and 
C + G observed/expected ratio of at least 0.6), I was not able to identify regions that met 
the selection criteria; I therefore decided to apply less stringent criteria, lowering the 
length of the islands to a minimum of 100 bp. By doing so, only one CpG island was 
identified, included in the genomic region non-coding region at the 5’ end of the Nd1 
gene was identified. In an additional attempt to identify more candidate regions, I further 
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lowered the length of the islands to a minimum of 50 bp; this process yielded a total of 4 
regions:  
 
 Mt-non-coding region (5’ end of the Mt-Nd1 gene); 
 Mt-Nd4 coding region; 
 Mt-Cytb coding region; 
 Mt-D-Loop. 
 
I designed, and attempted to optimize, primers for PCR amplification of bisulphite 
modified DNA, as described in section 2.18. However, the optimization failed to yield a 
unique product – or any product – in the PCR trials for the Mt-Nd4 and the Mt-Cytb 
sequences. These were removed from the gene panel and I therefore pursued methylation 
analyses of the other 2 genomic regions. Results of these analyses are reported in section 
7.5 below. 
 
7.5 Quantification of methylation at the single CpG level of resolution for two 
genomic regions within the murine mtDNA in liver samples from  ageing and from 
dietary energy restricted mice 
After total genomic DNA extraction (see section 2.3), I performed bisulphite modification 
(see section 2.17), BM-PCR (see section 2.18) and sequencing (see section 2.19) on 3 
liver samples from each of the following groups: young vs old and ad libitum fed vs 
short-term dietary energy restricted mice. I then performed statistical analyses on the 
measured methylation values using an unpaired t-tests to compare methylation levels 
between treatment groups at each CpG site within the analysed genomic regions These 
data are reported in section 7.5.1. 
 
7.5.1 Mus musculus musculus mitochondrion genome, non-coding region, NCBI 
Reference Sequence: NC_010339.1 
1741 gagtaacaag aattctaatt ctccaggcat acacatataa caactcggat aaccattgtt 
1801 agttaatcag actataggca ataattacac tataaataat tcacctataa cttctctgtt 
1861 aacccaacac cggaatgcct aaaggaaaga tctaaaaaga taaaaggaac tcggcaaaca 
1921 agaaccccgc ctgtttacca aaaacatcac ctctagcatt acaagtatta gaggcactgc 
1981 ctgcccagtg actaaagttt aacggccgcg gtatcctgac cgtgcaaagg tagcataatc 
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2041 acttgttcct taattaggga ctagcatgaa cggctaaacg agggtccaac tgtctcttat 
2101 ctttaatcag tgaaattgac ctttcagtga agaggctgaa atataataat aagacgagaa 
2161 gaccctatgg agcttaaatt atatgactta tctatttaat ttatttaaac ctaatggccc 
 
Figure 7.11. Portion of the murine mitochondrion genome non-protein-coding region. 
Genomic regions used as priming sites for methylation studies are underlined; CpG sites 
investigated in this study are indicated in bold orange font. 
 
Figure 7.12 shows the percentage of CpG methylation measured for each of the 8 CpG 
sites within the murine mitochondrion D-Loop sequence in DNA from young and old 
mouse livers (panel A) and from ad libitum and dietary energy restricted mouse livers 
(panel B). Regardless of experimental treatments, there were marked differences in extent 
of methylation at individual CpG sites. There was no detectable methylation at CpG sites 
6 and 7 and methylation was very low for CpG site1 (see Figure 7.12). In contrast, 
methylation levels were consistently high (around 40%) for CpG site 3 with intermediate 
values at the other 4 CpG sites. At CpG site 5 methylation was 5 times higher in the older 
compared with the yonger mice (p = 0.002; see Figure 7.12, panel A). There were no 
significant age-related effects at the other 7 CpG sites. In addition, dietary energy 
restriction had no detectable effects on methylation at any of the CpG sites investigated 
(see Figure 7.12, panel B). 
 
A 
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Figure 7.12. Murine mitochondrion genome non-coding region CpG methylation 
measured by BM PCR direct sequencing in livers. Panel A compares methylation levels in 
young and old mouse liver samples; panel B shows effects of ad libitum (AL) compared 
with dietary energy restriction (ER) feeding on mouse liver samples. Data are mean ± 
SD, n = 3 biological replicates. ** = p < 0.01 for student’s unpaired t-test. 
 
7.5.2 Mus musculus musculus mitochondrion genome, D-Loop, NCBI Reference 
Sequence: NC_010339.1 
15426 cgtac ataaatttac atagtacaat agtacattta tgtatatcgt acattaaact 
15481 attatcccca agcatataag caagtacatt taatcaatga tataggccat aaaacaatta 
15541 tcaacataaa ctgatacaaa ccatgaatat tatactaata catcaaatta atgctttaaa 
15601 gacatatctg tgttatctga catacaccat acagtcataa actcttctct tccatatgac 
15661 tatccccttc cccatttggt ctattaatct accatcctcc gtgaaaccaa caacccgccc 
15721 accaatgccc ctcttctcgc tccgggccca ttaaacttgg gggtagctaa actgaaactt 
15781 tatcagacat ctggttctta cttcagggcc atcaaatgcg ttatcgccca tacgttcccc 
15841 ttaaataaga catctcgatg gtatcgggtc taatcagccc atgaccaaca taactgtggt 
15901 gtcatgcatt tggtattttt ttattttggc ctactttcat caacatagcc gtcaaggcat 
15961 gaaaggacag cacacagtct agacgcacct acggtgaaga atcattagtc cgcaaaaccc 
16021 aatcacctaa ggctaattat tcatgcttgt tagacataaa tgctactcaa taccaaattt 
16081 taactctcca aaccccccaa ccccctcctc ttaatgccaa accccaaaaa cactaagaac 
16141 ttgaaagaca tatattatta actatcaaac cctatgtcct gatcgattct agtagttccc 
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16201 aaaatatgac tcatatttta gtacttgtaa aaattttaca aaatcatgct ccgtgaacca 
16261 aaactctaat cacactctat tacgcaataa atattaacaa 
 
Figure 7.13.Murine mtDNA D-Loop sequence. Genomic regions used as priming sites for 
methylation studies are underlined; CpG sites investigated in this study are indicated in 
bold orange font. 
 
Figure 7.14 shows the percentage of CpG methylation measured for each of the 5 CpG 
sites within a murine mitochondrion genome non-protein-coding region sequence in DNA 
from young and old mouse livers (panel A) and from ad libitum and dietary energy 
restricted mice livers (panel B). Regardless of experimental treatments, there were 
marked differences in extent of methylation at individual CpG sites. There was no 
detectable methylation at CpG sites 4 and 5 and methylation was very low for CpG site 1, 
but showed high biological variability among livers from dietary energy restricted 
animals (see Figure 7.14). In contrast, methylation levels were consistently high (around 
30%-40%) for CpG site 2 with intermediate values at CpG site 3 (around 10%-20%). 
There were no significant age-related or dietary energy restriction effects at any of the 
CpG sites investigated (see Figure 7.14, panel A and B). 
 
A 
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B 
 
 
Figure 7.14. mtDNA D-Loop CpG methylation in murine livers measured by BM PCR 
direct sequencing. Panel A compares methylation levels in young and old mouse liver 
samples; panel B shows effects of ad libitum (AL) compared with dietary energy 
restriction (ER) feeding on mouse liver samples. Data are mean ± SD, n = 3 biological 
replicates. 
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7.6 Discussion 
MtDNA is present in multiple copies in the mitochondria of each cell. This copy number 
is variable in a tissue specific manner (Naviaux, 2008; Kelly et al., 2012) and there is 
evidence that it progressively decreases with ageing in some tissues, in a proportional 
way to the tissue oxidative capacity (Barazzoni et al., 2000). However, there is limited 
and contrasting scientific evidence that mtDNA copy number per organelle/cell affects 
the extent of mitochondrial-encoded genes expression (Barazzoni et al., 2000; Hartmann 
et al., 2011). Hence, mechanisms other than gene dosage may be involved in the 
expression of mitochondrial genes. As for nuclear-encoded genes, regulation of 
mitochondrial gene expression relies on the activity of nuclear-encoded transcription 
factors (Leigh-Brown et al., 2010), as well as post-translational modifications (Taylor et 
al., 2003). Other mechanisms might involve snRNA, srpRNA and snoRNA – whose 
import into the mitochondria has been demonstrated recently (Sripada et al., 2012) – and 
DNA methylation. 
Mitochondria DNA methylation has been investigated since the early 1970s. The first 
studies were conducted in rodents (Nass, 1973) and human cells in vitro models 
(Shmookler Reis and Goldstein, 1983) and revealed limited 5’-methylCytosine content 
(3% to 5%). These studies were performed using sensitive techniques, e.g. radioactive 
assays or methylation-sensitive restriction enzymes-based assays, allowing the detection 
of very small amounts of 5’-methylated Cytosines. However, their main limitation was 
that they could not detect the specific methylation sites/patterns of methylation and so 
provide information on global mtDNA methylation content only. 
More recent observational studies have been performed to investigate alterations in the 
mtDNA methylation patterns at specific loci and whether these would correlate with 
cancer onset or progression (Maekawa et al., 2004) - with no success - and to exposure to 
airborne pollutants (Byun et al., 2013); the latter study provided evidence that metal-rich 
particulate matter exposure increased methylation in specific mtDNA genomic regions. 
 
To my knowledge, this is the first study which has investigated the effects of senescence, 
ageing and dietary energy restriction on site-specific mtDNA methylation patterns. We 
observed that CpG methylation was higher in ESIPS compared with YC and in RS 
compared with YC across the MT-COI and MT-ND1 coding sequences - in human MRC-
5 fibroblasts. These genes belong to Complex IV and to Complex I of the mitochondrial 
electron transport chain, respectively, and their dysregulation can lead to accumulation of 
hazardous superoxide species. Such increase in superoxide species has been well 
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documented in ageing cells, but a causal role in the biology of ageing is still 
controversial, as reviewed in (Cui et al., 2012). In addition, we observed that ageing was 
associated with significantly increased methylation at one single CpG site within the D-
Loop mitochondrial regulatory region (Figure 7.12). The D-Loop region is the starting 
point for the mitochondrial DNA replication process (Fish et al., 2004), so it is possible 
that increased methylation within it may impair the efficiency of such process by 
hindering the binding of the enzymes responsible for mtDNA replication. This hypothesis 
is consistent with the findings of previous studies that showed a progressive fall in 
mtDNA copy number in ageing tissues (Barazzoni et al., 2000). Since the D-Loop region 
is also involved in the mitochondrial DNA organization because it is recognized, and 
bound, by DNA binding proteins to form nucleoids (He et al., 2007), hypermethylation of 
this mitochondrial region may impair nucleoids formation. In the present study, there was 
no evidence that ER had any effect on methylation at any of the investigated CpG sites 
within the D-Loop region 
Measured methylation values were higher than the ones found in the literature, which are 
estimated to be around 2% to 5% of the total CpG sites (Shmookler Reis and Goldstein, 
1983). In my case, measured CpG methylation spanned from 0% to 38% for human cells 
and between 0% and 43% for murine samples; however, it is to noted that published data 
are based on much larger numbers of CpG sites compared with what analysed in my 
study, hence I believe that lower values might be due to a “dilution effect”. 
 
Bioinformatics analyses of the human and murine mitochondria genome applying one of 
the most commonly used criteria for the definiton of CpG island (Takai and Jones, 2002) 
revealed only one potential CpG island within the human mtDNA molecule (lying within 
the coding sequence of the MT-COX2 gene) and no CpG islands within the murine 
mtDNA. Application of less stringent criteria, i.e. shorter minimum island lengths, 
allowed the identification of regions relatively dense in CpG sites (CpG rich regions) 
which were worth of investigation with BM-DNA PCR and direct sequencing. 
Surprisingly, these regions did not correspond with any of the known mitochondria 
regulatory sites, i.e. the transcription termination region (TERM) within the tRNA
Leu(UUR)
, 
the heavy and light strand promoters (HSP and LSP) or the origin of replication of the 
light strand (OL) (Rebelo et al., 2009). This observation suggests that these newly 
identified mtDNA regions could be involved in the epigenetic regulation of gene 
expression through DNA methylation, if this occurs within the mitochondria.  
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Based on established understanding of the regulation of expression of genes encoded in 
nuclear DNA, it is logical to postulate that the presence of methylated Cytosines could 
modulate the binding/occupancy of transcriptional regulators (e.g. by remodelling the 
mtDNA molecule) and therefore regulate transcription of mitochondrially-encoded genes. 
Another putative function of mtDNA methylation could be the protection against 
deleterious mutation. Ageing is associated with accumulation of point mutations and 
deletions in mtDNA – for example linked to respiratory chain defects in replicating 
tissues (Greaves et al., 2010; Nooteboom et al., 2010) - (reviewed in (Trifunovic, 2006) 
and (Desler et al., 2011)). In this context, hypomethylation of Cytosine residues 
methylation could facilitate the accumulation of spontaneous point mutations C > T and C 
> G/A (very frequent within the nuclear genome) (Cooper and Krawczak, 1989) and 
hypermethylation of Cytosine residues could contribute to the accumulation of 
spontaneous 5mC > T transitions (Mazin, 2009). 
 
7.7 Conclusions 
In summary, this study has shown for the first time that:  
 
 in vitro replicative senescence and early stress-induced premature senescence are 
associated with changes in mtDNA methylation, specifically in the MT-COI and 
MT-ND1 gene coding sequences, which belong to Complex IV and to Complex I 
respectively. These changes may contribute to the accumulation of hazardous 
superoxide species, which is widely documented in ageing cells; 
 ageing is associated with aberrant methylation of the mtDNA D-Loop region in 
mouse liver. I hypothesize that this aberrant methylation may affect mtDNA 
replication and nucleoids formation; 
 aberrant methylation of the mitochondrial D-Loop observed in ageing mouse liver 
was not reversed by dietary energy restriction. 
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Chapter 8. Conclusions 
 
Although DNA methylation has been the subject of studies for more than fifty years, 
much work still needs to be done to completely elucidate its biological functions and its 
implications in the ageing process. Growing evidence, including results from this study, 
points to CpG methylation as a potential marker for ageing and age-related diseases. In 
addition, the fact that aberrant DNA methylation occurs at promoters of genes involved in 
the maintenance of cellular and tissue homeostasis and whose expression is altered in 
senescence and ageing suggests a potential causal role for altered CpG methylation in the 
aetiology of ageing. In parallel, this study has demonstrated that dietary energy restriction 
- at least in the short-term - can affect CpG methylation of several gene promoters in 
mouse tissues and, in some cases, can reverse the aberrant methylation associated with 
ageing. These findings suggest that some of the effects of dietary energy restriction in 
slowing down the ageing process and also delaying the onset of age-related diseases may 
occur via epigenetic mechanisms including amelioration of age-related aberrations in 
patterns of DNA methylation.    
 
8.1 Methodological issues in determining DNA methylation 
At the beginning of my study, I identified methodological issues in determining DNA 
methylation both at the global and at site-specific levels. In fact, when comparing various 
methods for the study of global DNA methylation, I found that results obtained by means 
of different methods for the same sample were often not comparable. However, some of 
the surrogate methods used for estimation of global DNA methylation level proved 
sufficiently sensitive to be able to detect small, but significant differences between 
samples in a particular experimental context. Each assay had its merits and none was 
clearly the best surrogate for total CpG methylation content quantified by HPLC. 
However, when chosen carefully, individual assays can be used as fast, cheap and good 
markers for the estimation of global DNA methylation in the samples under investigation 
(Chapter 3). 
 
Continuing with my study, I also identified a major limitation of the MeDIP technique, a 
method aimed at the study of site-specific DNA methylation. The specific issue in this 
case consisted in the sequence-specific partial loss (about one third) of enrichment of 
certain DNA fragments during the WGA step. The quality assurance steps which I 
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developed and validated provide users of the MeDIP technique with ways to address this 
issue. Further, these quality assurance steps allow the assessment of the overall quality of 
single experiments and the estimation of intra-experimental and inter-experimental 
variability. These improvements to the MeDIP method proved cost-effective and were 
easy to apply in routine assays (Chapter 4).  
With the inclusion of the modification described in Chapter 4, the MeDIP technique is a 
relatively cheap and reliable method for the preparation of samples for the genome-wide 
screening of CpG methylation and the identification of novel aberrantly methylated 
genomic regions under a variety of experimental conditions. In the present project, I used 
it in preparation for analysis using whole genome methylation arrays, but the approach 
would be equally applicable to methylation analysis by next generation sequencing. 
 
8.2 Genome-wide searches for senescence and age-dependent DNA methylation 
changes 
In contrast with the considerable overlap in gene expression changes between cells 
undergoing replicative senescence and those irradiated to induce premature senescence, 
there was quite limited overlap among genes showing changes in DNA methylation 
(Chapter 5). Given that altered DNA methylation is associated with changes in gene 
expression, this finding may appear unexpected. However, this finding may be explained 
if we consider the complexity of the transcription regulation process in which epigenetic 
mechanisms are just one set of regulators. In addition, it is possible that the specific CpG 
sites showing altered methylation in this study are not the most critical for regulating 
expression of the corresponding genes. It should be noted that the specific microarrays 
chosen for this study  included probes for gene promoter regions only. It is now known 
that methylation at other sites including CpGs within island shores, shelves and open sea, 
within gene bodies and within inter-genic regions may be involved in the regulation of 
gene expression. Further, CpG sites in such genomic regions are also affected by 
senescence and by age-related DNA methylation in addition to methylation changes at 
gene promoters. In the future,  study of methylation at these other genomic locations may 
give new insight into the regulation of gene transcription in senescence and ageing and 
may explain some of the changes in gene expression found in both premature and 
replicative senescence.   
The same considerations apply to the ageing mice tissue samples, in which there were 
>1000 genes showing age-related changes in promoter methylation in both heart and in 
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liver, but few of these genes showing methylation changes were in common between the 
two tissues. One of the limitations of the present study is that I did not have data on age-
related changes in expression profiles of the tissues under investigation and so I was 
unable to assess whether the genes showing changes in DNA methylation also showed 
changes in gene expression (Chapter 6). This issue is being addressed in follow up work 
by colleagues in Newcastle University. 
 
Costs in terms of money and time limited the number of genes for which methylation 
changes observed in the microarray data could be validated by pyrosequencing. This is 
because pyrosequencing assays can investigate only a few CpG sites at a time since it is 
restricted to interrogation of amplicons of up to 200 bp within a genomic region. For this 
reason, multiple pyrosequencing assays need to be set up and run to cover the whole 
genomic region for which there are probes on the methylation arrays. In my study, 
although I did not confirm all the changes in DNA methylation for the selected candidates 
in terms of direction (increase or decrease) or extent (fold change) in the groups of 
comparisons, I was able to detect changes in methylation at specific CpG sites with the 
chosen pyrosequencing assays. These methylation changes may be causal for gene 
expression changes, as supported by the literature (Chapter 5).  
 
A valid alternative to array-based studies is high-throughput (next generation) sequencing 
of MeDIP samples or bisulphite modified DNA samples. Using this method, single 
aberrantly methylated CpG sites could be identified and validation by pyrosequencing 
would be more time and cost effective. Unfortunately, when this project started, such 
technology was still novel and expensive and I therefore opted for the more widely used 
hybridization of MeDIP prepared samples to DNA microarrays. 
 
8.3 Dietary energy restriction modulation of DNA methylation changes 
Restriction of dietary energy intake by 40% compared with that of ad libitum-fed animals 
for 3 months counteracted some of the age-related DNA methylation changes occurring in 
mouse liver (Chapter 6). However, although significant, the number of identified changes 
was small. This finding may be due: i) to the chosen array design which included gene 
promoters only (see section 8.2); ii) to the small number of animals used in this study - 
including more animals may attenuate biological variability and increase statistical power 
- and iii) to the relatively short time of the dietary intervention. Nonetheless, this study 
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showed that dietary energy restriction has the potential of modulating DNA methylation 
alterations associated with ageing, thus confirming previous published results that have 
indicated this dietary intervention as a possible preventative measure for age-related 
diseases and for slowing down the ageing process itself. Future gene expression studies 
may help in focusing on those candidate genes which could be functionally important for 
the ageing process and may help in elucidating the molecular mechanisms responsible for 
the effects of dietary energy restriction. 
 
8.4 Epigenetic dysregulation of mitochondrial function in ageing 
The pilot study on mtDNA methylation showed aberrant methylation at some inter-genic 
regions occurring with premature senescence and replicative senescence in MRC-5 
fibroblasts and in mouse liver during ageing. These are novel findings that may indicate 
the involvement of aberrant CpG methylation in the dysregulation of mitochondrially-
encoded genes and, in turn, in age-related mitochondrial dysfunction. However, no effect 
of dietary energy restriction on methylation changes was found at the regions 
investigated. In future studies, the isolation of mtDNA molecules from cells/tissues 
samples followed by deep sequencing, may help in the identification of additional CpG 
sites whose methylation is affected by dietary energy restriction. This approach would 
overcome the main limitation of the present study i.e. the small number of CpG sites 
under investigation. Further studies should include determination of mitochondrial protein 
expression in senescence whilst a study of mitochondrial protein expression in mice liver 
during ageing and under dietary energy restriction has just been completed by other group 
members. These data will help in establishing the relationship (if any) between changes in 
mtDNA methylation and mitochondrial protein expression and, possibly, elucidating the 
role of mtDNA methylation in the ageing process. 
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Appendix A: Dilution curves and melt curves for qPCR and RT-qPCR assays 
 
 
E = 0.82 
 
Figure A.1. Dilution curve (left) and melt curve (right) for λ-Phage DNA Positive Control 
(Fragment A pair 2) primer pair. Dilution curve was obtained by plotting the average Cq 
of three replicates of 10-fold serial dilutions, with dilution 8 being equal to 500 ng/µL. 
“E” indicates the efficiency of amplification. 
 
 
E = 0.85 
 
Figure A.2. Dilution curve (left) and melt curve (right) for λ-Phage DNA Negative 
Control (Fragment B pair 2) primer pair. Dilution curve was obtained by plotting the 
average Cq of three replicates of 10-fold serial dilutions, with dilution 8 being equal to 
500 ng/µL. “E” indicates the efficiency of amplification. 
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E = 1.20 
 
Figure A.3. Dilution curve (left) and melt curve (right) for human H19 ICR primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of genomic DNA, with dilution 4 being equal to 200 ng/µL. “E” indicates 
the efficiency of amplification. 
 
 
E = 1.08  
 
Figure A.4. Dilution curve (left) and melt curve (right) for human HIST1H2BA primer 
pair. Dilution curve was obtained by plotting the average Cq of three replicates of 10-
fold serial dilutions of genomic DNA, with dilution 4 being equal to 200 ng/µL. “E” 
indicates the efficiency of amplification. 
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E = 1.03 
 
Figure A.5. Dilution curve (left) and melt curve (right) for human GAPDH primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of genomic DNA, with dilution 4 being equal to 200 ng/µL. “E” indicates 
the efficiency of amplification. 
 
 
E = 0.89 
 
Figure A.6. Dilution curve (left) and melt curve (right) for human CD7 primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 5-fold serial 
dilutions of genomic DNA, with dilution 4 being equal to 50 ng/µL. “E” indicates the 
efficiency of amplification. 
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E = 0.90  
 
Figure A.7. Dilution curve (left) and melt curve (right) for human DCHS1 primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 5-fold serial 
dilutions of genomic DNA, with dilution 4 being equal to 50 ng/µL. “E” indicates the 
efficiency of amplification. 
 
 
E = 0.98  
 
Figure A.8. Dilution curve (left) and melt curve (right) for human MLNR primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 5-fold serial 
dilutions of genomic DNA, with dilution 4 being equal to 50 ng/µL. “E” indicates the 
efficiency of amplification. 
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E = 0.95 
 
Figure A.9. Dilution curve (left) and melt curve (right) for human OR5AP2 primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 5-fold serial 
dilutions of genomic DNA, with dilution 4 being equal to 50 ng/µL. “E” indicates the 
efficiency of amplification. 
 
 
E = 0.83  
 
Figure A.10. Dilution curve (left) and melt curve (right) for human PRDM8 primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 5-fold serial 
dilutions of genomic DNA, with dilution 4 being equal to 50 ng/µL. “E” indicates the 
efficiency of amplification. 
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E = 0.98 
 
Figure A.11. Dilution curve (left) and melt curve (right) for human RAB5C primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 5-fold serial 
dilutions of genomic DNA, with dilution 4 being equal to 50 ng/µL. “E” indicates the 
efficiency of amplification. 
 
 
 E = 1.01 
 
Figure A.12. Dilution curve (left) and melt curve (right) for murine H19 primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of genomic DNA, with dilution 4 being equal to 200 ng/µL. “E” indicates 
the efficiency of amplification. 
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E = 0.98 
 
Figure A.13. Dilution curve (left) and melt curve (right) for murine Hist1h2ba primer 
pair. Dilution curve was obtained by plotting the average Cq of three replicates of 10-
fold serial dilutions of genomic DNA, with dilution 4 being equal to 200 ng/µL. “E” 
indicates the efficiency of amplification. 
 
 
E = 1.01 
 
Figure A.14. Dilution curve (left) and melt curve (right) for murine Actb primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of genomic DNA, with dilution 4 being equal to 200 ng/µL. “E” indicates 
the efficiency of amplification. 
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E = 0.91 
 
Figure A.15. Dilution curve (left) and melt curve (right) for murine Gapdh primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of genomic DNA, with dilution 4 being equal to 200 ng/µL. “E” indicates 
the efficiency of amplification. 
 
 
E = 0.86 
 
Figure A.16. Dilution curve (left) and melt curve (right) for λ Phage DNA Spike 208 
primer pair 2. Dilution curve was obtained by plotting the average Cq of three replicates 
of 10-fold serial dilutions of genomic DNA, with dilution 7 being equal to 50pg/µL. “E” 
indicates the efficiency of amplification. 
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E = 0.90 
 
Figure A.17. Dilution curve (left) and melt curve (right) for λ Phage DNA Spike 400 
primer pair 2. Dilution curve was obtained by plotting the average Cq of three replicates 
of 10-fold serial dilutions of genomic DNA, with dilution 7 being equal to 50pg/µL. “E” 
indicates the efficiency of amplification. 
 
 
E = 0.91 
 
Figure A.18. Dilution curve (left) and melt curve (right) for λ Phage DNA Spike 800 
primer pair 2. Dilution curve was obtained by plotting the average Cq of three replicates 
of 10-fold serial dilutions of genomic DNA, with dilution 7 being equal to 50pg/µL. “E” 
indicates the efficiency of amplification. 
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E = 0.88 
 
Figure A.19. Dilution curve (left) and melt curve (right) for λ Phage DNA Spike 1000 
primer pair 2. Dilution curve was obtained by plotting the average Cq of three replicates 
of 10-fold serial dilutions of genomic DNA, with dilution 7 being equal to 50pg/µL. “E” 
indicates the efficiency of amplification. 
 
 
E = 1.03 
 
Figure A.20. Dilution curve (left) and melt curve (right) for human DNMT1 primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
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E =0.97 
 
Figure A.21. Dilution curve (left) and melt curve (right) for human DNMT3A primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
 
 
E = 0.90 
 
Figure A.22. Dilution curve (left) and melt curve (right) for human DNMT3B primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
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E = 0.88 
 
Figure A.23. Dilution curve (left) and melt curve (right) for murine Dnmt1 primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
 
 
 
E = 0.91 
 
Figure A.24. Dilution curve (left) and melt curve (right) for murine Dnmt3a primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
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E = 0.85 
 
Figure A.25. Dilution curve (left) and melt curve (right) for murine Dnmt3b primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 3 being a dilution 1:2. “E” indicates the efficiency of amplification. 
 
  
 
E = 0.99 
 
Figure A.26. Dilution curve (left) and melt curve (right) for human CCNB2 primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
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E = 1.00 
 
Figure A.27. Dilution curve (left) and melt curve (right) for human DLGAP5 primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
 
 
E = 1.05 
 
Figure A.28. Dilution curve (left) and melt curve (right) for human FANCG primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
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E = 1.19 
 
Figure A.29. Dilution curve (left) and melt curve (right) for human MMP3 primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
 
 
E = 0.95 
 
Figure A.30. Dilution curve (left) and melt curve (right) for human PNMA2 primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 3 being a dilution 1:2. “E” indicates the efficiency of amplification. 
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E = 0.96 
 
Figure A.31. Dilution curve (left) and melt curve (right) for human TMSB15A primer 
pair. Dilution curve was obtained by plotting the average Cq of three replicates of 10-
fold serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, 
with dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
 
 
E = 0.95 
 
Figure A.32. Dilution curve (left) and melt curve (right) for human CTTN primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
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E = 0.95 
 
Figure A.33. Dilution curve (left) and melt curve (right) for human GLIPR2 primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
 
 
 
E = 0.98  
 
Figure A.34. Dilution curve (left) and melt curve (right) for human NPTX1 primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 20-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 3 being a dilution 1:2. “E” indicates the efficiency of amplification. 
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E = 1.00 
 
Figure A.35. Dilution curve (left) and melt curve (right) for human SLC39A14 primer 
pair. Dilution curve was obtained by plotting the average Cq of three replicates of 20-
fold serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, 
with dilution 3 being a dilution 1:2. “E” indicates the efficiency of amplification. 
 
 
E = 1.61 
 
Figure A.36. Dilution curve (left) and melt curve (right) for human mtDNMT1 primer 
pair. Dilution curve was obtained by plotting the average Cq of three replicates of 10-
fold serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, 
with dilution 3 being a dilution 1:2. “E” indicates the efficiency of amplification. 
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E = 0.95 
 
Figure A.37. Dilution curve (left) and melt curve (right) for murine mtDnmt1 primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 2 being a dilution 1:2. “E” indicates the efficiency of amplification. 
 
 
E = 0.97 
 
Figure A.38. Dilution curve (left) and melt curve (right) for human B2M primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
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E = 0.99 
 
Figure A.39. Dilution curve (left) and melt curve (right) for human GAPDH primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
 
 
 
E = 0.92 
 
Figure A.40. Dilution curve (left) and melt curve (right) for human HPRT1 primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
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E = 0.95 
 
Figure A.41. Dilution curve (left) and melt curve (right) for human UBE2B primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
 
 
E = 0.97  
 
Figure A.42. Dilution curve (left) and melt curve (right) for murine Actb primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being the undiluted cDNA. “E” indicates the efficiency of amplification. 
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E = 0.95 
 
Figure A.43. Dilution curve (left) and melt curve (right) for murine B2m primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
 
 
E = 0.96 
 
Figure A.44. Dilution curve (left) and melt curve (right) for murine Gapdh primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 4 being a dilution 1:2. “E” indicates the efficiency of amplification. 
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E = 0.89 
 
Figure A.45. Dilution curve (left) and melt curve (right) for murine Hprt primer pair. 
Dilution curve was obtained by plotting the average Cq of three replicates of 10-fold 
serial dilutions of cDNA obtained by reverse transcription of 500 ng of total RNA, with 
dilution 3 being a dilution 1:2. “E” indicates the efficiency of amplification. 
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Appendix B: Quality control outputs for BM-DNA PCR direct sequencing 
 
Table B.1. Quality control output for BM-DNA PCR sequences analyzed by BiQ 
BioAnalyzer software (Bock et al., 2005). 
 
Specificity BM-DNA PCR product Sequence alignment Bisulphite conversion rate 
Human LINE-1 MRC-5 YC A 95% 95% 
Human LINE-1 MRC-5 YC B 95% 95% 
Human LINE-1 MRC-5 YC C 95% 94% 
Human LINE-1 MRC-5 ESIPS A 95% 95% 
Human LINE-1 MRC-5 ESIPS B 95% 97% 
Human LINE-1 MRC-5 ESIPS C 96% 95% 
Human LINE-1 MRC-5 RS A 95% 95% 
Human LINE-1 MRC-5 RS B 95% 94% 
Human LINE-1 MRC-5 RS C 95% 95% 
Mouse B1 Heart 3 m. o. A 78% 95% 
Mouse B1 Heart 3 m. o. B 78% 100% 
Mouse B1 Heart 3 m. o. C 79% 95% 
Mouse B1 Heart 32 m. o. A 80% 100% 
Mouse B1 Heart 32 m. o. B 78% 94% 
Mouse B1 Heart 32 m. o. C 78% 100% 
Mouse B1 Liver 6 Young 79% 100% 
Mouse B1 Liver 7 Young 84% 100% 
Mouse B1 Liver 8 Young 76% 95% 
Mouse B1 Liver 6 Old 82% 100% 
Mouse B1 Liver 7 Old 79% 95% 
Mouse B1 Liver 8 Old 78% 100% 
Mouse B1 Colon 3 m. o. A 85% 100% 
Mouse B1 Colon 3 m. o. B 87% 100% 
Mouse B1 Colon 3 m. o. C 82% 100% 
Mouse B1 Colon 32 m. o. A 86% 100% 
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Mouse B1 Colon 32 m. o. B 82% 100% 
Mouse B1 Colon 32 m. o. C 88% 100% 
Mouse B1 Liver 6(B)AL 85% 100% 
Mouse B1 Liver 6(4)AL 77% 100% 
Mouse B1 Liver 7(1)AL 81% 100% 
Mouse B1 Liver 14(2)CR 81% 100% 
Mouse B1 Liver 14(3)CR 76% 100% 
Mouse B1 Liver 14(4)CR 80% 100% 
Human H19 ICR MRC-5 YC 89% 100% 
Human H19 ICR MRC-5 ESIPS 91% 97% 
Human H19 ICR MRC-5 RS 91% 100% 
Human HIST1H2BA MRC-5 YC 95% 100% 
Human HIST1H2BA MRC-5 ESIPS 92% 94% 
Human HIST1H2BA MRC-5 RS 95% 100% 
Human GAPDH MRC-5 YC 90% 100% 
Human GAPDH MRC-5 ESIPS 85% 96% 
Human GAPDH MRC-5 RS 86% 100% 
Mouse H19 ICR Colon 3 m. o. A 89% 100% 
Mouse H19 ICR Colon 3 m. o. B 89% 100% 
Mouse H19 ICR Colon 3 m. o. C 85% 100% 
Mouse H19 ICR Colon 32 m. o. A 82% 100% 
Mouse H19 ICR Colon 32 m. o. B 81% 93% 
Mouse H19 ICR Colon 32 m. o. C 83% 100% 
Mouse Hist1h2ba Colon 3 m. o. A 95% 98% 
Mouse Hist1h2ba Colon 3 m. o. B 95% 98% 
Mouse Hist1h2ba Colon 3 m. o. C 96% 98% 
Mouse Hist1h2ba Colon 32 m. o. A 96% 98% 
Mouse Hist1h2ba Colon 32 m. o. B 95% 98% 
Mouse Hist1h2ba Colon 32 m. o. C 95% 98% 
Mouse Actb Colon 3 m. o. A 79% 100% 
Mouse Actb Colon 3 m. o. B 85% 87% 
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Mouse Actb Colon 3 m. o. C 82% 93% 
Mouse Actb Colon 32 m. o. A 84% 92% 
Mouse Actb Colon 32 m. o. B 77% 91% 
Mouse Actb Colon 32 m. o. C 66% 92% 
Mouse Gapdh Colon 3 m. o. A 90% 97% 
Mouse Gapdh Colon 3 m. o. B 90% 100% 
Mouse Gapdh Colon 3 m. o. C 93% 100% 
Mouse Gapdh Colon 32 m. o. A 90% 93% 
Mouse Gapdh Colon 32 m. o. B 89% 100% 
Mouse Gapdh Colon 32 m. o. C 92% 100% 
 
Table B.2. Quality control output for BM-DNA PCR and cloning sequences analyzed by 
BiQ BioAnalyzer software (Bock et al., 2005). 
 
Specificity BM-DNA PCR product Sequence alignment Bisulphite conversion rate 
Mouse Actb Heart 3 m. o. B clone 2 100% 100% 
Mouse Actb Heart 3 m. o. B clone 3 100% 100% 
Mouse Actb Heart 3 m. o. B clone 4 100% 100% 
Mouse Actb Heart 3 m. o. B clone 5 100% 100% 
Mouse Actb Heart 3 m. o. B clone 6 100% 100% 
Mouse Actb Heart 3 m. o. B clone 7 100% 100% 
Mouse Actb Heart 3 m. o. B clone 8 100% 100% 
Mouse Actb Heart 3 m. o. B clone 9 100% 100% 
Mouse Actb Heart 3 m. o. B clone 10 100% 100% 
Mouse Actb Heart 3 m. o. B clone 11 100% 100% 
Mouse Actb Colon 3 m. o. B clone 11 100% 100% 
Mouse Actb Colon 3 m. o. B clone 12 100% 100% 
Mouse Actb Colon 3 m. o. B clone 13 100% 100% 
Mouse Actb Colon 3 m. o. B clone 14 100% 100% 
Mouse Actb Colon 3 m. o. B clone 15 100% 100% 
Mouse Actb Colon 3 m. o. B clone 16 100% 100% 
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Mouse Actb Colon 3 m. o. B clone 17 100% 100% 
Mouse Actb Colon 3 m. o. B clone 18 100% 100% 
Mouse Actb Colon 3 m. o. B clone 19 100% 100% 
Mouse Actb Colon 3 m. o. B clone 20 100% 100% 
 
Table B.3. Quality control output for BM-DNA PCR sequences analyzed by ESME 
software (Lewin et al., 2004). 
 
Specificity BM-PCR product Alignment error Signal admixtures 
λ-Phage Fragment A 0% methylation 1% 4% 
λ-Phage Fragment A 5% methylation 2% 6% 
λ-Phage Fragment A 25% methylation 6% 15% 
λ-Phage Fragment A 50% methylation 22% 22% 
λ-Phage Fragment A 75% methylation 1% 11% 
λ-Phage Fragment A 95% methylation 2% 3% 
λ-Phage Fragment A 100% methylation 2% 3% 
Human MT-COI YC 4% 23% 
Human MT-COI ESIPS 1% 25% 
Human MT-COI RS 2% 23% 
Human MT-non coding region YC 0% 4% 
Human MT-non coding region ESIPS 0% 7% 
Human MT-non coding region RS 0% 5% 
Human MT-ND1 YC 0% 15% 
Human MT-ND1 ESIPS 1% 14% 
Human MT-ND1 RS 0% 14% 
Human MT-ND4 YC 2% 12% 
Human MT-ND4 ESIPS 0% 11% 
Human MT-ND4 RS 1% 11% 
Human MT-ND5 YC 1% 10% 
Human MT-ND5 ESIPS 0% 10% 
Human MT-ND5 RS 1% 11% 
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Mouse Mt-D-Loop Liver 6 Young 1% 10% 
Mouse Mt-D-Loop Liver 7 Young 0% 9% 
Mouse Mt-D-Loop Liver 8 Young 1% 10% 
Mouse Mt-D-Loop Liver 6 Old 2% 8% 
Mouse Mt-D-Loop Liver 7 Old 1% 9% 
Mouse Mt-D-Loop Liver 8 Old 1% 8% 
Mouse Mt-D-Loop Liver 6(B)AL 1% 8% 
Mouse Mt-D-Loop Liver 6(4)AL 1% 8% 
Mouse Mt-D-Loop Liver 7(1)AL 1% 10% 
Mouse Mt-D-Loop Liver 14(2)ER 1% 9% 
Mouse Mt-D-Loop Liver 14(3)ER 1% 14% 
Mouse Mt-D-Loop Liver 14(4)ER 0% 9% 
Mouse Mt-non coding region Liver 6 Young 4% 11% 
Mouse Mt-non coding region Liver 7 Young 4% 11% 
Mouse Mt-non coding region Liver 8 Young 3% 15% 
Mouse Mt-non coding region Liver 6 Old 3% 10% 
Mouse Mt-non coding region Liver 7 Old 3% 17% 
Mouse Mt-non coding region Liver 8 Old 4% 8% 
Mouse Mt-non coding region Liver 6(B)AL 4% 9% 
Mouse Mt-non coding region Liver 6(4)AL 5% 10% 
Mouse Mt-non coding region Liver 7(1)AL 5% 9% 
Mouse Mt-non coding region Liver 14(2)ER 5% 7% 
Mouse Mt-non coding region Liver 14(3)ER 1% 19% 
Mouse Mt-non coding region Liver 14(4)ER 5% 14% 
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Appendix C: Pyrograms for pyrosequencing assays controls 
 
 
 
Figure C.1. 0% methylation control pyrogram for the Hs_CTTN_01 assay (Qiagen, 
catalog number PM00151844). Blue columns indicate the CpGs  under investigation and 
the yellow column indicates the site for completion of the bisulphite treatment control. 
 
 
 
Figure C.2. 100% methylation control pyrogram for the Hs_CTTN_01 assay (Qiagen, 
catalog number PM00151844). Blue columns indicate the CpGs  under investigation and 
the yellow column indicates the site for completion of the bisulphite treatment control. 
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Figure C.3. 0% methylation control pyrogram for the Hs_GLIPR2_01 assay (Qiagen, 
catalog number PM00141176). Blue columns indicate the CpGs  under investigation and 
the yellow column indicates the site for completion of the bisulphite treatment control. 
The red boxes on the top refer to sites that did not pass the quality controls and were 
excluded from further analyses. 
 
 
 
Figure C.4. 100% methylation control pyrogram for the Hs_GLIPR2_01 assay (Qiagen, 
catalog number PM00141176). Blue columns indicate the CpGs  under investigation and 
the yellow column indicates the site for completion of the bisulphite treatment control. 
The red boxes on the top refer to sites that did not pass the quality controls and were 
excluded from further analyses. 
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Figure C.5. 0% methylation control pyrogram for the Hs_NPTX1_03 assay (Qiagen, 
catalog number PM00182035). Blue columns indicate the CpGs  under investigation. 
 
 
 
Figure C.6. 100% methylation control pyrogram for the Hs_NPTX1_03 assay (Qiagen, 
catalog number PM00182035). Blue columns indicate the CpGs  under investigation. 
 
 
 
Figure C.7. 0% methylation control pyrogram for the Hs_NPTX1_07 assay (Qiagen, 
catalog number PM00182063). Blue columns indicate the CpGs  under investigation and 
yellow columns indicate sites for completion of the bisulphite treatment control. 
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Figure C.8. 100% methylation control pyrogram for the Hs_NPTX1_07 assay (Qiagen, 
catalog number PM00182063). Blue columns indicate the CpGs  under investigation and 
yellow columns indicate sites for completion of the bisulphite treatment control. 
 
 
 
Figure C.9. 0% methylation control pyrogram for the Hs_SLC39A14_01 assay (Qiagen, 
catalog number PM00136598). Blue columns indicate the CpGs  under investigation and 
the yellow column indicates a site for completion of the bisulphite treatment control. 
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Figure C.10. 100% methylation control pyrogram for the Hs_SLC39A14_01 assay 
(Qiagen, catalog number PM00136598). Blue columns indicate the CpGs  under 
investigation and the yellow column indicates a site for completion of the bisulphite 
treatment control. 
 
 
 
Figure C.11. 0% methylation control pyrogram for the Hs_SLC39A14_02 assay (Qiagen, 
catalog number PM00136605). Blue columns indicate the CpGs  under investigation and 
yellow columns indicate sites for completion of the bisulphite treatment control. 
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Figure C.12. 100% methylation control pyrogram for the Hs_SLC39A14_02 assay 
(Qiagen, catalog number PM00136605). Blue rectangles indicate the CpGs  under 
investigation and yellow columns indicate sites for completion of the bisulphite treatment 
control. 
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Appendix D: Confirmation of specificity of qPCR products used for calculations of 
methylation enrichments 
 
 
 
 
Figure D.1.  Agarose/TBE gel run of human qPCR products for MeDIP enrichment 
calculations. Lanes 1 and 8 = 100 bp DNA Ladder, lane 2 = H19 PCR product, lane 4 = 
HIST1H2BA PCR product, lane 6 = GAPDH PCR product. The remaining lanes show 
runs of PCR products not related to this study. 
 
 
 
 
Figure D.2.  Agarose/TBE gel run of murine qPCR products for MeDIP enrichment 
calculations. Lanes 1 and 8 = 100 bp DNA Ladder, lane 2 = H19 PCR product, lane 4 = 
Hist1h2ba PCR product, lane 5 = Actb PCR product, lane 7 = Gapdh PCR product. The 
remaining lanes show runs of PCR products not related to this study. 
 
 
 
1 2 3 4 5 6 7 8 
1 2 3 4 5 6 7 8 
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H19 = chr11:2020940-2021073. 100% sequence match 
Human genome assembly GRCh37/h19 
 
0000023 gagccgcaccagatcttcaggtcgggcattatccacagccccgtggcccc 0000072 
<<<<<<< |||||||||||||||||||||||||||||||||||||||||||||||||| <<<<<<< 
2021073 gagccgcaccagatcttcaggtcgggcattatccacagccccgtggcccc 2021024 
 
0000073 gggtcacactccgagggcttcagtgtcatggcctgggactcaagtcacgc 0000122 
<<<<<<< |||||||||||||||||||||||||||||||||||||||||||||||||| <<<<<<< 
2021023 gggtcacactccgagggcttcagtgtcatggcctgggactcaagtcacgc 2020974 
 
0000123 ctacttatgtgatgatcacagtgtgttccaccaaa.tctt 0000161 
<<<<<<< ||||||||||||||||||||||||||||||||||| |||| <<<<<<< 
2020973 ctacttatgtgatgatcacagtgtgttccaccaaaatctt 2020934 
 
 
HIST1H2BA = chr6:25727004+25727094. 100% sequence match 
Human genome assembly GRCh37/h19 
 
00000035 tgtttgtttacttggcgagacttggagctgaggtcatttggagctgttta 00000084 
>>>>>>>> |||||||||||||||||||||||||||||||||||||||||||||||||| >>>>>>>> 
25727004 tgtttgtttacttggcgagacttggagctgaggtcatttggagctgttta 25727053 
 
00000085 atactgaagagctgttgagcactggaaagtgctgtgtaacc 00000125 
>>>>>>>> ||||||||||||||||||||||||||||||||||||||||| >>>>>>>> 
25727054 atactgaagagctgttgagcactggaaagtgctgtgtaacc 25727094 
 
 
GAPDH = chr12:6645023+6645112. 100% sequence match 
Human genome assembly GRCh37/h19 
 
0000024 ctctctcccatcccttctccccacacacatgcacttacctgtgctcccac 0000073 
>>>>>>> |||||||||||||||||||||||||||||||||||||||||||||||||| >>>>>>> 
6645023 ctctctcccatcccttctccccacacacatgcacttacctgtgctcccac 6645072 
 
0000074 tcctgatttctggaaaagagctaggaaggacaggcaactt 0000113 
>>>>>>> |||||||||||||||||||||||||||||||||||||||| >>>>>>> 
6645073 tcctgatttctggaaaagagctaggaaggacaggcaactt 6645112 
 
Figure D.3. BLAT (BLAST-Like Alignment Tool) analyses output for cloned human qPCR 
products used for methylation enrichment calculations in Chapter 4. 
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H19 = chr7:149767910-149768055. 99.4% sequence match 
Mouse genome assembly NCBI37/mm9 
 
000000032 tacattcacacgagcatccaggaggcataagaattctgcaaggagaccat 000000081 
<<<<<<<<< |||||||||||||||||||||||||||||||||||||||||||||||||| <<<<<<<<< 
149768056 tacattcacacgagcatccaggaggcataagaattctgcaaggagaccat 149768007 
 
000000082 gccctactcttggacgtctgctgaatcagttgtggggtttatacgcggga 000000131 
<<<<<<<<< |||||| ||||||||||||||||||||||||||||||||||||||||||| <<<<<<<<< 
149768006 gccctattcttggacgtctgctgaatcagttgtggggtttatacgcggga 149767957 
 
000000132 gttgccgcgtggtggcagcaaaatcgattgcgccaaacctaaagagc 000000178 
<<<<<<<<< ||||||||||||||||||||||||||||||||||||||||||||||| <<<<<<<<< 
149767956 gttgccgcgtggtggcagcaaaatcgattgcgccaaacctaaagagc 149767910 
 
 
Hist1h2ba = chr13:24025814-24025892. 100% sequence match 
Mouse genome assembly NCBI37/mm9 
 
00000041 aggtgctg.aacaagtgcaccccgacaccggcatctcctccaaggccatg 00000089 
<<<<<<<< |||||||| ||||||||||||||||||||||||||||||||||||||||| <<<<<<<< 
24025892 aggtgctgaaacaagtgcaccccgacaccggcatctcctccaaggccatg 24025843 
 
00000090 agcatcatgaactcctttgtgacagacat 00000118 
<<<<<<<< ||||||||||||||||||||||||||||| <<<<<<<< 
24025842 agcatcatgaactcctttgtgacagacat 24025814 
 
Actb = chr5:143665852-143665948. 100% of sequence match 
Mouse genome assembly NCBI37/mm9 
 
000000025 tttctgtcactcttctcttaggtatggaatcctgtggcatccatgaaact 000000074 
<<<<<<<<< |||||||||||||||||||||||||||||||||||||||||||||||||| <<<<<<<<< 
143665948 tttctgtcactcttctcttaggtatggaatcctgtggcatccatgaaact 143665899 
 
000000075 acattcaattccatcatgaagtgtgacgttgacatccgtaaagacct 000000121 
<<<<<<<<< ||||||||||||||||||||||||||||||||||||||||||||||| <<<<<<<<< 
143665898 acattcaattccatcatgaagtgtgacgttgacatccgtaaagacct 143665852 
 
 
Gapdh = chr6:125115488-125115620. 97.8% sequence match 
Mouse genome assembly NCBI37/mm9 
 
00000107 ctggcactgcacaagaagatgcggccgtctctggaacagggaggagcaga 00000156 
<<<<<<<< ||||||  ||||||||||||||||| |||| | |||| |||||||||||| <<<<<<<< 
47061869 ctggcaaagcacaagaagatgcggctgtctgttgaac.gggaggagcaga 47061821 
 
00000157 ga 00000158 
<<<<<<<< || <<<<<<<< 
47061820 ga 47061819 
311 
 
Figure D.4. BLAT (BLAST-Like Alignment Tool) analyses output for cloned murine qPCR 
products used for methylation enrichment calculations in Chapter 4. 
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Appendix E: Differentially methylated Entrez Gene IDs in replicative senescent and 
early stress premature induced senescent compared with young confluent MRC-5 
cells 
Table E1. Significant differentially methylated Entrez Gene ID between replicative 
senescent and young confluent MRC-5 cells. 
  
Entrez Gene 
ID Gene symbol 
Delta 
enrichment 
Entrez Gene 
ID Gene symbol 
Delta 
enrichment 
2 A2M 3.11 1535 CYBA -2.32 
21 ABCA3 -1.95 1548 CYP2A6 1.87 
21 ABCA3 -3.73 1548 CYP2A6 0.37 
118 ADD1 -1.63 1553 CYP2A13 0.77 
182 JAG1 1.50 1553 CYP2A13 0.38 
398 ARHGDIG -2.41 1634 DCN -0.19 
475 ATOX1 0.62 1656 DDX6 3.14 
479 ATP12A 3.65 1773 DNASE1 -4.41 
481 ATP1B1 -1.75 1837 DTNA 0.83 
514 ATP5E -2.47 1843 DUSP1 -2.59 
547 KIF1A -2.11 1870 E2F2 -1.08 
658 BMPR1B -1.27 1875 E2F5 -2.31 
678 ZFP36L2 -1.31 1902 LPAR1 1.07 
757 TMEM50B -2.95 1908 EDN3 -1.35 
766 CA7 -3.63 1908 EDN3 -2.14 
766 CA7 -4.59 1952 CELSR2 -4.20 
793 CALB1 1.02 1991 ELA2 -3.25 
800 CALD1 0.18 2017 CTTN -2.15 
800 CALD1 0.15 2035 EPB41 1.81 
818 CAMK2G -2.76 2046 EPHA8 -2.49 
866 SERPINA6 -0.05 2051 EPHB6 -0.35 
924 CD7 0.00 2069 EREG -0.05 
1147 CHUK 1.64 2109 ETFB 2.54 
1159 CKMT1A 1.51 2178 FANCE -2.42 
1159 CKMT1A 1.22 2213 FCGR2C 0.93 
1191 CLU 0.63 2244 FGB 0.01 
1297 COL9A1 -2.60 2268 FGR -3.03 
1301 COL11A1 0.96 2302 FOXJ1 -2.88 
1393 CRHBP 0.32 2527 FUT5 3.09 
1396 CRIP1 -0.90 2664 GDI1 -0.98 
1429 CRYZ -0.10 2689 GH2 1.48 
1435 CSF1 -0.87 2898 GRIK2 0.60 
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1468 SLC25A10 -1.05 2915 GRM5 0.00 
1486 CTBS 3.06 2961 GTF2E2 3.85 
1497 CTNS -2.31 2972 BRF1 -1.95 
3000 GUCY2D -2.71 6154 RPL26 -1.76 
3149 HMGB3 1.91 6154 RPL26P6 -1.76 
3149 HMGB3 0.07 6232 RPS27 -1.74 
3201 HOXA4 -1.57 6310 ATXN1 -1.47 
3337 DNAJB1 -1.42 6310 ATXN1 -2.84 
3484 IGFBP1 0.32 6432 SFRS7 0.52 
3642 INSM1 -1.14 6506 SLC1A2 2.11 
3642 INSM1 -1.94 6553 SLC9A5 -1.15 
3732 CD82 -1.81 6570 SLC18A1 0.59 
3769 KCNJ13 0.04 6614 SIGLEC1 1.88 
3895 KTN1 -2.26 6620 SNCB 1.22 
3909 LAMA3 3.00 6622 SNCA 1.91 
3918 LAMC2 1.54 6643 SNX2 0.79 
3918 LAMC2 0.06 6760 SS18 -2.94 
4033 LRMP 0.85 6818 SULT1A3 -1.91 
4062 LY6H -1.88 6919 TCEA2 -5.60 
4099 MAG -2.56 7107 GPR137B -1.77 
4121 MAN1A1 -0.20 7138 TNNT1 1.53 
4121 MAN1A1 -0.67 7465 IE1 -0.64 
4359 MPZ 0.30 7483 WNT9A -2.58 
4482 MSRA -0.38 7512 XPNPEP2 0.66 
4833 NME4 -1.47 7536 SF1 -1.80 
4833 NME4 -1.93 7580 ZNF32 0.69 
4884 NPTX1 -2.27 7587 ZNF37A 1.05 
4900 NRGN 0.30 7587 ZNF37A 0.56 
4935 GPR143 1.26 7629 ZNF76 1.24 
4967 OGDH 0.59 8110 DPF3 -0.81 
5052 PRDX1 0.54 8284 JARID1D -0.02 
5105 PCK1 -4.14 8290 HIST3H3 -1.25 
5127 PCTK1 -4.00 8313 AXIN2 3.86 
5274 SERPINI1 -3.00 8322 FZD4 -2.91 
5321 PLA2G4A 0.75 8471 IRS4 -1.95 
5465 PPARA -1.64 8622 PDE8B -1.93 
5493 PPL -1.25 8644 AKR1C3 0.03 
5534 PPP3R1 -1.97 8655 DYNLL1 -1.73 
5654 HTRA1 2.88 8717 TRADD 6.95 
5726 TAS2R38 -0.15 8767 RIPK2 -0.42 
5793 PTPRG -2.44 8776 MTMR1 -2.78 
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5795 PTPRJ -1.59 8913 CACNA1G -3.38 
5830 PEX5 -2.03 8934 RAB7L1 2.95 
5878 RAB5C 3.75 8934 RAB7L1 0.29 
8938 BAIAP3 -2.47 22841 RAB11FIP2 1.02 
8997 KALRN 0.14 22853 LMTK2 -1.75 
9045 RPL14 1.34 22883 CLSTN1 -2.14 
9085 CDY1B -0.02 22883 CLSTN1 -2.97 
9103 FCGR2C 0.93 22884 WDR37 -2.64 
9144 SYNGR2 1.28 22897 CEP164 -1.14 
9261 MAPKAPK2 0.87 22911 WDR47 -2.04 
9308 CD83 -0.92 22978 NT5C2 1.35 
9604 RNF14 1.08 22978 NT5C2 0.37 
9622 KLK4 2.57 23126 POGZ -0.82 
9788 MTSS1 0.63 23126 POGZ -1.33 
9844 ELMO1 1.22 23303 KIF13B -1.24 
9942 XYLB -1.88 23498 HAAO 1.42 
9942 XYLB -2.11 23516 SLC39A14 -3.28 
9962 SLC23A2 -1.35 23521 RPL13A -1.16 
10073 SNUPN -0.43 23530 NNT -3.61 
10098 TSPAN5 1.65 23530 NNT -3.61 
10120 ACTR1B -0.51 23598 PATZ1 -0.65 
10225 CD96 1.14 23641 LDOC1 -4.94 
10312 TCIRG1 -2.71 23729 SHPK -2.31 
10312 TCIRG1 -4.43 23761 PISD 1.94 
10455 PECI 0.16 26012 NELF -0.24 
10463 SLC30A9 -2.39 26022 TMEM98 -2.13 
10509 SEMA4B -1.15 26059 ERC2 0.65 
10541 ANP32B 0.91 26059 ERC2 0.22 
10591 C6orf108 4.07 26136 TES 0.68 
10591 C6orf108 0.13 26249 KLHL3 0.56 
10602 CDC42EP3 -0.51 26292 MYCBP -1.48 
10668 CGRRF1 -1.25 26534 OR10G2 -1.70 
10762 NUP50 -1.04 26534 OR10G2 -2.93 
10797 MTHFD2 -1.27 27031 NPHP3 -1.11 
10808 HSPH1 -1.34 27031 ACAD11 -1.11 
10927 SPIN1 -1.88 27071 DAPP1 0.58 
10963 STIP1 -0.92 27071 DAPP1 0.48 
11072 DUSP14 -3.28 27164 SALL3 -0.29 
11085 ADAM30 4.48 28985 MCTS1 0.28 
11098 PRSS23 -0.69 29109 FHOD1 -1.15 
11228 RASSF8 -1.70 29761 USP25 -2.00 
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11228 RASSF8 -2.76 29801 ZDHHC8 -2.74 
11235 PDCD10 -3.00 30061 SLC40A1 3.27 
11326 VSIG4 -0.29 30819 KCNIP2 1.42 
30837 SOCS7 -2.74 57161 PELI2 -2.71 
50964 SOST 1.50 57182 ANKRD50 -1.68 
51083 GAL 2.11 57215 THAP11 -2.39 
51084 CRYL1 -1.89 57402 S100A14 1.86 
51087 YBX2 -2.66 57473 ZNF512B -0.80 
51151 SLC45A2 1.40 57473 ZNF512B -1.45 
51151 SLC45A2 0.00 57488 FAM62B -0.93 
51176 LEF1 0.86 57488 FAM62B -1.10 
51435 SCARA3 3.50 57509 MTUS1 0.78 
51646 YPEL5 -3.36 57529 RGAG1 -2.55 
51669 TMEM66 0.40 57563 KLHL8 0.98 
54361 WNT4 -2.04 57567 ZNF319 -0.45 
54463 FAM134B 0.35 57718 PPP4R4 -3.39 
54522 ANKRD16 0.70 60487 TRMT11 -0.41 
54537 FAM35A -0.04 60494 CCDC81 0.40 
54765 TRIM44 -1.00 63940  0.82 
54899 PXK 3.32 64064 OXCT2 0.00 
54899 PXK 2.18 64423 INF2 -1.74 
54970 TTC12 -0.48 64579 NDST4 0.01 
54984  -2.17 64856 VWA1 -2.51 
55080 TAPBPL 3.66 65059 RAPH1 1.38 
55105 GPATCH2 0.87 79058 ASPSCR1 -0.33 
55112 WDR60 -1.62 79091 C16orf68 0.22 
55160 ARHGEF10L -1.20 79258 MMEL1 1.02 
55196 C12orf35 -1.74 79650 C16orf57 -0.45 
55303 GIMAP4 0.29 79671 NLRX1 1.02 
55336 FBXL8 6.95 79671 NLRX1 0.92 
55558 PLXNA3 -1.70 79698 ZMAT4 0.87 
55608 ANKRD10 -1.57 79921 TCEAL4 0.66 
55608 ANKRD10 -1.94 79948  -3.43 
55624 POMGNT1 -1.38 80212 CCDC92 -3.17 
55786 ZNF415 2.35 80235 PIGZ -4.03 
55852 TEX2 -0.93 80274 SCUBE1 -2.52 
56122 PCDHB14 5.26 80305 TRABD -3.55 
56132 PCDHB3 0.42 80323 CCDC68 -0.80 
56172 ANKH -2.64 80331 DNAJC5 -1.50 
56888 KCMF1 -0.86 80709 AKNA 1.24 
56978 PRDM8 2.56 81566 CSRNP2 -0.71 
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57055 DAZ2 -3.61 81615 TMEM163 -0.86 
57088 PLSCR4 -0.65 81615 TMEM163 -1.08 
57156 TMEM63C -0.84 81618 ITM2C 2.31 
81894 SLC25A28 -2.18 158131 OR1Q1 0.72 
83737 ITCH -1.22 162517 FBXO39 -2.16 
83935 TMEM133 -0.05 163183 C19orf46 0.00 
83992 CTTNBP2 -2.51 192670 EIF2C4 -0.39 
84263 HSDL2 0.28 192670 EIF2C4 -1.08 
84309 NUDT16L1 -3.86 196883 ADCY4 2.11 
84309 NUDT16L1 -4.19 201633 TIGIT 0.06 
84504 NKX6-2 -0.78 202459 OSTCL -0.54 
84800 INF2 -1.74 219409 GSX1 -2.93 
84893 FBXO18 0.70 219429 OR4C11 0.01 
85474 LBX2 2.27 220988 HNRNPA3 -2.54 
90423 ATP6V1E2 0.62 246330 PELI3 -1.99 
91782 CHMP7 0.55 253175 CDY1B -0.02 
93010 B3GNT7 -1.21 253582 C6orf191 -0.87 
93343 FAM125A -0.71 253582 C6orf191 -1.10 
94081 SFXN1 -1.33 283643 C14orf80 -0.90 
115209 OMA1 1.76 284312 ZSCAN1 -2.69 
123876 ACSM2A 1.15 284340 CXCL17 2.06 
126123 C19orf41 -3.69 326624 RAB37 -2.09 
126328 NDUFA11 3.09 343071 PRAMEF10 0.00 
127253 TYW3 -0.10 343990 C2orf55 -1.05 
128372 OR6N1 -3.00 348093 RBPMS2 1.80 
130271 PLEKHH2 -2.69 348487 FAM131C 1.65 
130814 PQLC3 -2.80 374407 DNAJB13 0.60 
130951 C2orf65 2.67 374470 C12orf42 -1.58 
136259 KLF14 -1.23 374928 ZNF773 4.74 
138881 OR1L8 2.07 375607 C7orf52 2.47 
138881 OR1L8 1.57 378832 C21orf123 -3.30 
140731 ANKRD60 -1.06 389136 VGLL3 -3.79 
144348 ZNF664 -3.17 390152 OR8H3 -0.77 
145497 C14orf166B -5.86 400509 RUNDC2B 5.63 
145781 GRINL1A -2.26 400509 RUNDC2B 5.62 
146712 B3GNTL1 -1.45 440348  0.81 
147199 SCGB1C1 -1.98 440435 GPR179 2.57 
147339 C18orf25 -1.65 445329 SULT1A3 -1.91 
149175 MANEAL 0.79 448834 KPRP 0.74 
149650  -2.14 448834 KPRP 0.44 
151449 GDF7 -2.55 548596 CKMT1A 1.51 
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151473 SLC16A14 1.01 548596 CKMT1A 1.22 
644511 RPL13A -1.16 
648581 ASPSCR1 -0.33 
151835 CPNE9 -0.81 
152007 GLIPR2 -2.20 
652251 GPSM1 -2.36 
728513 PNMA6A -1.05 
100129905 RPS27 -1.74 
100130070 RPS27 -1.74 
100131572 RPS27 -1.74 
100132291 RPS27 -1.74 
100132353 GDI2 -0.78 
100133623 CKMT1A 1.51 
100133623 CKMT1A 1.22 
100134295 SLCO4A1 -2.14 
 
Table E2. Significant differentially methylated Entrez Gene ID between early stress-
induced premature senescent and young confluent MRC-5 cells. 
 
Entrez Gene 
ID Gene symbol 
Delta 
enrichment 
Entrez Gene 
ID Gene symbol 
Delta 
enrichment 
24 ABCA4 -3.65 820 CAMP -2.86 
24 ABCA4 -3.78 831 CAST -1.39 
118 ADD1 -1.73 831 CAST -1.96 
132 ADK -1.52 840 CASP7 -5.17 
320 APBA1 1.38 911 CD1C -3.65 
331 XIAP -3.36 924 CD7 0.00 
366 AQP9 -2.72 928 CD9 0.00 
366 AQP9 -3.77 1025 CDK9 -1.66 
430 ASCL2 -3.66 1063 CENPF -3.86 
522 ATP5J -3.69 1260 CNGA2 -0.63 
551 AVP -1.94 1267 CNP -2.28 
701 BUB1B 1.24 1298 COL9A2 -2.99 
722 C4BPA -4.37 1390 CREM -4.02 
727 C5 0.00 1572 CYP2F1 1.03 
745 C11orf9 -3.61 1634 DCN -0.19 
801 CALM2 -5.44 1727 CYB5R3 -3.09 
805 CALM2 -5.69 1727 CYB5R3 -3.10 
808 CALM2 -5.69 1780 DYNC1I1 0.45 
818 CAMK2G -3.40 1811 SLC26A3 -0.30 
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820 CAMP -1.59 1917 EEF1A2 1.59 
1967 EIF2B1 -5.26 2797 GNRH2 -4.54 
2049 EPHB3 0.00 2811 GP1BA 0.00 
2059 EPS8 -3.77 2848 GPR25 -2.76 
2059 EPS8 -5.07 2862 MLNR -5.08 
2060 EPS15 -4.99 2901 GRIK5 -2.69 
2119 ETV5 -3.52 2960 GTF2E1 -4.64 
2119 ETV5 -3.70 2967 GTF2H3 -1.43 
2245 FGD1 0.00 2972 BRF1 -2.63 
2268 FGR -3.56 3052 HCCS 0.00 
2551 GABPA -3.69 3052 HCCS -2.90 
2576 GAGE2C 0.00 3149 HMGB3 0.73 
2576 GAGE7 0.00 3158 HMGCS2 0.00 
2576 GAGE6 0.00 3158 HMGCS2 -4.11 
2576 GAGE3 0.00 3185 HNRNPF -0.16 
2576 GAGE12I -0.48 3297 HSF1 -2.22 
2576 GAGE5 -0.48 3417 IDH1 -1.61 
2576 GAGE4 -0.48 3481 IGF2 -0.53 
2577 GAGE12I 0.00 3481 IGF2 -3.16 
2577 GAGE5 0.00 3508 IGHMBP2 0.00 
2577 GAGE4 0.00 3587 IL10RA -4.33 
2577 GAGE2C -0.48 3592 IL12A 0.00 
2577 GAGE7 -0.48 3611 ILK -6.57 
2577 GAGE6 -0.48 3658 IREB2 -3.16 
2577 GAGE3 -0.48 3661 IRF3 -3.21 
2578 GAGE2C 0.00 3704 ITPA -1.42 
2578 GAGE7 0.00 3708 ITPR1 -3.26 
2578 GAGE6 0.00 3748 KCNC3 -2.07 
2578 GAGE3 0.00 3883 KRT33A 0.00 
2578 GAGE12I -0.48 3883 KRT33A -3.22 
2578 GAGE5 -0.48 3895 KTN1 -2.88 
2578 GAGE4 -0.48 3904 LAIR2 -2.88 
2579 GAGE12I 0.00 3958 LGALS3 -1.05 
2579 GAGE5 0.00 3992 FADS1 -1.29 
2579 GAGE4 0.00 4048 LTA4H -4.20 
2579 GAGE2C -0.48 4121 MAN1A1 -0.76 
2579 GAGE7 -0.48 4209 MEF2D 4.94 
2579 GAGE6 -0.48 4240 MFGE8 -0.85 
2579 GAGE3 -0.48 4325 MMP16 -3.43 
2596 GAP43 -2.14 4338 MOCS2 -1.31 
2627 GATA6 -3.35 4354 MPP1 -0.51 
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2764 GMFB 1.03 4359 MPZ -6.42 
4697 NDUFA4 0.00 7508 XPC -3.86 
4744 NEFH -3.60 7580 ZNF32 0.95 
4833 NME4 -2.27 7592 ZNF41 -3.38 
4867 NPHP1 -3.64 7644 ZNF91 2.04 
4884 NPTX1 -2.01 7743 ZNF189 -2.96 
4914 NTRK1 -0.97 7762 ZNF215 -6.37 
4978 OPCML -0.19 7905 REEP5 -3.71 
5032 P2RY11 -4.44 8263 F8A2 -2.62 
5188 PET112L -2.80 8294 HIST1H4C -1.89 
5191 PEX7 -5.24 8317 CDC7 -2.43 
5335 PLCG1 -1.34 8359 HIST1H4C -1.89 
5335 PLCG1 -3.69 8360 HIST1H4C -1.89 
5435 POLR2F 0.00 8361 HIST1H4C -1.89 
5534 PPP3R1 -2.28 8362 HIST1H4C -1.89 
5582 PRKCG -5.06 8363 HIST1H4C -1.89 
5648 MASP1 0.44 8364 HIST1H4C -1.89 
5653 KLK6 -3.17 8365 HIST1H4C -1.89 
5683 PSMA2 0.31 8366 HIST1H4C -1.89 
5830 PEX5 -3.03 8367 HIST1H4C -1.89 
5872 RAB13 -1.03 8368 HIST1H4C -1.89 
5877 RABIF -1.81 8370 HIST1H4C -1.89 
5898 RALA -5.79 8479 HIRIP3 0.00 
5908 RAP1B -0.37 8493 PPM1D 0.00 
5922 RASA2 -2.02 8519 IFITM1 -3.03 
5930 RBBP6 -6.08 8521 GCM1 -4.61 
6035 RNASE1 0.80 8614 STC2 -2.60 
6046 BRD2 -2.52 8638 OASL -1.82 
6228 RPS23 0.00 8642 DCHS1 -1.83 
6228 RPS23 -2.91 8773 SNAP23 -0.70 
6295 SAG 1.79 8774 NAPG -5.77 
6507 SLC1A3 -1.24 8879 SGPL1 -4.85 
6817 SULT1A1 -1.70 9047 SH2D2A -0.97 
7094 TLN1 -5.36 9099 USP2 -4.38 
7094 TLN1 -5.91 9131 AIFM1 -1.57 
7141 TNP1 -2.51 9232 PTTG1 -1.06 
7319 UBE2A -3.12 9232 PTTG2 -1.06 
7329 UBE2I -1.99 9352 TXNL1 -6.06 
7350 UCP1 -3.21 9362 CPNE6 -0.88 
7409 VAV1 -3.50 9425 CDYL -6.25 
7434 VIPR2 -4.66 9435 CHST2 -4.53 
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7483 WNT9A -0.68 9532 BAG2 -2.28 
9532 BAG2 -3.93 23127 GLT25D2 -2.50 
9542 NRG2 -4.68 23189 KANK1 -1.06 
9589 WTAP -0.78 23216 TBC1D1 -2.02 
9665 KIAA0430 -1.24 23246 BOP1 -4.07 
9742 IFT140 -1.72 23281 KIAA0774 0.44 
9847 KIAA0528 -3.72 23308 ICOSLG 0.53 
9848 MFAP3L -1.22 23316 CUX2 -1.01 
9853 RUSC2 -0.95 23317 DNAJC13 -1.53 
10013 HDAC6 -3.19 23366 KIAA0895 -6.90 
10169 SERF2 -3.89 23373 CRTC1 -0.14 
10401 PIAS3 -0.48 23378 KIAA0409 -6.57 
10422 UBAC1 -1.94 23411 SIRT1 -2.49 
10455 PECI 0.50 23436 ELA3B 0.30 
10488 CREB3 -5.36 23436 ELA3B 0.00 
10488 CREB3 -5.91 23559 WBP1 -0.48 
10509 SEMA4B -1.20 23598 PATZ1 -0.80 
10512 SEMA3C -3.67 23609 MKRN2 -2.85 
10512 SEMA3C -3.86 23633 KPNA6 -2.36 
10540 DCTN2 -2.63 23641 LDOC1 -6.09 
10569 SLU7 -1.06 24140 FTSJ1 0.00 
10608 MXD4 1.68 24140 FTSJ1 -0.85 
10635 RAD51AP1 0.00 25819 CCRN4L -1.69 
10693 CCT6B -2.41 25824 PRDX5 -3.73 
10887 PROKR1 -0.92 25917 THUMPD3 -1.63 
10919 EHMT2 -1.74 25984 KRT23 -2.26 
10926 DBF4 -3.12 25988 MIZF -3.82 
10930 APOBEC2 -4.51 26000 TBC1D10B -3.15 
10989 IMMT -3.06 26015 RPAP1 -4.68 
10989 IMMT -3.07 26053 AUTS2 -1.79 
11064 CEP110 -4.93 26128 KIAA1279 0.61 
11079 RER1 -4.01 26166 RGS22 -2.58 
11083 DIDO1 0.00 26292 MYCBP -1.40 
11083 DIDO1 -2.82 26524 LATS2 -4.38 
11170 FAM107A -5.42 26524 LATS2 -5.69 
11341  -4.93 26575 RGS17 -0.30 
22884 WDR37 -1.12 26748 GAGE12I 0.00 
22884 WDR37 -1.30 26748 GAGE5 0.00 
22884 WDR37 -1.84 26748 GAGE4 0.00 
22889 KIAA0907 -2.78 26748 GAGE2C -0.48 
22948 CCT5 0.64 26748 GAGE7 -0.48 
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23035 PHLPPL -5.34 26748 GAGE6 -0.48 
26748 GAGE3 -0.48 54839 LRRC49 -2.42 
26749 GAGE2E -0.48 54840 APTX -0.70 
26985 AP3M1 -1.52 54840 APTX -1.52 
27040 LAT -0.40 54893 MTMR10 -1.40 
27071 DAPP1 0.52 54960 GEMIN8 -1.04 
27101 CACYBP -2.11 54960 GEMIN8 -1.88 
27106 ARRDC2 1.21 54994 C20orf11 0.00 
27164 SALL3 -1.10 54994 C20orf11 -2.82 
27164 SALL3 -1.88 55101 ATP5SL -3.83 
27238 GPKOW -2.89 55176 SEC61A2 -1.30 
27258 LSM3 -1.48 55223 TRIM62 -3.99 
27309 ZNF330 -4.88 55293 UEVLD 1.48 
28991 COMMD5 -1.23 55293 UEVLD -0.26 
50508 NOX3 -2.96 55293 UEVLD -3.14 
50619 DEF6 2.56 55529 TMEM55A -3.87 
51175 TUBE1 -2.34 55608 ANKRD10 -1.09 
51214 IGF2AS -0.53 55608 ANKRD10 -1.44 
51301 GCNT4 0.00 55626 AMBRA1 -7.34 
51315 KRCC1 -6.32 55630 SLC39A4 -1.55 
51315 KRCC1 -8.23 55686 MREG 0.00 
51318 MRPL35 -3.06 55793 FAM63A -1.75 
51447 IP6K2 0.00 55894 DEFB103A -3.85 
51447 IP6K2 -0.90 55924 C1orf183 -2.48 
51493 C22orf28 -1.47 55929 DMAP1 -3.05 
51493 C22orf28 -2.87 56125 PCDHB11 0.57 
51504  -3.73 56172 ANKH -3.25 
51601 LIPT1 -4.28 56267 CCBL2 0.00 
51601 LIPT1 -5.91 56267 RBMXL1 0.00 
51646 YPEL5 -2.32 56548 CHST7 -4.60 
53339 BTBD1 3.78 56906 THAP10 -2.42 
54205 CYCS 1.65 57001 ACN9 -3.64 
54207 KCNK10 -3.08 57030 SLC17A7 0.00 
54496 PRMT7 -6.16 57030 SLC17A7 -0.30 
54518 APBB1IP -1.58 57102  0.00 
54518 APBB1IP -5.37 57154 SMURF1 -0.85 
54534 MRPL50 -2.96 57156 TMEM63C -1.12 
54550 NECAB2 -4.04 57167 SALL4 -2.63 
54680 ZNHIT6 -0.89 57181 SLC39A10 -2.29 
54820 NDE1 -1.24 57468 SLC12A5 -1.99 
54834 GDAP2 -3.14 57473 ZNF512B -1.99 
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54834 GDAP2 -3.64 57585 CRAMP1L -1.72 
57728 WDR19 -4.28 84138 SLC7A6OS -6.16 
58497 PRUNE -1.75 84141 FAM176A 0.00 
59351 PBOV1 -4.08 84146 ZNF644 -2.57 
60370 AVPI1 -2.97 84188 FAR1 -1.82 
60468 BACH2 -1.41 84311 MRPL45 -4.66 
60485 SAV1 0.00 84332 DYDC2 -1.28 
60485 SAV1 -0.70 84504 NKX6-2 -1.47 
64232 MS4A5 0.37 84557 MAP1LC3A -4.05 
64332 NFKBIZ -4.94 84557 MAP1LC3A -4.59 
64763 ZNF574 -2.69 84645 C22orf23 0.00 
64949 MRPS26 -4.54 84645 C22orf23 -5.43 
64965 MRPS9 0.49 84909 C9orf3 -4.61 
64983 MRPL32 0.31 84910 TMEM87B -3.95 
65078 RTN4R -2.49 84922 FIZ1 0.00 
79646 PANK3 -2.03 84935 C13orf33 -4.84 
79651 RHBDF2 -1.36 85438 C4orf35 -0.52 
79712 GTDC1 -4.83 85455 DISP2 -8.13 
79730 NSUN7 -3.02 85465  -1.03 
79898 ZNF613 0.38 85480 TSLP -2.99 
79903 NAT15 -0.05 89846 FGD3 2.71 
79906 MORN1 -4.01 89857 KLHL6 -4.42 
79935 CNTD2 -2.04 91147 TMEM67 -1.97 
80237 ELL3 -3.89 91147 TMEM67 -3.24 
80305 TRABD -2.01 91353 IGLL3 -4.47 
80318 GKAP1 -4.86 91603 ZNF830 -2.41 
80323 CCDC68 -0.45 91801 ALKBH8 -7.74 
80331 DNAJC5 -1.99 91862 MARVELD3 -3.08 
80705 TSGA10 -4.28 92014 MCART1 -2.09 
80705 TSGA10 -5.91 92270  0.00 
80739 C6orf25 -4.35 92270  -2.91 
80740 LY6G6C -4.35 92715 WDR85 -1.68 
80760 ITIH5 2.57 93426 SYCE1 -2.26 
81542 TXNDC1 -3.67 93663 ARHGAP18 -4.09 
81542 TXNDC1 -3.95 93973 ACTR8 0.00 
81557 MAGED4B -4.62 94032 CAMK2N2 -0.97 
83444 INO80B -0.48 112950 MED8 -3.07 
83550 GPR101 -7.58 114987 WDR31 -2.86 
83640 FAM103A1 -5.87 115416 C7orf30 -4.54 
83740 H2AFB2 -2.62 116224 FAM122A 0.00 
116224 FAM122A -0.30 196483 FAM86A -2.65 
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117248 GALNTL2 -0.70 219844 HYLS1 -2.05 
118813 ZFYVE27 -1.81 219927 MRPL21 0.00 
119774 OR52K2 -3.12 220988 HNRNPA3 -3.15 
120066 OR5P3 -3.67 246330 PELI3 -0.80 
120066 OR5P3 -4.64 255239 ANKK1 0.04 
121504 HIST1H4C -1.89 255324 EPGN -0.07 
124583 CANT1 -2.37 266812 NAP1L5 -0.48 
124583 CANT1 -4.32 283294 C11orf47 -2.34 
128372 OR6N1 -4.08 283899 INO80E 0.00 
129868 TRIM43 -1.31 284119 PTRF -0.97 
130271 PLEKHH2 -2.47 284207 METRNL -1.71 
130271 PLEKHH2 -3.71 284309 ZNF776 0.96 
130535 KCTD18 -2.35 284309 ZNF776 0.54 
131474 CHCHD4 -4.55 284309 ZNF776 -0.11 
134145 FAM173B 0.64 284611 FAM102B -3.59 
140467 ZNF358 -2.53 285242 HTR3E -1.20 
143241 DYDC1 -1.28 285282 RABL3 -4.64 
143279 HECTD2 -4.01 285349 ZNF660 -6.77 
143496 OR52B4 -0.98 286187 LRRC67 -3.75 
144165 PRICKLE1 2.40 338675 OR5AP2 -3.63 
147807 ZNF524 0.00 339345 NANOS2 0.65 
149469 KIAA0467 -3.07 340252 ZNF680 0.87 
152926 PPM1K -1.97 341676 NEK5 -2.61 
152926 PPM1K -2.66 342538 NACA2 -4.45 
152926 PPM1K -4.27 344807 CD200R1L -3.17 
158399 ZNF483 -2.50 345079 ANKRD56 -6.01 
160428 ALDH1L2 -2.58 347468 OR13H1 -2.96 
162605 KRT28 0.00 353164 TAS2R42 -1.52 
162605 KRT28 -2.43 375704 ENHO -4.74 
163126 EID2 0.80 387103 C6orf173 0.00 
164091 PAQR7 -1.95 387328 ZNF322B -1.48 
164237 WFDC13 0.01 387758 FIBIN -1.38 
165082 GPR113 -1.03 388228 SBK1 -3.60 
165140 OXER1 -2.21 388533 KRTDAP -5.82 
170506 DHX36 -5.17 388650 FAM69A -3.45 
170685 NUDT10 -2.64 388677 NOTCH2NL -1.66 
170692 ADAMTS18 -1.09 388759  -1.04 
192668 CYS1 -0.83 389136 VGLL3 -3.65 
192668 CYS1 -1.21 389151  -3.64 
389658 FAM150A -0.83 391358  -3.73 
390063 OR51I1 -6.30 391370 RPS12 0.02 
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390144 OR5D16 0.00 391723 HELT -0.95 
390151 OR8H2 -0.82 399947 C11orf87 -7.81 
391123 C1orf204 0.00 400360 C15orf54 -0.95 
391123 VSIG8 0.00 400823 FAM177B -4.16 
391358  -3.73 402415 XKRX 1.28 
391370 RPS12 0.02 408029  0.04 
391723 HELT -0.95 414325 DEFB103A -3.85 
399947 C11orf87 -7.81 440107 PLEKHG7 -2.01 
400360 C15orf54 -0.95 440275 EIF2AK4 0.00 
400823 FAM177B -4.16 474381 H2AFB2 -2.62 
402415 XKRX 1.28 474383 F8A2 -2.62 
408029  0.04 474384 F8A2 -2.62 
414325 DEFB103A -3.85 554313 HIST1H4C -1.89 
440107 PLEKHG7 -2.01 574016 CLLU1OS -1.18 
440275 EIF2AK4 0.00 642265 FAM75A2 1.24 
474381 H2AFB2 -2.62 643736  -1.13 
474383 F8A2 -2.62 645073 GAGE2C 0.00 
474384 F8A2 -2.62 645073 GAGE7 0.00 
554313 HIST1H4C -1.89 645073 GAGE6 0.00 
574016 CLLU1OS -1.18 645073 GAGE3 0.00 
642265 FAM75A2 1.24 645073 GAGE12I -0.48 
643736  -1.13 645073 GAGE5 -0.48 
645073 GAGE2C 0.00 645073 GAGE4 -0.48 
645073 GAGE7 0.00 653333 FAM86B2 -2.65 
645073 GAGE6 0.00 653506 METRNL -1.71 
645073 GAGE3 0.00 654258 LRRC49 -2.42 
645073 GAGE12I -0.48 728401  0.00 
645073 GAGE5 -0.48 729627  -3.64 
645073 GAGE4 -0.48 729915  0.00 
653333 FAM86B2 -2.65 100008586 GAGE2C 0.00 
653506 METRNL -1.71 391123 VSIG8 0.00 
654258 LRRC49 -2.42 391358  -3.73 
728401  0.00 391370 RPS12 0.02 
729627  -3.64 391723 HELT -0.95 
729915  0.00 399947 C11orf87 -7.81 
100008586 GAGE2C 0.00 400360 C15orf54 -0.95 
391123 VSIG8 0.00 400823 FAM177B -4.16 
402415 XKRX 1.28 474383 F8A2 -2.62 
408029  0.04 474384 F8A2 -2.62 
414325 DEFB103A -3.85 554313 HIST1H4C -1.89 
440107 PLEKHG7 -2.01 574016 CLLU1OS -1.18 
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440275 EIF2AK4 0.00 642265 FAM75A2 1.24 
474381 H2AFB2 -2.62 645073 GAGE4 -0.48 
474383 F8A2 -2.62 653333 FAM86B2 -2.65 
474384 F8A2 -2.62 653506 METRNL -1.71 
554313 HIST1H4C -1.89 654258 LRRC49 -2.42 
574016 CLLU1OS -1.18 728401  0.00 
642265 FAM75A2 1.24 729627  -3.64 
643736  -1.13 729915  0.00 
645073 GAGE2C 0.00 100008586 GAGE2C 0.00 
645073 GAGE7 0.00 100008586 GAGE7 0.00 
645073 GAGE6 0.00 100008586 GAGE6 0.00 
645073 GAGE3 0.00 100008586 GAGE3 0.00 
645073 GAGE12I -0.48 100008586 GAGE12I -0.48 
645073 GAGE5 -0.48 100008586 GAGE5 -0.48 
645073 GAGE4 -0.48 100008586 GAGE4 -0.48 
653333 FAM86B2 -2.65 100130430  -1.99 
653506 METRNL -1.71 100131294 RAB13 -1.03 
654258 LRRC49 -2.42 100131390  1.23 
728401  0.00 100133501 FAM75A2 1.24 
729627  -3.64 100133913 CXorf24 -3.38 
729915  0.00 100134431  -1.99 
100008586 GAGE2C 0.00 
391123 VSIG8 0.00 
391358  -3.73 
391370 RPS12 0.02 
391723 HELT -0.95 
399947 C11orf87 -7.81 
400360 C15orf54 -0.95 
400823 FAM177B -4.16 
402415 XKRX 1.28 
408029  0.04 
414325 DEFB103A -3.85 
440107 PLEKHG7 -2.01 
440275 EIF2AK4 0.00 
474381 H2AFB2 -2.62 
643736  -1.13 
645073 GAGE2C 0.00 
645073 GAGE7 0.00 
645073 GAGE6 0.00 
645073 GAGE3 0.00 
645073 GAGE12I -0.48 
326 
 
645073 GAGE5 -0.48 
 
